Development, Synthesis, and Characterization of G Protein-Coupled Receptor Kinase Inhibitors Using Structure Based Drug Design for the Advancement of Heart Failure Therapeutics by Waldschmidt, Helen
 
 
Development, Synthesis, and Characterization of G Protein-Coupled 
Receptor Kinase Inhibitors Using Structure Based Drug Design for 
the Advancement of Heart Failure Therapeutics 
by 
Helen V. Waldschmidt 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
(Medicinal Chemistry) 















 Research Professor Scott D. Larsen, Co-Chair 
 Professor John J. G. Tesmer, Co-Chair 
 Professor Henry I. Mosberg 











Helen V. Waldschmidt 
hwaldsch@umich.edu 















 The work described in this thesis would not have been possible without a number of 
people. I first wish to acknowledge my two mentors, Dr. Scott Larsen and Dr. John Tesmer. Dr. 
Scott Larsen allowed me to join his lab and come onto this project despite my lack of synthetic 
chemistry training or experience. Over the course of my four years in his laboratory he guided 
me with respect and patience. He allowed me to make my own mistakes and learn from them, 
test my own ideas, and grow as an independent scientist. Dr. John Tesmer took on the 
responsibility of being my co-mentor with very little interaction with me and little knowledge of 
my scientific merit. Over the years he has shown a great interest in making sure that I am 
knowledgeable about the structural biology and biological signaling of my project. He 
additionally made me feel welcome and included in Tesmer Lab activities. I was incredibly 
fortunate to have the support, respect, and guidance of these two talented scientists. I would not 
have been as successful and could not have hoped for anyone more incredible than Dr. Scott 
Larsen and Dr. John Tesmer to guide me in my doctorate studies. 
 In the Tesmer Lab there were a number of people who directly contributed to this project. 
Our collaboration began with Dr. Kristoff Homan who determined several of the crystal 
structures shown in this thesis. He trained me to run the biochemical assays and was patient with 
me as I made numerous mistakes.  Furthermore, his knowledge of the nuances of the g-protein 
coupled receptor kinase (GRK) crystal complexes was extensive and he was willing to answer 
my endless questions on the background of GRKs. Another prodigious comrade in this project, 
iii 
 
and friend, was Claire Cato. She generated a number of crystal structures, some with the help of 
Jessica Waninger-Saroni. Claire was also substantive in her contributions to the writing of the 
two Journal of Medicinal Chemistry papers we published on this project. Most of the ROCK1 
assay data was additionally generated by Claire, who was very patient and understanding with 
me when, unbeknownst to us, I had the inability to produce good data from this assay. Osvaldo 
Cruz – Rodríguez optimized the ROCK1 assay allowing for the use of less protein and 
additionally worked on generating some of the crystal complexes shown . He additionally was a 
great source of general lab support and knowledge, always having excellent scientific ideas and 
thoughts. More recently, Dr. Renee Bouley joined the Tesmer Lab and was very quick to 
generate further data. She produced a number of crystal structures of some of our more potent 
analogues allowing us to gain further insights into the overall kinase domain protein 
conformations between the different scaffolds.  
 In addition to these members of the Tesmer Lab who directly contributed to the 
development of these GRK inhibitors there were a number of people in the lab who were also 
sources of support, good science, and friendship. My baymates, Sumit Bandekar, Tyler Beyett, 
Louise Chang, and Emily Labudde always made me feel welcome in the lab although I was 
adding another body to an already crowded space. Dr. Jennifer Cash was always supportive and 
gave useful feedback in group presentations. She additionally has excellent taste in beer and I 
will never forget watching a burning Christmas tree at her house making its way around her 
backyard.  
 Coming into the Larsen Lab I was initially trained by Michael Wilson in synthetic 
chemistry, who had worked out the early synthesis on this project. Over my time in the lab, I 
gained further training from the other research scientists, Dr. Kim Hutchings and Dr. Walajapet 
iv 
 
Rajeswaran. Former graduate students of the Larsen Lab, Dr. Scott Barraza and Janice Sindac, 
were a strong presence in my first year, guiding me through my chemistry and introducing me to 
sushi. My later years in the lab were accompanied by an amazing group of guys, Jeffery 
Zwicker, Brandt Huddle, and Dylan Kahl. Although I was the senior graduate student, they often 
were the ones helping me with both my troubles in and out of the lab. I have to thank Jeff for my 
current caffeine addiction and need for coffee, as before graduate school I rarely drank coffee. If 
I ever felt a lack of brotherly affection and teasing growing up these three men have assuredly 
ameliorated that with their tireless efforts to embarrass me.  My last year in the lab has thus been 
accompanied by Rachel Rowlands who has been very supportive and easy to chat with. 
 I was incredibly fortunate to come into graduate school with a fun and fabulous group of 
peers: Jennifer Schmidt, Joseph Madak, Michael Agius, Maxwell Stefan, Eric Lachacz, Shasha 
Li, Megan Stewart, William Kaplan, and Elizabeth Rowland – Fisher. Graduate school would 
not have been the same without several other friends along the way as well: Taylor Johnson, 
Melissa Holt, and Meghan Breen. These three girls and Jennifer Schmidt were always willing to 
proofread my writing, lend support, and go to Sunday brunch. 
Lastly, I would like to thank my family. My dad and stepmom have been always very 
supportive and joyful of my accomplishments. My mother and sister have been my biggest fans 
and sources of encouragement throughout my life. Their visits to Ann Arbor to tour the city were 
welcome distractions from my graduate school work. My sister, Elise, has always been by my 
side, and I am grateful that I have her in my life. I thank my family for their understanding and 








Table of Contents 
Acknowledgements………………………………………………………………………….. ii 
List of Figures…………………………………………………………………………......... vii 
List of Tables……………………………………………………………………………....... ix 
List of Schemes…………………………………………………………………………....... x 
List of Abbreviations……………………………………………………………………....... xi 
Abstract……………………………………………………………………………………… xiii 
Chapter 1: Introduction and Background……………………………………………...... 1 
 Heart Failure Background and Pathophysiology………………………………............. 1 
 G protein-coupled receptor signaling and β adrenergic receptors………………........... 2 
 G protein-coupled receptor kinases……………………………………………….......... 4 
 AGC kinase domain structure…………………………………………………….......... 6 
 GRK inhibitors…………………………………………………………………............. 7 
Chapter 2: GRK Inhibitors Derived from GSK180736A……………………………...... 13 
 Rationale………………………………………………………………………….......... 13 
 First generation of GSK180736A derivatives………………………………….......... 15 
  Structure activity relationships………………………………………….............. 15 
  GRK2·Gβγ inhibitor crystal structures…………………………………….......... 23 
  GRK5·215022 crystal structure…………………………………………............. 26 
  Molecular basis for potency and selectivity…………………………………....... 28 
  Metabolic stability……………………………………………………….............. 33 
  Contractility in mouse cardiomyocytes………………………………….............. 36 
  Conclusions………………………………………………………………………. 40 
 Second generation of GSK180736A derivatives guided by molecular modeling……... 42 
  Pharmacophore design………………………………………………………........ 42 
  Structure activity relationship……………………………………………………. 44 
vi 
 
  Conclusions………………………………………………………………………. 49 
 Synthesis……………………………………………………………………………...... 50 
Chapter 3: GRK Inhibitors Derived from Paroxetine…………………………………... 56 
 Rationale………….………………………………………………………………......... 56 
 Structure activity relationships…………………………………………………………. 58 
 Evaluation of kinome selectivity……………………………………………………...... 68 
 Crystallographic analysis (benzodioxole paroxetine derivatives) ……………............... 69 
 Crystallographic analysis (indazole paroxetine derivatives) ……………....................... 75 
 Metabolic stability……………...……………...……………...……………................... 83 
 Contractility in mouse cardiomyocytes……………...……………...…………….......... 86 
 Preliminary pharmacokinetic study in mice……………...……………...……………... 88 
 Discussion and conclusions……………...……………...……………...………………. 89 
 Synthesis……………………………………………………………………………...... 91 
Chapter 4: Development of Covalent GRK5 Inhibitors………………………………… 96 
 Rationale……………………………………………………………………….............. 96 
 Structure activity relationships…………………………………………………………. 101 
 Conclusion………………………………………………………………………............ 106 
 Synthesis……………………………………………………………………….............. 107 
Chapter 5: Future Directions in the Expanding Era of GRK Inhibitors………………. 112 
 Further SAR of the GSK2180736A derived inhibitors……………………………… 112 
 Further in vivo studies of the Paroxetine derived inhibitor 258208…………………… 114 
 Improving GRK5 covalent inhibitor potency and evaluation………………………...... 115 
  Proposed SAR……………………………………............................................. 115 
  Proposed analysis to confirm covalent binding………………………………… 118 
 Synthesis……………………………………………………………………………... 119 
 Conclusions and future directions of GRK inhibitors………………………………….. 122 









List of Figures 
Figure 1.1: Mechanisms of β2 Adrenergic receptor mediated PKA activation and G protein-
coupled receptor internalization and degradation…………………………………………........ 4 
Figure 1.2: Crystal structure of  the GRK6· AMP complx………………………..................... 7 
Figure 1.3: Previously reported small molecule GRK Inhibitors……………………………… 9 
Figure 2.1: Superposition of GSK180736A and Takeda103A in Gβγ·GRK2……………… 14 
Figure 2.2: GRK2-Gβγ crystal complexes of 215022, 224062, 224406, and 224411………… 24 
Figure 2.3: Adaptive structural changes in the GRK2 active site………………….…………. 26 
Figure 2.4: Interactions of 215022 within the GRK5 active site………………………………. 27 
Figure 2.5: Structural differences in the hinge regions of PKA, GRK2, and GRK5………….. 28 
Figure 2.6: Comparison of GRK2 and GRK5 hydrophobic binding pockets when bound to 
215022………………………………………………………………………………………..... 30 
Figure 2.7: Molecular origins of selectivity for compound 224406…………………………… 32 
Figure 2.8: Mouse cardiomyocyte contractility of paroxetine, GSK180736A, 215022, 
215023, 224064, and 224406…………………………………………………………………... 36 
Figure 2.9: GSK180736A scaffolds used for the docking run………………………………… 42 
Figure 2.10: Pharmacophore used for molecular docking…………………………………….. 44 
Figure 3.1. Comparison of lead compounds bound in the GRK2 active site suggest that 
extension of the paroxetine scaffold into the hydrophobic subsite is a route towards molecules 
with higher potency and selectivity……………………………………………………………. 57 
Figure 3.2: Kinome Selectivity of 258747 at 1 µM...……………...………………………….. 67 
Figure 3.3: GRK2-Gβγ crystal complexes of 211998, 222886, and 258208………………... 71 
Figure 3.4: Comparison of 258208 and 258747 in GRK2…………………………………….. 74 
Figure 3.5: Crystal complexes of three indazole substituted paroxetine derivatives in the 
GRK2 active site……………………………………………………………………………….. 77 
Figure 3.6: Alignment of indazole paroxetine analogs 224061, 257284, and 258748………… 79 
viii 
 
Figure 3.7: A comparison of the binding modes of structurally similar paroxetine derived 
inhibitors and structurally dissimilar GRK2 inhibitors………………………………………… 82 
Figure 4.1: Previously identified pyrrolopyrimidine based GRK inhibitors and covalent 
inhibitor design rationale………………………………………………………………………. 98 
Figure 4.2: Utilizing the GSK2163632A-GRK1 (PDB ID: 4PNI) crystal complex to design 
similar GRK5 covalent inhibitors……………………………………………………………… 99 
Figure 4.3: Modeling of acrylamide derivatives 258903 (A) and 258904 (B) into GRK5 
(PDB ID: 4WNK) and GRK6 (PDB ID: 3NYN)……………………………………………… 101 
Figure 4.4: Models of dimethyl-butenoic amide analogs overlaid with GSK2163632A……… 105 
Figure 5.1: Potent GRK2 and GRK5 inhibitors identified in our campaign. …………………. 112 
Figure 5.2: Proposed GSK180736A derived inhibitors to probe GRK5 SAR. ………………. 113 
Figure 5.3. Preliminary in vivo efficacy of paroxetine, 258208, and 258747 in a mouse heart 
failure model…………………………………………………………………………………… 115 
Figure 5.4: Adding flexibility to the covalent warhead……………………………………….. 117 


















List of Tables 
Table 2.1: Kinase inhibitory activity of derivatives based on GSK180736A……………….. 16 
Table 2.2: Kinase inhibitory activity of hinge substitutions and N - methylation. ……………. 22 
Table 2.3: GRK1, GRK2, and GRK5 inhibitory activity of select 6C fluoro and chloro 
indazole GSK-hybrid compounds……………………………………………………………… 35 
Table 2.4: Mouse contractility results for GSK180736A at 0.5 and 1 μM………………….. 37 
Table 2.5: Mouse contractility results for compound 215022 from 0.1 μM to 10 μM……… 37 
Table 2.6: Mouse contractility results for compound 215023 from 0.1 μM to 10 μM……… 38 
Table 2.7: Mouse contractility results for compound 224064 from 0.1 to 10 μM…………... 38 
Table 2.8: Mouse contractility results for compound 224406 from 0.1 to 10 μM…………...... 39 
Table 2.9: GRK1, 2, and 5 activity of GSK18073A hybrid compounds designed from 
molecular docking……………………………………………………………………………… 45 
Table 3.1. Kinase inhibitory activity of benzodioxole paroxetine analogs……………………. 62 
Table 3.2. Kinase Inhibitory Activity and Half-Life in Mouse Liver Microsomes of Indazole 
Paroxetine Hybrid Compounds………………………………………………………………… 66 
Table 3.3. Kinase Inhibitory Activity and Half-Life in Mouse Liver Microsomes of Alkylated 
Indazole Paroxetine Hybrid Compounds……………………………………………………….. 68 
Table 3.4: Comparison of MLM stability between paroxetine and GSK180736A analogs…… 85 
Table 3.5: Mouse Cardiomyocyte Contractility of Paroxetine, GSK180736A, and 
Takeda101……………………………………………………………………………………… 87 
Table 3.6: Mouse Cardiomyocyte Contractility of Paroxetine Derivatives……………………. 88 
Table 3.7.  In Vivo Exposure Following IP Administration to Mice…………………………... 89 









List of Schemes 
Scheme 2.1. General preparation of indazole GSK180736A amide linked derivatives………. 50 
Scheme 2.2: Synthesis of halogenated indazole intermediates 2 and 3………………………... 51 
Scheme 2.3: Synthesis of acid intermediate 17…………...…………………………………… 51 
Scheme 2.4: Synthesis of ethanoic acid intermediate 18………………………………………. 51 
Scheme 2.5: Synthesis of propanoic acid intermediate 19…………...………………………... 52 
Scheme 2.6: Synthesis of amide N-methylated analogue 42…………………………………... 53 
Scheme 2.7: Synthesis of the benzodioxole, pyridine, and dichloro phenyl hinge binding 
analogs 52 – 54………………………………………………………………………….……… 54 
Scheme 2.8: Synthesis of 2,6-trifluoromethylbenzamide intermediate 58…...………………... 54 
Scheme 3.1: General synthesis of benzodioxole paroxetine derivatives……………….……… 91 
Scheme 3.2: Synthesis of indazole-substituted hybrid analogues 80 and 81…………………... 93 
Scheme 3.3: Synthesis of intermediates 91 and 92…………………………………………….. 93 
Scheme 3.4: Synthesis of non-carboxamide linked analogs 103-107………………………… 94 
Scheme 4.1: Synthesis of meta-substituted analogues 116 (258904 and 263115)…………….. 107 
Scheme 4.2: Synthesis of para-substituted analogues 121 (258903 and 263045)……………... 108 
Scheme 4.3. Synthesis of intermediate 112………………………………………………….. 109 
Scheme 4.4. Synthesis of intermediate 117……………………………………………………. 109 
Scheme 4.5: Synthesis of meta substituted ethyl amide analogue 129 (262606)……………… 110 
Scheme 4.6: Synthesis of ethyl analogue 131 (262604)……………………………………….. 110 
Scheme 5.1: In progress synthesis of benzylamine analog 146………………………………... 120 










List of Abbreviations 
AC - adenylyl cyclase 
ACE – Angiotensin converting enzyme 
ADP - adenosine diphosphate 
ADME - Absorption, distribution, metabolism, excretion 
AGC - kinase group containing PKA, PKG1 and PKC kinases 
ANOVA - analysis of variance 
AST – active site tether 
ATP - adenosine triphosphate 
βar - beta-adrenergic receptor 
cAMP - cyclic adenosine monophosphate 
CCG - Center for Chemical Genomics (University of Michigan) 
CMPD- compound 
DMSO - dimethyl sulfoxide 
GDP - guanosine diphosphate 
GPCR - G protein-coupled receptor 
GRK - G protein-coupled receptor kinase 
GSK – Glaxo – Smith - Kline 
IC50 - half maximal inhibitory concentration 
LC – liquid chromatography 
xii 
 
MLM - Mouse liver microsome 
MS -  Mass spectrometry 
MW - Molecular weight 
NMR - Nuclear magnetic resonance spectroscopy 
NSAID – Nonsteroidal anti-inflammatory drug 
P-loop - phosphate binding loop 
PDB - protein data bank 
PH - pleckstrin homology domain 
PKA - cAMP dependent protein kinase 
PKC - protein kinase C 
RGS - regulator of G protein signaling 
RH domain - RGS homology domain 
rmsd - root mean square deviation 
ROCK - Rho associated coiled-coiled kinase 
SDS-PAGE - sodium dodecyl sulfate Polyacrylamide electrophoresis 













In heart failure, the β-adrenergic receptors (βARs) become desensitized and uncoupled 
from heterotrimeric G proteins. This process is initiated by G protein-coupled receptor kinases 
(GRKs), some of which are upregulated in the failing heart, making them desirable therapeutic 
targets. Two structurally similar compounds, in both size and shape, were identified as GRK2 
inhibitors via high throughput screening. These compounds are the previously known Rho-
associated coiled-coiled kinase (ROCK) inhibitor, GSK180736A and the selective serotonin 
reuptake inhibitor, paroxetine. Both compounds were subsequently crystallized in the 
Gβγ·GRK2 crystal complex. Comparison of these two compounds in the active site with the 
previously crystallized Takeda101 and Takeda103A inhibitors, which are highly potent and 
selective, shows that paroxetine and GSK180736A do not extend out into a fourth subsite of the 
active site as do the Takeda compounds. We hypothesized that building off of our lead 
compounds into the hydrophobic subsite could improve their potency and selectivity. We 
initially made modifications to the scaffold of GSK180736A finding that larger bulkier 
appendages reaching out into the hydrophobic subsite lead to an increase in both potency and 
selectivity for GRK2 by successfully building out GRK1, GRK5, and ROCK inhibition. On this 
scaffold we also identified a pan GRK inhibitor, 215022, which led to one of the first crystal 
structures of GRK5. Crystallization of GRK5 with one of our inhibitors allowed us to compare 
the two active sites, revealing that GRK2, in general, has a larger hydrophobic subsite, whereas 




 These structure activity relationships (SAR) were then investigated with paroxetine, 
which is a more drug-like scaffold that might result in compounds with higher therapeutic 
potential. Unfortunately our SAR was not transferable. Further exploration of the SAR of the 
paroxetine scaffold led to a series of paroxetine derivatives containing small heterocyclic 
appendages that were advantageous to GRK2 potency. Included in this series is a highly potent 
and selective GRK2 inhibitor, 258208, with an IC50 of 30 nM against GRK2 and greater than 
230-fold selectivity over other GRKs and ROCK1. Crystallization of 258208 with Gβγ·GRK2 
revealed an additional three hydrogen bonds were being made via an added amide linked 
pyrazole explaining the significant 46 – fold increase in potency relative to paroxetine. Replacing 
the benzodioxole of 258208 with an indazole increased GRK2 potency to 8 nM, while 
maintaining 30–fold and >550-fold selectivity over GRK 5 and 1, respectively. Comparison of 
the GRK2-Gβγ crystal complexes of the indazole paroxetine derivatives to the benzodioxole 
paroxetine derivatives showed that the compounds make the same hydrogen bonds but the 
indazole derivatives tend to form slightly tighter hydrogen bonds in the hinge leading to an 
overall more closed conformation of the kinase domain. Furthermore, 258208 showed a 100-fold 
improvement in cardiomyocyte contractility assays over paroxetine, a plasma concentration 
higher than its IC50 for over seven hours, and is currently under investigation in heart failure 
mouse models for its ability to exhibit cardioprotective effects.  
In addition to development of potent GRK2 inhibitors we began a preliminary study to 
develop covalent GRK5 inhibitors. GRK5 contains a non-conserved cysteine (Cys474) on the 
active site tether that can be targeted by molecules binding to the active site of the kinase 
domain. Our initial compounds included both saturated and unsaturated acrylamides so that we 
could identify if we were achieving covalent inhibition. We synthesized two regioisomers of the 
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acrylamides off of a phenyl ring in the core scaffold. Of the two regioisomers synthesized one 
seems to be more favorable for general potency while the other gives evidence of binding 
covalently in the active site. Further analogs and biochemical testing are proposed to advance 







Chapter 1: Introduction and Background 
 
Heart Failure Background and Pathophysiology:  
Heart failure is the loss of the heart’s ability to effectively contract and pump blood to the 
rest of the body. This disease affects 5.7 million people in the United States alone (~2.2% of the 
population) with annual patient mortality rates of 25-30%.
1 
 The mortality rate then rises to 50% 
within five years of diagnosis.
1
 Approximately 670,000 new cases are diagnosed annually in the 
United States and 2 million new cases are diagnosed annually worldwide.
1, 2
  Hospitalizations for 
heart failure are currently higher than any other disease in the United States and Europe, 
contributing to the nearly $39 billion spent on heart failure treatment in the United States 
annually.
1, 3, 4
 Despite current therapies on the market, deaths due to heart failure continue to rise, 
creating a need for new therapies. 
Typical causes of heart failure are coronary artery disease, heart attacks, and 
hypertension. Less typically, infection, alcohol, and valvular dysfunction can lead to heart 
failure.
2, 5
 The heart’s inability to distribute blood throughout the body results as a function of 
inadequate pumping and relaxation the heart muscle due to stiff or weakened tissue.
5, 6
 In 
response to the failing heart, the sympathetic nervous system (SNS) is activated to produce 
cardioprotective effects
7
 and increases the levels of circulating catecholamines such as 
norepinephrine and epinephrine.
8-10
 Upon binding of these hormones to β-adrenergic receptors 
2 
 
(βARs) in cardiomyocytes, downstream signaling is initiated to improve the positive inotropic 




G protein-coupled receptor signaling and β adrenergic receptors 
The βARs are part of a larger family of receptors known as G protein-coupled receptors 
(GPCRs). GPCRs mediate cellular responses to many different kinds of extracellular stimuli
13
 
and, with over 800 members, they are the largest class of receptors in the human genome. Given 
their many physiological roles, they are targeted by a large fraction (30 – 50%) of the 
pharmaceuticals on the market, as well as illicit drugs.
14
 Upon agonist binding, GPCRs recruit 




There are three βAR subtypes, β1, β2, and β3, of which, the β1ARs and β2ARs are 
primarily responsible for signaling in the myocardium.
16-20
 β1ARs comprise 75-80% of the 
cardiac βARs.
16, 17
 Activation of the βARs via catecholamine binding leads to a conformational 
change in the receptor affecting the heterotrimeric G proteins, which consist of Gα, Gβ, and Gγ 
(Figure 1.1). This conformational change allows for the exchange of GTP for GDP on the Gα 
subunit. After release of GDP, the subunits dissociate into Gα-GTP and Gβγ.
21
 In the case of the 
stimulatory G protein, Gαs, this activation sequence leads to stimulation of adenylyl cyclase 




The second messenger cAMP, then activates cAMP – dependent protein kinase A (PKA). 
Activation of PKA phosphorylates several downstream proteins important for calcium 





 The proteins collectively increase Ca
2+
 levels in cardiomyocytes by 
increasing Ca
2+ 
efflux, reuptake, and myofilament sensitivity.
17
 This initial βAR signaling is 
beneficial to the heart, leading to increased cardiac fuction.
26
 This overstimulation of SNS 
catecholamine signaling, via the Gβγ heterotrimeric subunits, additionally leads to recruitment of 
GPCR kinases (GRKs) to the βARs, which regulate GPCRs through phosphorylation of serine 
and threonine residues on their cytoplasmic loops or tails.
11, 27
 In response to this 
phosphorylation, β-arrestins are recruited to the receptors to induce internalization of the GPCRs 
and promote β-arrestin dependent pathways.
28, 29
 Continuation of this regulatory cycle leads to 
desensitization and uncoupling of the βARs from G proteins,
8, 30, 31
 decreased βARs at the 
cellular membrane, and decreased cardiac output in response to hormonal stimulation. 
10, 26, 32
 
Current frontline heart failure therapeutics, such as β-blockers and angiotensin converting 
enzyme (ACE) inhibitors, target this mechanism by antagonizing βARs and reducing blood 
pressure, respectively.
33
 β-blockers take four to six weeks to ameliorate dysregulation of βARs 
and produce cardio protective effects.
34
 Furthermore, long term use of β-blockers leads to a 
myriad of side effects resulting from bradycardia such as dizziness, weakness, and low blood 
pressure.
35
 The inhibition of GRKs may serve as an alternative mechanism or a beneficial 
addition to β-blocker therapy to renormalize the βAR cascade and catecholaminergic axis and 







Figure 1.1: Mechanisms of β2 adrenergic receptor mediated PKA activation and G protein-
coupled receptor internalization and degradation. Upon agonist (pink circle) binding to the 
β2AR (purple) the heterotrimeric G-protein dissociates (Gα: blue, Gβγ: yellow). Activated Gα 
couples to adenylyl cyclase (AC: red oval) which promotes stimulation of PKA via production of 
cAMP. GRK (green) binds Gβγ and phosphorylates the β2AR leading to βarrestin (βArr: blue) 
recruitment and binding. βArr then promotes the endocytosis and internalization of the receptor. 
 
 
G protein-coupled receptor kinases 
There are seven known GRKs in humans, subdivided by homology into three sub-
families: GRK1, GRK2, and GRK4. The GRK1 subfamily consists of GRK1 and GRK7, and 
their expression is largely confined to the retina. The GRK2 subfamily consists of the 
ubiquitously expressed GRK2 as well as GRK3, which predominates in olfactory neurons. The 
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GRK4 subfamily consists of GRK4, which is mainly expressed in the testes and kidneys, and 




In the failing heart, activation of βARs also leads to upregulation of GRK2 and GRK5 
31, 
36, 43
 which leads to receptor internalization and decreased cardiac output.
26, 32
 Inhibition of 
GRK2 disrupts internalization of βARs, leading to an increase in activated βARs and other 
GPCRs on the cell membrane that will allow the heart to remain responsive to the sympathetic 
nervous system.
11, 12
 The effectiveness of targeting GRK2 has been demonstrated in mice. 
Cardiac-specific inhibition of GRK2 using adeno-associated viral delivery of βARKct, a portion 
of the c-terminus of GRK2 that acts to sequester Gβγ, following myocardial infarction led to 
improvement in both cardiac function and survival.
44
 Furthermore, βARKct mediated GRK2 
inhibition in several animal models, including swine, indicates that inhibition of GRK2 activity 
improves contractile function, reduces catecholamine levels, and reverses cardiac remodeling.
45
  
Notably, both GRK2 and GRK5 also act in non-GPCR pathways that are beneficial to the 
heart.
46, 47
 GRK2 influences cardiac glucose uptake leading to abnormal cardiac metabolism 
when upregulated, effecting the growth of new cardiomyocytes.
46
 Uniquely, GRK5 is the only 
known GRK that can be localized in the cell nuclei of cardiomyocytes
48, 49
 where it acts as a 
histone deacetylase (HDAC) kinase.
47
 Phosphorylation of HDAC5 leads to increased expression 
of the myocyte enhancer factor-2 which regulates the stress response in hypertrophy.
50, 51
 
Furthermore, knockdown of GRK5 in mice subjected to transverse aortic constriction showed 
cardio protective effects for hypertrophy 
52, 53
 Due to these GPCR independent benefits, GRK2 
and GRK5 serve as promising targets that offer unique therapeutic mechanisms that cannot be 
attained by current heart failure treatments. Because much is still unknown about the role of 
6 
 
GRK5 in the body, potent inhibitors for GRK5, either as GRK5-selective or dual GRK2/GRK5 
inhibitors, would also serve as tools to investigate synergistic GRK inhibition. 
  
AGC kinase domain structure: 
All GRKs belong to the protein kinase A, G, and C (AGC) family and their kinase 
domains share ~31% sequence identity with that of protein kinase A (PKA).
54
 The catalytic 
domain of AGC kinases is comprised of three key features (Figure 1.2A). The first is the small 
lobe of the kinase domain, primarily constructed of beta strands, the second is the large lobe of 
the kinase domain, primarily constructed of alpha helices, and the third is a C-terminal extension 
(C-tail) that is passes over the active site formed between the small and large lobes.
37
 The C-tail 
is further separated into three structural regions: the N-lobe tether, the active site tether (AST), 
and the C-lobe tether.
37, 55
 The AST is highly variable in sequence among the AGC kinases, and 
is typically the most disordered region in crystal structures of AGC kinase domains when they 
are in an inactive conformation.
42, 55, 56
    
The AGC kinase active site is formed between the small and large lobes and is where 
ATP and most small molecule AGC kinase inhibitors bind. Joining the two lobes of the kinase is 
the hinge which forms specific contacts to the adenine ring of ATP. The active site can be further 
subdivided into four subsites: the adenine subsite, adjacent to the hinge region of the kinase, the 
ribose subsite, the polyphosphate subsite, and the hydrophobic subsite (Figure 1.2B). The former 




Figure 1.2: Crystal structure of the GRK6·AMP complex. A) Overall view of the kinase 
domain with the regulator of G-protein signaling homology (RH) domain (grey). The small and 
large lobes of the kinase are colored in yellow and green, respectively. The C-tail is colored in 
cyan (C-lobe and N-lobe tethers) and pink (AST). B) Close up view of bound AMP labeling the 
subsites within the active site. The adenine subsite is highlighted in blue, the ribose subsite is 
highlighted in red, the polyphosphate subsite is highlighted in grey, and the hydrophobic subsite 




The first inhibitors of GRK2 reported were the polyanions heparin and dextran sulfate.
57
 
These compounds were fairly potent, both having a GRK2 IC50 = 0.15 µM, but due to their 
highly charged nature their utility as drugs or in vivo probes is limited.
37, 57
 Shortly thereafter, 
synthetic peptides derived from the first intracellular loop and C-terminus tail of hamster β2AR 
were reported as inhibitors, with the most potent (residues 56 – 74) having a modest IC50 of 40 
µM and poor solubility.
58
 Further optimization of these peptide inhibitors via addition of charged 







 Additional peptide sequences designed from the regulator of G-protein signaling 
homology (RH) domain and the N-terminus of GRK5 were reported to have pan GRK inhibitor 
activity but were more potent for PKA (IC50 = 3.2 – 5.3 µM).
61
 These peptides were further 
tested in cellulo to show that they could inhibit β2AR phosphorylation upon stimulation of the 
receptors to the β2AR agonist isoproterenol.
61
  
High potency and selectivity for GRK2 were achieved by AN RNA aptamer, C13, via 
systematic evolution of ligands by exponential enrichment (SELEX). This C13 RNA aptamer 
exhibited a GRK2 IC50 = 4.1 nM in rhodopsin phosphorylation assays with 20-fold selectivity 
over GRK5, which exhibited an IC50 = 79 nM. The C13 RNA aptamer additionally showed 
almost no detectable inhibition against a panel of 14 kinases, including PKA.
62
 A variant of the 
C13 RNA aptamer, C13.18, was later crystallized with GRK2 at 3.5 Å revealing that these 
aptamers bind to the cleft between the two kinase domains in the active site as well as basic 
regions to the large lobe.
63
 
A number of small molecule kinase inhibitors have been reported (Figure 1.3). Some 
early small molecule inhibitors were nucleoside-based, but exhibited poor potency.
64, 65
 A 
virtual screen led to the identification of a set of poor GRK2 inhibitors (IC50 = 130 µM to 400 
µM) with at least ten-fold selectivity over PKA.
64
 A more recent report identifies a series of 3-
(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives, some 
of which are highly potent for GRK2 and GRK5. Compound 1o from this study has a GRK2 IC50 
= 0.46 µM and is even more potent against GRK5 with an IC50 = 0.059 µM.
66
 This is currently 
one of the most potent reported GRK5 inhibitors as well as one of the few small molecule 
inhibitors that exhibits selectivity for GRK5 over GRK2. In addition to GRK activity, compound 






Figure 1.3: Previously reported small molecule GRK Inhibitors. 
The natural product balanol inhibits GRK2 with an IC50 of 50 nM (at 3 µM ATP), but 
also potently inhibits PKA and PKC.
68, 69
 Takeda Pharmaceuticals developed a series of 
compounds, including Takeda103A and Takeda101 (IC50 = 20 nM and 30 nM, respectively with 
>50-fold selectivity over other AGC kinases). In the presence of 500 µM ATP, both inhibitors are 
completely selective for GRK2.
70
 Despite their impressive in vitro profile, these compounds 
never advanced to clinical trials, presumably due to poor bioavailability. All three of these 





 All stabilize an inactive conformation of GRK2, and their C and D rings pack into 
the polyphosphate and hydrophobic subsites, respectively, which likely contributes to their high 
potency and selectivity.
70
 Although these compounds never advanced to clinical trials, they 
served as proof of principle for development of new GRK2 inhibitors in our laboratory.
71
  
Utilizing displacement of the previously reported highly potent and selective C13 RNA 
aptamer as a screen, the Tesmer lab identified GRK2 inhibitors that would bind to the kinase 
domain.
72
 From this screen the FDA-approved serotonin-reuptake inhibitor, paroxetine 
hydrochloride, was identified as a modest GRK2 inhibitor with an IC50 of 1.4 µM.
62, 72
 In vivo 
investigation in a mouse heart failure model revealed that paroxetine improves cardiac function 
post-myocardial infarction and renormalizes the levels of catecholamines and β-adrenergic 
receptor density in the heart, effects that persist for up to two weeks post-treatment.
73
 
Additionally, treatment of mice post myocardial infarction with paroxetine alone or in 
conjunction with the β-blocker metoprolol was more effective at reversing heart failure than 
metoprolol alone.
73
 Paroxetine provided the first in vivo proof of concept for beneficial small 
molecule inhibition of GRK2. 
 Further optimization of paroxetine utilized its co-crystal structure with GRK2-Gβγ in an 
effort to create stronger hinge interactions with the backbone residues of Asp272 and Met274. 
The benzodioxole of paroxetine was replaced with a lactam moiety to give CCG206583. 
Replacement of the benzodioxole by a benzolactam led to shorter hydrogen bonds in the 
hinge, 2.8 and 2.7 Å in CCG206583 instead of 2.9 and 3.4 Å for their equivalents in the 
paroxetine GRK2-Gβγ complex.
74
 Unfortunately, these improved hinge binding interactions also 
led to improved binding to PKA and PKC relative to GRK2 indicating that strengthening the 
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An additional high throughput screen of a library of known kinase inhibitors, compiled 
by the Structural Genomics Consortium at the University of Oxford, utilizing differential 
scanning fluorimetry identified a series of sub-family selective kinase inhibitors. Of these, was a 
potent GRK2 inhibitor, GSK180736A with an IC50 of 0.8 μM, a compound that is similar to 
paroxetine in both size and shape.
75
 This compound was originally developed as a Rho-
associated coiled-coil containing kinase 1 (ROCK1) inhibitor (IC50 = 100 nM), but exhibited 
limited bioavailability.
76
 Crystallization of GSK180736A with GRK2-Gβγ revealed that the 
indazole forms analogous hydrogen bonds in the hinge of the kinase as those observed with the 
benzodioxole and benzolactam of paroxetine and CCG206583. GSK180736A crystallizes in the 
same space group as the benzo lactam derivative indicating the effects of the hinge binding 
moiety to the overall conformation of the kinase.
74, 75
  
 Apart from the GRK2 potent compound, GSK180736A, several other potent GRK1 and 
GRK5 inhibitors were identified from this high throughput screen. These other compounds 
shared in common a pyrrolopyrimidine core. The previously known insulin growth like factor 
receptor 1 inhibitor, GSK2163632A, was identified as a potent GRK1 inhibitor with an IC50 = 
130 nM. Two modestly selective pyrrolopyrimidine GRK5 inhibitors were also identified 




 Despite the increasing repertoire of various small molecule GRK inhibitors there are few 
that are submicromolar and highly selective. Additionally, of those that do exhibit high potency 
or selectivity, their poor bioavailability or high polar surface area limit their utility as potential 
12 
 
therapeutics. With the advent of more recent small molecule GRK inhibitors in complex with 
GRKs 1, 2, and 6 there is a solid foundation for the rational design and development of improved 
GRK2 and GRK5 inhibitors. This thesis focuses on the development of highly potent and 
selective GRK2 inhibitors with potential for in vivo utility, and concludes with more preliminary 




























Efforts to develop a potent and selective GRK2 inhibitor upon the GSK180736A scaffold 
were initially prioritized as it was almost two-fold more potent than paroxetine and its ease of 
synthesis was advantageous over analogous paroxetine derived inhibitors. Although 
GSK180736A is a potent ROCK1 inhibitor it was envisioned that we could design out the 
ROCK1 inhibition while creating a more potent GRK2 inhibitor. Utilizing this more 
synthetically feasible scaffold we could build a library of compounds that would probe the SAR 
of GRK2 and then hopefully translate our findings into the more pharmacokinetically promising 
scaffold of the FDA approved drug paroxetine. 
Design of the GSK180736A derived GRK2 inhibitors began with the GRK2 crystal 
structure of the potent and selective inhibitor Takeda103A. Structural and functional analysis of 
the GRK2·Takeda103A complex (PDB entry 3PVW) suggests that the selectivity of compound 
Takeda103A for GRK2 results from its ability to recognize a conformation that is more readily 
accessible to GRK2 than to the other GRKs.
70
 Docking of Takeda103A into the inactive 
conformations of GRK1 and GRK6 predicts steric clashes (not shown here – see Thal et. al. 
2011) of the terminal difluorophenyl ring of Takeda103A with residues that form what is 
referred to as the hydrophobic subsite (Figure 2.1
phosphate in the ATP binding site.
70
 Alignment of the crystal complexes of Takeda103A and 
                                                          
1
 This chapter includes published work  reported in Homan et. al. JBC, 2015 and Waldschmidt et. al. JMC, 2016. 
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GSK180736A in GRK2 (Figure 2.1) revealed that although the compounds are chemically 
unrelated, they occupy the adenine, ribose, and P-loop subsites of the ATP-binding pocket in 
remarkably similar ways. However, unlike Takeda103A, GSK180736A does not have a 
substituent that can occupy the hydrophobic subsite.
75
 We hypothesized that extending the 
scaffold of GSK180736A into the hydrophobic subsite would increase potency and, potentially, 
selectivity against other AGC kinases such as PKA and ROCK1.
56
 Utilizing a hybrid approach, 
we added moieties to the position ortho to the fluorine of the C ring of GSK180376A through an 
amide linker appending a fourth aromatic ring. 
 
Figure 2.1: Superposition of GSK180736A and Takeda103A in Gβγ·GRK2. The 
hydrophobic subsite is unexploited in the Gβγ·GRK2-GSK180736A complex. Shown is a 
superposition of the small lobes of GRK2 in complex with GSK180736A (salmon) and 
Takeda103A (purple) (PDB entries 4PNK and 3PVW, respectively). Hydrophobic surfaces are 









First Generation of GSK180736A Derivatives: 
Biochemical Evaluation. Kinetic activity of the compounds were evaluated in vitro 
against bovine GRK1, 2, and 5 as well as PKA and ROCK1. The GRK assays measured the 
phosphorylation of tubulin (500 nM)  in the presence of GRK (50 nM) and ATP (500 µCi. 5 µM) 
with varying doses of inhibitor. All assays were run with a negative (no inhibitor) control and 
one or two positive controls (paroxetine or GSK180736A).  The resulting data was then fit to a 
Hill slope of 1 and analyzed in GraphPad Prism to give IC50 values. All reported IC50 values are 
the mean of three independent experiments run in duplicate. PKA and ROCK1 inhibition assays 
were performed using the ADP-Glo Kinase Assay system (Promega). This kinetic assay 
indirectly measured the phosphorylation of a small peptide substrate, either CREBTide or 
KEMPTide (100 µM), by PKA or ROCK1 (50 nM) in the presence of ATP (100 µ) and varying 
doses of inhibitor.  Luminescence was measured using a BMG Labtech PHERAstar imaging 
system, and inhibition curves were analyzed using GraphPad Prism. More complete 
experimental protocols are found in Chapter 6 – Experimentals. 
Structure–Activity Relationships. Our hybrid design utilized an amide linker between 
the template of GSK180736A and the new substituents intended to fill the hydrophobic subsite 
of GRK2 to give a small library of compounds (Table 2.1). Although it was hypothesized that 
addition of a methyl amide group alone would establish an extra hydrogen bond interaction with 
the P-loop of GRK2 similar to that observed in the crystal complex with Takeda103A, prototype 
compound 224409 exhibited a 5-fold loss in potency against GRK2. However, the compound 
maintained selectivity against GRK1 and GRK5. It is possible that the additional hydrogen bond 
formed by the amide with the enzyme cannot overcome a desolvation penalty or an entropic 
penalty for fixing the conformation of the P-loop. Notably, incorporation of the methyl amide did 
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result in a favorable loss in potency against PKA (IC50 > 100 μM). The carboxylic acid derivative 
7, on the other hand, gave a dramatic 20-fold decrease in potency for GRK2 and only a 2-fold 
loss against PKA.  
As both Takeda103A and balanol place an aromatic ring into the hydrophobic pocket of 
GRK2, we introduced a benzyl amide (224407), which was essentially equipotent with the lead 
(GSK180736A) with respect to GRK2 and ROCK1, but gained substantial potency for GRK5.
68, 
70
 Adding a single fluorine atom in the meta position of the benzyl (221302) resulted in a “pan” 
GRK inhibitor, in that it inhibited GRK1, 2 and 5 but lacked PKA activity. The results with both 
224407 and 221302 suggest that addition of lipophilicity to the amide appendage is a path to 
higher potency, but not necessarily GRK2 selectivity. Incorporation of the 2,6-difluorobenyzl 
amide (215023), the same D ring as in Takeda103A, did not improve upon the GRK2 potency of 
the 3-fluorobenzyl amide, but restored selectivity for GRK2 versus GRK1 and GRK5, providing 
a clue that the size of the amide substituent may be an important selectivity determinant among 
GRKs.  
























GSK180736A H 0.77±0.5 >100 >100 30±19 0.10±0.09 
7 COOH 20±10 >100 >100 78.1±72 0.19±0.14 
224409 CONHMe 4.3±0.7 >100 >100 >100 0.56±0.68 











0.22±0.2 >100 5.0±1.2 >100 0.11±0.084 
221303 
 
0.060±0.03 16±6.4 2.3±2.7 >100 0.057±0.044 
224414 
 
0.42±0.05 >100 3.8±0.9 >100 0.097±0.076 
221304 
 









0.28±0.1 >100 6.2±3.8 >100 0.023±0.022 
222882 
 






1.8±0.54 ND 0.012±0.004 
224063 
 
0.13±0.03 >100 >100 >100 6.7±8.2 
224064 
 
0.07±0.01 >100 63±32 >100 5.8±5.5 
224406 
 
0.13±0.03 >100 >100 >100 0%* 
224413 
 
1.2±0.7 >100 >100 >100 22%* 
224410 
 
2.7±2.3 >100 >100 >100 1.9±0.25 
224412 
 





25±12 >100 88±60 >100 0.45±.28 
232401 
 
>100 >100 >100 >100 0.40±0.32 
232405 
 
0.45±0.29 >100 >100 >100 0.20±0.05 
224411 
 
0.23±0.05 >100 58±13 >100 0.29±0.033 
*All IC50 measurements are an average of three separate experiments run in duplicate. Errors 
shown represent standard error of the mean. *Percent inhibition at 10 µM inhibitor 
concentration. 
 
Next, the effect of adding polar groups to the D-ring extension was explored as the D-
ring of balanol has two polar groups in the 2 and 6 positions. The 2-methoxy benzyl amide 
221303 gave a 13-fold increase in potency against GRK2 (IC50 = 60 nM) with selectivity of 270- 
and 38-fold over GRK1 and GRK5, respectively. Unfortunately, 221302 retained potency against 
ROCK1 (IC50 = 57 nM). Movement of the methoxy substituent around the benzyl ring to the 
meta (224414) and para (221304) positions resulted in a significant loss of potency compared to 
the 2-methoxy benzyl amide (221303) for GRK2 and GRK1, but was more tolerated in GRK5 
and ROCK1. Further investigation of the ortho position of the benzyl ring led to the 2-
pyridylmethyl amide analog 215022 which showed little selectivity among the GRKs and 
ROCK1 (thus a pan-inhibitor) having sub-µM affinity for all 3 GRKs and exhibiting a 10-fold 
increase in potency over GSK180736A for ROCK1. Extending the linker between the amide 
bond and the terminal pyridine ring by one carbon (215024) substantially improved selectivity in 
comparison to 215022 against GRK1 and GRK5 but somewhat reduced inhibition of GRK2. The 
4-pyridyl ethyl amide (222882) was not well tolerated by any of the GRKs, suggesting the 
importance of the 2-pyridyl nitrogen to binding. 
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 We next investigated the potential of increasing the size of the pyridine of 215022 to an 
isoquinoline (224062), which improved selectivity against GRK5 6.4-fold (versus 2.5-fold for 
215022). However, there was no change in ROCK1 inhibition between 215022 and 224062 (both 
~10 nM). Interestingly, 224062 achieved the highest potency and selectivity for GRK1 with an 
IC50 of 100 nM – a 50-fold increase in comparison to the 2-pyridylmethyl analog 215022 and a 
greater than 100-fold increase in comparison to the parent compound GSK180736A. 
 As the 2,6-difluorobenzyl (215023) showed marginally improved selectivity in 
comparison to the unsubstituted benzyl 224407, the potential for achieving greater selectivity for 
GRK2 by further increasing the size of the D-ring amide substituents was explored.  Both the 
2,6-dichloro (224063) and the 2,6-dimethyl (224064) resulted in dramatic improvements in 
GRK2 selectivity. Both analogs had over 770-fold selectivity against GRK1 and GRK5, as well 
as 50-fold (224063) and 80-fold (224064) selectivity against ROCK1. Thus, for the first time we 
observed that ROCK inhibition can be mitigated via the introduction of steric bulk into the 
hydrophobic subsite. Extending this line of reasoning to the larger dimethoxy (224406) and di-
trifluoromethyl (224413) analogs essentially eliminated all kinase inhibitory activity except for 
GRK2. The dimethoxy analog 224406 retains excellent potency against GRK2 compared to the 
parent compound (0.13 versus 0.77 µM) and is one of our most selective GRK2 inhibitors. 
Compared to the 2-methoxy benzylamide analogue 221303, addition of the second methoxy in 
224406 was clearly a key step in building in selectivity for GRK2 (over 175-fold decrease in 
potency at ROCK1, 6-fold at GRK1, and 43-fold at GRK5). Moving the added bulk to the meta 
positions (with the 3,5-bis(trifluoromethyl)benzyl amide 224410)  produced a profound loss in 
GRK2 potency revealing that the 2,6 disubstitution pattern of the D ring is critical for potency 
and selectivity. The remarkable impact of sterics on GRK2 selectivity is further highlighted by 
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comparing 2-pyridyl amide 215022 with the corresponding ortho-methyl analog 224412. The 
latter compound, although less potent at GRK2, had increased selectivity versus GRK1 (>50-
fold) and GRK5 (36-fold) versus 215022 (33-fold and 2-fold, respectively). 
 In general, homologating the amide substituent led to decreases in potency and 
selectivity. This was particularly evident with 232400 and 232401. In each case, GRK2 potency 
dropped precipitously and, oddly, sub-µM ROCK1 activity returned. Homologation of 224406 
(232405) resulted in a less dramatic decrease in GRK2 potency, but also restored ROCK1 
inhibition. The pattern continued with homolog 224411, which has decreased GRK2 potency and 
increased ROCK1 potency versus the shorter 224064.  
We briefly explored replacing the indazole moiety of the GSK180736A derivatives, 
which binds to the hinge of the kinase domain, with the benzodioxole group of paroxetine (Table 
2).
72
 Because paroxetine has excellent selectivity for GRK2 versus ROCK1, we anticipated that 
the benzodioxole might increase selectivity. Despite the potent pan-kinase inhibition of 215022, 
the corresponding benzodioxole analog 222682 that incorporated the pyridine substituent in the 
hydrophobic subsite was completely inactive. Several other benzodioxole analogs of other 
hybrids were similarly inactive with the 3 – methoxy benzylamide analog 222885 being the most 
GRK2 potent of these compounds at a very modest IC50 of 16 µM. Perhaps the added length of 
the meta methoxy allowed the substituent to pack more effectively into the hydrophobic subsite. 
Moving the methoxy to the para position (222880) annulled the activity again indicating that 
perhaps then it was too lengthy and could not pack effectively. Overall this series of 
benzodioxole hinge binding GSK180736A compounds were poor GRK inhibitors. 
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To further explore the SAR of the hinge binding moiety to improve selectivity of this 
scaffold a 4-pyridine was installed, as this is the hinge binder in the highly selective GRK2 
inhibitor Takeda101,
77
 and a 3,4 dichlorophenyl was installed, as incorporation of halogen 
mediated hinge binders has resulted in other highly selective kinase inhibitors.
78, 79
 Both the 4 – 
pyridine and the 3, 4 di-chloro phenyl were incorporated onto the dihydropyrimidine core of  
GSK180736A with an amide linked 2-pyridine reaching into the hydrophobic subsite to give 
analogues 224405 and 222887, respectively. Both 224405 and 222887 showed poor or no 
inhibition across all three GRKs and PKA. In addition to the benzodioxole hinge binding 
derivatives these further analogues exploring alternative, looser, hinge binding moieties to give 
added selectivity further confirm the need of a tight hinge binding moiety on this scaffold, such 
as the indazole, to induce binding of the inhibitor to the kinase. Due to their poor GRK inhibition 
profiles these compounds were not further evaluated against ROCK1. 
 In a final attempt to further design out ROCK1 affinity, the nitrogen of the amide bond 
linking the indazole and the dihydropyrimidone core was methylated. Prior crystallization of a 
close analog of GSK180736A into ROCK1 revealed that the amide nitrogen forms a water-
mediated hydrogen bond to ROCK1-Asp216,
76
 and therefore, methylation of the amide would be 
expected to weaken its affinity. The methylated amide of potent hybrid 224064 was thus 
synthesized. The resulting compound 224408 however showed ROCK1 potency similar to 
224064 having an IC50 of 2.1 µM, and a nearly 70-fold decrease in potency at GRK2, 





Table 2.2: Kinase inhibitory activity of hinge substitutions and N - methylation.  
 

































































4.6±3.0 >100 >100 >100 
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All IC50 measurements are an average of three separate experiments run in duplicate. Errors are 




 To gain insight into the molecular basis for 
the relative potency and selectivity of this series of compounds, 215022, 224062, 224406, and 
224411 were each co-crystallized with GRK2–Gβγ and their resulting X-ray crystal structures 
were determined (Figure 3). All four complexes crystallized in space group C2221 with nearly 
identical unit cell constants with resolution limits ranging from 2.56 Å – 3.26 Å. In comparison 
to the previously reported structure of GSK180736A in complex with GRK2–Gβγ (PDB entry 
4PNK)
75
, all four inhibitor complexes exhibit nearly identical kinase domain conformations with 
differences in relative rotations between the large and small lobes no greater than 1˚. This result 
is consistent with the idea that the indazole, which occupies the adenine subsite and forms two 
hydrogen bonds with the hinge of the kinase domain, dictates the overall conformation of the 
large and small lobes.
56, 75
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Figure 2.2. GRK2-Gβγ crystal complexes of 215022, 224062, 224406, and 224411. Co-crystal 
structures reveal that the inhibitors bind in the ATP-binding pocket in a similar conformation as 
the compound 2 parent structure. 3σ |Fo| – |Fc| omit maps of compounds 215022 (a), 224062 (b), 
224406 (c), and a 2σ |Fo| – |Fc| omit map of 224411 (d) are represented as magenta wire cages 
superimposed onto the refined X-ray crystal structures. Hydrogen bonds with the labeled GRK2 
residues are shown as black dashed lines. The P-loop and hinge region are indicated for 
reference. 
 
As expected, the four inhibitors bind in the ATP pocket of GRK2 in essentially the same 
manner as the parent compound GSK180736A, with the exception that the amide bond 
connecting the indazole and the dihydropyrimidine is flipped relative to the binding pose of 
GSK180736A (Figure 2.2). However, the electron density for this amide in the complex with 
GSK180736A is ambiguous and hence the linker may adopt multiple configurations in the 
previous structure. As noted above, the indazole rings bind in the adenine subsite forming two 
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hydrogen bonds with backbone atoms of the hinge residues Asp272 and Met274, and the 
dihydropyrimidine and fluorophenyl rings fill the ribose and polyphosphate subsites, 
respectively. However, the presence of the D-rings, and presumably their interactions in the 
hydrophobic subsite, seems to alter the conformation of the A-C rings to some extent among the 
four complexes (Figure 2.3). Compared to the GRK2–Gβγ·GSK180736A complex, the 215022, 
224062, and 224406 compounds form additional hydrogen bonds in the ribose subsite with 
Asp335 and Asn322. As predicted, their variable amide-linked D-rings occupy the hydrophobic 
subsite of GRK2, and the carbonyls of the amide bond linker ortho to the fluorine atom in the C-
ring form a hydrogen bond with the backbone nitrogen of Phe202 in the P-loop. The D-ring of 
224411, however, flips out of the hydrophobic site towards the solvent, and there is no 
interpretable electron density beyond the amide linker. 
The largest conformational changes induced by the various inhibitors occur in the P-loop 
(Figure 2.3). Relative to GSK180736A, each of the four inhibitors causes the P-loop to shift 
away from the polyphosphate subsite as if to accommodate the terminal aromatic rings. 
Compounds 215022, 224406, and 224411 each have a maximum P-loop shift of 2.2 Å at the 
Gly201 Cα relative to the parent structure (GSK180736A). Compound 224062 demonstrates the 
largest P-loop shift of 3.0 Å, possibly because it has the bulkiest substituent. In addition, the 
benzene ring of Phe202 rotates to allow space for the terminal aromatic substituents depending 
on their orientation (Figure 2.2). Notably, AST loop residues 487-493, which are typically 
ordered in active conformations of AGC kinases, but are disordered in most GRK2 kinase 
domain structures to date, are visible in the 224406 electron density map and pack on top of the 
P-loop. It is unclear why these residues are more ordered in the 224406 complex relative to the 
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others, but the density may simply reflect the higher quality of this particular crystallographic 
data set. 
 
Figure 2.3. Adaptive structural changes in the GRK2 active site. Compared to the P-loop 
conformation when bound to compound 2 (green), the Cα carbon of Gly201 shifts away from the 
binding site by 2.2 Å when bound to compound 224406 (blue), 215022 or 224411 (not shown), 
and by 3.0 Å when bound to 224062 (orange). The magnitude of the shift thus appears to depend 




 In addition to the GRK2–Gβγ·inhibitor crystal 
structures a crystal structure of 215022 bound to GRK5 was obtained (Figure 2.4).
56
 Previously, 
there had been no crystal structures of GRK5 (now there exists three, including this one). This 
new crystal structure serves as an excellent tool for further selectivity rationale and development 
as outlined in the next section of this chapter. This is the only crystal structure of GRK5 bound to 
one of our inhibitors. The other two GRK5 crystal structures are complexes of the non-
hydrolyzable ATP analogue AMP-PNP and the pan-kinase inhibitor sangivamycin.
80
 
                                                          
3
 This crystal structure was determined by Kristoff Homan. 
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Compound 215022 binds to the GRK5 active site similarly to that described for the 
GRK2–Gβγ·215022 structure. The indazole forms two hydrogen bonds in the hinge of the kinase 
with backbone atoms of Thr264 and Met266, the fluorophenyl ring packs under the P-loop, and 
the amide makes a hydrogen bond with the backbone nitrogen of Phe197. Notably, the 2-
pyridine of 215022 picks up an additional hydrogen bond in GRK5 not seen in the GRK2 crystal 
complex with the side chain of Lys215, explaining its dramatically improved potency for GRK5 
with respect to the parent compound GSK180736A. Overall, in comparison to previously 
reported GRK4 subfamily structures this GRK5·215022 complex adopts a more closed 
conformation in comparison to the GRK2–Gβγ·GSK180736A and GRK2–Gβγ·215022 
structures. 
 
Figure 2.4. Interactions of 215022 within the GRK5 active site. The inhibitor is drawn with 
yellow carbons, and black dashed lines depict hydrogen bonds. A 3 σ |Fo|-|Fc| omit map for the 







Molecular Basis for Potency and Selectivity: Analysis of these four crystal structures in 
comparison to structures of other AGC kinase domains provides insight into the molecular basis 
for their relative potencies and selectivities. Interestingly, neither GSK180736A nor any of its 
derivative compounds reported here inhibit PKA below concentrations of 30 μM despite its 
kinase domain being highly homologous to those of GRKs and ROCK1. Comparison to both the 
PKA·AMPPNP substrate analog structure (PDB entry 4HPT) and the PKA-balanol complex 
(PDB entry 1BX6) indicates that the derivatives (of GSK180736A) should not be sterically 
blocked from binding in the PKA binding site. However, the hinge in the structures of PKA is 
shifted 1.5-1.7 Å away from the adenine subsite relative to the position of the hinge in both 
GRK2 and GRK5 (Figure 2.5). This difference may prevent the formation of favorable contacts 
between hinge backbone atoms and the indazole ring common to GSK180736A and all of its 
derivatives.  
 
Figure 2.5. Structural differences in the hinge regions of PKA, GRK2, and GRK5. Cα traces 
of PKA bound to AMPPNP (PDB entry 4HPT, red) or balanol (PDB entry 1BX6, orange), 
superimposed onto GRK2∙compound 2 (PDB entry 4PNK, blue). GRK2∙224406 (purple) and 
GRK5∙215022 (green) are also shown for comparison. Hinge residues that form hydrogen bonds 
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with the indazole nitrogens of compound 2 and its derivatives are 1.5-1.7 Å closer to the 
inhibitor in the structures of GRK2 and GRK5 relative to those of PKA.  
 
GSK180736A, 224406, and 224411 do not bind tightly to either GRK1 or GRK5, but 
215022 and 224062 inhibit these kinases with potencies in the low µM or nM range. To explore 
the molecular basis of this selectivity among GRK subfamilies, the structures of GRK5·215022 
and GRK2·215022 were further compared (Figure 2.6). The hydrophobic subsite in GRK5 is 
deeper and narrower than that of GRK2.
56
 Thus, one would predict that compounds with larger 
D-ring substituents would tend to be excluded from the hydrophobic subsite of GRK5. In the 
GRK5·215022 complex, a hydrogen bond is formed between the catalytic lysine (Lys215 in 
GRK5) and the pyridine nitrogen of the inhibitor. In the crystal structure of GRK2·215022, the 
pyridine nitrogen most likely faces the solvent. The fact that 215022 buries nearly identical 
surface area in each complex (only 5 Å
2
 additional buried surface area when bound to GRK5) is 





Figure 2.6: Comparison of GRK2 and GRK5 hydrophobic binding pockets when bound to 
215022 (yellow) (a) GRK2 has a much wider and shallower binding pocket (non-polar residues 
highlighted in purple) and (b) GRK5 has a deeper, narrower, and overall smaller binding pocket 
(non-polar residues are highlighted in teal). 
 
Based on the hydrophobic subsite hypothesis above, the isoquinoline ring of 224062 was 
predicted to select against GRK5 and its close homolog GRK1. However, it was an efficacious 
inhibitor of all three GRKs as well as ROCK1, with 56-fold and 1000-fold increases in potency 
against GRK5 and GRK1 relative to the parent compound GSK180736A. The crystal structure 
shows that the isoquinoline reorganizes local structure in the hydrophobic subsite of GRK2, in 
particular the P-loop, such that its fused phenyl ring forms a π-π stacking interaction with the 
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side chain of Phe202 (Figure 2.2b). Superimposing 224062 from the GRK2-Gβγ structure in the 
active sites of GRK1 and GRK5 illustrates that the isoquinoline group would be compatible with 
their hydrophobic subsites as well, provided their P-loops can similarly reorganize. This 
modeling exercise also suggests that the nitrogen of the isoquinoline ring could form an 
additional hydrogen bond with the active site lysine as 215022 does in GRK5. A greater degree 
of kinase domain closure in GRK1 and GRK5 relative to GRK2 may account for why 
enhancement of potency is higher for GRK1 and GRK5. 
The dimethoxybenzyl D-ring of the most selective inhibitor, 224406, binds snugly in the 
hydrophobic subsite of GRK2 with one methoxy group packing deep in the pocket, and the other 
projecting towards solvent (Figures 2.2c, 2.7a). Docking the compound in the active site of 
GRK5 (Figure 2.7b) demonstrates that the 2,6-dimethoxybenzyl substituent of 224406 would 
collide with the DFG loop, which is shifted towards the hydrophobic subsite due to a greater 
degree of kinase domain closure in GRK5 than in GRK2. This collision also likely explains the 
GRK2 selectivity seen with the similar, but not quite as bulky, hybrids 224063 and 224064. The 
packing of 224406 is likely mimicked by the analogous potent ortho methoxy hybrid 221303. 
Movement of the methoxy substituent to the meta and para positions (as in 224414 and 221304) 
would cause the methoxy to collide with the αC-helix or DFG loop, respectively, explaining their 




Of the four inhibitors structurally characterized here, only 224406 achieves selectivity 
over both the GRK1 and GRK4 subfamilies and ROCK1. Upon superimposing these inhibitor 
structures on ROCK1 in complex with an indazole derivative similar to GSK180736A (3V8S)
81
, 
it is apparent that ROCK1-Phe120 (Leu235 in GRK2) sterically clashes with each of the four 
characterized inhibitor D-rings. However, ROCK1-Phe120 must be able to adopt a rotamer more 
Figure 2.7. Molecular origins of 
selectivity for compound 224406. Surface 
representations of GRK2∙224406 (a), GRK5 
(PDB entry 4WNK, (b), and ROCK1 (PDB 
entry 3V8S, (c) with hydrophobic and 
polar/charged residues colored green and 
gray, respectively. 224406 is superimposed 
onto GRK5 and ROCK1 to demonstrate 
potential clashes. (b) In GRK5, 224406 
appears to clash with both Met230 from the 
αC helix (Leu235 in GRK2) and Gly331 
from the DFG loop (Gly337 in GRK2). (c) 
In ROCK1, 224406 may clash with Phe120 
(Leu-235 in GRK2) and backbone atoms of 
Gly218 in the DFG loop (Gly337 in 
GRK2). For this modeled complex, 
ROCK1-Asp216 was changed to the 
rotamer of the analogous residue in the 




similar to that of GRK2-Leu235 because 215022, 224062, and 224411 all inhibit ROCK1 with 
high potency. Compound 224406, however, also sterically clashes with the backbone carbonyl of 
ROCK1-Gly218 (Gly337 in GRK2, Figure 2.7c) in the DFG loop, which is shifted towards the 
hydrophobic subsite by 2.9 Å in ROCK1 relative to GRK2. The other inhibitors avoid generating 
this collision but 224406 cannot, as a consequence of its two methoxy substituents, which greatly 
restrict its ability to alter its conformation within the hydrophobic subsite. The analogous 
ethylene linked inhibitor 232405 has low nanomolar affinity for ROCK1 despite having a bulky 
2,6-dimethoxyphenyl substituent. It is likely that the extra carbon extension allows the inhibitor 
to pack outside of the hydrophobic pocket to avoid steric clashes, as does 224411. 
 Electron density for the 2,6-dimethyl phenethyl moiety of 224411 is not evident after the 
amide linker (Figure 2.2d), suggesting that this arm of the inhibitor is flexible while bound to 
GRK2. This flexibility likely results from the extra degree of rotational freedom conferred by the 
longer ethylene linker and its inability to be accommodated within the hydrophobic subsite. For 
the same reasons, the D-ring of 224411 likely would not be able to occupy the hydrophobic 
subsites of GRK1 and GRK5. Thus, the compound would bind no better than GSK180736A 
alone, consistent with the relatively poor binding of 224411 to GRK1 and GRK5 (Table 2.1). 
Metabolic Stability:
4
 In order to develop compounds with therapeutic potential select 
compounds were evaluated by the pharmacokinetic core for stability in mouse liver microsomes 
(MLMs): GSK180736A, 215022, 224063, 224064, and 224406. These experiment monitor the 
degradation of inhibitors in MLMs. Inhibitor is added to MLMs and incubated for one hour. 
Over the course of this hour aliquots are taken out at varying timepoints, quenched, and analyzed 
using LC/MS to evaluate the amount of compound left in the sample at each time point. The 
                                                          
4
 These experiments were performed by the University of Michigan Pharmacokinetic Core. 
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varying timepoints are then plotted against the concentration of remaining inhibitor in each one 
and a curve is fitted using Excel to give the resulting half-life values.  
Of the five compounds evaluated, the lead compound, GSK180736A had a half-life of 
20.6 minutes and 215022 had a half-life of 11.32 minutes while the other three hybrid analogs all 
had half-lives of less than 4 minutes. As previous efforts to improve stability of GSK180736A 
have been made we looked to those to improve these compounds. Sehon et. al. reported that 
addition of a fluorine or chlorine at the C6 position of the indazole ring nearly doubled half-life 
alone.
76
 Therefore, in an effort to improve the metabolic stability of the compounds the 6-fluoro-
indazole compounds 257376 and 257377 (Table 2.3) were synthesized. Additionally, the 6-
chloro-indazole compound 258745 (Table 2.3) was synthesized. Looking just at potency, 
addition of the fluorine to 215022 (2-pyridine) yielding 257377 resulted in a slight decrease in 
binding of all GRKs (6-fold at GRK2, 16-fold at GRK1, and 10-fold at GRK5). Interestingly, 
addition of the fluorine to 224406 (2,6 – dimethoxy) yielding 257376 resulted in improved 
GRK2 potency (IC50 = 50nM) to give the most potent GRK2 inhibitor on this scaffold while 
retaining selectivity against GRK1 and GRK5 (IC50 is > 100 µM). Unlike, 257376, addition of a 
chlorine to the indazole of 224406 to give 258745 resulted in a substantial loss in potency for all 
GRKs. Due to the close positioning of the chlorine to the dyhydropyrimidine core it may be that 
the bulkier substitution cause the compound to adopt a more orthogonal conformation that is not 
tolerated by GRK2. The analog was not further tested for metabolic stability due to its loss in 
potency. The two fluorinated derivatives, 257376 and 257377, were subsequently tested for their 
metabolic stability. The 2-pyridine analog 257377 had a three minute drop in half-life in 
comparison to the non-fluorinated 215022, while the 2,6 – dimethoxy analog, 257376 went down 
to 2.11 minutes in comparison to the nearly four minutes the unfluorinated 224406 analog 
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exhibited. Therefore, in the case of the halogenated indazole compounds, in all cases except for 
the 224406/257376, potency was not maintained and there was no gain in metabolic stability of 
the compounds. The loss in potency for these other analogs may be due to the fluorine causing a 
different conformational rotation of the molecule or perhaps the added bulk is not easily 
accommodated in the adenine subsite. Because the 2,6 – dimethoxy phenyl compounds 
224406/257376 pack so well in the hydrophobic subsite relative to the pyridine analogs 
(215022/257377) it may be that the change in the adenine subsite is not enough in the first case 
to cause a decrease in potency and the add lipophilicity is then slightly favorable. Although this 
additional substitution was previously successful in improving pharmacokinetics of the 
GSK180736A compound it seems the addition of the added halogens is not transferable.  
 
Table 2.3: GRK1, GRK2, and GRK5 inhibitory activity of select 6C  
fluoro and chloro indazole GSK-hybrid compounds. 
 














F 0.94±0.64 63±45 3.7±0.54 8.07 
257376 
 
F 0.05±0.01 >100 >100 2.11 
258745 
 
Cl 5.65±2.84 >100 >100 NT 
All IC50 measurements are an average of three separate experiments run in duplicate.  




Contractility in Mouse Cardiomyocytes: To ascertain the ability of these inhibitors to 
produce a myocardial effect, they were incubated with cardiomyocytes isolated from adult mice, 
and then stimulated with the βAR agonist isoproterenol as described previously (Figure 2.8, 
Tables 2.4-2.8).
56
 In the presence of a GRK2 inhibitor, the strength of the resulting contraction 
should increase as there is more βAR signaling. Previously, it was shown that paroxetine induces 
a significant increase in contractility in comparison to the DMSO control when dosed at 10 
μM.
72
 In comparison, GSK180736A showed similar efficacy as paroxetine when dosed at 1 μM 
(Figure 2.8, Table 2.4), consistent with the increased potency of this compound of GRK2 
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Figure 2.8. Mouse cardiomyocyte contractility of paroxetine, GSK180736A, 215022, 
215023, 224064, and 224406. Maximum contraction amplitudes of the known GRK2 inhibitor 
paroxetine, the lead GSK180736A, 215022, 215023, 224064 and 224406 before and after 
isoproterenol stimulation. Doses shown are the minimum inhibitory concentrations that exhibit a 
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12 ± 0.48 16 ± 2.1 18± 0.76* 
 
% increase in 
contraction 
amplitude 
114 ± 12 
 
181 ± 42 201 ± 27* 
 










0.5 μM 1 μM 10 μM 
Baseline before isoproterenol 
max contraction 
amplitude (% cell 
length) 
5.7 ± 0.37 5.6 ± 0.48 5.9 ± 0.23 
 
5.9 ± 0.55 4.6  ± 0.53 
After Isoproterenol 
max contraction 
amplitude (% cell 
length) 
12 ± 0.48 18 ± 1.2 16 ± 1.1* 
 
17  ± 1.04* 13  ± 0.99 
% increase in 
contraction 
amplitude 
114 ± 12 
 
115 ± 21 175 ± 18* 
 
171 ± 21* 220 ± 44* 













0.1 μM 0.5 μM 1 μM 10 μM 
Baseline before isoproterenol 
max contraction 
amplitude (% cell 
length) 
5.7 ± 0.37 6.0 ±  1.7 4.6 ± 0.9 
 
 
5.6 ± 0.58 5.7 ± 0.23 
After Isoproterenol 
max contraction 
amplitude (% cell 
length) 
12 ± 0.48 12 ± 1.7 17 ± 0.97* 
 
16 ± 0.6* 15 ± 0.62* 
% increase in 
contraction 
amplitude 
114 ± 12 107 ± 34 341 ± 72* 
 
202 ± 30* 175 ± 16* 
Values represent the mean ± SEM for 8-10 cardiomyocytes. *,p<0.05 vs control 
 
 




0.1 μM 0.5 μM 1 μM 10 μM 
Baseline before isoproterenol 
max contraction 
amplitude (% cell 
length) 
5.7 ± 0.37 5.2 ± 0.37 5.1 ± 0.49 
 
5.5 ± 0.72 
 
5.1 ± 1.0 
After Isoproterenol 
max contraction 
amplitude (% cell 
length) 
11.9 ± 0.48 13 ± 0.79 13 ± 0.64 15 ± 0.58* 
 
17 ± 1* 
% increase in 
contraction 
amplitude 
114 ± 12 
 
153 ± 15 175 ± 27* 210 ± 36* 
 
275 ± 50* 












0.1 μM 0.5 μM 1 μM 10 μM 
Baseline before isoproterenol 
max contraction 
amplitude (% cell 
length) 
4.5 ± 0.32 4.5 ± 0.49  3.9 ± 0.54  
 
4.4 ± 0.71  4.8 ± 0.44  
After Isoproterenol 
max contraction 
amplitude (% cell 
length) 
12 ± 0.97 12 ± 1.4 15 ± 1.2* 18 ± 0.71* 16 ± 0.64*  
% increase in 
contraction 
amplitude 
157 ± 23 
 
169 ± 33 338 ± 65* 
 
353 ± 66* 241 ± 28* 
Values represent the mean ± SEM for 6-8 cardiomyocytes. *,p<0.05 vs control 
 
 
 Four of the hybrid molecules were evaluated in cardiomyocytes (Figure  2.8): 215022 
(Table 2.5), 215023 (Table 2.6), 224064 (Table 2.7) and 224406 (Table 2.8). The less selective 
215023 and 215022 compounds were able to induce significantly increased contractility at 0.5 
μM, a 20-fold improvement over paroxetine. The more potent and selective GRK2 inhibitor, 
224064, had a significant response at only 1 μM, analogous to GSK180736A. Therefore, the 10-
fold improvement in GRK2 potency of 224064 (IC50 = 0.07 μM) versus GSK180736A (IC50 = 
0.77 μM) conferred no added benefit in efficacy. Interestingly, the other potent and selective 
GRK2 inhibitor 224406, showed a similar profile to the less selective 214023 and 215022 
compounds having a significant response at 0.5 μM. Relative selectivities of the four 
compounds, 215023, 215022, 224064, and 224406 for GRK2 over GRK5 are 22-fold, 2-fold, 
900-fold, and >780-fold respectively. As the selective and equally potent GRK2 inhibitor, 
224406, was equipotent in the contractility assay relative to the non-selective 215023 and 
215022 GRK inhibitors it is surmised that inhibition of GRK5 in addition to GRK2 is not 
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necessarily advantageous or detrimental to contractile function in these myocyte shortening 
experiments. However, differential ability to cross the cell membranes may also impact the 
relative potencies of these compounds leading to these observed results. 
 Conclusions: Utilizing a hybrid approach we envisioned development of selective and 
potent GRK2 inhibitors constructed from the potent ROCK1 inhibitor GSK180736A and the 
selective GRK2 inhibitor Takeda103A. Overlaying the binding poses of the two compounds 
(Figure 1) in the active site of GRK2 revealed that it might be possible to utilize the hydrophobic 
binding site of GRK2 to achieve selectivity over other AGC kinases. A small library of 
compounds was thus synthesized in which a variety of amide substituents were appended to the 
fluoro-aromatic ring of GSK180736A to mimic the difluorobenzyl amide of Takeda103A. The 
major SAR findings from this study were that small benzyl amide substituents lead to significant 
inhibition of GRK5 in addition to GRK2, and that addition of steric bulk to the benzyl amides 
favors GRK2 selectivity over all of the other AGC kinases tested. This ultimately led to the 
identification of 224406, a 2,6-dimethoxybenzylamide with remarkable potency against and 
selectivity for GRK2 and complete loss of the optimized ROCK inhibitory activity of the lead 
GSK180736A. We also identified some potent pan-inhibitors of GRKs 1, 2 and 5, including 2-
pyridyl amide 215022. Collectively these new hybrid analogs represent an important start in the 
design of small molecule probes that can be used to explore the physiological roles of the 
individual GRKs.  
Co-crystal structures of several representative analogs bound to GRK2 were solved to 
help define the molecular basis for their differing selectivities.   Comparison of the GRK2-
215022 structure with the previously determined  GRK5-215022 crystal structure showed that 
the hydrophobic subsite of GRK5 is much narrower and deeper than the shallower, wider subsite 
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of GRK2, helping to rationalize the increased GRK2 selectivity seen with bulkier D-ring GRK2-
224062, GRK2-224406, and GRK2-224411. Overall, the structures confirm that the size and 
shape of the hydrophobic subsite, which is in part dependent on the degree of kinase domain 
closure, puts constraints on the chemical nature of the D-ring amide substituent that can be 
accommodated. Larger substituents, such as the 2,6-dimethoxy benzyl of 224406, can fit into 
GRK2 more readily than the other AGC kinases tested in this study.  These conclusions were 
supported by overlays of the bound poses of our analogs in GRK2 with other published kinase 
structures.  Based on the published GRK5-215022 structure and the selectivity data we observed, 
we also conclude that smaller hydrogen-bonding benzyl amides can interact effectively with the 
hydrophobic subsite of GRK5, conferring potent inhibitory activity to the GRK5-inactive lead 
GSK180736A.  
Finally, evaluation of selected inhibitors in cardiomyocytes suggests that pan-GRK 
inhibition or dual GRK2/ GRK5 inhibition is no more effective than GRK2 inhibition alone at 










Second Generation of GSK180736A Derivatives Guided by Molecular Modeling: 
Pharmacophore design: A campaign to discover possible new chemical motifs for 
binding into the hydrophobic pockets of GRK2 and GRK5 to generate both GRK2-selective and 
GRK5 selective compounds began with an extensive virtual screen utilizing two of our crystal 
structures, GRK2–Gβγ·GSK180736A (4PNK) and GRK5·215022 (4WNK), and a library of 
commercially available amines (docking performed by Dr. Paul Kirchhoff). Virtual compounds 
were enumerated based on the GSK180736A template that incorporated our amide linked 
terminal appendages. Three base scaffolds were used in the screen: a direct amide linker to the 
fluorophenyl, a methylene linked amide to the fluorophenyl, and an ethylene linked amide to the 
fluorophenyl (Figure 2.9). These three scaffolds were then matched to a commercially available 
library of 11,347 primary and secondary amines from Sigma Aldrich with molecular weights less 
than 215. The resulting unique amide compounds were then filtered through a molecular weight 
cut off of 550 to give 9,183 unique virtual amide structures.  
 
Figure 2.9: GSK180736A scaffolds used for the docking run: no homologation, a methylene 
linked acid, and an ethylene linked acid. 
  
A pharmacophore model was used based on the ligand orientations in the GRK2–
Gβγ·GSK180736A and GRK5·215022 crystal structures used for docking. The pharmacaphore 
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restricted the docked ligands to be in an orientation similar to what was seen in the respective 
crystal structures (Figure 2.10). In Figure 2.10B the center of the aromatic rings (the two rings 
of the indazole and the fluorophenyl) are pinpointed by a green dot. This green dot was allowed 
to move anywhere within the respective green mesh spheres surrounding the aromatic ring to 
allow a defined movement of space. The two nitrogens that form hydrogen bonds with the hinge 
of the kinase domain are pinpointed by a cyan dot and a purple dot. These two points were then 
similarly allowed to flex or move within the confines of the mesh sphere surrounding each of 
them. This rigid pharmacophore allowed for the biased development of hybrid compounds that 
would likely bind similarly to our previously synthesized GSK180736A hybrid compounds by 
restricting the indazole to the hinge, forcing it to make hydrogen bonds with Met274 and 
Asp272, and restricting the fluorophenyl group to bind underneath the P-loop. This allowed us to 
specifically probe flexibility of various amide linked virtual derivatives in the hydrophobic 
subsite. 
 The compounds were then docked into both the GRK2·Gβγ·GSK180736A and  the 
GRK5·215022 crystal structures using rigid side chains of the protein but allowing the 
compound to flex in accordance with the pharmacophore that was built. The results were sorted 
by highest docking scores and then further split into six groups. The first group contains 
compounds that were only successfully docked into GRK2, the second group contained the 
highest GRK2/GRK5 ratios (GRK2 selective), the third group contained the highest 
GRK5/GRK2 ratios (GRK5 selective), the fourth group contained the best scoring value for 
GRK2 (GRK2 potent), the fifth contained the best scoring value for GRK5 (GRK5 potent), and 
the sixth category contained compounds that had good scores for both GRK2 and GRK5 (GRK2 
and GRK5 potent). After filtering out any compounds that had additional primary or secondary 
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amines, carboxylic acids, or other reactive, unstable, or toxic motifs, forty compounds were 
selected, synthesized, and tested.   
 
Figure 2.10: Pharmacophore model used for molecular docking. A) GSK180736A – GRK2 
crystal structure. The green circles represent regions in which the aromatic rings were confined. 
The green and purple circles represent the hydrogen bonds made between the indazole and the 
backbone of the hinge in GRKs 2 and 5. The nitrogens of the indazole were confined to these 
spheres. The pink oval show where the appendages were built from that were then allowed to 
freely dock into the hydrophobic subsite. B) The exact pharmacophore model used in MOE. The 
spheroid coloring matches that shown in panel A. 
  
Structure Activity Relationships: Biochemical evaluation of these compounds was 
performed as previously described in the first part of this chapter. Of the forty hybrid compounds 
that were docked, synthesized and tested 23 (57.5%) showed activity against either GRK2 or 
GRK5 exactly as predicted and 17 (42.5%) showed unpredicted activity. The compounds ranged 
dramatically in terms of both potency and selectivity with both sub-micromolar and high 
micromolar values. The results of the forty compounds in terms of their activity against GRKs 1, 
2, and 5 as well as their predicted and actual selectivities are summarized in Table 2.9 below. 
Across all compounds some predictive patterns were seen. Predictions looking at either GRK5 
selectivity or GRK5 potency in almost all cases failed. Only a small subset of the compounds 
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that were predicted to bind both potently to GRK2 and GRK5 proved to show potency at GRK5 
(although no selectivity). The observed lack of binding to GRK5 in general may be due to the 
fact that the initial GSK180736A compound already has GRK2 selectivity over GRK5. Here we 
were not only attempting to build in potency for GRK5 but are also attempting to build out 
potency of GRK2. Of the 15 direct amide linked analogs 9 followed their predicted 
selectivitywhile 6 did not. Of these six, five were predicted to be either GRK5 potent or GRK5 
selective. The one outlier was, 257151, which was predicted to be GRK2 selective. Although it 
was potent for GRK2 with an IC50 of 0.40 µM it also showed activity against GRK5 with an IC50 
of 2.8 µM and therefore, although, not highly selective, was still seven-fold selective for GRK2. 
Of the 19 methylene amide linked compounds 8 were correctly predicted while 11 were not. Of 
those 11only one was not predicted to bind to GRK5 either selectively or potently. Conversely, 
all but one of the six ethylene amide linked derivatives exhibited their predicted GRK2 and 
GRK5 selectivities, although, none of the five were predicted to be either GRK5 potent or 
selective.  
Table 2.9: GRK1, 2, and 5 activity of GSK18073A hybrid compounds designed from 
molecular docking. 
   

























































































































































































































































































All IC50 measurements are an average of three separate experiments run in duplicate. Errors 
shown represent standard error of the mean.  
 
Overall, it seems the model was able to accurately predict compounds that would be 
selective or potent for GRK2, but not for GRK5. However, it was able to predict a few 
compounds with added potency against both GRK2 and GRK5 (257064 and 257142). The 
ethylene linked compounds were the most accurately predicted. This is likely due to their added 
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flexibility, which allows for the appendages to flip out of the pocket if needed. Although most of 
these ethylene linked compounds are GRK2 selective, none of them have increased potency in 
comparison to the parent GSK180736A suggesting that the addition of the substituents via an 
ethylene amide does not have an additive effect. The direct amide bond linked compounds were 
the next well predicted, likely due to the fact that the two crystal structures used for docking 
were crystallized with ligands that have the direct amide bond linker. 
Favorably, two compounds with nearly equipotent binding to GRK2 and GRK5 were 
developed from this series of compound: 257064 and 257142. Both compounds were 
successfully predicted to be both GRK2 and GRK5 potent and incorporated a direct amide linked 
oxadiazole. These compounds have a nitrogen analogous to the pyridine nitrogen in 215022 that 
is probably able to interact with the side chain of Lys215, likely explaining the successfully 
predicted GRK5 potency. Additionally, predicted GRK5 potent compounds, 257141 and 257143 
shared this characteristic by having small heterocycles with analogous nitrogens to that of the 2-
pyridine in 215022, but both showed poor GRK5 potency as they were either on the methylene 
(257141) or ethylene linked scaffolds (257143). Had these substituents been appended to the 
direct amide linked scaffold they may have proven to be more GRK5 potent. Analogs 257141 
and 257148 had the nitrogen of the amide linker methylated. As the amide nitrogen in the 
GRK5·215022 structure participates in a hydrogen bond with Asp329, methylation of this 
nitrogen is likely very detrimental to potency further explaining why these compounds are not 
more potent despite their D-rings being small heterocyles. 
Conclusions: Although the predictive molecular modeling was not highly accurate 
among the three core scaffolds we utilized, this large variety of compounds did give further 
insight into the SAR of the GSK180736A derivatives. Most favorable to GRK activity is the 
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direct linked amide moieties as opposed to the methylene linked and ethylene linked derivatives. 
The tertiary amides were better tolerated in the methylene and ethylene linked compounds likely 
as the added linkers pushed the amide bond further into the hydrophobic subsite or solvent. 
Generally, addition of large lipophilic appendages was unfavorable and resulted in a decrease in 
potency except for cases where there was a more basic nitrogen that may have contributed to 
improved water solubility. Moving forward with this series of compounds it would appear to be 
most promising to further investigate the oxadiazole, isoxazole, and pyrazole compounds on the 
direct amide linked scaffold to improve GRK5 potency. 
Synthesis: 
 Scheme 2.1. General preparation of indazole GSK180736A amide linked derivatives 
 The indazole hinge binding GSK180736A amide linked derivatives were prepared as 
shown in Scheme 2.1. Treatment of 5-aminoindazole 1, or the analogues halogen substituted 
compounds 2 or 3, with 2,2,6-trimethyl-4H-1,3-dioxin-4-one resulted in the acetylated 
compounds 4-6.
82
 Through a Biginelli cyclization, catalyzed by ytterbium triflate, acids 17-19 
were condensed with urea and acetamides 4-6 to yield the dihydropyrimidones 7-11.
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Scheme 2.2: Synthesis of halogenated indazole intermediates 2 and 3. 
 The halogenated indazole intermediates 2 and 3 were similarly prepared as described in 
Scheme 2.2. Synthesis of fluorinated intermediate began with acetylation of aniline 20 using 
acetic anhydride. Nitration of the aromatic ring under standard conditions followed by acidic 
hydrolysis of the acetate yielded intermediate 22. The analogous chloro intermediate 23 was 
commercially available. The anilines 22 or 23 were then cyclized in the presence of sodium 
nitrite and acetic acid to give the indazoles 24 and 25. Hydrogenation of the remaining nitro 
group with catalytic palladium furnished intermediates 2 and 3. 
 
Scheme 2.3: Synthesis of acid intermediate 17. 









Synthesis of the ethanoic acid intermediate 18 is outlined in Scheme 2.4 beginning with 
Fischer esterification of 4-fluoro-3-methylbenzoic acid 26 followed by benzylic bromination 
under radical conditions to give the methyl ester 27. After reduction of the ester, displacement of 
the bromine using sodium cyanide afforded the nitrile 28. The nitrile was hydrolyzed under basic 
conditions to yield the carboxylic acid 29.  Oxidation of the benzylic alcohol of 29 using 2-
iodoxybenzoic acid or under Swern conditions proved unsuccessful. Fortunately, Parikh Doering 
oxidation yielded the aldehyde 18 cleanly and in high yield. 
 
 
Scheme 2.5: Synthesis of propanoic acid intermediate 19. 
The propanoic acid intermediate 19 was synthesized as shown in Scheme 2.5 beginning 
with TBS protection of (4-fluorophenyl)methanol 30 to give intermediate 31. Directed lithiation 
followed by formylation gives the aldehyde 32 which is then TBS deprotected to furnish alcohol 
33. Condensation with malonic acid followed by hydrogenation of the resulting alkene gives acid 










Scheme 2.6: Synthesis of amide N-methylated analogue 42. 
 
  Synthesis of the N-methylated hybrid molecule 42 commenced with acylation of 5-
aminoindazole 1 using trifluoroacetic anhydride to give 36.
84
 Attempts at selective methylation 
of the acetylated amine through the use of varying basic conditions led to competing N-
methylation of the indazole. Therefore, protection of the indazole nitrogen was necessary, and 
was accomplished using Boc-anhydride to give two regioisomers 37. Methyl iodide in the 
presence of sodium hydride then furnished the methylated amide 38. Removal of the 
trifluoroacetate and Boc under refluxing basic conditions afforded the monomethylated amine 39 
which was then acylated with 2,2,6- trimethyl-4H-1,3-dioxin-4-one to give 40. Final analogue 42 







Scheme 2.7: Synthesis of the benzodioxole, pyridine, and dichloro phenyl hinge binding analogs 
52 – 54. 
 
Incorporation of the benzodioxole, dichloro phenyl, or pyridine moieties was undertaken 
as shown in Scheme 2.7. Synthesis began with alkylation of the respective aryl amines through 
heating with ethyl acetoacetate and pyridine to give ketoamides 46-48. Biginelli cyclization 




Scheme 2.8: Synthesis of 2,6 – ditrifluorobenzylamine intermediate 58.  
 All amines incorporated in the final steps of these analogs were commercially available 
with the exception of the bulky 2,6 – ditrifluorobenzylamine 58. Synthesis of 2,6 – 
ditrifluorobenzylamine proceeded as described in Scheme 2.8. The acid chloride 55 was 
55 
 
displaced with ammonia to give benzamide 56. Efforts to directly reduce the benzamide 56 to the 
primary amine with LAH, NaBH4, or BH3 were unsuccessful. Thionyl chloride was used to 
deoxygenated 56 to give nitrile 57 which was then successfully reduced to the primary amine 





























The FDA-approved serotonin-reuptake inhibitor, paroxetine hydrochloride, was 
identified as a modest GRK2 inhibitor with an IC50 of 1.4 µM.
72
 Further in vivo investigation in a 
mouse heart failure model revealed that paroxetine improves cardiac function post-myocardial 
infarction and renormalizes the levels of catecholamines and  β-adrenergic receptor density in the 
heart, effects that persist for up to two weeks post-treatment.
73
 Because paroxetine is only a 
modestly potent and selective inhibitor of GRK2, but also an FDA-approved drug with excellent 
ADMET properties, it was an attractive lead compound for further optimization as a GRK2 
selective compound.  
Because our campaign to improve the GRK2 potency of GSK180736A (Figure 1.3) 
while minimizing ROCKI inhibition and retaining GRK2 selectivity was successful we sought to 
improve the GRK2 potency and selectivity of paroxetine. As paroxetine and GSK180736A are 
similar in size and shape we sought to improve upon GRK2 potency of paroxetine in a similar 
manner as we had done with GSK180736A. Comparison of the binding poses of paroxetine and 
GSK180736A in the active site of GRK2 (Figure 3.1A) shows that both compounds form 
interactions with the adenosine, ribose, and polyphosphate subsites, but neither occupies the 
hydrophobic subsite like the Takeda compounds (Figure 3.1B), leaving room to increase 
potency and selectivity through the addition of favorable moieties to their fluorophenyl rings. In 
the adenine subsite, the benzodioxole ring of paroxetine makes analogous hydrogen bonds to the 
                                                          
5
 Some work in this chapter has been published in Waldschmidt et. al. JMC, 2017. 
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backbone of atoms in the kinase domain hinge as the indazole ring of GSK180736A, with the 
exception that one of the paroxetine hydrogen bonds is a weaker CH–O hydrogen bond. The B-
rings of the two compounds both occupy the ribose subsite, where paroxetine makes a hydrogen 
bond with the carbonyl of Ala321 that is not seen with GSK180736A. The fluorophenyl rings of 
both molecules pack underneath the P-loop, superimposing nearly perfectly.
72, 75
 Based on these 
largely overlapping binding modes, we hypothesized that the structure activity relationships from 
the GSK180736A hybrid campaign would be transferable, providing guidance for novel 
extensions to the paroxetine scaffold.  
 
 
Figure 3.1. Comparison of lead compounds bound in the GRK2 active site suggest that 
extension of the paroxetine scaffold into the hydrophobic subsite is a route towards 
molecules with higher potency and selectivity. A) Overlay of paroxetine (gray carbons) and 
GSK180736A (hot pink carbons) bound to the GRK2–Gβγ complex (PDB entries 3V5W and 
4PNK, respectively). B) Overlay of paroxetine (gray carbons) and Takeda103A (purple carbons) 
bound to the GRK2–Gβγ complex (PDB entries 3V5W and 3PVW, respectively). The A, B, C, 
and D ring systems, which occupy the adenine, ribose, polyphosphate and hydrophobic subsites, 
respectively, are labeled for each compound, if present.  
 
Furthermore, because paroxetine is an FDA-approved drug we anticipated that the 
analogous paroxetine-series of compounds would exhibit superior pharmacokinetic properties. In 
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addition to being a potent ROCK1 inhibitor (IC50 = 100 nM), GSK180736A was known to 
exhibit limited bioavailabilty.
76
 Paroxetine has nearly two-fold lower polar surface area, a lower 
molecular weight, and fewer hydrogen bond donors and acceptors than GSK180736A,  physical 
properties that are all predictive of better absorption and permeability.
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In addition to building hybrid paroxetine – Takeda103A compounds we sought to 
improve these derivatives further by replacing the hinge binding benzodioxole of paroxetine with 
the hinge binding indazole of GSK180736A. As GSK180736A was initially more potent than 
paroxetine for GRK2 (IC50 = 0.77µM vs 1.38 µM) and many kinase inhibitors have the indazole 
functionality as a hinge binding moiety we hypothesized that this could greatly improve potency. 
We additionally looked at the effects of alkylating the nitrogen of the piperdine ring as this 
nitrogen forms H-bonds in GRK2 with Ala 321, in GRK1 with Asp271 and Glu318, and likely in 
GRK5 with analogous residues in the ribose subsite, whereas GSK180736A does not form an 
analogues interaction in GRK2.  Seven representative compounds were crystallized revealing a 
new hydrogen bond with the amide linker and new polar contacts formed with the extensions in 
the hydrophobic subsite, as well as larger conformational changes for the indazole hinge binding 
analogs. Lastly, we demonstrate that one of the optimized inhibitors (258208) enhances 
cardiomyocyte contractility with approximately 100-fold greater potency than paroxetine.
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Structure Activity Relationships. All new compounds were assayed for in vitro activity 
against bovine GRK1, 2 and 5, as well as PKA and ROCK1 as described in Chapter 2 (Table 
3.1). We envisioned that incorporation of an amide linker between the paroxetine scaffold and 
new hydrophobic subsite-binding substituents (Table 3.1) would allow for the formation of a 
hydrogen bond to the backbone nitrogen of Phe202 in the P-loop, as observed in our 
GSK180736A derived series.
70, 71
 However, simple methyl amide (258753) was two-fold less 
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potent than paroxetine against GRK2, suggesting that any hydrogen bond that forms does not 
overcome desolvation and/or entropic penalties. Increasing the size of the amide substituent from 
a methyl to a benzyl (258202) was tolerated but not any more potent than paroxetine alone. 
Lengthening the amide substituent to phenethyl 258201 resulted in a slight loss in potency 
against GRK2, indicating that more lipophilicity on its own is not beneficial to improving 
potency. Moving to the 2,6–difluorobenzylamide (208947), mimicking the D-ring of compound 
Takeda103A and adding bulk, had no change in potency versus GRK2 and resulted in a 
decrease in selectivity against GRK5. Additionally, the added lipophilicity gave a modest 
increase in ROCK1 inhibition (34% at 10 µM). Further lengthening the substituent to the 2,6–
difluorophenethylamide (211990) resulted in an even further decrease in selectivity for GRK2 
over GRK5 as it exhibited a 10-fold increase in potency for GRK5 and a 2-fold decrease in 
potency for GRK2. Moving to a hybrid of Takeda101 we investigated the addition of an ortho-
trifluoromethyl benzyl (211991) which resulted in a loss in potency for all three GRKs, 
suggesting a limit to the size of the substituent that could be tolerated.  
We then investigated homologation of the scaffold to incorporate a methylene linker in 
between the fluorophenyl and the amide ring as this may give a more optimal placement for the 
amide to pick up additional hydrogen bonds in the polyphosphate subsite as seen with the amide 
in Takeda103A and Takeda101. Homologation resulted in the methylene and ethylene linked 
2,6 – difluorophenyl analogues 208945 and 215086. Both compounds resulted in a decrease in 
potency for GRK2 relative to their non-homologated analogues 208947 and 211990 (~ 5 fold and 
2 fold loss in GRK2 potency, respectively). Surprisingly both of the homologated compounds 
did have additional selectivity for GRK5 and ROCK1 indicating that movement of the amide 
60 
 
linker over or having a longer or larger substituent in the hydrophobic pocket may be more 
favorable for GRK2 selectivity.  
 We next tested structure activity relationships generated by our previously reported 
GSK180736A-based series, which revealed that bulkier substituents in the hydrophobic subsite 
of GRK2 can achieve both increased potency for GRK2 as well as increased selectivity over the 
other GRKs and related AGC kinases like ROCK and PKA.
71
 Four representative substituents 
from this endeavor are 2,6–dimethylbenzylamide, 232403, 2,6–dichlorobenzylamide, 232407, 
2,6–dimethoxybenzylamide, 232402¸ and 2,6-ditrifluoromethylbenzylamide, 232404. All 
compounds displayed reduced selectivity for GRK2 over GRK1 and 5, and no improvement in 
potency, suggesting inadequate engagement of the hydrophobic subsite. 
 Less bulky but still lipophilic amide substituents were then investigated. In our previous 
SAR campaign, the most potent compound against GRK2 (IC50 = 60 nM) placed a 2-
methoxybenzylamide substituent in the hydrophobic subsite.
71
 Surprisingly, translating the 2-
methoxybenzylamide onto the paroxetine scaffold resulted in our least potent GRK2 inhibitor, 
211993 (IC50 = 40 μM). Interestingly, homologating the 2-methoxybenzylamide by adding a 
methylene group between the amide and fluorophenyl ring (215140) brought back some GRK2 
potency (IC50 = 2.4 μM) but also picked up affinity for PKA. The slightly smaller homologated 
2- chlorobenzyl analogue 215141 additionally showed poor GRK2 inhibition (IC50 = 4.2 μM) 
while picking up potency for PKA (29 µM) and was not further pursued. These results, in 
addition to those above, revealed that although the binding poses and structures of GSK180736A 
and paroxetine are similar, the SAR of their extended scaffolds are poorly translatable. One 
possible explanation is that the overall conformation of the GRK2 kinase domain in complex 
with GSK180736A is more closed than in the GRK2·paroxetine complex due to different 
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interactions formed by their hinge-binding moieties. This results in small but significant 
structural differences in the polyphosphate and hydrophobic subsites and the relative orientation 
of the small and large lobes that form the active site.
72, 74
  
 As bulky and lipophilic groups were not tolerated, we turned our attention to smaller 
more polar groups including a series of regioisomeric pyridyl methylamides. The 2-pyridine, 
211998, afforded a 2-fold increase in potency for GRK2 along with a 5-fold increase in GRK5 
potency. The corresponding 3- and 4-pyridyl analogs (258203 and 258204) were less potent, 
suggesting that the added potency of 211998 was due to the position of the nitrogen rather than 
the aromatic ring alone. Lengthening the carbon linker between the amide and the pyridines 
(258205, 258207, 258206) or between the amide and the phenyl ring (215143, 215142) also 
reduced potency relative to 211998, providing evidence for the importance of the position of the 
pyridyl nitrogen relative to the fluorophenyl ring. From the overall SAR of these pyridine 
amides, it was clear that the ortho position of the nitrogen in 211998 is key for potency against 
both GRK2 and GRK5.  
To more efficiently exploit this polar contact we next sought to design molecules that 
would have a stronger hydrogen bond acceptor in a similar position as the pyridine nitrogen of 
211998. The 2-imidazolylmethyl amide 258209, as well as the ethylene linked imidazole 
258210, showed potency comparable to 211998. They also had increased potency for GRK5, 
presumably by making a hydrogen bond to Lys220 as we observed previously in the 
GRK5·215022 complex.
56
 Replacing the imidazole amide with 3-pyrazolylmethyl amide 
(258208), resulted in a dramatic increase in potency for GRK2 (IC50 = 30 nM) while maintaining 
230-fold selectivity over GRK5 and more than 2500-fold selectivity over GRK1, PKA, and 
ROCK1. Lengthening the amide linker to give 3-pyrazolylethyl amide, 258750, resulted in a 26-
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fold decrease in potency for GRK2, relative to 258208. Furthermore, methylation of either 
nitrogen of 258208 (258752 and 258751) resulted in 40-fold and 70-fold decreases in GRK2 
affinity, respectively, whereas placing a methyl group adjacent to the two nitrogens (258754) did 
not diminish potency. These results strongly suggest that both nitrogens of the pyrazole of 
258208 are necessary for its high GRK2 potency and are likely making either one or two polar 
interactions. Simple one-atom transposition of the two pyrazole nitrogens (258749) resulted in a 
10-fold loss in GRK2 potency relative to 258208, further confirming the importance of the 
location of the nitrogens. Homologation of the 4-pyrazole methyl amide of 258749 (224060, 
222886) could not rescue the loss in potency. To further exploit the pyrazole 258208 a phenyl 
was fused to the pyrazole giving the indazole in hopes the larger ring system could additionally 
pack well into the hydrophobic subsite to increase potency. The resulting indazole analogue 
258747 had a further increase in GRK2 potency (IC50 = 18 nM) while retaining 83 fold 
selectivity over the other GRKs and ROCK1.  
 
Table 3.1. Kinase inhibitory activity of benzodioxole paroxetine analogs  
 













H Paroxetine 1.38±1.00 > 100 > 100 > 100 10% 
n/a Takeda103A 0.02±0.001 9.1±3.2 2.2±0.9 ND ND 
n/a Takeda101 0.03±0.006 52.1±26.3 9.2±3.0 ND ND 
n/a GSK180736A 0.77±0.5 > 100 > 100 30±19 65% 
n/a 224406 0.13±0.03 >100 >100 >100 0%* 
 258753 2.1±0.72 > 100 > 100 > 100 11% 
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 258202 0.77±0.17 > 100 84.3±35.8 > 100 17% 
 258201 2.68±2.11 > 100 > 100 > 100 22% 
 208947 1.53±0.49 > 100 37.2±28.9 > 100 34% 
 211990 2.03±0.33 > 100 10.2±1.8 > 100 0% 
 211991 12.4±7.7 > 100 75.7±39.9 > 100 5% 
 208945 7.42±5.8 > 100 > 100 > 100 3% 
 215086 3.98±2.9 > 100 > 100 77±43 21% 
 232403 2.17±0.79 24.5±19.6 42.3±16.3 > 100 0% 
 232407  1.76±1.43 25.8±16.1 33.2±2.48 > 100 0% 
 232402 2.04±1.02 32.0±14.0 38.4±16.1 >100 13% 
 232404 1.01±0.07 26.1±18.8 74.3±82.7 >100 0% 
 211993 37.7±9.14 > 100 > 100 > 100 1% 
 215140 2.37±2.27 > 100 > 100 25.8±25 18% 
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 215141 4.20±2.57 72.2±20.8 > 100 28.5±19 NT 
 211998 0.61±0.12 > 100 17.1±5.9 > 100 6% 
 258203 1.52±0.78 > 100 76.3±15.3 > 100 6% 
 258204 2.04±0.74 > 100 > 100 > 100 8% 
 258205 3.28±1.8 > 100 > 100 > 100 15% 
 258207 3.02±0.99 > 100 > 100 > 100 18% 
 258206 3.24±1.0 > 100 > 100 > 100 21% 
 215143 6.01±2.08 60.0±2.07 > 100 48.2±35 0% 
 215142 5.9±3.2 > 100 > 100 > 100 0% 
 258209 0.75±0.32 > 100 14.8±3.2 > 100 18% 
 258210 0.6±0.21 > 100 > 100 > 100 11% 
 258208 0.03±0.001 87.3±27.9 7.09±0.73 > 100 9% 
 258750 0.77±0.20 > 100 > 100 > 100 18% 
 258754 0.03±0.02 86.5±7.0 4.0±0.52 > 100 12% 
 258752 1.25±0.30 > 100 > 100 > 100 17% 
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 258751 2.11±0.52 > 100 > 100 > 100 14% 
 258749  0.39±0.11 > 100 > 100 > 100 19% 
 224060  16.7±5.4 > 100 > 100 > 100 13% 
 222886 0.63±0.33 > 100 > 100 > 100 27% 
 258747 0.018±0.006 9.33±2.76 1.49±0.50 >100 27% 
a
All IC50 measurements are an average of three separate experiments run in duplicate. Errors shown 
represent error of the mean. *Percent inhibition at 10 μM inhibitor concentration. ND, not determined. 
 
In order to improve binding of the inhibitors to the hinge of the kinase we replaced the 
benzodioxole of paroxetine with an indazole, analogous to what is present in GSK180736A.  
(Table 3.2). This resulted in a 20-fold increase in potency for GRK2 (224061, IC50 = 66 nM) 
relative to the lead paroxetine. Analogue 224061 also gained affinity for the other GRKs, PKA, 
and ROCK. Although it was still selective for GRK2 it was much less selective than paroxetine 
having only an 8-fold selectivity factor over ROCK1. We additionally explored addition of 
fluorine to the indazole ring in hopes of improving compound stability to oxidative metabolism, 
giving 258002. Addition of the fluorine (258002) resulted in a decrease in GRK2 potency by two 
fold and an increase in both GRK1 and GRK5 potency resulting in a less potent and selective 
GRK2 inhibitor. 
 In an effort to build back in selectivity to this potent compound, 2,6 – 
dimethoxybenzylamide was appended (232406) to the fluorophenyl ring, based on our previous 
success with this amide on the GSK180736A template.
71
 Compound 232406 indeed showed 
improvement in selectivity for GRK2 over the GRKs and PKA, but resulted in an unacceptable 
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boost in potency for ROCK1. Again we investigated addition of a fluorine to the indazole on 
232406 to give 258003. The fluorinated analogue 258003 was tolerated at GRK2 having nearly 
identical potency with respect to the non-fluorinated 232406, but again, as seen with 258002, 
potency at both GRKs 1 and 5 was increased. We did not further investigate fluorinated 
analogues as fluorination resulted in reduced selectivity against the other GRKs. 
 
Table 3.2. Kinase Inhibitory Activity and Half-Life in Mouse Liver Microsomes of Indazole 





















t1/2   
(min) 
H H 






258002 0.14±0.06 3.67±0.91 0.82±0.18 
3.7± 






















H 258748 0.008±0.002 4.5±1.2 0.24±0.04 66±29 85%* 8.11 
a
All IC50 measurements are an average of three separate experiments run in duplicate. Errors shown 
represent error of the mean. *Percent inhibition at 10 μM inhibitor concentration. 
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 Next we attempted to achieve additional potency on the indazole paroxetine analogues 
through polar interactions or hydrogen bonding in the hydrophobic subsite, using two of the 
favorable amides from our earlier SAR. The 2-pyridylmethylamide 257284 showed no 
improvement in GRK2 binding relative to 224061 and lost selectivity against GRK1 and GRK5, 
effectively becoming a potentially useful pan-GRK inhibitor (like the similar 2-
pyridylmethylamide GSK10736A analogue 215022) as it retained 150-fold selectivity over 
PKA.  Incorporation of the optimal 3-pyrazolylmethylamide of 258208 (258748) yielded our 
most potent inhibitor to date (258748), having an IC50 for GRK2 of 8 nM, while retaining greater 
than 30-fold selectivity over the other GRKs and PKA. Although 258748 is selective for GRK2 
it is also very potent for GRK5 with an IC50 of 240 nM.  
 Lastly, we investigated alkylating the piperidine nitrogen of 224061 (Table 3.3). N-
methylation (258001) resulted in a 4-fold decrease in GRK2 potency (IC50 = 290 nM) but had 
much more dramatic decreases in potency for GRK1, GRK5, and PKA, resulting in >100 fold-
selectivity for GRK2 over all three kinases. Increasing the size of the methyl to either the ethyl or 
the isopropyl (258211 and 258746, respectively) was not as well tolerated. The GRK2 potency 
dropped with the increasing N-alkyl substituent size. Therefore, larger alkyl groups were not 
explored. As the piperidine nitrogen is involved in a hydrogen bond with Ala321, which is 
conserved throughout the GRKs, the decrease in potency is not surprising.
72
 The increased 
GRK2-selectivity of the N-alkyl analogs suggests that in GRK2 the angle of the protonated 
tertiary amine must remain favorable for making a hydrogen bond with the backbone carbonyl of 





Table 3.3. Kinase Inhibitory Activity and Half-Life in Mouse Liver Microsomes of Alkylated 
Indazole Paroxetine Hybrid Compounds 
 













t1/2   
(min) 
H 224061 0.066±0.005 6.57±1.79 1.28±0.2 2.67±1.1 0.54±0.39 30.3 
Methyl 258001 0.29±0.11 51.8±5.2 33.0±5.3 87±18 65% NT 
Ethyl 258211 0.99±.27 >100 >100 >100 40% NT 
Isopropyl 258746 1.81±0.33 >100 >100 NT 33% NT 
a
All IC50 measurements are an average of three separate experiments run in duplicate. Errors shown 
represent error of the mean. *Percent inhibition at 10 μM inhibitor concentration. 
 
Evaluation of Kinome Selectivity
6
. Selectivity within the kinase interactome has 
become increasingly important with the advent of kinase inhibitors. Off target kinase activity can 
lead to a myriad of undesired side effects as kinases act as a key part of many cellular 
processes.
87-89
 To assess a broader kinome-wide selectivity of our paroxetine derivatives apart 
from GRK, ROCK1, and PKA selectivity we selected 258747 for evaluation in a kinome scan 
(from DiscoverX) at 1 µM against a panel of 104 kinases including GRKs 1, 2, 3, 4, and 7 as 
controls (Figure 3.2). The assay evaluated thermodynamic inhibitor binding affinity to the 
kinases and reported a remaining percent control activity.  Our resulting S(35) selectivity score 
was 0.021 indicating a highly selective inhibitor. Our percent control activities for GRKs 2 and 3 
were 2.5% and 2.1% respectively with the next lowest activity at 47% control for ROCK1 and 
only five other kinases with a percent control activity below 70.  
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Figure 3.2: Kinome Selectivity of CCG258747 at 1 µM. Each kinase subfamily is highlighted 
in the kinome. Under the AGC kinase subfamily two red dots show the reported affinity for 
GRK2 and GRK3. In green are the other tested kinases, all of which showed a percent control 
above 35%.  
 
Crystallographic Analysis (Benzodioxole Paroxetine Derivatives).
7
 To confirm our 
design strategy and to guide our analogue design early in our campaign, we determined the 2.6 Å 
crystal structure of 211998 bound to the GRK2–Gβγ complex (Figure 3.3A). The complex 
crystallized in an unusual space group (P2) not previously observed for this assembly, suggesting 
unique conformational changes in the kinase domain. We then additionally determined co-crystal 
structures of 222886 and 258208 in the space group C2 at resolutions of 2.2 Å and 3.0 Å, 
respectively (Figure 3.3B and 3.3C). Due to the addition of their various amide linked D rings, 
there are slight variations in the fitting of their A, B and C rings among the molecules, although 
overall they bind similarly to paroxetine (PDB ID: 3V5W).
72
 The benzodioxole A rings of the 
three inhibitors form analogous hinge interactions, the piperidine B ring sits puckered in the 
                                                          
7
 Crystal structures in this section were determined by Kristoff Homan, Claire Cato, Osvaldo Cruz-Rodríguez, Renee 
Bouley, and John Tesmer. 
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ribose subsite where it forms a hydrogen bond with the backbone carbonyl of Ala321, and the 
fluorophenyl C ring packs under the P-loop in the polyphosphate subsite. As seen in our 
previously reported GSK180736A derived inhibitors, the carbonyl of the amide linkers of all 
three inhibitors forms a hydrogen bond with the backbone nitrogen of Gly201. Beyond the amide 
linker of 222886, the electron density for the pyrazole is relatively poor, likely because it extends 
out of the active site towards solvent. Because the D rings of 211998 and 258208 do occupy the 
hydrophobic subsite, we interpret the divergent packing of 222886 as a consequence of the extra 
methylene preceding its amide group, which makes the substituent too long to pack into the 
subsite. Phe202 in the 222886 complex also adopts a distinct rotamer from the paroxetine, 
211998, and 258208 complexes, which may allow it to interact with the solvent-extended 
pyrazole of 222886. Relative to 222886, the amide nitrogen of 211998 and 258208 forms an 
additional hydrogen bond with the side chain of Asp335, which is also a consequence of the fact 
that 222886 is homologated, moving this nitrogen out of reach. 
The co-crystal structure of the 222886 crystal complex was the most analogous to the 
parent paroxetine complex in that it aligns nearly identically (r.m.s.d. deviation of 0.22 Å for the 
C atoms of residues 185-271 in the small lobe). This is consistent with our SAR in that 222886 
has only a 2-fold increase in GRK2 potency relative to paroxetine but retains similar IC50 values 
for both GRK1 and GRK5. The increase in potency for GRK2 seems unlikely to be due to the 
additional hydrogen bond picked up by the amide linker because 258753, which contains just an 
amide substituent, is two-fold less potent. Selectivity is likely similar to that of paroxetine 




Figure 3.3: GRK2-Gβγ crystal complexes of 211998, 222886, and 258208. Binding modes of 
three paroxetine derivatives in the GRK2 active site reveal rules for productive engagement of 
the hydrophobic subsite. 3σ |Fo|-|Fc| omit maps of A) 211998 (pdb: 5UKK), B) 222886 (pdb: 
5UKL), and C) 258208 (pdb: 5UKM) are shown as magenta wire cages superimposed on the 




Although the 2-pyridine of analogue 211998 packs snugly into the hydrophobic subsite of 
GRK2, this seems to require displacement of the B helix and adjoining loops away from the 
active site by up to 1.3 Å, consistent with a larger r.m.s.d. of 0.76 Å for the C atoms in the 
small lobe of the kinase compared to the paroxetine complex, as well as a unique hinge 
conformation that changes the relative orientation of the small and large lobes by ~15˚ relative to 
the 258208 and 222886 co-crystal structures. These changes are probably responsible for the 
unique crystal form that this complex adopts. Because the SAR showed that placement of the 
pyridine nitrogen at the 3 or 4 position was detrimental to potency, it had been surmised that a 
polar contact or hydrogen bond might exist between the nitrogen and the catalytic lysine as seen 
in our formerly reported GRK5·215022 inhibitor complex.
56
 Here the pyridine nitrogen is too 
distant (4.5 Å) and not in the right orientation to form a hydrogen bond with the side chain of the 
catalytic lysine (GRK2-Lys220), as does the analogous pyridine D ring in the GRK5·215022 co-
crystal structure. Thus, it is instead modeled facing the solvent, as in our GRK2-Gβγ·215022 
structure.
71
 The loss in GRK2 potency upon migration of the pyridine nitrogen to the 3 or 4 
position (258203 and 258204) is likely a consequence of the loss of lipophilicity at those 
positions, which can make non-polar contacts in the hydrophobic subsite. The increased potency 
exhibited by 211998 for both GRK2 and GRK5 relative to paroxetine is therefore likely due to 
additional van der Waals interactions formed by the D ring in the hydrophobic subsite. 
 The small lobe in the 258208 co-crystal structure is more similar to the paroxetine 
complex (r.m.s.d. of 0.41 Å) than the 211998 complex (r.m.s.d. of 0.86 Å). As in 211998, the 
non-homologated pyrazole moiety of 258208 packs in the hydrophobic subsite but packs lower 
in the site than the pyridine of 211998. The pyrazole nitrogens are within hydrogen bond 
distance of the side chains of both Glu239 and Lys220, with the closest being formed with 
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Glu239. Therefore, it is most likely that the significant increase in potency for GRK2 results 
from not only the specific interactions picked up by the pyrazole nitrogens, but also because the 
pyrazole does not require a conformational change ( pushing out the B helix) as required for the 
pyridine of 211998. The carbon of the pyrazole adjacent to the two nitrogens packs against 
Leu235 in the αC helix, thus it is not clear how 258754 (methylated) retains high potency, but 
the observed interactions explain why 258752 and 258751 (N-methylated variants), 258749 and 
258209 (pyrazole nitrogens moved around the ring and analogous imidazole) exhibit large 
decreases in potency, as does lengthening the linker between the amide and the pyrazole 
(258750). 
 Additionally, the slightly more potent D-ring indazole analogue 258747 was then 
crystallized (Figure 3.4A) giving further insight into the ability of the hydrophobic subsite to not 
only form additional hydrogen bonds with the pyrazole but its ability to adapt and fit the added 
bulk of the fused phenyl ring. Analogue 258747 crystallized in space group C2221, which had 
not been previously seen with these paroxetine derivatives, at a resolution of 2.44 Å. This crystal 
form is surprisingly more analogous to the GSK180736A hybrid compounds.  
 Similar to the previous three structures, 258747, bound in the adenine and ribose subsites. 
In the adenine subsite backbone hinge interactions with Met274 and Asp272 are made via 
hydrogen bonds. The piperdine nitrogen additionally makes a hydrogen bond with Ala321 in the 
ribose subsite. The fluorophenyl ring packs under the P-loop which sits slightly more open 
relative to the other three paroxetine structures. In comparison (Figure 3.4B) to the pyrazole 
amide 258208, the amide linker of the indazole analogue 258747 is rotated ~180˚ so that the 
carbonyl is pointed down in the active site and the amide is not making hydrogen bonds as seen 
in the 211998, 222886¸and 258208 crystal structures likely explaining the slight upward shift of 
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the P-loop. As expected, the indazole nitrogens of 258747 make H-bonds to Glu239 and Lys220 
in the hydrophobic subsite that are analogous to 258208. The phenyl of the indazole ring 
additionally packs up into the hydrophobic subsite similarly to what is seen with 211998, 
pushing the αB helix out slightly and making edge to face π – stacking interactions with the side 
chain of Phe202.  
 
Figure 3.4: Comparison of 258208 and 258747 in GRK2. A) GRK2-Gβγ-258747 crystal 
structure, GRK2 is in light grey and 258747 is colored in salmon. Hydrogen bonds are 
highlighted by dashes black lines. B) Overlay of the GRK2-Gβγ-258208 (yellow/dark grey) and 
GRK2-Gβγ-258747 (light grey/salmon) crystal structures.  
 
 As the crystal structure of 258208 shows packing of the pyrazole carbons against Leu235 
in the αC helix it was unclear as to how the hydrophobic pocket could additionally accommodate 
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the very bulky indazole. The indazole angles towards the top of the pocket more than the 
pyrazole of 258208 pushing the αB and αC helices out ~1.5Å to form a larger hydrophobic 
subsite. This larger conformational change is likely overcome by the gain in packing and edge to 
face π-stacking made with Phe202. Due to this shift of the indazole the amide linker no longer 
seems to make additional hydrogen bond contacts as expected (although further refinement of 
the crystal structure is necessary and may show this is not the case), but a decrease in potency 
relative to 258208 is not observed presumably due to the advantageous packing of the indazole 
in 258747.  
Crystallographic Analysis (Indazole Paroxetine Derivatives).
8
 To rationalize the 
increases in potency exhibited by the indazole hinge binding derivatives, three of their crystal 
structures were determined. The first crystal structure that was obtained was of the simple 
paroxetine derivative, 224061 in complex with GRK2-Gβγ at a resolution of 3.1 Å (Figure 
3.5A). This crystal complex crystallized in a space group not previously seen with the other 
paroxetine derived inhibitors (C2221), but instead in the same space group as the GSK180736A 
derived inhibitors. Additionally, two of the amide linked D – ring derivatives of this indazole 
paroxetine based series were solved in complex with GRK2-Gβγ, the pyridine 257284 (Figure 
3.5B) and the pyrazole 258748 (Figure 3.5C). Both GRK2-Gβγ-257284 and GRK2-Gβγ-258748 
crystallized in the same space group as the initial GRK2-Gβγ-224061 crystal structure (C2221) at 
resolutions of 2.31 Å and 2.89 Å, respectively. The indazole of all three analogs binds in the 
hinge of GRK2 analogously to the indazole of GSK180736A forming two hydrogen bonds, one 
with the backbone carbonyl of Asp272 and one with the backbone carbonyl of Met274.  The 
piperidine ring of all three analogs binds in the ribose subsite forming a hydrogen bond with 
Ala321 while the fluorophenyl, as expected, packed up under the P-loop. As 224061 has no 
                                                          
8
 Crystal structures in this section were determined by Kristoff Homan, Renee Bouley, and Claire Cato.  
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amide linked D – ring it makes no contacts in the hydrophobic subsite. The aromatic rings of 
257254 and 258748 both reach into the hydrophobic subsite, overlaying nearly identically 
(Figure 3.6).  
 The GRK2-Gβγ-224061 complex is a more closed kinase domain conformation as seen 
with GSK180736A, as opposed to the more open structure observed upon paroxetine binding. 
Alignment of the small lobes of the kinase domains (residues 185 – 270) of GRK2-Gβγ-224061 
and GRK2-Gβγ-paroxetine crystal structures gives an rmsd value of 0.45 Å (Figure 3.7A) 
indicating relatively large conformational differences. In the overlay of the two crystal 
complexes the chemical structures of 224061 and paroxetine align very similarly. Furthermore, 
both 224061 and paroxetine make analogous contacts in the hinge whether it be with an indazole 
(224061) or a benzodioxole  
(paroxetine) leaving one to wonder how the indazole analogue 224061 has a nearly twenty fold 
increase in potency. This increase in potency may be attributed to stronger hydrogen bonds made 
by the indazole relative to the paroxetine and perhaps from an ability of the indazole of 224061 
to engage and stabilize a much more closed structure of the kinase. This is more clearly seen by 
comparing the P-loops of the two structures. The P-loop of 224061 is shifted and flipped tighter 
down into the active site relative to paroxetine. The alpha carbon of Gly201, which resides on the 
P-loop, between the two complexes shows a shift of 1.8 Å (Figure 3.7A, orange arrow). 
Although both analogs exhibit hinge binding interactions it may be that in the active 
conformation of the binding site the indazole can more easily lock these hydrogen bonds down 
while the benzodioxole exhibits an added amount of flexibility not as readily observed in the 




Figure 3.5: Crystal complexes of three indazole substituted paroxetine derivatives in the 
GRK2 active site. A) 2224061 B) 257284 and C) 258748 are shown in pale pink. Hydrogen 




 Spatially, the other two indazole based paroxetine hybrid analogue complexes GRK2-
Gβγ-257284 and GRK2-Gβγ-258748 bind very similarly, having nearly identical crystal cell 
contacts and an rmsd of only 0.23 Å upon alignment of the small lobes of the kinases (Figure 
3.6). Relative to the GRK2-Gβγ-224061 complex the two amide linked derivatives vary in 
alignment with rmsds of 0.32 Å  and 0.37 Å (257284 and 258748). Overall, relative to the 
benzodioxole hinge binding analogs, these two compounds do exhibit a more closed 
conformation, but the GRK2-Gβγ-224061 structure does show an even more closed P-loop 
(Figure 3.6). This shift is likely due to the fact that 224061 does not have additional amide 
linked appendages that bind into the hydrophobic subsite. Although 257284 and 258748 bind 
analogously in the hinge, the ribose subsite, and up under the P-loop they differ in electronics 
within the hydrophobic subsite. The amide linker of the D-ring appendages makes two hydrogen 
bonds in both compounds with the backbones of Asp335 and Phe202 (Figures 3.5B and 3.5C). 
Moving deeper into the hydrophobic pocket of GRK2, there are clear differences in binding of 
257284 and 258208 that explain their differences in potency. The pyridine analog 257284 packs 
its carbons up against the αC helix and into the hydrophobic pocket while exposing the pyridine 
nitrogen to solvent. In the pyrazole analog 258748 the pyrazole is flipped so that the nitrogens 
are no longer facing the solvent. The two pyrazole nitrogens are then positioned to make 
additional hydrogen bonds with Glu239 and Lys220 deep within the pocket while the carbons of 
the ring then additionally pack up against the αC helix. As the pyrazole analogue 258748 is 
nearly thirteen fold more potent than the pyridine analogue 257284 it is clear that these 




Figure 3.6: Alignment of indazole paroxetine analogs 224061, 257284, and 258748. 
Alignment of the GRK2-Gβγ-224061 (light grey), GRK2-Gβγ-257284 (green), and GRK2-Gβγ-
258748 (slate) crystal complexes reveals a shift of the P-loop for GRK2-Gβγ-224061 relative to 
the amide linked compounds.  
 
Interestingly, these additional hydrogen bonds lead to only a two-fold increase in potency 
for 258748 relative to 257284 for GRK5. Although there is no crystal structure of 257284 in 
complex with GRK5 it is likely that it binds highly similarly to the previously crystallized 
215022 analogue, of which it mainly differs in the ribose binding subsite. Compound 257284 has 
a piperidine whereas 215022 has a dihydropyrimidinone. Both compounds exhibit nearly 
identical potency for GRKs 1, 2, and 5 as well as ROCK1. As 215022 forms a hydrogen bond in 
the hydrophobic subsite of GRK5 with Lys 220 it is likely that the pyridine of 257284 is also 
forming this hydrogen bond explaining its higher potency against GRK5. 
The largest structural dissimilarity was seen between GRK2-Gβγ-257284 and GRK2-
Gβγ-Takeda103A with an rmsd between the small lobes of their kinases of 0.54 Å (Figure 
3.7B). This is not unexpected due to the highly dissimilar chemical nature of the two compounds. 
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However the two compounds are both highly potent and achieve their potencies by binding all 
four subsites. The Takeda103A compound forms only one hydrogen bond in the hinge in 
contract to the two hydrogen bonds formed with 257284 as well as the other GRK2 inhibitors in 
this serious. Overall the Takeda103A compound binds slightly further away from the hinge than 
does 257284, and due to its vastly different ring structure its phenyl “C” ring which packs under 
the P-loop is shifted over by nearly 0.7 Å with respect to the C ring of 257284. Further 
differences are seen in a shift of both the αB and αC helices out in order to accommodate the 
larger di-fluorophenyl ring of Takeda103A, effectively making a larger subsite. In the case of 
257284 and our other indazole based hybrid analog 258208, potency is achieved through a 
conformational locking down of the hinge via the indazole moiety with adjacent contacts made 
via the amide linkers and D-ring substituents in the hydrophobic subsite. Conversely, the 
Takeda103A D-ring sits flipped into a much more hydrophobic region of the pocket and seems 
to lock the inhibitor into the hydrophobic subsite and then into the ribose site while making a 
weaker interaction in the hinge of the kinase via the pyrimidine, perhaps leading to its high 
selectivity.  
Excitingly, crystal complexes of two of our most interesting inhibitors of structural 
similarity (258208 and 258748) were obtained allowing us to directly compare the role of the 
indazole vs the benzodioxole in the hinge region. The structures of 258208 and 258748 are 
identical except for the different hinge binding motifs (benzodioxole vs indazole, respectively). 
Alignment of the GRK2-Gβγ-258208 and GRK2-Gβγ-258748 small lobes reveals an rmsd of 
0.48 Å (Figure 3.7C), which is fairly similar to the comparison between the non amide linked 
derivatives (paroxetine vs. 224061, rmsd = 0.45 Å). The two compounds crystallized in different 
space groups, which likely results from the ability of the compounds to stabilize GRK2 via 
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differing mechanisms. In the hinge of the kinase, the benzodioxole and indazole rings 
superimpose upon eachother which is consistent with the nearly identical overlay of the 
backbone of the hinges. The two compounds begin to differ in the pucker of the ether linkage to 
the piperdine ring in the ribose and then again differ in conformations of the piperidine ring. In 
both analogues, however, a hydrogen bond is maintained with Ala321 and the the ribose binding 
subsite does not appear to contribute much to GRK2 potency (for reference look at the N-methyl 
alkylated analog 258001). Further analogs with differing ring systems in the ribose subsite would 
be needed in order to further confirm this hypothesis. Again, the P-loop of the indazole analog 
GRK2-Gβγ-258748 complex as seen with the other indazole based compounds is shifted down 
relative to GRK2-Gβγ-258208. Furthermore, a shift is also seen in the αC helix. It may be that 
the compound is slightly shifted over in order for the pyrazole of 258748 to make hydrogen 
bonds with Lys220 and Glu239. As Glu239 resides on the αC helix it does makes sense that 
there would be a shift of the helix relative to any shift in the compound to accommodate the 
change. Again, these P-loop and αC helix shifts may just be artifacts of the different crystal 
packing. Overall, both compounds lock GRK2 down in the hydrophobic subsite through identical 
hydrogen bond interactions. The higher potency for 258748 is most likely due to its ability to 
further tightly bind and stabilize GRK2 in the hinge of the kinase relative to 258208. As both 
compounds have similar binding modes overall that rely heavily on key interactions of the amide 
linked pyrazole in the hydrophobic subsite it is reasonable that the indazole analog 258748 only 





Figure 3.7: A comparison of the binding modes of structurally similar paroxetine derived 
inhibitors and structurally dissimilar GRK2 inhibitors. A) GRK2-Gβγ-224061 (light grey: 
pale pink) and GRK2-Gβγ-paroxetine (purple: dark grey, 3V5W) alignment, the orange arrow 
highlight the 1.8 Å shift of the P-loop B) GRK2-Gβγ-257284 (light grey; pale pink) and GRK2-
Gβγ-Takeda103A (yellow: dark grey, 3PVW) alignment, C) GRK2-Gβγ-258748 (light grey; 
pale pink) and GRK2-Gβγ-258208 (salmon; dark grey, 5UKM) alignment 
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 Without a crystal structure of GRK5 in complex with one of our paroxetine-derived 
compounds, the ability of these pyrazole derivatives to retain such high selectivity over GRK5 
remains unclear. We have observed that the hydrophobic subsite in GRK2 can accommodate 
bulkier D-rings than GRK5.
56, 71, 80
 Furthermore, of the compounds reported here only those with 
non-homologated amide linkages exhibit any potency for GRK5, suggesting that the hydrogen 
bond formed between the amide nitrogen and GRK2-Asp335 (GRK5-Asp329) is important for 
potency against GRK5. The non-homolgated methylene-linked pyrazoles, 258208 and 258754, 
exhibited the highest potency for GRK5 (but retained >100 fold selectivity for GRK2), consistent 
with the idea that hydrogen bond formation by the amide linker in combination with favorable 
polar contacts is similarly important for GRK5 potency. Thus, it seems most likely that 
differences in the kinase domain hinges and, consequently, the overall conformation of the 
GRK2 and GRK5 kinase domains are responsible for the observed selectivity in the paroxetine-
derived compounds. For example, if one overlays the small lobe of the GRK2·258208 complex 
with that of the GRK5·215022 complex, the glycine in the DFG loop of the large lobe of GRK5 
would sterically collide with the pyrazole of 258208. The preferred conformation of the GRK5 
hinge may also engender less optimal interactions with the benzodioxole of paroxetine derived 
inhibitors. 
Metabolic Stability. To guide the design and selection of analogs with favorable 
pharmacokinetic (PK) properties, we evaluated the stability of selected compounds to incubation 
with mouse liver microsomes (MLM) (Tables 3.2 and 3.4). Our lead compound, paroxetine, had 
a t1/2 of 24 min in our MLM assay while the other series lead GSK180736A had a t1/2 of 21 min 
and Takeda101 had a t1/2 of only 1.9 min. Replacing the benzodioxole ring with an indazole 
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(224061) resulted in a longer half-life of 30 min, suggesting that the methylene carbon of the 
benzodioxole ring in paroxetine is a likely site of metabolism. 
We briefly explored the addition of fluorine to the C6 position of the indazole ring to help 
increase potency and further improve metabolic stability as previous work showed this addition 
improved half-life and bioavailability with similar inhibitors.
76, 90
  Addition of fluorine to 224061 
yielded analogue 258002. As previously discussed the fluorine was tolerated in terms of potency 
but was not successful in improving metabolic stability. Compound 258002 had a half-life of 
only 22 min, nearly 8 min shorter than that of 224061   
Appending lipophilic carboxamides onto GSK180736A, giving our previously reported 
GRK2 inhibitors (224063, 224064, 224406), resulted in a substantial drop in stability with all 
three compounds having a t1/2 lower than 4 min (Table 3.4).
71
 Conversely, addition of the same 
moieties onto the paroxetine scaffold (analogs 232407, 232403, 232402, Table 3.4) could be 
done without eroding metabolic stability and in the case of 232403 improving upon the t1/2 of 
paroxetine two-fold (MLM t1/2 = 46 min). Conversely MLM stability of the carboxamide 
indazole paroxetine analogues 232406, 257284, and 258748 (Table 3.2, t1/2 = 8.3, 2.7, and 8.1 
min, respectively)  was reduced at nearly four-fold in comparison to 224061 in all three cases. 
Fluorination of the 2,6-dimethoxy analogue 232406  resulted in a slight increase in metabolic 
stability (Table 3.2, t1/2 = 13 min vs 8.3 min) perhaps giving some utility to the fluorine addition. 
 Surprisingly, on the paroxetine template, the polar carboxamides (211998, 258208, and 
258754, Table 3.4) exhibited substantial metabolic instability (t1/2 = 3.2, 7.0, and 10.4 min, 
respectively) perhaps due to targeting of the heterocyclic nitrogens to the heme of cytochrome 
P450. As the bulkier indazole appendage from the paroxetine scaffold (258747) exhibits a half-
life in MLMs of 40 min this is further confirmed. The added bulk to the heterocycle may be 
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blocking its ability to coordinate well to the heme in comparison to the smaller pyrazoles 
(258208 and 258754). These conflicting results between the paroxetine and GSK180736A 
scaffolds suggest that they have different mechanisms of clearance. 
 
Table 3.4: Comparison of MLM stability between 
paroxetine and GSK180736A analogs 
 




N/A Takeda101A N/A 1.91 
H GSK180736A B 20.6 
H Paroxetine A 24.3 
 
232407 A 36.4 
224063 B 3.37 
 
232403 A 45.9 
224064 B 3.46 
 
232406 A 24.9 
224406 B 3.82 
 
211998 A 3.15 
215022 B 11.32 
 258208 A 7.0 
 258754 A 10.3 




Contractility in Mouse Cardiomyocytes. As an underlying mechanism of heart failure 
is the inability of the heart to properly contract, we selected compounds 211998, 224061, 
258747, and 258208 in addition to Takeda101 for evaluation in an in vivo contractility assay 
(Tables 3.5 and 3.6). Following incubation with varying doses of the inhibitors to give a baseline 
contraction mouse cardiomyocytes were then stimulated with the βAR agonist isoproterenol. The 
resulting maximal increase in contraction was then measured.
56
 As inhibition of GRK2 should 
increase the number of activated βARs, we would expect our inhibitors to enhance the maximal 
increase in comparison to a DMSO-treated control. Previously, we showed that both paroxetine 
and GSK180736A produce an increase in contractility (Table 3.5). The minimum dose needed 
for paroxetine to produce a significant response was 10 μM, whereas GSK180736A showed 
similar efficacy at 1 μM.
71, 72
 These results agree with the higher potency of GSK180736A 
relative to paroxetine. 
 The indazole substituted compound 224061 showed significantly increased contractility 
at a dose of 1 μM, a similar potency to GSK180736A and a ten-fold increase in efficacy in 
comparison to paroxetine (Table 3.6). Evaluation of 211998 and 258747 (data is preliminary and 
not yet reported) in the cardiomyocyte contractility assay did not show a significant increase in 
contractility at 0.5 μM or 1 μM. For 211998 this result was consistent with its modest two-fold 
increase in GRK2 inhibition potency, but was unexpected for 258747 as it is highly potent for 
GRK2. Perhaps 258747 aggregates more readily leading to its poor in vivo potency or its high 
molecular weight leads to poor cell membrane permeability. The highly potent 258208, on the 
other hand, showed a significant increase in contractility at a concentration of only 0.1 μM, a 
100-fold lower concentration than paroxetine, consistent with the approximately 50-fold 
increase in potency 258208 has for GRK2 relative to paroxetine. Additionally, 258208 showed a 
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5-fold improvement over Takeda101, although both compounds had equal potency for GRK2 
(30 nM), suggesting that 258208 may have better cell permeability.  In comparison to our 
previously reported compound 224406, this paroxetine hybrid inhibitor also shows a 5-fold 
improvement in efficacy.
71
 Importantly, these results suggest that significant improvement in 
βAR-stimulated contractility in mouse cardiomyocytes can be achieved with potent GRK2-
selective inhibition. 
 
Table 3.5: Mouse Cardiomyocyte Contractility of Paroxetine, GSK180736A, and Takeda101 
 Paroxetine  GSK180736A Takeda101 




























5.0 ±  
0.5 
4.0 ±  
0.3 
4.3 ±  
0.8 











4.8 ±  
0.5 















13 ±  
0.8 












12 ±  
0.7 
16  ± 
1* 
17  ± 
1.3* 
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26.5* 
 



















Table 3.6: Mouse Cardiomyocyte Contractility of Paroxetine Derivatives 
 211998 224061 258208 

























5.1 ±  
1.1 
5.1 ±  
1.1 
 
5.2 ±  
0.6 
 
































16 ±  
1.1 
 
17 ±  
1.2*  
 
11 ±  
0.9 
14 ±  
0.7* 
 
18  ±  
1.3* 
15  ±  
1.2* 
% increase in 
contraction 
amplitude 











154 ±  
45 
 
284 ±  
92 
 
177 ±  
26 
 






433 ±  
90* 
342 ±  
65* 
Values represent the mean ± SEM for 6-8 cardiomyocytes. *,p<0.05 vs Control 
 
Preliminary Pharmacokinetic Study in Mice. Compounds Takeda101, 224061, 
258747, and 258208, were evaluated in an abbreviated in vivo pharmacokinetic study in mice 
(Table 3.7). The compounds were intraperitoneally injected into CD-1 mice at a dose of 10 
mg/kg, plasma samples were collected at four different time points over seven hours, and drug 
levels in plasma were quantified. Due to the abbreviated nature of this study, PK parameters 
could not be rigorously calculated. Nevertheless, it is clear the half-lifes in vivo for 224061, 
258747, and 258208 are all superior to that of Takeda101 which is too low to quantify in this 
study.  Compounds 224061 and 258747 both initially achieved similar plasma concentrations 
(1360 nM and 1530 nM, respectively). The pyrazole analogue 258208 was much higher at 2710 
nM but had a steeper curve of clearance relative to 2458747. Of particular relevance to future in 
vivo efficacy studies in mice, both 258208 and 258747 maintain total plasma drug levels after 
single IP administration that exceed the GRK2 IC50 for at least 7 hours. More detailed 
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pharmacokinetic parameters and potential hERG liability due to the piperidine will need to be 
assessed during further development of these compounds as potential heart failure therapeutics. 
 
Table 3.7.  In Vivo Exposure Following IP Administration to Mice 
 plasma (nM) AUC 0 – 7h
obs  
(hr*nM) 
Compound (dose) 30 min 2 h 4 h 7 h  
Takeda101 (10 mg/kg) 1830 320 50 60 1900 
224061 (10 mg/kg) 1360 280 890 20 2130 
258208 (10 mg/kg) 2710 1440 270 430 5970 
258747 (10 mg/kg) 1530 1150 470 170 4970 
CD-1 mice were injected IP with a single indicated dose. The data shown are mean values from 
three mice at each time point.  
 
Discussion and Conclusions 
 Because paroxetine was identified as a modestly potent GRK2 inhibitor with good 
selectivity we sought to improve potency for GRK2 while retaining selectivity. Our previous 
GRK2 inhibitor series based on GSK180736A successfully utilized a hybrid approach to develop 
improved GRK2 inhibitors, and thus it was hypothesized that a similar approach could be used 
with paroxetine. A small library of paroxetine-derived GRK2 inhibitors were then synthesized, 
most of which retained selectivity for GRK2. Although we discovered that the SAR of our 
previous series was not translatable to the paroxetine series, we did learn that smaller 
heterocycles incorporated into the D-ring carboxamide and replacement of the benzodioxole 
moiety of paroxetine with an indazole were both advantageous to increasing GRK2 potency. 
Addition of a 3-pyrazolylmethyl amide to the paroxetine scaffold (258208), resulted in a highly 
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potent GRK2 inhibitor (IC50 = 30 nM) with high selectivity over GRK1, GRK5, PKA, and 
ROCK1 (2900, 237, >3000, and >330 – fold, respectively). Expansion of the pyrazole of 258208 
to an indazole to give 258748 resulted in the most potent GRK2 inhibitor reported to date (IC50 = 
8 nM) while retaining modest selectivity over the other tested GRKs (560-fold over GRK1 and 
30-fold over GRK5).  
Co-crystal structures of four of the synthesized paroxetine derivatives were determined, 
revealing additional hydrogen bonds with the added amide linker and the ability of GRK2 to 
adopt a more open conformation than in the GSK180736A-based series, perhaps due to a weaker 
and more flexible packing of the benzodioxole group with the hinge. This probably underlies the 
high selectivity of these compounds. This conclusion is then further confirmed by the three 
indazole hinge-binding paroxetine derivatives that were crystallized which all show a much more 
closed conformation of the kinase domain that is more similar to the GSK180736A series of 
compounds.  
The hydrophobic subsite exhibits some conformational flexibility in GRK2, as evidenced 
by the 211998 and 258747 complexes compared to the other benzodioxole based structures 
(222886 and 258208) and excludes the D ring if it is too big to bind in the pocket or is unable to 
overcome a desolvation penalty (both of which probably apply to 222886).The conformational 
flexibility of the pocket is further observed as a whole when comparing the indazole-based 
paroxetine hybrid analog 257284 to the previously reported Takeda103A complex.  
 Lastly, we successfully improved contractility in mouse cardiomyocytes at concentrations 
as low as 100 nM (258208), which is 100-fold lower than paroxetine and 5-fold lower than the 
Taked101, suggesting that selective and potent inhibition of GRK2 is sufficient for cardiac 
stimulation in the failing heart (i.e. does not require inhibition of GRK5). Evaluation in a short 
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pharmacokinetics study revealed that 258208 was able to maintain plasma concentrations higher 
than its IC50 for over seven hours, indicative of its potential as an in vivo therapeutic. Because 
258208 shows such improved potency in cardiomyocyte assays, we hypothesize that it will 
exhibit superior results in vivo relative to paroxetine, confirming the utility of this series of 
GRK2 inhibitors as optimized leads for heart failure therapeutics.   
Synthesis: 
Scheme 3.1. General synthesis of benzodioxole paroxetine derivatives. Reagents and 
conditions. a) TBSCl, DIEA, imidazole, DCM, b) PCF, toluene, 110 ˚C then TEA, c) 8N NaOH, 
IPA, 80 ˚C, d) Boc2O, DIEA, DCM, e) TMEDA, sBuLi, THF, then CO2, f) TMEDA, sBuLi, 
THF, then DMF, g) NaBH4, THF, MeOH, h) TMS-diazomethane, MeOH/Toluene, i) Ms2O, 
DIEA, DCM, j) NaCN, DMSO, k) TBAF, THF, l) Ms2O, DIEA, DCM, m) NaH, 3,4-
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(methylenedioxy)phenol, DMF, 0 ˚C to 65 ˚C, n) 1N NaOH, MeOH, o) 50% NaOH, EtOH, 98 ˚C, 
p) DIEA, EDC, HOBt, R2NH2, q) HCl/dioxanes. 
 
Initial benzodioxole-based hybrid analogues 74 were synthesized as described in Scheme 
3.1. Synthesis commenced with commercially available ((3S,4R)-4-(4-fluorophenyl)-1-
methylpiperidin-3-yl)methanol (59). Silyl protection of 59 using tert-butyl dimethylsilyl (TBS) 
chloride followed by N-demethylation with phenyl chloroformate (PCF) gave the phenyl 
carbamate 60.
91
 Basic hydrolysis provided the free amine, which was then protected to give t-
butyl carbamate 61. Sec-butyllithium mediated aryl lithiation of the position ortho to the 
fluorine, followed by trapping with carbon dioxide, yielded acid 62.
92
 The acid was then 
methylated using trimethylsilyldiazomethane to give 64. TBS deprotection of the alcohol 
followed by mesylation and nucleophilic displacement with sesamol afforded 66. The methyl 
ester was then hydrolyzed under basic conditions to give the carboxylic acid 70. Coupling of the 
free acid to various amines and final Boc deprotection yielded the carboxamides 74. 
Synthesis of homologated analogues 75 began with sec-butyllithium-mediated ortho 
lithiation of intermediate 61 followed by formylation with N, N-dimethylformamide to yield the 
carboxaldehyde.
92
 Subsequent reduction with sodium borohydride gave the alcohol 63. 
Mesylation of the benzylic alcohol with methanesulfonic anhydride followed by nucleophilic 
substitution with sodium cyanide produced 65.  TBS deprotection of the remaining alcohol 
followed by mesylation and nucleophilic substitution with sesamol gave 69. Basic hydrolysis of 
the nitrile afforded carboxylic acid 71. The acid was then coupled to various amines to give the 









Scheme 3.2. Synthesis of indazole-substituted hybrid analogues 80 and 81. Reagents and 
conditions. a) Ms2O, DIEA, DCM, b) NaH, DMF, 91 or 91, c) 1N NaOH, MeOH, d) DIEA, 
EDC, HOBt, R2NH2, e) HCl/dioxanes 
 
Analogs 80 and 81 were synthesized from intermediate 66 (Scheme 3.2). Mesylation of 
alcohol 66 followed by displacement with 91 or 92 gives intermediates 76/77. Basic hydrolysis 
of 76/77 followed by amide coupling and Boc deprotection yields analogues 80/81. 
 
 
Scheme 3.3. Synthesis of intermediates 91 and 92. a) AcOH, H2SO4, 0˚C, then NaNO2, b) 20% 
HNO3, 45˚C, c) 10% Pd/C, H2, EtOH, THF, d) KOAc, Ac2O, CHCl3, 0˚C then isoamyl nitrite 
and 80˚C, e) 6N HCl, MeOH, f) TBSCl, DIEA, imidazole, DCM, g) Boc2O, DIEA, DMAP, 
THF, h) TBAF, THF 
 
 Analogs incorporating an indazole in place of the benzodioxole were prepared by a 
convergent approach (Scheme 3.3). Intermediate 92 was synthesized from commercially 
available 2-fluoro-5-methylphenol 82. Nitration of compound 82 proceeded first through the 
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nitroso intermediate generated via sulfuric acid and sodium nitrate, then nitric acid was used to 
afford nitro 83. Amine 84 was readily accessed via palladium-catalyzed reduction of nitro 83.
93
 
Acetylation followed by cyclization of the acetamide with isoamyl nitrite and subsequent 
hydrolysis yielded 6-fluoro-1H-indazol-5-ol 86.
94
 Silyl protection of the alcohol gave 88. In the 
presence of catalytic dimethylaminopyridine the indazole was then Boc-protected giving 90. 
Final silyl deprotection gave the free alcohol 92. Intermediate 91 was synthesized from the 
commercially available 1H-indazol-5-ol 85 as described for 92. 
 
 
Scheme 3.4: Synthesis of non-carboxamide linked analogs 103-107. Reagents and conditions: 
a) K2CO3, EtI, DMF, b) NaCNBH3, Acetone, THF, AcOH, c) Ms2O, DIEA, DCM, d) NaH, 
DMF, 91 or 92, e) 4M HCl/Dioxanes, f) 20% TFA/DCM 
 
 Synthesis of the non-hybrid analogues are shown in Scheme 3.4. Intermediate 93 was N-
alkylated via two different methods. The N-ethyl 94 was achieved through alkylation using ethyl 
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iodide under basic conditions. The N-isopropyl 95 was prepared through reductive amination 
with acetone. Respective N-substituted analogues (compound 97 is commercially available) were 
then mesylated at the benzylic alcohol which was subsequently displaced with alcohols 91 or 92 


























Chapter 4: Development of Covalent GRK5 Inhibitors 
 
Rationale:  
Our success with the development of selective GRK2 inhibitors led us to next develop 
GRK5 selective inhibitors. Adjacent to the active site of GRK5 exists a nonconserved cysteine 
residue, Cys474, that is not found in the GRK1 and GRK2 subfamilies.
95
 As cysteine contains a 
free thiol the active site of GRK5 has the unique potential to form a covalent bond with a small 
molecule ATP-competitive inhibitor. In the last ten years citations in SciFinder relating to 
covalent inhibitors have exponentially increased in number supporting their prevalence as a 
novel mechanism of selectivity.
96, 97
 The scope of covalent modifiers includes electrophiles that 
are reactive with nucleophiles in solution such as epoxides as well as electrophiles that are more 
dependent upon target binding such as nitriles.
98, 99
 In the design of a covalent binding drug it is 




Some common mechanisms of covalent inhibitors include irreversible and reversible 
acylation of residues in the active site, such as seen with amoxicillin (irreversible via a β-lactam) 
and aspirin (reversible via an ester).
98
 A possible covalent modification of a cysteine residue 
directly includes formation of a disulfide bond via a sulfonamide (omeprazole, irreversible) or a 
thiol (clopidogrel, irreversible).
98, 101, 102
  Another large class of covalent inhibitors includes 
electrophiles that are good Michael acceptors such as acrylamides which can be reversible 
(floxuridine) but are typically irreversible (selegiline, ibrutinib).
98, 102
 Addition of a cyano group 
to give the cyanoacrylamides has evolved some of these irreversible acrylamide inhibitors into 
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slowly reversible covalent inhibitors.
102-104
    
Previously, active site cysteine residues in kinases have been used to successfully 
develop potent and selective irreversible inhibitors.
105, 106
 Initial successful development of 
covalent kinase inhibitors was with the tyrosine kinase EGFR that could overcome mutations 
that arise from first line reversible inhibitors.
106-111
 These approaches typically append utilize the 
class of Michael acceptor covalent modifications by appendending an acrylamide, halogen 
acetamide, or N,N-dimethyl-butenoic amide functionality to an already submicromolar inhibitor 
to give a potent and selective inhibitor.
104, 106, 112, 113
 Here we began our studies with inhibitors 
utilizing the acrylamide warhead to covalently target the Cys474 of GRK5. 
A high throughput screen formerly run in the Tesmer Lab tested known kinase inhibitors 
against GRKs 1, 2, and 5 using a differential scanning fluorimetry assay. Hits were then 
confirmed with radiometric assays. From these compounds several were identified as GRK5 
inhibitors with varying levels of selectivity (Figure 4.1).
75
 Of note, two compounds were very 
modestly selective for GRK5 over GRKs 1 and 2, GSK1713088A and GSK1326255A. 
GSK1713088A was a more pan-GRK inhibitor with IC50s for GRKs 1, 2, and 5 of 13 µM, 6.3 
µM, and 3.2 µM. The latter compound, GSK1326255A had IC50s for GRKs 2 and 5 of 6.3 µM 
and 2.5 µM, respectively, and greater than 100 µM for GRK1. Although efforts were made to 
crystallize these compounds with GRK5 and GRK6 to enable rational drug design these were not 
successful.  
Additionally identified in this screen was a GRK1-selective compound, GSK2163632A, 
which exhibited an IC50 for GRK1 of 130 nM. Its GRK5 potency was 25-fold less potent with an 
IC50 of 3.2 µM. This potent GRK1 inhibitor, which was originally developed as an insulin 





  As GRK1 is high in sequence similarity to GRK5 (more so than GRK2) it can 
serve as a useful tool for GRK5 drug design. Furthermore, as the chemical structure of 
GSK2163632A is similar to the modestly potent GRK5 inhibitors GSK1713088A and 
GSK1326255A we envisioned utilizing its crystal structure to design covalent inhibitors based 
on the latter two compounds. All three compounds contain the same pyrrolopyrimidine core 
which is connected to two aromatic rings, one of which is substituted consistently with an amide 
and the other with a methoxy. Additionally all three compounds have a tertiary basic nitrogen 




Figure 4.1: Previously identified pyrrolopyrimidine based GRK inhibitors and covalent 
inhibitor design rationale. Green ovals highlight the base of the scaffold that was generally 
conserved and orange circles represent a basic nitrogen that was seen in all three analogs that 
was removed. 
 
 The GRK1-GSK2163632A crystal complex reveals that the pyrrolopyrimidine core 
makes three hydrogen bonds in the hinge of the kinase, the thiophene packs under the P-loop 
with the amide situated towards the back of the pocket, and the tetrahydroquinoline projects 
towards the active site tether (AST) region at the front of the pocket. Additional hydrogen bonds 
are then made between the carbonyl of the tertiary amide and the backbone of Asp271 and 




Figure 4.2: Utilizing the GSK2163632A-GRK1 (PDB ID: 4PNI) crystal complex to design 
similar GRK5 covalent inhibitors. A) The crystal complex of GSK2163632A-GRK1 aligned 
with the 215022-GRK5 (PDB ID: 4WNK) crystal complex (215022 not shown). GSK2163632A 
is shown in salmon and H-bonds are show as black dashes. B)  Overlay of GSK2163632A 
(salmon) with a model of 258903 (green). Expected hydrogen bonds to 258903 are shown as 
black dashes. GRK1 is light blue and GRK5 is dark grey.  
 
 Although crystallization of one of these lead GSK compounds in GRK5 was not 
successful, the crystallization of GRK5 with one of our rationally designed GRK pan inhibitors, 
215022, as introduced in Chapter 2, was later achieved (PDB ID: 4WNK). Due to the high 
flexibility of the AST, which encompasses the Cys474 residue, this region of the crystal complex 
is disordered from residues Cys474 to Phe492.  Despite the missing region we can still envision 
where Cys474 would be expected as the structure is resolved up to Tyr473. Overlaying the 
GRK1 – GSK2163632A crystal complex with the GRK5 – 215022 crystal complex shows where 
a covalent binding moiety such as an acrylamide may be appended (Figure 4.2A). Tyr473 is 
within 4 Ả of the tetrahydroquinoline, indicating that addition of a Michael acceptor in this 
region of the molecule may allow for covalent binding to Cys474.  
As the more selective GRK5 inhibitors GSK1713088A and GSK1326255A did not have 
the tetrahydroquinoline but merely a substituted phenyl linking the compound to a tertiary amine 
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(Figure 4.1, orange circles) we envisioned that an acrylamide could be appended to the phenyl 
ring of these compounds. As addition of the acrylamide to the phenyl would result in a highly 
substituted phenyl ring we envisioned that we could replace the tertiary amine with the 
acrylamide substituent in hopes that the potency gained by the covalent bond would overcome 
the loss of the hydrogen bond the tertiary amine likely participates in. By simply removing 
structural aspects of the GSK2163632A molecule (Figure 4.1, highlighted in green ovals) and 
building an acrylamide residue off of the amide one can see that a potential covalent inhibitor 
would likely make many similar interactions as seen with GSK2163632A (Figure 4.2B, 
modelled inhibitor 258904 is in green). Of importance is that we are maintaining the three 
hydrogens bonds that lock the pyrrolopyrimidine to the hinge of the kinase. Optimal placement 
of the acrylamide is not certain, therefore, two starting covalent inhibitors were developed 
(Figures 4.3A and 3B). To help guide our design we overlaid the GRK5-215022 protein crystal 
structure with that of the previously reported GRK6-sangivamycin crystal complex (PDB ID: 
3NYN), as this complex has the AST region resolved (Figure 4.3).
115
 The overlay of GRK5 and 
GRK6 shows a close alignment of Cys474 (of GRK6) right next to the terminal Tyr473 residue 
of GRK5 allowing us to visualize what may be happening in the active site. Building the 
acrylamide meta to the aniline of the ring likely retains the hydrogen bond of the amide carbonyl 
that GSK2163632A exhibits in the GRK1 crystal complex with the backbone of Asp271 (Asp 
270 in GRK5) but this would orient the Michael acceptor nearly 6.0 Å away from Cys474 
(Figures 4.2 and 4.3A). Alternatively, building the acrylamide para to the aniline would likely 
hinder the carbonyl of the amide from making a hydrogen bond with Asp271 (Asp 270 in 
GRK1), but it would put the Michael acceptor within 1.5 Å of Cys474 to allow the thiol to attack 
and covalently bind (Figure 4.3B). As optimal placement of the acrylamide was therefore 
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uncertain both the meta and para substituents were synthesized along with their saturated ethyl 
amide analogs to use as controls as these would not have the ability to covalently bind to Cys474 
(Table 1).  
 
Figure 4.3: Modeling of acrylamide derivatives 258903 (A) and 258904 (B) into GRK5 
(PDB ID: 4WNK) and GRK6 (PDB ID: 3NYN). The ligands are each colored in green. GRK6 
is colored in tan and its AST loop has been highlighted in lavender with the Cys474 depicted as 
sticks. GRK5 is in grey and the last residue (Tyr463) before the unresolved AST loop is 
highlighted in yellow. Predicted sites for hydrogen bonding are represented as black dashed 
lines.  
 
Structure Activity Relationships:  
The resulting four analogues were evaluated in our radiometric phosphorylation assays as 
described in Chapter 2 to determine their IC50s (Table 4.1). To look for time-dependent covalent 
inhibition of GRK 5 by the two acrylamide analogues we modified the assay to measure IC50s 
following different preincubation times of protein (kinase) and inhibitor before running the five 
minute phosphorylation reaction with ATP. Four time points were initially evaluated, 0 min 
(added ATP and inhibitor at the same time), 30 min, 1 hour, and 2 hours, but no increase in 
potency was seen after two hours and thus that data point was not further explored or run in 
triplicate, and so the data is not shown.  
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Table 4.1: Kinase Activity for the GRK5 Covalent Kinase Inhibitors 
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6.2 ± 
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 7.6  
5.9 ±  
4.0  
> 100 > 100 
258904 H 
 
20 ±  
12  
6.3 ± 
 4.4  

















*All experiments were run in duplicate three times. Standard control compounds were additionally run with all 
three kinases (paroxetine and GSK180736A).  
 
The two ethylamide derivatives, 262604, and 262606 showed substantially different 
biochemical results indicating a possible SAR cliff between meta and para (relative to the 
aniline) substitutions on the methoxy phenyl ring. The para substituted ethyl amide, 262604, 
showed no activity measurable below 100 µM against all three of the GRKs whereas the meta 
substituted ethyl amide, 262606, showed no inhibition measurable below 100 µM for GRKs 1 
and 2 but low micromolar inhibition for GRK5 with an IC50 of 5.9 µM. There did not seem to be 
a time dependent inhibition of the inhibitor relative to GRK5. Looking then at the acrylamide 
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substituted analogs we saw somewhat unexpected results. The para substituted acrylamide, 
258903, showed no inhibition of GRKs 1 and 2 but did show low micromolar potency for GRK5 
with an IC50 of 6.2 µM after an hour of preincubation of inhibitor and kinase. Furthermore, 
258903 was the only inhibitor of the four tested that seemed to show a modest dependence on 
time indicating that it may be interacting via covalent inhibition. Additionally, the difference in 
GRK5 potency for 258903 relative to its non-covalent control, 262604, suggests a possible 
covalent mechanism of action as it exhibited a seventeen-fold increase in potency. The meta 
acrylamide analog, 258904, had nearly identical potency for GRK5 with respect to its ethyl 
amide, non-covalent control, 262606, at all three time points, suggesting it is not interacting 
productively with the cysteine. It showed no inhibition at GRK1 and modest GRK2 inhibition 
with an IC50 of 39 µM.      
The stark difference in potency differential between the saturated controls and 
acrylamides of each regioisomeric set of compounds is intriguing. Both the meta substituted 
analogs 258904 and 262606 have nearly identical potency whereas the para substituents, 258903 
and 262604, have a seventeen-fold difference. Looking back at the models of the two acrylamide 
analogs in Figure 4.3 we can rationalize the observed results with the following hypotheses. In 
the models of the meta substituted analogs, 258904 and 262606, the amide aligns exactly with 
the tertiary amide of GSK2163632A (Figure 4.2B). As the carbonyl of this amide in 
GSK2163632A participates in a hydrogen bond with the backbone nitrogen of Asp 271, it can be 
hypothesized that the carbonyl of the amide linker in both 258904 and 262606 can likely form 
this hydrogen bond as well. This hydrogen bond then locks the acrylamide into a conformation 
where it is likely no longer susceptible to attack (either due to distance or sterics) by the thiol of 
Cys474, explaining why it exhibits nearly equipotent inhibition as the non-covalent control 
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analog 262606. In the case of the para substituted analogs (258903 and 262604) the amide is no 
longer in a position where it can form a hydrogen bond with the backbone of Asp 270 in GRK5 
(Asp271 in GRK1). In our model (Figure 4.3B), the acrylamide is much close to the AST and 
Cys474 (within 2 Å). The non-covalent ethyl amide analog, 262604, likely exhibits such poor 
potency with respect to the other non-covalent meta substituted ethyl amide, 262606, as it no 
longer picks up an additional hydrogen bond, but it may also be sterically clashing with the AST 
since it is so close. In the case of the para acrylamide, 258903, no hydrogen bond is formed, 
likely limiting its potency, but instead of sterically clashing with the AST it can now instead 
form a covalent bond with Cys474 explaining its 17-fold increase in potency as well as time-
dependent inhibition relative to the non-covalent ethyl amide analog, 262606.   
In addition to the more well-known acrylamide covalent binding appendage as utilized in 
our first set of covalent inhibitors, more recent advances have been made with the use of an N,N-
dimethyl-butenoic amide.
106, 112
 In addition to improving solubility, the N,N-dimethyl-butenoic 
amide acts as an internal base to deprotonate and activate the thiol of the cysteine more 
quickly.
106, 112, 113
 Several of these covalent inhibitors, pelitinib, neratinib, and afatinib have 
advanced to clinical trials.
106, 116-118
 One of these has recently been approved for treatment of 
small cell lung carcinoma under the trade name of Gilotrif (afatinib) and another, neratinib, has 
applied for FDA approval for the treatment of HER2 positive breast cancer, confirming the 
utility of a dimethyl-butenoic amide as a covalent warhead. For our purposes this warhead can 
somewhat mimic the scaffolds of the original lead hits by placing a basic tertiary amine out 
towards the ribose subsite. Modeling two variations of this warhead onto our scaffold and 
overlaying onto the GSK2163632A crystal structure shows that we cannot exactly mimic the 
Asp270 hydrogen bond that GSK2163632A establishes via its tertiary amine, but we can 
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potentially reach into this more polar region and gain potency through a different hydrogen 
bonding interaction (Figure 4.4). Of the two models shown the meta substituted analog shows 
nearly perfect alignment of the amide linker with that of GSK2163632A and its tertiary nitrogen 
projects right towards the ribose subsite (Figure 4.4A). The carbon of the thiol side chain of 
Cys474 (from GRK6 overlay) is 4.9 Å from the acrylamide indicating that a possible covalent 
bond can be formed, especially as this AST loop is highly flexible. The para substituted analog 
(Figure 4.4B) collides with the AST loop when modeled into the GRK5 and GRK6 overlay. 
Although the tertiary amine does not sit towards the Asp270 or ribose subsite, the flexibility of 
the appendage may allow it to flip towards them. Furthermore, the beta carbon of the acrylamide 
is within 1.5 Å of the Cys474 indicating that if it is not too close it can form a covalent bond.  
 
Figure 4.4: Models of dimethyl-butenoic amide analogs overlaid with GSK2163632A. 
GRK5 is in dark grey and GRK6 is in tan. A) Overlay of the meta substituted analog 
(periwinkle) and GSK2163632A (salmon) reveals excellent alignment of the amide linked 
warhead. B) Overlay of the para substituted analog (white) and GSK2163632A (salmon) reveals 
that the warhead may protrude into the AST loop but is closer to Cys474. 
 
 Biochemical evaluation of these two dimethyl-butenoic amide inhibitors, 263045 and 
263115, is reported in Table 4.1. Both inhibitors had increased potency for all three GRKs 
relative to just the acrylamide inhibitors 258903 and 258904 indicating that addition of the basic 
nitrogen is favorable for potency in all three kinases. The para substituted analog, 263045, was 
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predicted be closer to the AST loop, and thus more likely to form a covalent bond with Cys474. 
In our time dependent inhibition of GRK5 it shows a very modest improvement from 0 min to 1 
hr (GRK5 IC50 from 0.57 µM to 0.35 µM). It also has modest selectivity over GRKs 1 and 2 
(IC50 = 0.76 µM and 0.68 µM, respectively). The meta substituted analog, 263115, also did not 
show a time dependent GRK5 inhibition have nearly equipotency at all three GRK5 time points 
tested (IC50 range = 0.22 µM – 0.27 µM). Favorably 263115 showed approximately ten-fold 
selectivity for GRK5 over GRKs 1 and 2 (IC50 = 2.1 µM and 2.7 µM, respectively). This 
difference in GRK selectivity between the meta and para substituted analogs 263115 and 263045 
indicates that the substitution of the amide linked appendage from the methoxyphenyl ring may 
be important for GRK5 selectivity. Further SAR investigating more substituents would further 




 From two lead compounds, GSK1713088A and GSK1326255A, and a co-crystal 
structure of a third structurally similar compound, GSK2163632A, with GRK1 we were able to 
design and model possible covalent inhibitors of GRK5 engaging a non-conserved cysteine. Our 
design methodology further utilized previously reported inhibitor structures of GRK5 and GRK6. 
Of the four compounds synthesized and tested three showed inhibitory activity of GRK5 with 
IC50s between 5.5 µM and 6.2 µM. Compared to the leads GSK1713088A and GSK1326255A,  
these three compounds are only a modest two fold less potent despite cleavage of the fourth 
saturated rings that include tertiary amines believed to be important for binding. Furthermore 
these three new compounds exhibited much higher selectivity for GRK5 relative to the initial 
three GSK compounds. Lastly, there seems to be a clearly favored regioisomer of the amide 
substituent wherein a meta substitution pattern favors hydrogen bond formation favorable for 
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GRK5 inhibition whereas the para substitution, as seen in 258903, seems more amenable to 
covalent bond formation, either due to its closer proximity to Cys474 or to its higher flexibility 
as it is not restricted by a hydrogen bond as in the case of the meta substituted analog 258904. 
Utilization of the dimethyl-butenoic amide in place of acrylamide will served to increase the 
potency of these compounds by building back in a tertiary amine to the binding site but also 
decreased the selectivity. Additionally, there is no strong evidence that either 263045 or 263115 
are binding covalently.  
 
Synthesis:  
Scheme 4.1: Synthesis of meta-substituted analogues 116 (258904 and 263115). 
 
Synthesis of analogs 258904 and 263115 began as described in Scheme 4.1 with tosyl 
protection of the commercially available pyrrolopyrimidine 108 followed by aromatic 
nucleophilic substitution under basic conditions with compound 110 to yield 111.
119
 A second 
nucleophilic aromatic substitution under acidic conditions with intermediate 112 followed by 
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spontaneous cyclization gave the lactam 113. In the presence of ammonium hydroxide and 
heating the lactam was opened and the Fmoc was removed to furnish the free aniline 114. 
Hydrolysis of the tosyl protecting group under basic conditions followed by amide coupling of 
the aniline produced the final compounds 258904 and 263115.  
 
 Scheme 4.2: Synthesis of para-substituted analogues 121 (258903 and 263045). 
 
The para substituted analogs 121 were synthesized as described in Scheme 4.2 utilizing 
the same series of steps as described for the synthesis of the meta substituted analogs 116 but 
replacing intermediate 112 with intermediate 117. Cyclization followed by aromatic substitution 
of intermediate 111 with aniline 117 gave the tetracycle 118 which was then subsequently 
opened and deprotected to give aniline 119. The final analogs 121 were furnished following 





Scheme 4.3. Synthesis of intermediate 112. 
 
Intermediate 112 was synthesized as described in Scheme 4.3. Aniline 122 was Fmoc 
protected to give intermediate 123. Initially palladium reduction of the nitro was attempted but 
that resulted in deprotection of the Fmoc to give the dianiline. Alternatively, iron reduction of the 
nitro group successfully furnished intermediate 112.  
 
 
Scheme 4.4. Synthesis of intermediate 117. 
 
The corresponding intermediate 117 was synthesized as described in Scheme 4.4 
beginning with Boc protection of aniline 120. Initial attempts at protecting under milder 
conditions without DMAP were not successful. Palladium reduction of nitro 121 cleanly 
afforded aniline 122. The free amine was then Fmoc protected and subsequently Boc deprotected 





Scheme 4.5: Synthesis of meta substituted ethyl amide analogue 129 (262606). 
  
 The ethyl amide analog 129 was synthesized as described in Scheme 4.5. Amide 
coupling of the aniline intermediate 114 gave ethyl amide 128. Tosyl deprotection with NaOH 
then afforded the final analog 129. This approach was initially attempted for the acrylamide 
analogs as having the tosyl protected during the amide coupling afforded a cleaner reaction, but 
was hampered by competing tosyl hydrolysis. For the hydrolysis to occur a strong base in the 
presence of catalytic MeOH was necessary. The conditions likely made sodium methoxide in situ 
which was then reactive with the acrylamide affording two undesired products in the last step of 
the synthesis.   
 
 




 Synthesis of the para substituted ethyl amide analog 131 was synthesized as described in 
Scheme 4.6. Amide coupling of intermediate aniline 119 followed by tosyl deprotection with 2N 



























Chapter 5: Future directions in the expanding era of GRK inhibitors. 
 
Further SAR of the GSK180736A derived inhibitors: 
 In designing analogs of GSK180736A to improve potency and selectivity for GRK2 we 
began to explore the SAR of building in GRK5 selectivity with our docking studies. From this 
docking campaign we did not achieve GRK5 selectivity but we were able to increase GRK5 
potency and develop two compounds that were nearly equipotent for GRK5 and GRK2, 257064 
and 257142 (Figure 5.1). In addition, from our SAR campaign to find a potent and selective 
GRK2 inhibitor we developed the potent pan-GRK inhibitor 215022 with which we have done 
limited SAR investigations with (Figure 5.1).  
 
Figure 5.1: Potent GRK2 and GRK5 inhibitors identified in our campaign.  
 As the pyridine of 215022 has been crystallized in GRK5, SAR modifications to this 
molecule can be rationalized using its crystal structure.
56, 71
 We did investigate linker lengths and 
movement of the nitrogen around the pyridine ring but these modifications were all detrimental 
to the potency of GRK5, likely because the pyridine nitrogen could no longer participate in a 
hydrogen bond interaction with Lys220 in the hydrophobic subsite of the pocket.
71
 There is some 
space in the hydrophobic pocket behind the pyridine and analogs of the basic structure 128 
(Figure 5.2) that would retain the position of the nitrogen but incorporate additions to the 
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aromatic ring to probe the back of the pocket may give an additive effect to improve GRK5 
potency.  
 Efforts to crystallize the equipotent GRK2 and GRK5 inhibitors 257064 and 257141 with 
GRK5 are currently underway in the Tesmer lab. As these two analogs each contain a nitrogen in 
a similar position to the pyridine nitrogen of 215022 we can hypothesize that the nitrogens of the 
oxadiazoles of 257064 and 257142 likely form analogous hydrogen bonds in GRK5. Both of 
these compounds had additional lipophilic appendages that could reach further into the GRK5 
hydrophobic subsite. As the GRK5 hydrophobic subsite seems to be deeper and narrower than 
GRK2 these appendages may be more favorable for GRK5 selectivity.
56, 71
 In Figure 5.2¸ 
compounds 129 – 133 are systematic derivatives of 257064 and 257141 that would look at 
differing lengths of the alkyl appendages off of the oxadiazole rings. Hopefully a clear trend in 
alkyl length could be determined between the methyl, ethyl, and propyl groups of the two 
oxadiazole substitutions. Lastly, proposed is analog 134 which would investigate the ethyl ether 
as oppose to the methyl ether of 257142.   
 






Further in vivo studies of the Paroxetine derived inhibitor 258208: 
 Two of our paroxetine-derived compounds, 258208 and 258747, were highly potent and 
selective for GRK2, and exhibited good preliminary pharmacokinetics with total plasma 
concentrations higher than the GRK2 IC50 for up to seven hours.
86
 Additional studies of 258208 
in mouse cardiomyocytes confirmed its ability to induce contractility at a 100-fold lower dose 
(0.1 µM vs 10 µM) than the parent paroxetine, whereas preliminary studies of 258747 at doses of 
0.5 µM and 1 µM showed no significant effect on cardiomyocyte contractility. Nonetheless both 
compounds were then further subjected to short preliminary experiments to ascertain their 
abilities to induce a pharmacological response in mouse models of heart failure. To develop the 
myocardial infarction (MI) heart failure model the mice were subjected to ligation of the left 
main descending coronary artery after which they were untreated for two weeks to allow 
development of heart failure.
72, 73
 After two weeks the mice were then randomly divided into 
subject groups and treated for two weeks with either phosphate buffered saline (PBS), 
paroxetine, 258208, or 258747 at 5 mg/kg dosing. Although this study was only preliminary and 
used a small number of mice, it did not group mice based on their severity of the disease and 
investigated only one dose of drug, it did show that 258208 displayed some significant 
cardioprotective effects while 258747 did not (Figure 5.3). Both 258208 and 258747 showed 
similar preliminary pharmacokinetics that were not able to predict the differences observed in the 
in vivo experiments. In measurements for both ejection fraction (Figure 5.3A) and fractional 
shortening, 258208 (Figure 5.3B) showed a slight increase in both after two weeks of dosing. 
Again, this study was preliminary, and in the case of 258208 there was an n = 4 of mice making 
it difficult to see statistical differences. For example, paroxetine itself shows little significance in 
these experiments, despite its previous efficacy in vivo (Figure 5.3).
72, 73
 Nonetheless, as 
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258747did not show any efficacy we decided to not pursue it further. In the case of 258208, 
repeat studies are underway that will utilize a larger sample size of mice and investigate three 
doses (1 mg/kg, 3 mg/kg, and 10 mg/kg).  
 
Figure 5.3. Preliminary in vivo efficacy of paroxetine, 258208, and 258747 in a mouse heart 
failure model. A) Echocardiography measures of left ventricular ejection fraction in mice 2 and 
4 weeks after sham or MI surgery. B) Serial echocardiography measures of left ventricular 
fractional shortening in mice 2 and 4 weeks after Sham or MI surgery. Mice were untreated for 
the first 2 weeks following surgery then treated with PBS, paroxetine, compound 8 (258208), or 
compound 747 (258747) at 5 mg/kg/day from weeks 2 to 4 after surgery. n = 10 Sham, 6 PBS, 6 
Parox, 4 compound 8, and 6 compound 747mice. *P = 0.01; **P = 0.001; ***P < 0.0001 as 
determined by one-way ANOVA with Tukey post-hoc test relative to corresponding 2 or 4 week 
sham. 
 
Improving GRK5 covalent inhibitor potency and evaluation: 
Proposed SAR: Although the prototype GRK5 covalent inhibitors 258903 and 258904 
from our preliminary work show some promise as selective GRK5 inhibitors, they are not very 
potent. As we have explored very limited SAR in the covalent GRK5 inhibitors series based on 
the GSK1713088A and GSK1326255A, there are a lot of advances that can be made here. As 
covalent inhibitors are becoming more and more prevalent in the literature we can turn to 
previously reported covalent inhibitors to additionally further our campaign and utilize new 
warheads for attack by Cys474.




 Our previous acrylamide inhibitors, 258903 and 258904, utilized a direct linkage of the 
acrylamide warhead to the adjacent phenyl. This direct linkage does not afford much flexibility 
to the acrylamide. We hypothesize that incorporating a methylene group between the phenyl and 
the amide would provide additional flexibility by adding a rotatable bond (Figure 5.4A). This 
would then allow the acrylamide greater conformational freedom to get oriented for attack by the 
nucleophilic Cys474. Addition of a methylene into both 258903 and 258904 is proposed. If the 
acrylamide in the para substituted analog 258903 is too close to the AST, which explains the 
poor potency of the ethyl analog 262604, the added flexibility will allow it to rotate to avoid any 
steric clashes. In the case of the meta analog, 258904, the added methylene would not only 
increase flexibility of the acrylamide appendage but it would also add length that could orient the 
acrylamide closer to Cys474. To also be considered here though, is that addition of a methylene 
in the 258904 scaffold may push the amide too far over hindering it from making a hydrogen 
bond to Asp270. This could be detrimental due to the loss of a hydrogen bond, but also 
beneficial as the acrylamide is no longer locked down to Asp270 hindering it from binding to 
Cys474.  
An alternative avenue to building in flexibility of the warhead would be to add in another 
amide and either a methylene or ethylene linker (Figure 5.4B, appendages g and h). This 
approach may overcome a loss of the hydrogen bond the amide likely makes in the meta 
substituted analogs (258904 and 262606) that would occur by incorporating a linker between the 
amide and phenyl ring. Since the ethyl amide analog 262606 binds GRK5 with an IC50 of 5.9 µM 
addition of an acrylamide off of the ethyl that can effectively engage Cys474 would result in an 
even more potent compound.  Further SAR to expand on this region of the molecule would be 
incorporation of additional warheads apart from just the acrylamides and N,N-dimethyl-butenoic 
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Figure 5.4: Adding flexibility to the covalent warhead. A) Depiction of the overall scaffold 
where n is variable linker lengths. B) Panel showing variable R groups as possible warheads. 
 
The original two lead compounds GSK1713088A and GSK1326255A both contain a 
fluorine on the benzamide albeit in different positions on the ring (Figure 4.1). As we were 
unsure of which fluorine substitution pattern was favored or the role of the fluorine, it was 
removed in our early design because the first aromatic substitution steps utilized in the synthesis 
of 258903 and 258904 were reportedly much higher for the unsubstituted benzamide.
119
 Now 
that a synthesis has been developed for these compounds it would be beneficial to expand upon 
the SAR of this benzamide ring by building back in the two different fluorine substitutions seen 
with the original GSK1713088A and GSK1326255A compounds. Additional substitutions out 
on this ring could also be explored if addition of the fluorine is found to be favorable, and the 
SAR could be expanded to include difluoro or chloro alternatives as well (Figure 5.5, R2 and 
R3). 
A last point of exploration could be the free amide (Figure 5.5, R4) as the synthesis of 
this scaffold is readily amenable to incorporation of diversity at the amide.
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ring is opened ammonium hydroxide is used to give the free amide but by using primary amines 
in this step one could easily functionalize the amide. The binding pose depicts the amide oriented 
towards the back of the pocket and making no hydrogen bond interactions (Figure 4.2). This 
suggests that smaller groups such as a methyl may be tolerated but likely larger groups will 
sterically clash with the back of the pocket. On the other hand, large groups may cause the 
aromatic ring to flip allowing larger substituents to pack further up under the P-loop.  
 
 
Figure 5.5: Further possible SAR on the GRK5 covalent inhibitors. R groups depict the 
different regions of possible substitution on the GRK5 covalent inhibitor scaffold.  
 
Proposed analysis to confirm covalent binding: Although analogs were synthesized 
that lacked an appropriate electrophile for attack by Cys474 (ethyl analogs 262904 and 262906) 
additional studies should be completed to provide further evidence of covalent inhibition. Initial 
testing of the GRK5 covalent inhibitors included a time dependent incubation period, which has 
been shown previously to be useful in evaluating covalent inhibition.
110, 122
 Unfortunately in our 
case, our compounds showed little time dependence, due to either their complete lack of covalent 
inhibition or possibly just to their overall modest potency.  
 To further confirm covalent inhibition there are several standard experiments. To directly 
measure the addition of the small molecule inhibitors to GRK5 mass spectrometry can be utilized 
following inhibitor and protein incubation.
110, 120, 121, 123
 This method has been used successfully 
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to determine the stoichiometry of the protein to small molecule binding for EGFR and Janus 
Kinase 3 (JAK3) inhibitors.
110, 120, 121, 123
 As we also know what cysteine residue we are 
targeting, testing inhibition of mutant GRK5 where Cys474 has been replaced by the structurally 
similar but non-nucleophilic amino acid serine to give Ser474 would provide further evidence if 
the mutant is more poorly inhibited than the wild type GRK5.
110, 124
 Additional, more in depth, 
methods using C
14
 radiolabelling of the small molecule as well as in cellulo wash out and pull 
down experiments have been reported that could potentially be used if we are unable to confirm 




 As we have yet to obtain a crystal structure of any of our covalent GRK5 inhibitors or the 
lead compounds GSK1713088A and GSK1326255A, successful crystallization would directly 
confirm that a covalent bond is being formed with the Cys474. Currently none of our analogues 
exhibit sub micromolar potency and GRK5 has proven difficult to crystallize so a GRK5-
inhibitor complex may be difficult to acheive.
56, 75
 Advantageously, Cys474 resides in the most 
flexible region of the active site the AST.
37, 56, 125
 Effectively engaging Cys474 in a covalent 
bond and locking the AST in place may lead to a more stable GRK5 complex that is more 
amenable to crystallization. 
 
Synthesis: 
Efforts to synthesize the extended methylene linked analogues have recently commenced. 
Although these compounds are structurally similar to the non- homologated analogs some 
modifications to the synthesis will be necessary. The in-progress and proposed steps to complete 




Scheme 5.1: In progress synthesis of benzylamine analog 146. 
 Synthesis of 146 is progressing through a similar but different pathway than the original 
acrylamide analogues 121 (258903) and 116 (258904). Originally aromatic substitution, utilizing 
in situ activation of the chlorine of the pyrrolopyrimidine 111 and then displacement with aniline 
142, was pursued. This resulted in a mix of more than 15 separate products and an alternative 
strategy needed to be employed. Fortunately, the activated chlorine tetracyclic intermediate 141 
had been reported and isolated.
119
  Synthesis of this intermediate was achieved as previously 
reported via the aromatic substitution of intermediate 108 with 2-aminobenzoic acid followed by 
cyclization promoted by oxayl chloride to give intermediate 141. With the activated chlorine 
intermediate in hand we then accomplished the substitution under neutral pH and high heat to 
afford 143 with fewer side products than the original route. Carboxamide 143 was then heated in 
THF and ammonium hydroxide to give the free amide 144. The synthesis is proposed to be 






Scheme 5.2: Synthesis of intermediate 142. 
 Synthesis of intermediate 142 was initially pursued similarly to intermediate 117 
(Scheme 4.4) through a Boc protection of the aniline 149 and then palladium-catalyzed reduction 
of a nitrile to give the primary amine 151. This route was unsuccessful, as reduction of the nitrile 
using palladium resulted in formation of the secondary amine 152 (where the imine formed and a 
separate amine was able to add into the molecule) or the tertiary amine 153 wherein the 
secondary amine added into a third imine and eliminated off ammonia.
126, 127
 Adding acid, 
changing solvent, or changing catalyst loading did not reduce undesired product formation. 
Reduction of the nitrile via other hydride sources was also unsuccessful (lithium aluminium 
hydride, nickel(II) chloride with sodium borohydride, and sodium borohydride). Efforts then 
were made to achieve the desired primary amine via the amide by instead using 3-amino-4-





 Selective protection of the primary amine over the aniline was completed using 
Fmoc-succinimide to give intermediate 142. 
 
Conclusions and Future Directions of GRK inhibitors: 
 Our initial GRK2 inhibitor series based on GSK180736A successfully utilized a hybrid 
approach to develop more potent and selective GRK2 inhibitors. The potent pan GRK inhibitor 
215022 not only led to crystal structures in both GRK2 and GRK5 (the latter of which none had 
previously been reported) but also showed improved potency in mouse cardiomyocytes relative 
to the lead.
56, 71
 Furthermore, this compound has been sent to several additional labs interested in 
using it to probe GRKs in cellulo. One of these collaboration, here at the University of Michigan 
with the Antonetti lab was able to use 215022 to determine that occludin in tight junction cells is 
regulated via phosphorylation of GRKs 5 and 6.
130
 Additionally developed was the highly potent 
and selective 224406 which showed high potency and selectivity for GRK2 as well as five-fold 
improvement of potency in cardiomyocyte cells.
71
  
Although we discovered that the SAR of our GSK180736A series was not translatable to 
the paroxetine series, we were able to develop the 3-pyrazolylmethyl amide 258208 which 
resulted in a highly potent GRK2 inhibitor (IC50 = 30 nM) with high selectivity over GRK1, 
GRK5, PKA, and ROCK1. This compound additionally has shown a 100-fold potency 
improvement over paroxetine in mouse cardiomyocyte contractility.
86
 Its additional efficacy in 
preliminary in vivo studies of mouse heart failure models has led us to advance the compound for 
further in vivo experiments. Because 258208 shows such improved potency in cardiomyocyte 
assays, we hypothesize that it will exhibit superior results in vivo relative to paroxetine, 
confirming the utility of this series of GRK2 inhibitors as optimized leads for heart failure 
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therapeutics. Although not as selective as 258208 the indazole hinge binding analogue 258748 to 
date it the most potent known GRK2 inhibitor with an IC50 = 8 nM.  
 As the previously reported repertoire of known selective and potent GRK2 inhibitors was 
limited to the poorly bioavailable and unstable Takeda103A and Takeda101 these new 
compounds represent an advent of GRK2 inhibitors useful for in vivo therapeutic potential or 
probing of GRK2.
71, 86, 130
 Our pan GRK inhibitors as well as selective and potent GRK2 and 
GRK5 inhibitors may now serve as probes to further elucidate the utility of targeting GRK2 
alone or in concert with GRK5. GRK5 and GRK2 have both been shown to be upregulated in 
heart failure, and so further studies to probe the effect of targeting GRK2 and GRK5 together 
with a pan inhibitor versus selective inhibitors may elucidate which target is more favorable.
52, 56, 
131
 GRK2 and GRK5 inhibition may work synergistically as a therapeutic for heart failure better 
than inhibition of either alone. Future studies in the cardiomyocyte contractility assays and in 
receptor internalization assays to investigate the effects of selective GRK2 inhibition vs GRK2 
and GRK5 inhibition will utilize small panels of a mix of our GRK2 selective, and our GRK pan 
inhibitors.  
 GRKs regulate the largest class of receptors (GPCRs), and thus have been implicated in 
several disease states in addition to heart failure, although heart failure is the best studied.
132, 133
 





 GRK5 has additionally been implicated in several cancers with its ability to 
regulate tumor growth progression.
137-140
 Also of considerable interest are the roles of GRK2 and 
GRK5 in cell growth and insulin levels leading to diabetes.
141, 142
 With these varying disease 
states relying on regulation by GRKs, small molecules inhibitors of GRKs may serve as future 
probes and have therapeutic potential in a variety of diseases. Interest in small molecule GRK 
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inhibitors is increasing as our recent work has led to material transfer agreements and sharing of 
our compounds with over ten labs across the United States and Europe. As interest in GRK 
inhibitors progresses so perhaps will their utility as therapeutics in different disease states alone 


























Appendix – Experimental Data 
 
All reagents were used without further purification as received from commercial sources 
unless noted otherwise. 
1
H NMR spectra were taken in DMSO-d6, MeOD, or CDCl3 at room 
temperature on Varian Inova 400 MHz or Varian Inova 500 MHz instruments. Reported 
chemical shifts for the 
1
H NMR spectra were recorded in parts per million (ppm) on the δ scale 
from an internal standard of residual tetramethylsilane (0 ppm). Mass spectrometry data was 
measured using a Waters Corporation Micromass LCT or Agilent6230 Q-TOF. HPLC was used 
to determine purity of biologically tested compounds on an Agilent 1100 series with an Agilent 
Zorbax Eclipse Plus−C18 column. A gradient of 10-90% acetonitrile/water over 6 min followed 
by 90% acetonitrile/water for 7 min was used with detection at 254 nm. 
Reagent abbreviations and acronyms: AcOH (acetic acid), Ac2O (acetic anhydride), 
Boc2O (di-tert-butyl dicarbonate),  DCM (dichloromethane), DIEA (N,N-diisopropylethylamine, 
Hünig’s base), DMF (N,N-dimethylformamide), EDC (1-Ethyl-3-(3- 
dimethylaminopropyl)carbodiimide hydrochloride, Et2O (diethyl ether), EtOAc (ethyl acetate), 
EtOH (ethanol), H2 (hydrogen), HATU (1-[bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate), H2O (water), HCl (hydrogen chloride or 
hydrochloric acid), Hex (hexanes), HOBT (1- hydroxybenzotriazole),  iPrOH (isopropanol), 
K2CO3 (potassium carbonate), KOH (potassium hydroxide), LAH (lithium aluminum hydride), 
MeOH (methanol), MgCl2 (magnesium chloride), MgSO4 (magnesium sulfate), N2 (nitrogen), 
NaBH4 (sodium borohydride), NaBH3CN (sodium cyanoborohydride), Na2CO3 (sodium 
carbonate), NaCN (sodium cyanide), Na2SO4 (sodium sulfate), NaH (sodium hydride), NaHCO3 
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(sodium bicarbonate), NaNO2 (sodium nitrite), NaOH (sodium hydroxide), NH4OH (ammonium 
hydroxide), PCF (phenyl chloroformate), Pd/C (palladium on on carbon), s-BuLi (sec-butyl 
lithiumTEA (triethylamine), TFA (trifluoracetic acid), TFE (trifluoroethanol), TFFA 
(trifluoroacetic anhydride), TFE (2,2,2-trifluoroethanol); THF (tetrahydrofuran), tol (toluene), 




Enzymatic Assays: PKA and ROCK1 inhibition assays were performed using the ADP-Glo 
Kinase Assay system (Promega) in accordance with the manufacturer’s recommendations and as 
described previously.
75
 Luminescence was measured using a BMG Labtech PHERAstar imaging 
system, and inhibition curves were analyzed using GraphPad Prism. Kinetic activity of the 
inhibitors with respect to the bovine GRKs were run in a buffer comprised of 20 mM HEPES 
(pH 7.0), 2 mM MgCl2, and 0.025% DDM with 50 nM GRK and 500 nM tubulin. ATP (500 μCi, 
5μM) initiated the kinetic reactions which were then run for 5 min, at which time SDS loading 
buffer was added to quench the reactions and they were then separated via SDS-PAGE. The 
resulting gels were dried using a vacuum gel drying system, and exposed with a 
phosphorimaging screen. The images were then scanned and quantification via Typhoon imager 
and Image Quant respectively, as previously reported.
56, 75 Data were analyzed and inhibition 
curves were fit via GraphPad Prism with a three variable dose-inhibitor response curve and a 








6-fluoro-1H-indazol-5-amine (2, HVW 6 -20): To a 100 mL flask was added 6-fluoro-5-nitro-
1H-indazole 24 (2.93 mmol, 0.580g), 10% Pd/C (0.200g), DCM (10 mL), and MeOH (40 mL). 
Argon was then bubbled through the reaction mixture, the atmosphere was then vacuumed and 
replaced with H2 via a balloon. The reaction was stirred overnight then filtered through celite, 
washing with MeOH/DCM (1:1). The filtrate was then concentrated and purified using a silica 
gel plug of 50% EtOAc/Hex to give 6-fluoro-1H-indazol-5-amine as a light purple solid (0.234g, 
53% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 12.65 (s, 1H), 7.78 (s, 1H), 7.18 (d, J = 11.2 Hz, 
1H), 6.96 (d, J = 8.6 Hz, 1H), 4.82 (s, 2H). 
 
6-chloro-1H-indazol-5-amine (3, HVW 9 -24): To a 100 mL flask was added 6-chloro-5-nitro-
1H-indazole 25 (5.24 mmol, 1.035 g), 10% Pd/C (0.345 g), DCM (12 mL), and MeOH (48 mL). 
Argon was then bubbled through the reaction mixture, the atmosphere was then vacuumed and 
replaced with H2 via a balloon. The reaction was stirred for 2 hours (overnight stirring resulted in 
loss of the chloro) then filtered through celite, washing with MeOH/DCM (1:1). The filtrate was 
then concentrated and purified using a gradient of 0 – 5% MeOH/DCM to give 6-chloro-1H-
indazol-5-amine as an off white solid (0.84g, 96% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 
12.68 (s, 1H), 7.81 (t, J = 1.3 Hz, 1H), 7.47 (s, 1H), 7.04 (s, 1H), 4.95 (s, 2H). 
 
N-(1H-Indazol-5-yl)-3-oxobutanamide (4):  To a 50 mL pressure vessel was added 1H-indazol-
5-amine (0.800 g, 6.00 mmol), 2,2,6-trimethyl-4H-1,3-dioxin-4-one (1.57 g, 12.00 mmol), 
sodium acetate (0.492 g, 6.00 mmol), and acetonitrile (5 mL). The reaction was stirred overnight 
at 100˚C. The reaction was diluted with citric acid (10%) and EtOAc. After separating, the 
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organic layer was washed 2x with NaCl, dried over MgSO4, and concentrated to give a brown 
residue. The residue was then triturated with 2:1 dichloromethane:ethyl acetate and filtered off to 
give a light brown solid. The solid was then purified on flash chromatography in a gradient of 
0% to 3% MeOH/DCM to afford 4 as an off white solid (0.901 g, 69% yield). 
1
H NMR (400 
MHz, DMSO-d6) δ 12.99 (s, 1H), 10.08 (s, 1H), 8.12 (s, 1H), 8.02 (s, 1H), 7.49 (d, J = 8.9 Hz, 
1H), 7.38 (d, J = 9.2 Hz, 1H), 3.56 (s, 2H), 2.23 (d, J = 1.6 Hz, 3H). 
 
N-(6-fluoro-1H-indazol-5-yl)-3-oxobutanamide (5, HVW 6 – 40):  To a 100 mL pressure vessel 
was added intermediate 2 (1.20 g, 7.94 mmol), 2,2,6-trimethyl-4H-1,3-dioxin-4-one (1.24 g, 8.73 
mmol), and acetonitrile (30 mL). The reaction was stirred overnight at 90˚C. The reaction was 
concentrated to give a brown residue. The residue was then purified on flash chromatography in 
a gradient of 0% to 5% MeOH/DCM to afford 5 as an off white solid (0.362 g, 19% yield). 
1
H 
NMR (400 MHz, DMSO-d6) δ 13.10 (s, 1H), 9.85 (s, 1H), 8.23 (d, J = 7.4 Hz, 1H), 8.07 (s, 1H), 
7.43 (d, J = 10.8 Hz, 1H), 3.64 (s, 2H), 2.21 (s, 3H). 
 
N-(6-chloro-1H-indazol-5-yl)-3-oxobutanamide (6): Intermediate 6 was prepared as described 
for intermediate 5 replacing intermediate 2 with intermediate 3. Purification proceeded using 
50% EtOAc/Hexanes to give the desired compound as a white solid. (Yield: 68%). 
1
H NMR 
(400 MHz, DMSO-d6) δ 13.18 (s, 1H), 9.80 (s, 1H), 8.11 (t, J = 1.3 Hz, 1H), 8.03 (s, 1H), 7.72 
(s, 1H), 3.63 (s, 2H), 2.24 (s, 3H). 
 
5-(5-((1H-Indazol-5-yl)carbamoyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-4-yl)-2-
fluorobenzoic acid (7): To a 100 mL pressure vessel equipped with a stir bar was added 2-fluoro-
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5-formylbenzoic acid (0.682 g, 4.054 mmol), 4 (0.801 g, 3.686 mmol), urea (0.332 g, 5.529 
mmol), ytterbium trifluormethanesulfonate (0.229 g, 0.3686 mmol) and acetonitrile (15.0 mL).  
The reaction mixture was heated to 100 
o
C and stirred. The reaction mixture went from a white 
suspension to a clear solution, and then back to a white suspension. After four hours, the reaction 
was diluted with 2 mL of water then ethyl acetate (~60 mL).  The resulting white precipitate was 
filtered off and washed with ethyl acetate followed by diethyl ether yielding 7 as a white powder 
(84% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 13.13 (s, 1H), 9.59 (s, 1H), 8.79 (s, 1H), 7.98 (t, J 
= 2.1 Hz, 2H), 7.88 – 7.78 (m, 1H), 7.64 (s, 1H), 7.50 (s, 1H), 7.46 – 7.33 (m, 2H), 7.33 – 7.22 
(m, 1H), 5.42 (s, 1H), 2.06 (s, 3H). 
 
2-(5-(5-((1H-Indazol-5-yl)carbamoyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-4-yl)-2-
fluorophenyl)acetic acid (8):  Compound 8 was prepared as described for compound 7, replacing 
2-fluoro-5-formylbenzoic acid (17) with 18 (72% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 12.80 
(s, 1H), 12.53 (s, 1H), 9.54 (s, 1H), 8.69 (d, J = 2.0 Hz, 1H), 7.99 – 7.92 (m, 2H), 7.58 (s, 1H), 




fluorophenyl)propanoic acid (9): Compound 9 was prepared as described for compound 7 
replacing 2-fluoro-5-formylbenzoic acid (17) with intermediate 19 (63% yield). 
1
H NMR (500 
MHz, DMSO-d6) δ 12.91 (s, 1H), 12.25 (s, 1H), 9.55 (s, 1H), 8.68 (d, J = 2.0 Hz, 1H), 8.01 – 
7.87 (m, 2H), 7.53 (s, 1H), 7.42 (d, J = 8.9 Hz, 1H), 7.37 (dd, J = 9.1, 1.8 Hz, 1H), 7.26 – 7.21 
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(m, 1H), 7.19 – 7.14 (m, 1H), 7.11 (t, J = 9.2 Hz, 1H), 5.38 (d, J = 2.8 Hz, 1H), 3.33 (s, 2H), 
2.79 (t, J = 7.9 Hz, 2H), 2.48 – 2.42 (m, 2H), 2.05 (s, 2H). 
 
2-fluoro-5-(5-((6-fluoro-1H-indazol-5-yl)carbamoyl)-6-methyl-2-oxo-1,2,3,4-
tetrahydropyrimidin-4-yl)benzoic acid (10): Intermediate 10 was prepared as described for 
intermediate 7 replacing intermediate 4 with intermediate 5 to give the desired compound as a 
white solid (96% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 13.21 (bs, 2H), 9.31 (s, 1H), 8.85 (s, 




2-fluorobenzoic acid (11): Intermediate 11 was prepared as described for intermediate 7 
replacing intermediate 4 with intermediate 6 to give the desired compound as a white solid (86% 
yield). 
1
H NMR (400 MHz, DMSO-d6) δ 13.16 (bs, 2H), 9.26 (s, 1H), 8.84 (s, 1H), 8.06 (s, 1H), 
7.86 (d, J = 6.8 Hz, 1H), 7.69 (s, 2H), 7.65 (s, 1H), 7.55 (s, 1H), 7.32 (t, J = 9.7 Hz, 1H), 5.44 (s, 
1H), 2.17 (s, 3H). 
 
Final Analogues (12) 
4-(4-Fluoro-3-(methylcarbamoyl)phenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (224409) : Compound 7 (0.100 g, 0.244 mmol), HATU 
(0.185 g, 0.489 mmol), DIEA (0.085 mL, 0.489 mmol), and 2N methylamine (0.245 mL, 0.489 
mmol) were added to 5 mL of DMF in a 25 mL round bottom flask and allowed to stir overnight 
at room temperature. The reaction was diluted with water and ethyl acetate giving a white 
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suspension in the organic layer. The layers were separated and the organic layer was washed 
once with Na2CO3 and twice with NaCl. The organic suspension was then filtered off and 
washed with water giving a white solid. The solid was then washed with dichloromethane and 
purified using flash chromatography (0-15% MeOH/DCM) yielding 224409 as a white solid: 
80.7 mg (78%). 
1
H NMR (500 MHz, DMSO-d6) δ 12.93 (s, 1H), 9.58 (s, 1H), 8.75 (d, J = 1.9 
Hz, 1H), 8.20 (t, J = 1.3 Hz, 1H), 7.98 (d, J = 7.1 Hz, 2H), 7.63 – 7.57 (m, 2H), 7.44 – 7.35 (m, 
3H), 7.24 (dd, J = 10.3, 8.6 Hz, 1H), 5.43 (d, J = 2.9 Hz, 1H), 3.17 (d, J = 4.6 Hz, 1H), 2.75 (d, J 
= 4.6 Hz, 3H), 2.07 (s, 3H). 
13
C NMR (126 MHz, DMSO) δ 164.92, 163.71, 152.24, 140.48, 
138.29, 136.77, 133.18, 131.90, 130.01, 128.19, 123.70, 122.50, 120.85, 115.97, 115.79, 110.25, 
109.72, 104.96, 54.32, 26.17, 16.98. HPLC purity: 96%; MS (ESI+) m/z: 445.1 (M+1). 
 
4-(3-(Benzylcarbamoyl)-4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (224407): Compound 224407 was prepared as described 
for 224409, replacing methylamine with benzylamine. Yield: 21.0 mg, 17% yield). 
1
H NMR 
(500 MHz, DMSO-d6) δ 12.93 (s, 1H), 9.59 (s, 1H), 8.83 (td, J = 5.4, 1.5 Hz, 1H), 8.77 (d, J = 
1.4 Hz, 1H), 7.98 (d, J = 18.6 Hz, 2H), 7.65-7.60 (m, 2H), 7.44 – 7.37 (m, 3H), 7.32 – 7.20 (m, 
6H), 5.45 (d, J = 2.9 Hz, 1H), 4.45 (d, J = 6.1 Hz, 2H), 2.08 (s, 3H). 
13
C NMR (126 MHz, 
DMSO) δ 164.92, 163.46, 159.13, 157.15, 152.26, 140.51, 139.09, 138.40, 136.78, 133.18, 
131.91, 130.12, 128.14, 126.95, 126.62, 123.71, 123.59, 122.51, 120.85, 116.06, 115.87, 110.26, 
109.72, 104.91, 54.28, 42.52, 16.99. HPLC purity: 95%; MS (ESI+) m/z: 499.1 (M+1). 
 
4-(4-Fluoro-3-((3-fluorobenzyl)carbamoyl)phenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (221302): Compound 221302 was prepared as described 
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for 224409, replacing methylamine with 3-fluorobenzylamine. Yield: 46.8 mg (37%). 
1
H NMR 
(500 MHz, DMSO-d6) δ 12.90 (s, 1H), 9.58 (s, 1H), 8.88 (s, 1H), 8.76 (s, 1H), 7.97 (d, J = 18.0 
Hz, 2H), 7.63 (s, 2H), 7.46 – 7.31 (m, 4H), 7.27 (t, J = 9.4 Hz, 1H), 7.12 (dd, J = 15.2, 9.0 Hz, 
2H), 7.08 – 7.02 (m, J = 11.8, 5.3 Hz, 1H), 5.44 (s, 1H), 4.46 (d, J = 5.8 Hz, 2H), 2.07 (s, 3H). 
13
C NMR (126 MHz, DMSO) δ 171.71, 165.49, 164.12, 163.62, 161.69, 159.73, 157.75, 152.83, 
142.48, 141.11, 139.00, 132.47, 130.85, 130.67, 128.82, 124.02, 123.50, 123.06, 121.44, 116.57, 
114.18, 113.97, 110.85, 110.36, 105.45, 54.85, 42.65, 17.56. HPLC purity: 99%; MS (ESI+) m/z: 
516.9 (M+1), 538.8 (M+Na+). 
 
4-(3-((2,6-Difluorobenzyl)carbamoyl)-4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide (215023): Compound 215023 was prepared as 
described for 224409, replacing methylamine with 2,6-difluorobenzylamine. Yield: 60.1 mg 
(31%). 
1
H NMR (400 MHz, DMSO-d6) δ 12.91 (s, 1H), 9.55 (s, 1H), 8.74 (s, 1H), 8.70 (s, 1H), 
7.96 (d, J = 10.5 Hz, 2H), 7.59 (s, 1H), 7.52 (d, J = 6.6 Hz, 1H), 7.42-7.35 (m, 4H), 7.19 (t, J = 
9.5 Hz, 1H), 7.05 (t, J = 7.8 Hz, 2H), 5.40 (s, 1H), 4.47 (d, J = 4.9 Hz, 2H), 2.05 (s, 3H). 
13
C 
NMR (126 MHz, DMSO) δ 164.90, 163.22, 152.25, 140.41, 138.43, 136.78, 133.17, 131.89, 
130.11, 129.72, 128.12, 123.47, 122.50, 120.87, 115.96, 115.78, 113.79, 111.43, 111.23, 110.28, 




1,2,3,4-tetrahydropyrimidine-5-carboxamide (221303): Compound 221303 was prepared as 





H NMR (400 MHz, DMSO-d6) δ 12.94 (s, 1H), 9.60 (s, 1H), 8.78 (s, 1H), 8.64 (s, 1H), 
8.01 (s, 1H), 7.97 (s, 1H), 7.67 – 7.61 (m, 2H), 7.45 – 7.36 (m, 3H), 7.31 – 7.17 (m, 3H), 6.98 (d, 
J = 8.0 Hz, 1H), 6.88 (t, J = 7.4 Hz, 1H), 5.45 (s, 1H), 4.42 (d, J = 6.0 Hz, 2H), 3.81 (s, 3H), 2.08 
(s, 3H). 
13
C NMR (126 MHz, DMSO) δ 164.92, 163.45, 163.44, 157.21, 156.46, 152.27, 140.52, 
138.43, 136.78, 133.18, 131.91, 130.14, 128.26, 127.88, 127.05, 126.29, 123.63, 122.51, 120.86, 
119.99, 115.96, 110.34, 109.57, 104.91, 55.20, 54.28, 37.75, 16.99. HPLC purity: 95%; MS 
(ESI+) m/z: 528.8 (M+1), 550.8 (M+Na+). 
 
4-(4-Fluoro-3-((3-methoxybenzyl)carbamoyl)phenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide (224414): Compound 224414 was prepared as 
described for 224409, replacing methylamine with (3-methoxyphenyl) methanamine. Yield: 74.3 
mg (58%). 
1
H NMR (400 MHz, DMSO-d6) δ 12.93 (s, 1H), 9.58 (s, 1H), 8.82 (broad s, 1H), 8.76 
(s, 1H), 7.98 (d, J = 16 Hz, 2H), 7.65 – 7.57 (m, 2H), 7.46 – 7.34 (m, 3H), 7.32 – 7.17 (m, 2H), 
6.91 – 6.84 (m, 2H), 6.80 (dt, J = 8.2, 1.4 Hz, 1H), 5.45 (d, J = 2.8 Hz, 1H), 4.43 (d, J = 6.1 Hz, 




1,2,3,4-tetrahydropyrimidine-5-carboxamide (221304):  Compound 221304 was prepared as 
described for 224409, replacing methylamine with 4-methoxybenzylamine. Yield: 10.7 mg (8%).  
1
H NMR (400 MHz, DMSO-d6) δ 12.94 (s, 1H), 9.60 (s, 1H), 8.77 (s, 2H), 7.98 (d, J = 14.1 Hz, 
2H), 7.63 (s, 1H), 7.60 (dd, J = 6.9, 2.3 Hz, 1H), 7.44 – 7.35 (m, 3H), 7.27 (d, J = 10.2 Hz, 1H), 
7.22 (d, J = 8.5 Hz, 2H), 6.86 (d, J = 8.7 Hz, 2H), 5.44 (s, 1H), 4.37 (d, J = 6.0 Hz, 2H), 3.71 (s, 
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3H), 2.07 (s, 3H). 
13
C NMR (101 MHz, DMSO) δ 165.47, 163.86, 158.60, 157.43, 152.83, 
138.93, 137.32, 133.74, 132.46, 131.57, 128.91, 128.73, 125.28, 124.22, 123.06, 121.40, 116.62, 
116.39, 114.09, 110.80, 110.29, 105.47, 55.47, 54.81, 42.53, 17.55. HPLC purity: 99%; MS 
(ESI-) m/z: 527.0 (M-1).  
 
4-(4-Fluoro-3-((pyridin-2-ylmethyl)carbamoyl)phenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide (215022): Compound 215022 was prepared as 
described for 224409, replacing methylamine with 2-(aminomethyl)pyridine. Yield: 41.2 mg 
(20%) 
  1
H NMR (400 MHz, DMSO-d6) δ ppm 12.93, 9.59, 8.87, 8.77, 8.50, 7.98, 7.73, 7.69, 
7.63, 7.46-7.37, 7.33-7.24, 5.46, 4.56, 2.08. 
1
H NMR (400 MHz, DMSO-d6) δ 12.96 (s, 1H), 
9.64 (s, 1H), 8.91 (q, J = 5.3 Hz, 1H), 8.76 (d, J = 2.0 Hz, 1H), 8.48 (d, J = 4.3 Hz, 1H), 7.99 (s, 
1H), 7.94 (s, 1H), 7.71 (td, J = 7.7, 1.8 Hz, 1H), 7.66 (dd, J = 6.9, 2.4 Hz, 1H), 7.62 (t, J = 2.4 
Hz, 1H), 7.47 – 7.36 (m, 3H), 7.33 – 7.20 (m, 3H), 5.45 (d, J = 2.9 Hz, 1H), 4.53 (d, J = 5.9 Hz, 
2H), 2.06 (s, 3H). 
13
C NMR (126 MHz, DMSO) δ 164.89, 164.024, 158.56, 157.90, 152.83, 
149.28, 141.14, 138.93, 137.17, 133.74, 132.47, 130.94, 128.94, 123.77, 123.65, 122.55,121.43, 
121.12, 116.71, 116.52, 110.83, 110.30, 105.49, 54.88, 45.15, 17.55. HPLC purity: 97%; MS 
(ESI+) m/z: 500.3 (M+1), 522.2 (M+Na+). 
 
4-(4-Fluoro-3-((2-(pyridin-2-yl)ethyl)carbamoyl)phenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide (215024): Compound 215024 was prepared as 
described for 224409, replacing methylamine with 2-pyridin-2-ylethylamine. Yield: 38 mg 
(20%).  
1
H NMR (400 MHz, DMSO) δ ppm 
1
H NMR (400 MHz, DMSO-d6) δ 12.92 (s, 1H), 
9.58 (s, 1H), 8.77 (s, 1H), 8.47 (d, J = 4.0 Hz, 1H), 8.37 (dd, J = 8.2, 5.1 Hz, 1H), 7.97 (d, J = 
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13.9 Hz, 2H), 7.67 (td, J = 7.6, 1.8 Hz, 1H), 7.62 (s, 1H), 7.57 (dd, J = 6.9, 2.3 Hz, 1H), 7.43 – 
7.34 (m, 3H), 7.26-7.15 (m 3H), 5.42 (d, J = 2.1 Hz, 1H), 3.57 (dd, J = 13.2, 6.9 Hz, 2H), 2.94 (t, 
J = 7.2 Hz, 2H), 2.05 (s, 3H). 
13
C NMR (126 MHz, DMSO) δ 164.91, 163.16, 159.33, 158.86, 
156.86, 152.26, 148.93, 140.49, 138.32, 136.75, 136.34, 133.18, 131.90, 130.03, 128.17, 123.05, 
122.50, 121.40, 120.84, 116.02, 110.238, 109.74, 104.93, 54.31, 36.90, 16.99. HPLC purity: 
95%; MS (ESI+) m/z: 514.0 (M+1), 536.0 (M+Na+). 
 
4-(4-Fluoro-3-((2-(pyridin-4-yl)ethyl)carbamoyl)phenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide (222882): Compound 222882 was prepared as 
described for 224409, replacing methylamine with 2-(4-pyridyl)ethyl amine.  Yield: 95.8 mg 
(51%). 
1
H NMR (400 MHz, DMSO) δ 12.94 (s, 1H), 9.59 (s, 1H), 8.78 (s, 1H), 8.45 (d, J = 5.5 
Hz, 2H), 8.38 (s, 1H), 7.99 (d, J = 13.9 Hz, 2H), 7.63 (s, 1H), 7.55 (d, J = 4.7 Hz, 1H), 7.47 – 
7.34 (m, 3H), 7.29 – 7.18 (m, J = 7.5 Hz, 3H), 5.44 (s, 1H), 3.50 (dd, J = 12.8, 6.6 Hz, 2H), 2.82 
(t, J = 7.0 Hz, 2H), 2.07 (s, 3H). 
13
C NMR (126 MHz, DMSO) δ 165.48, 163.94, 152.83, 149.87, 
148.68, 141.05, 138.95, 137.34, 133.75, 132.47, 130.63, 128.61, 124.50, 123.07, 121.42, 116.56, 
116.37, 114.22, 110.82, 110.30, 105.48, 54.86, 39.47, 34.50, 17.55. HPLC purity: 99%; MS 
(ESI+) m/z: 514.1 (M+1), 536.1 (M+Na+). 
 
4-(4-Fluoro-3-((isoquinolin-1-ylmethyl)carbamoyl)phenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide (224062): Compound 226062 was prepared as 
described for 224409, replacing methylamine with isoquinolin1-ylmethylamine. Yield: 5.3 mg 
(4%). 
1
H NMR (400 MHz, DMSO-d6) δ ppm 12.92 (s, 1H), 9.58 (s, 1H), 8.87 (d, J = 5.7 Hz, 
1H), 8.77 (s, 1H), 8.42 (d, J = 5.7 Hz, 1H), 8.29 (d, J = 8.4 Hz, 1H), 8.00 (d, J = 7.3 Hz, 2H), 
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7.95 (s, 1H), 7.83-7.73 (m, 3H), 7.69 (t, J = 7.6 Hz, 1H),  7.63 (s, 1H),  7.47-7.34 (m, 3H), 7.28 
(t, J = 9.5 Hz, 1H), 5.46 (s, 1H), 5.13 (d, J = 5.0 Hz, 2H), 2.06 (s, 3H). MS (ESI+) m/z: 550.1 
(M+1). HPLC purity: 98%. 
 
4-(3-((2,6-Dichlorobenzyl)carbamoyl)-4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide (224063): Compound 224063 was prepared as 
described for 224409, replacing methylamine with 2,6-dichlorobenzylamine. Yield: 68.0 mg 
(49%).  
1
H NMR (500 MHz, DMSO-d6) δ 12.91 (s, 1H), 9.56 (s, 1H), 8.74 (d, J = 2.0 Hz, 1H), 
8.55 (t, J = 5.3 Hz, 1H), 7.98 (s, 1H), 7.95 (s, 1H), 7.61 – 7.59 (m, 1H), 7.52 (dd, J = 6.7, 2.4 Hz, 
1H), 7.45 (s, 1H), 7.43 (s, 1H), 7.41 – 7.35 (m, 3H), 7.33 (dd, J = 8.5, 7.6 Hz, 1H), 7.18 (dd, J = 
10.0, 8.7 Hz, 1H), 5.41 (d, J = 2.2 Hz, 1H), 4.70 – 4.61 (m, 2H), 2.05 (s, 3H). 
13
C NMR (126 
MHz, DMSO) δ 164.90, 163.37, 152.28, 140.30, 138.50, 136.78, 135.55, 133.18, 132.88, 131.91, 
130.07, 128.38, 128.02, 123.83, 123.71, 122.51, 120.88, 115.92, 115.73, 110.28, 109.71, 104.88, 
54.20, 38.91, 16.99. MS (ESI+) m/z: 568.1 (M+1). HPLC purity: 97%;  
 
4-(3-((2,6-Dimethylbenzyl)carbamoyl)-4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-
1,2,3,4-tetrahydropyrimidine-5 carboxamide (224064): Compound 224064 was prepared as 
described for 224409, replacing methylamine with 2,6-dimethylbenzylamine. Yield: 82.9 mg 
(65%). 
1
H NMR (500 MHz, DMSO-d6) δ 12.93 (s, 1H), 9.58 (s, 1H), 8.76 (d, J = 1.6 Hz, 1H), 
8.41 (t, J = 4.6 Hz, 1H), 7.99 (d, J = 18.7 Hz, 2H), 7.51 (dd, J = 6.7, 2.3 Hz, 1H), 7.43 – 7.34 (m, 
3H), 7.19 (dd, J = 9.9, 8.7 Hz, 1H), 7.10 – 7.03 (m, 1H), 6.99 (d, J = 7.5 Hz, 2H), 5.43 (d, J = 2.4 
Hz, 1H), 4.43 (t, J = 4.7 Hz, 2H), 2.32 (s, 6H), 2.07 (s, 3H).
 






1,2,3,4-tetrahydropyrimidine-5-carboxamide (224406): Compound 224406 was prepared as 
described for 224409, replacing methylamine with 2,6-dimethoxybenzylamine. Yield: 86.0 mg 
(32%). 
1
H NMR (400 MHz, DMSO-d6) δ 12.94 (s, 1H), 9.58 (s, 1H), 8.77 (d, J = 1.9 Hz, 1H), 
8.03 – 7.93 (m, 3H), 7.62 (dt, J = 5.0, 2.4 Hz, 2H), 7.45 – 7.32 (m, 3H), 7.29 – 7.14 (m, 2H), 
6.65 (d, J = 8.4 Hz, 2H), 5.43 (d, J = 2.9 Hz, 1H), 4.48 (d, J = 4.9 Hz, 2H), 3.77 (s, 6H), 2.07 (s, 
3H). 
13
C NMR (126 MHz, DMSO) δ 164.89, 158.21, 152.26, 140.43, 138.40, 136.76, 133.68, 
133.17, 131.91, 128.98, 128.59, 123.41, 123.30, 122.50, 120.85, 115.93, 115.74, 112.95, 110.24, 
109.71, 104.95, 103.99, 55.68, 54.28, 32.25, 16.98. HPLC purity: 97%; MS (ESI+) m/z: 559.1 
(M+1), 581.1 (M+Na+). 
 
4-(3-((2,6-Bis(trifluoromethyl)benzyl)carbamoyl)-4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-
2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (224413): Compound 224413 was prepared 
as described for 224409, replacing methylamine with 2,6 bis(trifluoromethyl)benzylamine. 
Yield: 82.5 mg (53%). 
1
H NMR (400 MHz, DMSO-d6) δ 12.93 (s, 1H), 9.57 (s, 1H), 8.76 (s, 
1H), 8.61 (s, 1H), 8.10 (d, J = 8.0 Hz, 2H), 7.97 (d, J = 10.9 Hz, 2H), 7.80 (t, J = 8.0 Hz, 1H), 
7.62 (s, 1H), 7.51 (dd, J = 6.7, 2.4 Hz, 1H), 7.45 – 7.34 (m, 3H), 7.19 (dd, J = 9.9, 8.6 Hz, 1H), 
5.43 (d, J = 2.9 Hz, 1H), 4.73 – 4.59 (m, 2H), 2.07 (s, 3H). 
13
C NMR (126 MHz, DMSO) δ 
165.44, 163.55, 159.45, 157.54, 152.90, 140.89, 139.16, 137.34, 133.98, 133.69, 132.44, 130.09, 
128.33, 125.24, 125.14, 123.05, 121.41, 116.50, 116.24, 110.96, 110.31, 105.40, 54.65, 37.73, 





2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (224410): Compound 224410 was prepared 
as described for 224409, replacing methylamine with 3,5 bis(trifluoromethyl)benzylamine. 
Yield:24.6 mg (16%). 
1
H NMR (400 MHz, DMSO-d6) δ 12.93 (s, 1H), 9.58 (s, 1H), 9.05 (s, 1H), 
8.77 (s, 1H), 8.03 (s, 2H), 8.00 (d, J = 4.3 Hz, 2H), 7.95 (s, 1H), 7.65 – 7.59 (m, 2H), 7.46 – 7.28 
(m, 4H), 5.44 (s, 1H), 4.64 (d, J = 5.9 Hz, 2H), 2.07 (s, 3H). HPLC purity: 95%; MS (ESI+) m/z: 
635.0 (M+1), 657.0 (M+Na+). 
 
4-(4-Fluoro-3-(((3-methylpyridin-2-yl)methyl)carbamoyl)phenyl)-N-(1H-indazol-5-yl)-6-methyl-
2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (224412): Compound 224412 was prepared 
as described for 224409, replacing methylamine with (3-methylpyridin-2-yl)methanamine. 
Yield: 29.8 mg (24%). 
1
H NMR (400 MHz, DMSO-d6) δ 12.93 (s, 1H), 9.60 (s, 1H), 8.87 (broad 
s, 1H), 8.77 (s, 1H), 8.35 – 8.29 (m, 2H), 7.99 (d, J = 16 Hz, 2H), 7.65 – 7.61 (m, 2H), 7.47 – 
7.36 (m, 3H), 7.30 (dd, J = 10.3, 8.5 Hz, 1H), 7.17 (d, J = 5.0 Hz, 1H), 5.46 (s, 1H), 4.43 (d, J = 
5.9 Hz, 2H), 2.28 (s, 3H), 2.08 (s, 3H). 
13
C NMR (126 MHz, DMSO-d6) δ 165.48, 164.28, 
157.75, 155.04, 152.83, 150.47, 147.76, 146.21, 139.12, 137.25, 133.59, 132.48, 131.28, 130.82, 
128.71, 123.94, 123.07, 121.40, 116.63, 116.41, 110.74, 110.19, 105.43, 98.78, 54.74, 40.56, 
17.45, 15.74. HPLC purity: 97%; MS (ESI+) m/z: 514.1 (M+1), 536.1 (M+Na+). 
 
4-(3-((2,6-Dimethylphenethyl)carbamoyl)-4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide (224411): Compound 224411 was prepared as 
described for 224409, replacing methylamine with 2-(2,6-dimethylphenyl)ethanamine. (Yield: 
89.7 mg, 93%). 
1
H NMR (500 MHz, DMSO-d6) δ 12.93 (s, 1H), 9.59 (s, 1H), 8.77 (s, 1H), 8.50 
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(dd, J = 8.4, 5.6 Hz, 1H), 7.98 (d, J = 19.6 Hz, 2H), 7.66 (dd, J = 7.0, 2.3 Hz, 1H), 7.63 (broad s, 
1H), 7.45-7.36 (m, 3H), 7.26 (dd, J = 10.3, 8.6 Hz, 1H), 6.98 (d, J = 1.1 Hz, 3H) 5.45 (d, J = 1.8 
Hz, 1H), 3.32 – 3.23 (m, 2H), 2.82 (dd, J = 10.0, 6.5 Hz, 2H), 2.33 (s, 6H), 2.08 (s, 3H). 
13
C 
NMR (126 MHz, DMSO) δ 165.49, 163.73, 157.76, 152.81, 141.14, 138.84, 137.35, 136.67, 
136.04, 133.73, 132.45, 130.78, 128.91, 128.33, 126.37, 124.01, 123.07, 121.45, 116.50, 110.88, 
110.28, 105.53, 54.94, 38.91, 30.03, 19.84, 17.54. HPLC purity: 97%; MS (ESI+) m/z: 541.1 
(M+1), 563.1 (M+Na+). 
 
4-(3-(sec-butyl(methyl)carbamoyl)-4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (257061). Compound 257061 was prepared as described 
for 224409, replacing methylamine with N-methylbutan-2-amine (Yield: 16%). 
1
H NMR (400 
MHz, cd3od, 55°C) δ 7.94 (s, 1H), 7.88 – 7.80 (m, 1H), 7.55 – 7.45 (m, 1H), 7.44 (d, J = 9.0 Hz, 
1H), 7.35 – 7.23 (m, 2H), 7.21 – 7.15 (m, 1H), 5.52 (d, J = 13.1 Hz, 1H), 4.59 (dq, J = 13.2, 6.7 
Hz, 0.5H), 3.40 (s, 0.5H), 2.87 (d, J = 2.6 Hz, 2H), 2.56 (s, 1H), 2.12 (d, J = 3.3 Hz, 3H), 1.53 – 
1.48 (m, 1H), 1.17 – 1.05 (m, 3H),  0.87 (dt, J = 20.4, 7.4 Hz, 2H), 0.70 – 0.57 (m, 2H). HPLC 
purity: 95%; MS (ESI+) m/z: 479.2 (M+1), 501.1 (M+Na+). 
 
4-(3-((2-(azepan-1-yl)propyl)carbamoyl)-4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide (257062). Compound 257062 was prepared as 
described for 224409, replacing methylamine with 2-(azepan-1-yl)propan-1-amine (Yield: 7%) . 
1
H NMR (400 MHz, Methanol-d4) δ 7.96 (s, 1H), 7.90 (dd, J = 7.1, 2.4 Hz, 2H), 7.87 (s, 1H), 
7.54 (ddd, J = 8.6, 4.8, 2.5 Hz, 1H), 7.44 (d, J = 8.9 Hz, 1H), 7.32 (dd, J = 8.9, 1.9 Hz, 1H), 7.21 
(dd, J = 11.1, 8.5 Hz, 1H), 5.54 (s, 1H), 3.40 (dt, J = 13.5, 5.3 Hz 1H), 3.23 (ddd, J = 13.4, 8.9, 
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4.3 Hz, 1H), 2.93 (p, J = 6.3 Hz, 1H), 2.75 (d, J = 12.9 Hz, 2H), 2.58 (d, J = 12.6 Hz, 2H), 2.14 
(d, J = 1.1 Hz, 3H), 1.70 – 1.52 (m, 8H), 1.00 (d, J = 6.6 Hz, 3H). 
13
C NMR (126 MHz, cd3od) δ 
168.15, 162.23, 155.08, 142.20, 141.59, 138.23, 132.96, 132.88, 132.67, 130.53, 123.49, 117.75, 
117.55, 113.45, 111.63, 111.27, 107.64, 102.14, 73.58, 62.31, 60.46, 57.38, 52.00, 44.02, 30.53, 
27.91, 17.21, 12.21. HPLC purity: 96%; MS (ESI+) m/z: 548.2 (M+1). 
 
4-(4-fluoro-3-(methyl((tetrahydro-2H-pyran-2-yl)methyl)carbamoyl)phenyl)-N-(1H-indazol-5-
yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257063). Compound 257063 
was prepared as described for 224409, replacing methylamine with N-methyl-1-(tetrahydro-2H-
pyran-2-yl)methanamine (Yield: 31%). 
1
H NMR (400 MHz, cd3od) δ 7.99 – 7.88 (m, 2H), 7.50 
(ddd, J = 11.8, 5.7, 3.2 Hz, 1H), 7.45 (d, J = 9.1 Hz, 1H), 7.39 – 7.30 (m, 2H), 7.23 – 7.14 (m, 
1H), 5.56 – 5.51 (m, 1H), 3.92 – 3.76 (m, 1H), 3.64 – 3.55 (m, 1H), 3.44 – 3.33 (m, 1H), 3.26 – 
3.06 (m, 3H), 2.83 (d, J = 4.6 Hz, 2H), 2.12 (d, J = 5.9 Hz, 3H), 1.82 (s, 1H), 1.63 – 1.43 (m, 
3H), 1.37 – 1.10 (m, 2H). HPLC purity: 96%; MS (ESI+) m/z: 521.1 (M+1), 543.1 (M+Na+). 
 
4-(3-(((5-ethyl-1,2,4-oxadiazol-3-yl)methyl)carbamoyl)-4-fluorophenyl)-N-(1H-indazol-5-yl)-6-
methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257064). Compound 257064 was 
prepared as described for 224409, replacing methylamine with (5-ethyl-1,2,4-oxadiazol-3-
yl)methanamine (Yield: 45%). 
1
H NMR (400 MHz, DMSO-d6) δ 12.92 (s, 1H), 9.58 (s, 1H), 
8.86 (td, J = 5.9, 3.2 Hz, 1H), 8.77 (d, J = 2.0 Hz, 1H), 7.99 (d, J = 8.0 Hz, 2H), 7.67 - 7.62 (m, 
2H), 7.45 – 7.33 (m, 3H), 7.26 (dd, J = 10.4, 8.5 Hz, 1H), 5.43 (d, J = 3.0 Hz, 1H), 4.51 (d, J = 
5.8 Hz, 2H), 2.89 (q, J = 7.6 Hz, 2H), 2.05 (s, 3H), 1.23 (t, J = 7.6 Hz, 3H). 
13
C NMR (101 MHz, 
dmso) δ 181.32, 168.27, 165.46, 164.06, 160.08, 157.61, 152.82, 141.16, 138.88, 137.33, 132.43, 
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128.96, 123.28, 123.13, 123.05, 121.44, 110.80, 110.29, 109.98, 105.47, 54.91, 35.67, 19.89, 
17.59, 10.86. HPLC purity: 98%; MS (ESI+) m/z: 519.1 (M+1), 541.0 (M+Na+). 
 
Methyl 1-(5-(5-((1H-indazol-5-yl)carbamoyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-4-yl)-
2-fluorobenzamido)cyclohexanecarboxylate (257065). Compound 257065 was prepared as 
described for 224409, replacing methylamine with methyl 1-aminocyclohexanecarboxylate 
(Yield: 27%). 
1
H NMR (400 MHz, cd3od) δ 7.96 (s, 1H), 7.89 (s, 1H), 7.67 (dd, J = 6.7, 2.3 Hz, 
1H), 7.53 (ddd, J = 8.1, 4.8, 2.4 Hz, 1H), 7.45 (d, J = 9.0 Hz, 1H), 7.34 (dd, J = 9.0, 1.7 Hz, 1H), 
7.20 (dd, J = 10.1, 8.7 Hz, 1H), 5.53 (s, 1H), 3.65 (s, 3H), 2.14 (s, 3H), 2.13 – 1.97 (m, 2H), 1.91 
– 1.79 (m, 2H), 1.67 – 1.48 (m, 6H). 
13
C NMR (126 MHz, cd3od) δ 174.74, 166.69, 164.86, 
160.45, 158.46, 153.59, 139.86, 136.85, 133.43, 131.07, 131.00, 128.46, 122.02, 16.19, 116.00, 
111.99, 109.79, 106.15, 103.54, 59.46, 55.85, 51.29, 31.97, 31.64, 24.93, 21.11, 21.08, 15.75. 
HPLC purity: 95%. 
 
4-(4-fluoro-3-(((3-(methoxymethyl)-1,2,4-oxadiazol-5-yl)methyl)carbamoyl)phenyl)-N-(1H-
indazol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257142). Compound 
257142 was prepared as described for 224409, replacing methylamine with (3-(methoxymethyl)-
1,2,4-oxadiazol-5-yl)methanamine (Yield: 12%). 
1
H NMR (400 MHz, Methanol-d4) δ 7.96 (s, 
1H), 7.89 – 7.83 (m, 2H), 7.56 (ddd, J = 7.8, 4.7, 2.5 Hz, 1H), 7.44 (d, J = 8.9 Hz, 1H), 7.31 (dd, 
J = 8.9, 1.9 Hz, 1H), 7.22 (dd, J = 10.7, 8.5 Hz, 1H), 5.54 (s, 1H), 4.81 (s, 2H), 4.52 (s, 2H), 3.39 






yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257147). Compound 257147 
was prepared as described for 224409 replacing methylamine with 1,7,7-
trimethylbicyclo[2.2.1]heptan-2-amine (Yield: 24%). (1:1)
 1
H NMR (500 MHz, dmso) δ 12.93 
(s, 1H), 9.62 – 9.56 (m, 1H), 8.77 (s, 1H), 8.17 (t, J = 7.8 Hz, 0.5 H), 8.01 (s, 1H), 7.96 (s, 1H), 
7.67 – 7.59 (m, 1H), 7.53 (dd, J = 15.6, 5.6 Hz, 1H), 7.47 (dd, J = 12.2, 6.9 Hz, 0.5 H), 7.43 – 
7.36 (m, 3H), 7.27 – 7.19 (m, 1H), 5.45 (s, 1H), 4.28 (dd, J = 17.5, 12.8 Hz, 0.5 H), 3.96 – 3.89 
(m, 1H), 2.17 – 2.11 (m, 0.5 H), 2.08 (d, J = 4.7 Hz, 3H), 1.79 – 1.58 (m, 2H), 1.57 – 1.48 (m, 




yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257148). Compound 257148 
was prepared as described for 224409, replacing methylamine with N-methyl-1-(5-methyl-1H-
pyrazol-3-yl)methanamine (Yield: 58%). 
1
H NMR (400 MHz, dmso) δ 12.95 (s, 1H), 12.34 (s, 
1H), 9.60 (s, 1H), 8.77 (s, 1H), 7.99 – 7.92 (m, 2H), 7.63 (broad s, 1H), 7.44 – 7.22 (m, 5H), 5.87 
(s, 0.5 H), 5.67 (s, 0.5 H), 5.44 (s, 1H), 4.52 (s, 1H), 4.15 (broad s, 0.5 H), 2.86 (s, 1.5 H), 2.66 
(s, 1.5 H), 2.15 (d, J = 25.6 Hz, 3H), 2.10 – 2.01 (m, 3H). HPLC purity: 96%; MS (ESI+) m/z: 
517.0 (M+1), 539.0 (M+Na+). 
 
4-(4-fluoro-3-((1-(2-methoxyphenyl)ethyl)carbamoyl)phenyl)-N-(1H-indazol-5-yl)-6-methyl-2-
oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257151). Compound 257151 was prepared as 





H NMR (400 MHz, DMSO-d6) δ 12.94 (s, 1H), 9.60 (d, J = 2.2 Hz, 1H), 8.78 (d, J = 1.9 
Hz, 1H), 8.69 (t, J = 8.7 Hz, 1H), 8.00 (s, 1H), 7.97 (s, 1H), 7.65 (s, 1H), 7.55 (dt, J = 6.8, 2.2 
Hz, 1H), 7.44 – 7.36 (m, 3H), 7.34 – 7.18 (m, 3H), 6.98 (d, J = 8.2 Hz, 1H), 6.88 (qd, J = 7.4, 1.1 
Hz, 1H), 5.45 (d, J = 2.9 Hz, 1H), 5.42 – 5.33 (m, 1H), 3.83 (s, 3H), 2.10 – 2.04 (m, 3H), 1.32 (d, 
J = 7.0 Hz, 3H). HPLC purity: 97%; MS (ESI+) m/z: 543.0 (M+1), 565.0 (M+Na+). 
 
4-(3-((2-(3,5-dimethylisoxazol-4-yl)ethyl)carbamoyl)-4-fluorophenyl)-N-(1H-indazol-5-yl)-6-
methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257282, 6 – 78). Compound 257282 
was prepared as described for 224409, replacing methylamine with 2-(3,5-dimethylisoxazol-4-
yl)ethan-1-amine (Yield: 22%). 
1
H NMR (400 MHz, DMSO-d6) δ 12.94 (s, 1H), 9.59 (s, 1H), 
8.78 (d, J = 1.9 Hz, 1H), 8.35 (q, J = 5.1, 4.3 Hz, 1H), 8.02 – 7.94 (m, 2H), 7.63 (t, J = 2.5 Hz, 
1H), 7.57 (dd, J = 6.9, 2.4 Hz, 1H), 7.45 – 7.35 (m, 3H), 7.24 (dd, J = 10.3, 8.5 Hz, 1H), 5.44 (d, 
J = 2.9 Hz, 1H), 3.32 – 3.27 (m, 2H), 2.53 (d, J = 7.1 Hz, 2H), 2.24 (s, 3H), 2.15 (s, 3H), 1.29 – 
1.23 (m, 2H). HPLC purity: 97%; MS (ESI+) m/z: 532. 2 (M+1). 
 
4-(4-fluoro-3-((imidazo[1,2-a]pyridin-2-ylmethyl)carbamoyl)phenyl)-N-(1H-indazol-5-yl)-6-
methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257283 – 6-79). Compound 257283 
was prepared as described for 224409, replacing methylamine with imidazo[1,2-a]pyridin-2-
ylmethanamine (Yield: 37%).
1
H NMR (400 MHz, DMSO-d6) δ 12.94 (s, 1H), 9.61 (s, 1H), 8.81 
– 8.74 (m, 2H), 8.48 (dt, J = 6.8, 1.2 Hz, 1H), 8.03 – 7.93 (m, 2H), 7.78 – 7.73 (m, 1H), 7.66 (dd, 
J = 6.9, 2.4 Hz, 1H), 7.63 (d, J = 2.8 Hz, 1H), 7.50 – 7.45 (m, 1H), 7.45 – 7.36 (m, 3H), 7.27 (dd, 
J = 10.4, 8.5 Hz, 1H), 7.19 (ddd, J = 9.1, 6.7, 1.3 Hz, 1H), 6.84 (td, J = 6.8, 1.2 Hz, 1H), 5.45 (d, 
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J = 1.8 Hz, 1H), 4.56 (d, J = 5.7 Hz, 2H), 3.17 (d, J = 5.3 Hz, 1H), 2.11 – 2.03 (m, 3H). HPLC 
purity: 99%. MS (ESI+) m/z: 539.2 (M+1). 
 
4-(3-(((6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl)methyl)carbamoyl)-4-fluorophenyl)-N-(1H-
indazol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257285 – 6-81). 
Compound 257285 was prepared as described for 224409, replacing methylamine with (6,7-
dihydro-5H-cyclopenta[b]pyridin-3-yl)methanamine (Yield: 24%).
1
H NMR (500 MHz, DMSO-
d6) δ 12.93 (s, 1H), 9.59 (s, 1H), 8.84 (dt, J = 6.0, 3.1 Hz, 1H), 8.76 (d, J = 2.0 Hz, 1H), 8.24 (d, 
J = 2.0 Hz, 1H), 8.01 – 7.93 (m, 2H), 7.67 – 7.58 (m, 2H), 7.51 (d, J = 2.0 Hz, 1H), 7.45 – 7.34 
(m, 3H), 7.30 – 7.17 (m, 1H), 5.40 (s, 1H), 4.41 (d, J = 5.9 Hz, 2H), 3.49 (q, J = 5.3 Hz, 1H), 
3.42 (dd, J = 5.5, 4.6 Hz, 1H), 2.85 (q, J = 7.1 Hz, 4H), 2.08 – 2.06 (m, 3H), 2.03 (p, J = 7.5 Hz, 
2H). HPLC purity: 98%; MS (ESI+) m/z: 540.0. 
 
 4-(4-fluoro-3-(2-(3-methoxypropyl)piperidine-1-carbonyl)phenyl)-N-(1H-indazol-5-yl)-6-
methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257286 – 6-83). Compound 257285 
was prepared as described for 224409, replacing methylamine with 2-(3-
methoxypropyl)piperidine (Yield: 13%). 
1
H NMR (400 MHz, DMSO-d6) δ 12.92 (s, 1H), 9.33 
(s, 1H), 8.45 (s, 1H), 7.94 (d, J = 5.6 Hz, 2H), 7.45 – 7.36 (m, 3H), 7.27 – 7.16 (m, 2H), 5.46 (s, 
1H), 3.52 – 3.19 (m, 8H), 2.09 (s, 3H), 1.78 – 1.24 (m, 10H). HPLC purity: 96%; MS (ESI+) 
m/z: 549.1 (M+1), 571.1 (M+Na+).  
 
4-(4-fluoro-3-(quinuclidin-3-ylcarbamoyl)phenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (257373 – 6-89). Compound 257373 was prepared as 
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described for 224409, replacing methylamine with 1-azabicyclo[2.2.2] oct-3-ylamine (Yield: 
22%).
1
H NMR (400 MHz, DMSO-d6) δ 12.92 (s, 1H), 9.63 (d, J = 2.4 Hz, 1H), 8.74 (d, J = 1.9 
Hz, 1H), 8.56 (d, J = 6.6 Hz, 1H), 8.00 – 7.92 (m, 2H), 7.61 (t, J = 2.4 Hz, 1H), 7.51 (dt, J = 6.7, 
2.3 Hz, 1H), 7.44 – 7.35 (m, 3H), 7.25 (ddd, J = 10.0, 8.6, 1.5 Hz, 1H), 5.43 (s, 1H), 4.13 (bs, 
1H), 3.40 (t, J = 11.8 Hz, 2H), 2.99 (dt, J = 16.0, 8.8 Hz, 4H), 2.86 (d, J = 9.0 Hz, 1H), 2.06 (s, 
3H), 1.74 (bs, 2H). HPLC purity: 96%; MS (ESI+) m/z: 518.2 (M+1), 540.1 (M+Na+).  
 
4-(4-fluoro-3-(octan-2-ylcarbamoyl)phenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (257381 – 6-99). Compound 257381 was prepared as 
described for 224409, replacing methylamine with 1-methyl heptylamine (Yield: 51%). 
1
H NMR 
(400 MHz, DMSO-d6) δ 12.90 (s, 1H), 9.57 (s, 1H), 8.73 (s, 1H), 8.00 (dd, J =8.5, 1.7 hz, 1H), 
7.98 – 7.92 (m, 2H), 7.60 (t, J = 2.4 Hz, 1H), 7.49 (dt, J = 6.7, 2.4 Hz, 1H), 7.42 – 7.34 (m, 3H), 
7.21 (ddd, J – 9.7, 8.6, 1.0 Hz, 1H), 5.43 (d, J = 2.9Hz, 1H), 3.91 (p, J = 6.3 Hz, 1H), 2.06 (s, 
3H), 1.28 – 1.16 (m, 9H), 1.06 (dd, J = 6.5, 1.9 Hz, 3H), 0.82 (td, J = 6.9, 2.0 Hz, 3H). HPLC 
purity: 91%; MS (ESI+) m/z: 521.2 (M+1), 543.2 (M+Na+).  
 
4-(4-fluoro-3-((6-methylheptan-2-yl)carbamoyl)phenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide (257386 – 7-5). Compound 257386 was prepared 
as described for 224409, replacing methylamine with 6-methylheptan-2-amine (Yield: 58%). 
1
H 
NMR (400 MHz, DMSO-d6) δ 12.92 (s, 1H), 9.58 (s, 1H), 8.76 (d, J = 1.9 Hz, 1H), 8.04 (d, J = 
8.3 Hz, 1H), 8.01 – 7.92 (m, 2H), 7.62 (d, J = 2.7 Hz, 1H), 7.48 (dt, J = 6.5, 2.8 Hz, 1H), 7.44 – 
7.31 (m, 3H), 7.26 – 7.16 (m, 1H), 5.45 – 5.39 (m, 1H), 3.92 (s, 1H), 2.06 (s, 3H), 1.52 – 1.20 
(m, 6H), 1.10 (td, J = 6.7, 2.9 Hz, 1H), 1.06 (dd, J = 6.6, 2.0 Hz, 3H), 0.81 (ddd, J = 6.6, 2.9, 1.0 
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Hz, 6H). HPLC purity: 97%; MS (ESI+) m/z: 521.2 (M+1), 543.2 (M+Na+).  
 
Final Analogues (13) 
4-(3-(2-((2,6-Dimethylbenzyl)amino)-2-oxoethyl)-4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-
2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (232400): Compound 232400 was prepared 
as described for 224409, replacing methylamine with 2,6-dimethylbenzylamine and 7 with 8. 
Yield: 52.3 mg (68%). 
1
H NMR (400 MHz, DMSO-d6) δ 12.98 (s, 1H), 9.61 (s, 1H), 8.70 (s, 
1H), 8.15 (s, 1H), 7.99 (d, J = 21.7 Hz, 2H), 7.60 (s, 1H), 7.41 (s, 2H), 7.28 – 7.15 (m, 2H), 7.15 
– 6.96 (m, 4H), 5.40 (s, 1H), 4.25 (s, 2H), 3.45 (s, 2H), 2.28 (s, 6H), 2.06 (s, 3H). 
13
C NMR (126 
MHz, DMSO) δ 169.05, 165.61, 159.38, 152.90, 140.63, 138.38, 138.38, 137.69, 137.34, 135.06, 
133.71, 132.53, 130.25, 128.34, 127.62, 123.83, 121.47, 115.41, 110.85, 110.25, 109.99, 105.84, 
55.02, 37.86, 35.77, 19.83, 17.52. HPLC purity: 95% 
 
4-(3-(2-((2,6-Bis(trifluoromethyl)benzyl)amino)-2-oxoethyl)-4-fluorophenyl)-N-(1H-indazol-5-
yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (232401): Compound 232401 
was prepared as described for 232400, replacing 2,6-dimethylbenzylamine with 2,6 – 
bis(trifluoromethyl)benzylamine. Yield: 15.9 mg (17%). 
1
H NMR (500 MHz, DMSO-d6) δ 12.93 
(s, 1H), 9.55 (s, 1H), 8.68 (d, J = 2.0 Hz, 1H), 8.35 (t, J = 3.9 Hz, 1H), 8.13 (d, J = 8.0 Hz, 2H), 
8.00 (d, J = 1.4 Hz, 1H), 7.96 (s, 1H), 7.82 (t, J = 8.0 Hz, 1H), 7.58 (t, J = 2.5 Hz, 1H), 7.44 – 
7.36 (m, 2H), 7.26 – 7.16 (m, 2H), 7.10 (t, J = 7.5 Hz, 1H), 5.40 (d, J = 2.9 Hz, 1H), 4.48 (d, J = 
3.7 Hz, 2H), 3.43 (s, 2H), 2.09 (s, 3H). 
13
C NMR (126 MHz, DMSO) δ 168.04, 165.15, 158.92, 
152.44, 140.10, 137.99, 136.88, 134.15, 133.24, 132.05, 130.872, 130.03, 126.54, 124.68, 
123.01, 122.56, 121.03, 114.92, 114.75, 110.42, 109.77, 105.34, 54.52, 38.57, 36.23, 17.04.  
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HPLC purity: 95% 
 
4-(3-(2-((2,6-Dimethoxybenzyl)amino)-2-oxoethyl)-4-fluorophenyl)-N-(1H-indazol-5-yl)-6-
methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (232405): Compound 232405 was 
prepared as described for 232400, replacing 2,6-dimethylbenzylamine with 2,6 – 
dimethoxybenzylamine. Yield: 30.2 mg (56%). 
1
H NMR (500 MHz, DMSO-d6) δ 12.93 (s, 1H), 
9.56 (s, 1H), 8.67 (d, J = 2.0 Hz, 1H), 7.98 (d, J = 20.4 Hz, 2H), 7.70 (t, J = 4.6 Hz, 1H), 7.57 (s, 
1H), 7.45 – 7.35 (m, 2H), 7.27 – 7.15 (m, 3H), 7.09 (t, J = 9.1 Hz, 1H), 6.64 (d, J = 8.4 Hz, 2H), 
5.40 (s, 1H), 4.24 (d, J = 4.6 Hz, 2H), 3.74 (s, 6H), 3.42 (s, 2H), 2.06 (s, 3H). 
13
C NMR (126 
MHz, DMSO) δ 168.73, 165.52, 159.29, 158.82, 152.86, 140.57, 138.21, 137.35, 133.68, 132.46, 
130.37, 129.42, 126.78, 123.86, 123.00, 121.51, 115.26, 113.65, 110.81, 110.16, 105.92, 104.46, 
56.10, 54.77, 35.41, 32.35, 17.22. HPLC purity: 97% 
 
4-(4-fluoro-3-(2-(2-(2-hydroxyethyl)morpholino)-2-oxoethyl)phenyl)-N-(1H-indazol-5-yl)-6-
methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257146). Compound 257146 was 
prepared as described for 232400, replacing 2,6-dimethylbenzylamine with 2-(morpholin-2-
yl)ethanol (Yield: 35%). 
1
H NMR (400 MHz, DMSO-d6, 80°C) δ 12.70 (s, 1H), 9.26 (s, 1H), 
8.40 (s, 1H), 7.92 (s, 2H), 7.41 – 7.36 (m, 2H), 7.29 (s, 1H), 7.24 – 7.18 (m, 2H), 7.06 (dd, J = 
9.8, 8.3 Hz, 1H), 5.39 (d, J = 3.0 Hz, 1H), 4.15 (s, 1H), 3.84 – 3.71 (m, 2H), 3.67 (s, 2H), 3.47 
(broad s, 2H), 3.43 – 3.29 (m, 2H), 3.05 (broad s, 3H), 2.07 (d, J = 2.5 Hz, 3H), 1.63 – 1.45 (m, J 





5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257145). Compound 257145 
was prepared as described for 232400, replacing 2,6-dimethylbenzylamine with 2-((furan-2-
ylmethyl)amino)ethanol (Yield: 26%).
 1
H NMR (400 MHz, DMSO-d6, 80°C) δ 12.67 (s, 1H), 
9.22 (s, 1H), 8.35 (s, 1H), 7.92 (d, J = 4.0 Hz, 2H), 7.53 (broad s, 1H), 7.44 – 7.35 (m, 2H), 7.24 
(broad s, 3H), 7.06 (t, J = 9.4 Hz, 1H), 6.37 (s, 1H), 6.26 (broad s, 1H), 5.41 (s, 1H), 4.58 (s, 
2H), 4.37 (broad s, 1H), 3.79 (s, 2H), 3.51 (s, 2H), 3.41 (s, 2H), 2.10 (d, J = 3.4 Hz, 3H). HPLC 
purity: 97%; MS (ESI+) m/z: 547.0 (M+1), 569.0 (M+Na+). 
 
4-(3-(2-(((1-cyclopropylpiperidin-4-yl)methyl)amino)-2-oxoethyl)-4-fluorophenyl)-N-(1H-
indazol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257144). Compound 
257144 was prepared as described for 232400, replacing 2,6-dimethylbenzylamine with (1-
cyclopropylpiperidin-4-yl)methanamine (Yield: 13%).
 1
H NMR (400 MHz, dmso) δ 12.91 (s, 
1H), 9.52 (s, 1H), 8.67 (s, 1H), 7.98 (s, 1H), 7.94 (s, 1H), 7.56 (s, 1H), 7.42 – 7.35 (m, 2H), 7.22 
– 7.14 (m, 3H), 7.11 – 7.05 (m, 1H), 5.37 (s, 1H), 3.47 (dd, J = 14.9, 7.2 Hz, 1H), 3.38 (s, 2H), 
2.79 (d, J = 10.9 Hz, 2H), 2.11 (t, J = 12.3 Hz, 2H), 2.04 (s, 3H), 1.63 (d, J = 10.4 Hz, 2H), 1.52 
(s, 1H), 1.25 (d, J = 7.5 Hz, 2H), 0.36 (s, 2H), 0.22 (s, 2H). HPLC purity: 96%; MS (ESI+) m/z: 
546.1 (M+1), 568.0 (M+Na+). 
 
4-(4-fluoro-3-(2-(methyl((4-methyl-1H-imidazol-2-yl)methyl)amino)-2-oxoethyl)phenyl)-N-(1H-
indazol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257141). Compound 
257141 was prepared as described for 232400, replacing 2,6-dimethylbenzylamine with N-
methyl-1-(4-methyl-1H-imidazol-2-yl)methanamine (Yield: 40%). 
1
H NMR (400 MHz, DMSO-
d6, 80 ˚C) δ 12.92 (s, 1H), 11.74 (s, 1H), 9.55 (s, 1H), 8.69 (s, 1H), 7.97 (d, J = 14.9 Hz, 2H), 
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7.58 (s, 1H), 7.44 – 7.33 (m, 2H), 7.21 – 7.04 (m, 3H), 6.64 (s, 0.5H), 6.59 (s, 0.5H), 5.38 (s, 
1H), 4.47 (s, 1H), 4.40 (s, 1H), 3.88 (s, 1H), 3.71 (s, 1H), 2.99 (s, 1.5H), 2.77 (s, 1.5H), 2.11 – 
1.99 (m, 6H). HPLC purity: 95%; MS (ESI+) m/z: 531.1 (M+1), 553.0 (M+Na+). 
 
4-(4-fluoro-3-(2-((furan-2-ylmethyl)(prop-2-yn-1-yl)amino)-2-oxoethyl)phenyl)-N-(1H-indazol-
5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257066). Compound 257066 
was prepared as described for 232400, replacing 2,6-dimethylbenzylamine with N-(furan-2-
ylmethyl)prop-2-yn-1-amine (Yield: 32%). 
1
H NMR (400 MHz, DMSO-d6, 80 ˚C) δ 12.92 (s, 
1H), 9.55 (s, 1H), 8.69 (s, 1H), 7.97 (d, J = 15.2 Hz, 2H), 7.66 – 7.55 (m, 2H), 7.43 – 7.35 (m, 
2H), 7.23 – 7.13 (m, 2H), 7.09 (t, J = 8.8 Hz, 1H), 6.43- 6.39 (m, 1H), 6.38 – 6.28 (m, 1H), 5.39 
(d, J = 2.9 Hz, 1H), 4.69 (s, 1H), 4.51 (s, 1H), 4.22 (d, J = 2.5 Hz, 1H), 4.04 (s, 1H), 3.83 (d, J = 
17.6 Hz, 2H), 3.29 (t, J = 2.4 Hz, 0.5H), 3.13 (t, J = 2.4 Hz, 0.5H), 2.04 (s, 3H). HPLC purity: 
95%; MS (ESI+) m/z: 563.1 (M+1). 
 
4-(4-fluoro-3-(2-(isobutyl(prop-2-yn-1-yl)amino)-2-oxoethyl)phenyl)-N-(1H-indazol-5-yl)-6-
methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257150). Compound 257150 was 
prepared as described for 232400, replacing 2,6-dimethylbenzylamine with N-isobutylprop-2-yn-
1-amine (Yield: 9%). 
1
H NMR (400 MHz, Methanol-d4, 60 ˚C) δ 7.97 (s, 1H), 7.88 (s, 1H), 7.45 
(d, J = 9.0 Hz, 1H), 7.34 – 7.27 (m, 2H), 7.24 (ddd, J = 6.7, 3.9, 2.4 Hz, 1H), 7.06 (t, J = 9.0 Hz, 
1H), 5.48 (s, 1H), 4.19 – 4.12 (m, 2H), 3.88 (d, J = 3.5 Hz, 1H), 3.76 (d, J = 8.1 Hz, 1H), 3.29 – 
3.28 (m, 1H), 3.21 (dd, J = 7.6, 3.7 Hz, 1H), 2.79 (t, J = 2.4 Hz, 0.5H), 2.59 (t, J = 2.5 Hz, 0.5H), 
2.11 (s, 3H), 2.08 – 2.02 (m, 0.5H), 1.95 (p, J = 6.9 Hz, 0.5H), 0.92 (dd, J = 7.7, 6.6 Hz, 3H), 





2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257281 – 6-77). Compound 257281 was 
prepared as described for 232400, replacing 2,6-dimethylbenzylamine with (2,5-
dimethylphenyl)methanamine (Yield: 7%). 
1
H NMR (400 MHz, DMSO-d6) δ 12.93 (s, 1H), 9.57 
(s, 1H), 8.71 (s, 1H), 8.37 (s, 1H), 8.01 (s, 1H), 7.96 (s, 1H), 7.60 (s, 1H), 7.40 (s, 2H), 7.26 (d, J 
= 7.0 Hz, 1H), 7.19 (s, 1H), 7.12 (t, J = 9.0 Hz, 1H), 7.05 – 6.98 (m, 2H), 6.95 (d, J = 7.9 Hz, 
1H), 5.40 (s, 1H), 4.17 (d, J = 5.7 Hz, 2H), 3.51 (s, 2H), 2.22 (s, 3H), 2.16 (s, 3H), 2.05 (s, 3H). 
HPLC purity: 95%; MS (ESI+) m/z: 540.0 (M+1). 
 
4-(4-fluoro-3-(2-(9-methyl-3,9-diazabicyclo[4.2.1]nonan-3-yl)-2-oxoethyl)phenyl)-N-(1H-
indazol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257290 – 6-87). 
Compound 257290 was prepared as described for 232400, replacing 2,6-dimethylbenzylamine 
with 9-methyl-3,9-diazabicyclo[4.2.1]nonane (Yield: 17%). 
1
H NMR (400 MHz, Methanol-d4, 
60 ˚C) δ 7.97 (s, 1H), 7.89 (d, J = 5.3 Hz, 1H), 7.45 (d, J = 8.9 Hz, 1H), 7.35 – 7.28 (m, 2H), 
7.24 (q, J = 8.5, 7.9 Hz, 1H), 7.12 – 7.03 (m, 1H), 5.48 (s, 1H), 3.78 (q, J = 6.3, 5.7 Hz, 3H), 
3.50 – 3.33 (m, 2H), 3.25 (s, 2H), 2.42 – 2.35 (m, 3H), 2.21 (t, J = 11.2 Hz, 1H), 2.11 (s, 3H), 
1.94 – 1.76 (m, 1H), 1.67 – 1.46 (m, 3H), 1.39 (s, 1H). HPLC purity: 95%; MS (ESI+) m/z: 
546.1 (M+1), 568.1 (M+Na+). 
 
4-(4-fluoro-3-(2-((2-hydroxyethyl)(2-methylbutyl)amino)-2-oxoethyl)phenyl)-N-(1H-indazol-5-
yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257372 – 6-88). Compound 
257372 was prepared as described for 232400, replacing 2,6-dimethylbenzylamine with 2-((2-
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methylbutyl)amino)ethan-1-ol (Yield: 21%). 
1
H NMR (400 MHz, DMSO-d6, 80 ˚C) δ 12.93 (s, 
1H), 9.55 (s, 1H), 8.73 – 8.64 (m, 1H), 7.98 (d, J = 14.7 Hz, 2H), 7.59 (s, 1H), 7.43 – 7.34 (m, 
2H), 7.21 – 7.03 (m, 3H), 5.39 (s, 1H), 4.88 (d, J = 5.4 Hz, 0.5 H), 4.65 (t, J = 5.4 Hz, 0.5 H), 
3.56 – 3.37 (m, 3H), 3.29 – 3.06 (m, 3H), 2.05 (s, 3H), 1.66 (d, J = 11.1 Hz, 1H), 1.38 – 1.21 (m, 
1H), 1.00 (tt, J = 15.0, 7.6 Hz, 1H), 0.89 – 0.77 (m, 4H), 0.73 (dd, J = 6.7, 1.5 Hz, 2H). HPLC 
purity: 97%; MS (ESI+) m/z: 537.2 (M+1), 559.2 (M+Na+). 
 
4-(4-fluoro-3-(2-(5-methylisoindolin-2-yl)-2-oxoethyl)phenyl)-N-(1H-indazol-5-yl)-6-methyl-2-
oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257374 – 6-92). Compound 257374 was 
prepared as described for 232400, replacing 2,6-dimethylbenzylamine with 5-methylisoindoline 
(Yield: 36%). 
1
H NMR (400 MHz, DMSO-d6, 80 ˚C) δ 12.90 (s, 1H), 9.52 (s, 1H), 8.67 (d, J = 
1.9 Hz, 1H), 7.95 (d, J = 13.2 Hz, 2H), 7.57 (s, 1H), 7.37 (s, 2H), 7.20 (dt, J = 14.8, 8.7 Hz, 3H), 
7.14 – 7.05 (m, 3H), 5.39 (d, J = 2.1 Hz, 1H), 4.84 (s, 2H), 4.55 (d, J = 11.9 Hz, 2H), 3.74 (s, 




oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257375 – 6-93). Compound 257375 was 
prepared as described for 232400, replacing 2,6-dimethylbenzylamine with 3-propoxypyrrolidine 
(Yield: 36%). 
1
H NMR (400 MHz, DMSO-d6, 80 ˚C) δ 12.79 (s, 1H), 9.32 (s, 1H), 8.44 (s, 1H), 
7.93 (s, 1H), 7.41 – 7.31 (m, 3H), 7.21 (t, J = 6.2 Hz, 2H), 7.06 (t, J = 8.7 Hz, 1H), 5.39 (s, 1H), 
3.99 (t, J = 18.0, 1H), 3.60 – 3.30 (m, 7H), 2.07 (s, 3H), 1.92 (broad s, 1H), 1.84 (broad s, 1H), 
1.47 (h, J = 8.2, 7.7 Hz, 2H), 0.84 (t, J = 7.4 Hz, 3H). HPLC purity: 97%; MS (ESI+) m/z: 535.2 
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(M+1), 557.1 (M+Na+). 
 
4-(4-fluoro-3-(2-((1-methyl-5-oxopyrrolidin-3-yl)amino)-2-oxoethyl)phenyl)-N-(1H-indazol-5-
yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257379 – 6-97). Compound 
257379 was prepared as described for 232400, replacing 2,6-dimethylbenzylamine with 4-
amino-1-methylpyrrolidin-2-one (Yield: 14%). 
1
H NMR (400 MHz, DMSO-d6) δ 12.90 (s, 1H), 
9.52 (s, 1H), 8.66 (s, 1H), 8.51 (d, J = 6.7 Hz, 1H), 7.97 (d, J = 10.2 Hz, 2H), 7.55 (s, 1H), 7.43 – 
7.34 (m, 2H), 7.23 – 7.14 (m, 2H), 7.09 (t, J = 9.1 Hz, 1H), 5.38 (s, 1H), 3.60 – 3.50 (m, 1H), 
3.41 (s, 2H), 3.15 (d, J = 4.8 Hz, 1H), 3.06 (dd, J = 10.1, 3.7 Hz, 1H), 2.67 (s, 3H), 2.59 – 2.50 
(m, 1H), 2.11 (d, J = 4.5 Hz, 1H), 2.04 (s, 3H). HPLC purity: 93%; MS (ESI+) m/z: 520.1 
(M+1), 542.1 (M+Na+). 
 
4-(3-(2-(((6-cyanopyridin-3-yl)methyl)amino)-2-oxoethyl)-4-fluorophenyl)-N-(1H-indazol-5-yl)-
6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257380 – 6-98). Compound 
257380 was prepared as described for 232400, replacing 2,6-dimethylbenzylamine with 5-
(aminomethyl)picolinonitrile (Yield: 14%). 
1
H NMR (400 MHz, DMSO-d6) δ 12.93 (s, 1H), 9.58 
(s, 1H), 8.72 (d, J = 6.4 Hz, 2H), 8.61 (d, J = 2.1 Hz, 1H), 8.02 – 7.94 (m, 3H), 7.82 (dd, J = 8.0, 
2.1 Hz, 1H), 7.59 (s, 1H), 7.44 – 7.35 (m, 2H), 7.26 (dd, J = 7.3, 2.3 Hz, 1H), 7.23 – 7.16 (m, 
1H), 7.12 (t, J = 9.1 Hz, 1H), 5.40 (d, J = 2.9 Hz, 1H), 4.35 (d, J = 5.8 Hz, 2H), 3.54 (s, 2H), 
2.05 (s, 3H). HPLC purity: 98%; MS (ESI+) m/z: 537.1 (M+1), 561.1 (M+Na+). 
 
4-(3-(2-(but-2-yn-1-yl(butyl)amino)-2-oxoethyl)-4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-
2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257382 – 6-100). Compound 257382 was 
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prepared as described for 232400, replacing 2,6-dimethylbenzylamine with N-butylbut-2-yn-1-
amine (Yield: 30%). 
1
H NMR (400 MHz, DMSO-d6, 80 ˚C) δ 12.98 – 12.86 (m, 1H), 9.56 (s, 
1H), 8.70 (d, J = 1.9 Hz, 1H), 7.98 (d, J = 13.7 Hz, 2H), 7.60 (d, J = 2.8 Hz, 1H), 7.44 – 7.35 (m, 
2H), 7.23 – 7.06 (m, 3H), 5.40 (d, J = 2.9 Hz, 1H), 4.14 (d, J = 2.6 Hz, 1H), 4.04 (d, J = 2.6 Hz, 
1H), 3.75 (s, 1H), 3.68 (s, 1H), 3.40 – 3.35 (m, 1H), 3.27 (t, J = 7.4 Hz, 1H), 2.05 (s, 3H), 1.78 
(dt, J = 12.3, 2.3 Hz, 3H), 1.46 (dq, J = 29.6, 7.6 Hz, 2H), 1.23 (dq, J = 19.2, 7.4 Hz, 2H), 0.85 
(q, J = 7.5 Hz, 3H). HPLC purity: 95%; MS (ESI+) m/z: 553.1 (M+Na+). 
 
4-(3-(2-(sec-butyl(hydroxymethyl)amino)-2-oxoethyl)-4-fluorophenyl)-N-(1H-indazol-5-yl)-6-
methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257384, 7-3). Compound 257384 
was prepared as described for 232400, replacing 2,6-dimethylbenzylamine with (sec-
butylamino)methanol (Yield: 42%). 
1
H NMR (400 MHz, DMSO-d6, 80 ˚C ) δ 12.94 (s, 1H), 9.56 
(s, 1H), 8.69 (d, J = 1.9 Hz, 1H), 8.03 – 7.94 (m, 2H), 7.76 (dd, J = 8.8, 4.1 Hz, 1H), 7.58 (t, J = 
2.5 Hz, 1H), 7.45 – 7.36 (m, 2H), 7.23 (dt, J = 7.1, 3.4 Hz, 1H), 7.21 – 7.14 (m, 1H), 7.09 (td, J 
= 9.0, 8.4, 1.7 Hz, 1H), 5.39 (s, 1H), 4.53 (td, J = 5.4, 3.4 Hz, 1H), 3.50 – 3.37 (m, 2H), 2.05 (s, 
3H), 1.56 (d, J = 9.2 Hz, 1H), 1.41 (broad s, 1H), 1.22 (broad s, 1H), 1.10 – 0.98 (m, 1H), 0.84 – 
0.78 (m, 6H). HPLC purity: 97%; MS (ESI+) m/z: 523.1 (M+1), 545.1 (M+Na+). 
 
4-(3-(2-(4-(tert-butyl)azepan-1-yl)-2-oxoethyl)-4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-
oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257385, hvw 7 – 4). Compound 257385 was 
prepared as described for 232400, replacing 2,6-dimethylbenzylamine with 4-(tert-butyl)azepane 
(Yield: 47%). 
1
H NMR (400 MHz, DMSO-d6, 80 ˚C) δ 12.91 (s, 1H), 9.54 (s, 1H), 8.68 (d, J = 
1.9 Hz, 1H), 8.03 – 7.92 (m, 2H), 7.58 (s, 1H), 7.44 – 7.33 (m, 2H), 7.22 – 7.04 (m, 3H), 5.38 (d, 
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J = 2.9 Hz, 1H), 3.63 (d, J = 4.4 Hz, 2H), 3.61 – 3.45 (m, 2H), 3.30 – 3.06 (m, 1H), 2.06 – 2.01 
(m, 3H), 1.82 – 1.69 (m, 2H), 1.41 – 1.26 (m, 1H), 1.24 – 1.11 (m, 1H), 0.99 (dd, J = 26.8, 8.0 




methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257387 – 7- 6). Compound 257387 
was prepared as described for 232400, replacing 2,6-dimethylbenzylamine with 2-
(isopentylamino)ethan-1-ol (Yield: 19%). 
1
H NMR (400 MHz, DMSO-d6, 80 ˚C) δ 12.92 (s, 1H), 
9.53 (d, J = 3.4 Hz, 1H), 8.71 – 8.64 (m, 1H), 7.96 (d, J = 14.8 Hz, 2H), 7.57 (s, 1H), 7.43 – 7.33 
(m, 2H), 7.22 – 7.02 (m, 3H), 5.38 (s, 1H), 4.91 – 4.83 (m, 1H), 4.70 – 4.62 (m, 1H), 3.76 – 3.60 
(m, 2H), 3.50 (d, J = 5.1 Hz, 1H), 3.43 (dd, J = 10.1, 4.2 Hz, 1H), 3.30 – 3.17 (m, 1H), 2.04 (s, 
3H), 1.43 (tt, J = 14.3, 7.0 Hz, 1H), 1.31 (dq, J = 15.0, 7.7 Hz, 2H), 0.82 (d, J = 6.5 Hz, 6H). 
HPLC purity: 95%; MS (ESI+) m/z: 537.2 (M+1), 559.1 (M+Na+). 
 
4-(3-(2-(bis(3-hydroxypropyl)amino)-2-oxoethyl)-4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-
2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257388 – 7- 7). Compound 257388 was 
prepared as described for 232400, replacing 2,6-dimethylbenzylamine with 3,3'-
azanediylbis(propan-1-ol) (Yield: 31%). 
1
H NMR (400 MHz, DMSO-d6, 80 ˚C) δ 12.94 (s, 1H), 
9.55 (s, 1H), 8.69 (d, J = 1.9 Hz, 1H), 8.02 – 7.95 (m, 2H), 7.59 (d, J = 2.5 Hz, 1H), 7.44 – 7.35 
(m, 2H), 7.18 (tt, J = 7.4, 2.3 Hz, 2H), 7.09 (t, J = 9.0 Hz, 1H), 5.41 – 5.37 (m, 1H), 4.57 (t, J = 
4.9 Hz, 1H), 4.41 (t, J = 5.2 Hz, 1H), 3.68 (s, 2H), 3.41 (q, J = 5.4 Hz, 2H), 3.35 (s, 2H), 3.29 – 
3.22 (m, 3H), 3.17 (d, J = 4.8 Hz, 1H), 2.05 (s, 3H), 1.62 (dp, J = 27.6, 6.6 Hz, 4H). HPLC 
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purity: 97%; MS (ESI+) m/z: 539.2 (M+1), 561.1 (M+Na+). 
 
Final Analogues 14  
4-(4-fluoro-3-(3-(((5-methyloxazol-2-yl)methyl)amino)-3-oxopropyl)phenyl)-N-(1H-indazol-5-
yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257143). Compound 257143 
was prepared as described for 232400, replacing 2-(aminomethyl)pyridine with (5-methyloxazol-
2-yl)methanamine and 5-(5-((1H-indazol-5-yl)carbamoyl)-6-methyl-2-oxo-1,2,3,4-
tetrahydropyrimidin-4-yl)-2-fluorobenzoic acid 7 with 3-(5-(5-((1H-indazol-5-yl)carbamoyl)-6-
methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-4-yl)-2-fluorophenyl)propanoic acid 9 (Yield: 13%). 
1
H NMR (400 MHz, DMSO-d6) δ 12.92 (s, 1H), 9.55 (s, 1H), 8.68 (s, 1H), 8.50 (t, J = 5.8 Hz, 
1H), 7.96 (d, J = 12.7 Hz, 2H), 7.52 (s, 1H), 7.38 (q, J = 8.9 Hz, 2H), 7.21 (d, J = 7.3 Hz, 1H), 
7.17 – 7.05 (m, 2H), 6.72 (d, J = 1.4 Hz, 1H), 5.36 (s, 1H), 4.30 – 4.23 (m, 2H), 2.82 – 2.71 (m, 
2H), 2.39 – 2.29 (m, 2H), 2.23 (s, 3H), 2.04 (s, 3H). HPLC purity: 95%; MS (ESI+) m/z: 532.0 
(M+1), 554.0 (M+Na+). 
 
4-(4-fluoro-3-(3-oxo-3-(phenethylamino)propyl)phenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide (257149). Compound 257149 was prepared as 
described for 257143, replacing (5-methyloxazol-2-yl)methanamine with 2-phenylethanamine 
(Yield: 71%). 
1
H NMR (500 MHz, DMSO-d6) δ 12.93 (s, 1H), 9.56 (s, 1H), 8.68 (s, 1H), 8.03 – 
7.88 (m, 3H), 7.52 (s, 1H), 7.40 (q, J = 9.0 Hz, 2H), 7.30 – 7.07 (m, 8H), 5.38 (s, 1H), 3.23 (q, J 
= 6.9 Hz, 2H), 2.76 (t, J = 8.1 Hz, 2H), 2.66 (t, J = 7.5 Hz, 2H), 2.28 (broad s, 2H), 2.06 (s, 3H). 





methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257287 -6-84). Compound 257287 
was prepared as described for 257143, replacing (5-methyloxazol-2-yl)methanamine with 3-
ethylpiperidin-3-ol (Yield: 77%). 
1
H NMR (400 MHz, DMSO-d6, 80 ˚C) δ 12.71 (s, 1H), 9.29 (s, 
1H), 8.39 (s, 1H), 7.92 (q, J = 1.5 Hz, 2H), 7.42 – 7.34 (m, 2H), 7.27 – 7.15 (m, 3H), 7.04 (dd, J 
= 10.0, 8.4 Hz, 1H), 5.40 – 5.36 (m, 1H), 4.09 – 3.76 (m, 2H), 3.42 – 3.17 (m, 2H), 2.98 – 2.67 
(m, 4H), 2.57 – 2.50 (m, 1H), 2.08 (s, 3H), 1.65 – 1.37 (m, 3H), 1.31 (d, J = 7.7 Hz, 3H), 1.18 (s, 
2H), 0.80 (t, J = 7.5 Hz, 3H). HPLC purity: 95%; MS (ESI+) m/z: 549.1 (M+1), 571.1 (M+Na+). 
 
4-(4-fluoro-3-(3-(isobutyl(isopropyl)amino)-3-oxopropyl)phenyl)-N-(1H-indazol-5-yl)-6-methyl-
2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257288 - 6 – 85). Compound 257288 was 
prepared as described for 257143, replacing (5-methyloxazol-2-yl)methanamine with N-
isopropyl-2-methylpropan-1-amine (Yield: 23%). 
1
H NMR (400 MHz, DMSO-d6, 80 ˚C) δ 12.69 
(s, 1H), 9.27 (s, 1H), 8.37 (s, 1H), 7.91 (s, 1H), 7.38 (t, J = 1.8 Hz, 2H), 7.29 – 7.15 (m, 3H), 
7.05 (t, J = 9.3 Hz, 1H), 5.38 (s, 1H), 3.93 (q, J = 6.9, 1Hz, 1H), 2.93 (d, J = 7.4 Hz, 2H), 2.80 (t, 
J = 7.9 Hz, 2H), 2.07 (s, 3H), 1.90 (broad s, 1H), 1.09 (broad s, 6H), 0.82 – 0.75 (m, 6H). HPLC 
purity: 92%; MS (ESI+) m/z: 535.4 (M+1), 538.2 (M+Na+). 
 
4-(4-fluoro-3-(3-(((1-methylcyclohexyl)methyl)amino)-3-oxopropyl)phenyl)-N-(1H-indazol-5-yl)-
6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257289 – 6 – 86). Compound 
257289 was prepared as described for 257143, replacing (5-methyloxazol-2- yl)methanamine 
with (1-methylcyclohexyl)methanamine (Yield: 77%). 
1
H NMR (400 MHz, DMSO-d6) δ 12.92 
(s, 1H), 9.56 (s, 1H), 8.68 (d, J = 1.9 Hz, 1H), 7.98 (d, J = 1.7 Hz, 1H), 7.95 (s, 1H), 7.66 (t, J = 
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6.3 Hz, 1H), 7.51 (t, J = 2.4 Hz, 1H), 7.42 – 7.34 (m, 2H), 7.21 (dd, J = 7.4, 2.3 Hz, 1H), 7.14 
(ddd, J = 7.5, 5.1, 2.2 Hz, 1H), 7.08 (dd, J = 9.9, 8.4 Hz, 1H), 5.35 (d, J = 2.9 Hz, 1H), 2.88 (d, J 
= 6.3 Hz, 2H), 2.79 – 2.72 (m, 2H), 2.37 – 2.29 (m, 2H), 2.07 (s, 3H), 1.43 – 1.05 (m, 10H), 0.72 
(s, 3H). HPLC purity: 99%; MS (ESI+) m/z: 547.5 (M+1), 570.3 (M+Na+). 
 
4-(4-fluoro-3-(3-(((1-(hydroxymethyl)cyclopropyl)methyl)amino)-3-oxopropyl)phenyl)-N-(1H-
indazol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (257378 – 6- 96). 
Compound 257378 was prepared as described for 257143, replacing (5-methyloxazol-2- 
yl)methanamine with (1-(aminomethyl)cyclopropyl)methanol (Yield: 69%). 
1
H NMR (400 MHz, 
DMSO-d6) δ 12.92 (s, 1H), 9.55 (s, 1H), 8.67 (d, J = 1.9 Hz, 1H), 7.98 (d, J = 9.7 Hz, 2H), 7.84 
(t, J = 5.9 Hz, 1H), 7.50 (d, J = 2.4 Hz, 1H), 7.44 – 7.35 (m, 2H), 7.24 – 7.20 (m, 1H), 7.16 (t, J 
= 6.8 Hz, 1H), 7.10 (dd, J = 9.9, 8.4 Hz, 1H), 5.37 (d, J = 2.8 Hz, 1H), 4.45 (t, J = 5.9 Hz, 1H), 
3.19 (d, J = 5.8 Hz, 2H), 3.05 (d, J = 5.9 Hz, 2H), 2.78 (t, J = 8.1 Hz, 2H), 2.36 – 2.29 (m, 2H), 
2.06 (s, 3H), 0.30 (d, J = 4.0 Hz, 4H). HPLC purity: 98%; MS (ESI+) m/z: 521.2 (M+1), 543.1 
(M+Na+). 
 
Final Analogues 15: 
N-(6-fluoro-1H-indazol-5-yl)-4-(4-fluoro-3-((pyridin-2-ylmethyl)carbamoyl)phenyl)-6-methyl-2-
oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (15a – CCG257377 – 6-95): Compound 15a 
(257377) was prepared as described for 224409 (12), replacing intermediate 7 with intermediate 
10 and methylamine with pyridin-2-ylmethanamine. Yield: 6.4 mg (6 %). 
1
H NMR (400 MHz, 
DMSO-d6) δ 13.10 (s, 1H), 9.32 (s, 1H), 8.90 (d, J = 4.4 Hz, 1H), 8.83 (s, 1H), 8.51 (dd, J = 4.8, 
1.5 Hz, 1H), 8.01 (s, 1H), 7.78 – 7.66 (m, 4H), 7.47 (ddd, J = 7.8, 4.8, 2.4 Hz, 1H), 7.36 – 7.23 
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(m, 4H), 5.44 (d, J = 2.9 Hz, 1H), 4.57 (d, J = 5.8 Hz, 2H), 2.13 (s, 3H). HPLC purity: 91%; MS 
(ESI+) m/z: 518.1 (M+1), 540.1 (M+Na+). 
 
4-(3-((2,6-dimethoxybenzyl)carbamoyl)-4-fluorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-6-methyl-
2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (15b – CCG257376 – 6-94): Compound 15b 
(257376) was prepared as described for 224409 (12), replacing intermediate 7 with intermediate 
10 and methylamine with 2,6 – di- methoxy benzylamine. Yield: 32.8 mg (27 %). 
1
H NMR (400 
MHz, DMSO-d6) δ 13.04 (s, 1H), 9.24 (s, 1H), 8.78 (s, 1H), 8.00 (s, 1H), 7.91 (d, J = 5.1 Hz, 
1H), 7.73 (d, J = 7.3 Hz, 1H), 7.67 – 7.59 (m, 2H), 7.39 (ddd, J = 7.9, 4.8, 2.4 Hz, 1H), 7.34 – 
7.27 (m, 1H), 7.27 – 7.17 (m, 2H), 6.65 (d, J = 8.4 Hz, 2H), 5.39 (d, J = 3.0 Hz, 1H), 4.48 (d, J = 




2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (16, 258745, 9-31): Compound 16 (258745) 
was prepared as described for 224409 (12), replacing intermediate 7 with intermediate 11 and 
methylamine with 2,6 – di – methoxy benzylamine. Yield: 8.0 mg (6 %). 
1
H NMR (400 MHz, 
DMSO-d6) δ 13.13 (s, 1H), 9.22 (s, 1H), 8.81 (s, 1H), 8.04 (s, 1H), 7.95 (d, J = 5.5 Hz, 1H), 7.74 
– 7.61 (m, 4H), 7.42 (s, 1H), 7.29 – 7.19 (m, 2H), 6.67 (d, J = 8.4 Hz, 2H), 5.41 (s, 1H), 4.50 (d, 
J = 4.9 Hz, 2H), 3.79 (s, 6H), 2.17 (s, 3H). HPLC purity: 93%; MS (ESI+) m/z: 593.1 (M+1). 
 
2-fluoro-5-formylbenzoic acid (17): To a 50 mL round bottom flask was added 2-fluoro-5-
formylbenzonitrile (0.50 g, 3.35 mmol) followed by HCl (9 mL). The reaction was heated at 
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reflux overnight forming a white precipitate. The reaction was cooled and diluted with water (15 
mL). The white precipitate was then extracted by dissolving in EtOAc. The organic layer was 
separated and washed 2x with brine, dried with MgSO4, and concentrated to give the title 
compound as a white solid (0.560 g, 92% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 13.66 (s, 
1H), 10.03 (s, 1H), 8.43 (dd, J = 7.2, 2.2 Hz, 1H), 8.17 (ddd, J = 8.6, 4.7, 2.3 Hz, 1H), 7.56 (dd, J 
= 10.6, 8.5 Hz, 1H). 
 
2-(2-Fluoro-5-formylphenyl)acetic acid (18): To a 100 mL round bottom flask at room 
temperature was added 29 (1.26g, 7.58 mmol), triethylamine (8.46 mL, 60.66 mmol), and 
DMSO (20 mL). Sulfur trioxide pyridine complex (4.83 g, 30.33 mmol) in DMSO (20 mL) was 
then added to the reaction and the reaction was stirred for 20 minutes. The reaction was diluted 
with Na2CO3 then extracted with ether. To the aqueous layer 2N HCl was added to give a pH of 
3. The aqueous layer was then extracted with ethyl acetate (2x). The ethyl acetate layers were  
combined and washed with NaCl (2x), dried over MgSO4, and concentrated in vacuo to give 18 
as a white solid (1.24g, 100% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 12.49 (s, 1H), 9.96 (s, 
1H), 7.98 – 7.85 (m, 2H), 7.43 (dd, J = 9.6, 8.3 Hz, 1H), 3.76 (d, J = 1.4 Hz, 2H). 
 
3-(2-fluoro-5-formylphenyl)propanoic acid HVW 6-17 / 6-19 (19): To a 100 mL round bottom 
flask at room temperature was added 35 (0.98g, 5.03 mmol), triethylamine (5.62 mL, 40.26 
mmol), and DMSO (15 mL). Sulfur trioxide pyridine complex (3.20 g, 20.13 mmol) in DMSO 
(10 mL) was then added to the reaction and the reaction was stirred for 20 minutes. The reaction 
was diluted with Na2CO3 then extracted with ether. To the aqueous layer 2N HCl was added to 
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give a pH of 3. The aqueous layer was then extracted with ethyl acetate (2x). The ethyl acetate 
layers were combined and washed with NaCl (2x), dried over MgSO4, and concentrated in vacuo 
to give 19 as a white solid (0.782 g, 79 % yield). 
1
H NMR (500 MHz, DMSO-d6) δ 12.25 (s, 
1H), 9.95 (s, 1H), 7.90 (dd, J = 7.5, 2.2 Hz, 1H), 7.85 (ddd, J = 8.4, 5.2, 2.2 Hz, 1H), 7.40 (dd, J 
= 9.9, 8.4 Hz, 1H), 2.92 (t, J = 7.5 Hz, 2H), 2.59 (t, J = 7.5 Hz, 2H). 
 
N-(5-fluoro-2-methylphenyl)acetamide (21, HVW6-10): Procedure from PCT/US2004/019692 – 
Example 138a p128. To a 250 mL round bottom flask cooled to 0 ºC was added 5-fluoro-2-
methylaniline 20 (79.9 mmol, 10.0g) and toluene (50 mL). Acetic anhydride (120 mmol, 11.3 
mL) was then added dropwise. Upon addition of acetic anhydride a white precipitate began to 
form. Following precipitate formation the reaction was stirred an additional 20 minutes and then 
the white solid was filtered off and dried in vacuo to give the desired product: N-(5-fluoro-2-
methylphenyl)acetamide (12.90 g, 97% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 9.29 (s, 1H), 
7.42 (dd, J = 11.3, 2.7 Hz, 1H), 7.21 (dd, J = 8.4, 6.8 Hz, 1H), 6.88 (td, J = 8.4, 2.8 Hz, 1H), 2.18 
(s, 3H), 2.08 (s, 3H). 
 
5-fluoro-2-methyl-4-nitroaniline (22, HVW 6-12): N-(5-fluoro-2-methylphenyl)acetamide 21 
(29.9 mmol, 5.0g) was added to a 250 mL round bottom flask, cooled to 0 ºC and then H2SO4 (30 
mL) was added, dissolving the compound. Concentrated nitric acid (2.2 mL) was then slowly 
added via a glass pipet and the reaction was further stirred at 0 º for an additional 30 minutes. 
The reaction was then poured over approximately 200 mL of crushed ice and warmed to room 
temperature while stirring. A light yellow solid precipitate was then filtered off. The resulting 
precipitate was added to a 100 mL round bottom flask with 6N HCl and refluxed for two hours, 
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then cooled to room temperature and stirred further overnight. The reaction was neutralized with 
saturated potassium carbonate and diluted with water. The resulting light orange precipitate was 
filtered off and dried in vacuo to give 5-fluoro-2-methyl-4-nitroaniline (82% HPLC purity, 3.78 
g, 74% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 7.81 (d, J = 8.7 Hz, 1H), 6.75 (s, 2H), 6.44 (d, J 
= 14.6 Hz, 1H), 2.07 (s, 3H). 
 
6-fluoro-5-nitro-1H-indazole (24, HVW 6-15): To a 500 mL round bottom flask was added 
sodium nitrate (22.1 mmol, 1.53 g) and H2O (6 mL). Once the sodium nitrate was dissolved the 
reaction was cooled to 0 ºC and 5-fluoro-2-methyl-4-nitroaniline (22.1 mmol, 3.76g) in AcOH 
(100 mL) was added. A deep red color was observed. The reaction was stirred overnight 
allowing it to come to room temperature. The reaction was then poured over crushed ice to give 
an orange solid which was subsequently filtered off. The resulting solid was purified using a 
linear gradient of 20 – 60% EtOAc/Hex and dried in vacuo to give 6-fluoro-5-nitro-1H-indazole 
(2.44g, 73% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 13.75 (s, 1H), 8.79 (d, J = 7.3 Hz, 1H), 
8.39 (d, J = 1.5 Hz, 1H), 7.69 (dd, J = 11.8, 1.0 Hz, 1H). 
 
 6-chloro-5-nitro-1H-indazole (25, HVW 9-15): Intermediate 25 was synthesized as described for 
intermediate 24 replacing 5-fluoro-2-methyl-4-nitroaniline with 5-chloro-2-methyl-4-nitroaniline 
23, but was purified using a gradient of 0 – 5% MeOH/DCM to give the desired product as an 
orange solid (1.24 g, 58% yield). 
1
H NMR (500 MHz, DMSO-d6) δ 13.78 – 13.73 (m, 1H), 8.68 




Methyl 3-(bromomethyl)-4-fluorobenzoate (27):To a 100 mL round bottom flask with 40 mL of 
methanol was added 4-fluoro-3-methyl benzoic acid 26 (4.0 g, 25.96 mmol) followed by 
concentrated H2SO4 (1.0 mL). The reaction vessel was equipped with a condenser and refluxed 
overnight at 65°C. Cooled down reaction and diluted with ether and NaHCO3.The organic layer 
was washed with brine (3x), dried over MgSO4, and concentrated at room temperature under 
reduced pressure to give methyl 4-fluoro-3-methylbenzoate as a clear liquid (98% yield, 4.38g). 
1
H NMR (400 MHz, DMSO-d6) δ 7.90 (dd, J = 7.5, 2.2 Hz, 1H), 7.83 (ddd, J = 7.9, 5.0, 2.3 Hz, 
1H), 7.27 (t, J = 9.1 Hz, 1H), 3.83 (s, 3H), 2.28 (s, 3H). HPLC purity: 100%. To a 250 mL 
closed pressure vessel was added methyl 4-fluoro-3-methylbenzoate (4.02 g, 23.91 mmol) 
dissolved in anhydrous carbon tetrachloride (40 mL). N-bromosuccinimide (3.83g, 21.50 mmol) 
was then added to the reaction vessel followed by benzoyl peroxide (0.290g, 1.20 mmol). The 
reaction was stirred for 1 hour at 65
o
C then cooled, filtered through celite with dichloromethane 
and concentrated. The resulting residue was purified using flash chromatography with a gradient 
of 0%-1% EtOAc/Hexanes to give 27 as a clear oil (82% yield, 4.31g). 
1
H NMR (400 MHz, 
DMSO-d6) δ 8.19 (dd, J = 7.4, 2.3 Hz, 1H), 8.00 (ddd, J = 8.7, 5.0, 2.3 Hz, 1H), 7.41 (dd, J = 
9.8, 8.7 Hz, 1H), 4.79 (d, J = 1.1 Hz, 2H), 3.87 (s, 3H). 
 
2-(2-Fluoro-5-(hydroxymethyl)phenyl)acetonitrile  (28): To a dry 250 mL flask was added 
toluene (30 mL) followed by 1M DIBAL in toluene (23.16 mL, 23.16mmol). The flask was then 
cooled to 0°C and then intermediate 27 (2.73 g, 11.05 mmol) in toluene (5 mL) was added. The 
reaction stirred for 2 hours and was then quenched (on ice) with 2N HCl to a pH of 2. The 
reaction was extracted with ethyl acetate (2x), the organic layers were combined and washed 
with NaCl (2x), dried over MgSO4, and concentrated to give (3-(Bromomethyl)-4-
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fluorophenyl)methanol as a white solid (94% yield, 2.09g). 
1
H NMR (500 MHz, DMSO-d6) δ 
7.46 (dd, J = 7.5, 2.2 Hz, 1H), 7.32 (ddd, J = 7.8, 5.1, 2.2 Hz, 1H), 7.18 (dd, J = 10.0, 8.4 Hz, 
1H), 5.28 (s, 1H), 4.69 (s, 2H), 4.46 (s, 2H). To a 250 mL round bottom flask was added (3-
(Bromomethyl)-4-fluorophenyl)methanol (2.06 g, 10.26 mmol) dissolved in DMSO (40 mL) 
followed by sodium cyanide (1.51 g, 30.77 mmol). After stirring at room temperature for 2 hours 
the reaction was diluted with H2O and ethyl acetate. The layers were separated and the aqueous 
layer was further extracted with ethyl acetate (2x). The organic layers were combined, washed 3x 
with NaCl, dried over MgSO4, and concentrated. Using flash chromatography (15% - 30% 
EtOAc/Hexanes) the residue was purified to obtain 25 as a clear liquid (1.50 g, 99% yield). 
1
H 
NMR (400 MHz, DMSO-d6) δ 7.42 (dd, J = 7.5, 2.1 Hz, 1H), 7.32 (ddd, J = 7.7, 5.1, 2.1 Hz, 
1H), 7.21 (dd, J = 9.9, 8.4 Hz, 1H), 5.31 (t, J = 5.7 Hz, 1H), 4.48 (d, J = 5.6 Hz, 2H), 4.06 (s, 
2H).  
 
2-2-Fluoro-5-(hydroxymethyl)phenyl)acetic acid (29): To a 100 mL round bottom flask was 
added 28 (0.881 g, 5.33 mmol) followed by 2N NaOH (20 mL). The reaction vessel was 
equipped with a condenser and refluxed overnight. After cooling the reaction down HCl was 
added to reach a pH of 3. The reaction was extracted with ethyl acetate (2x). The organic layers 
were combined, washed with NaCl (2x), dried over MgSO4, and concentrated in vacuo to give 29 
as a white solid (0.969 g, 99% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 12.45 (s, 1H), 7.28 – 
7.20 (m, 2H), 7.11 (dd, J = 9.7, 8.5 Hz, 1H), 5.22 (s, 1H), 4.45 (s, 2H), 3.60 (s, 2H). 
 
tert-butyl((4-fluorobenzyl)oxy)dimethylsilane (31, HVW 5 - 79): To a 100 mL round bottom flask 
was added 4-fluorobenzyl alcohol 30 (2.0 g, 15.86 mmmol), TBSCl (3.58 g, 23.78 mmol), 
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imidazole (1.08 g, 15.86 mmol), DIEA (4.15 mL, 23.78 mmol), and dichloromethane (35 mL). 
The reaction was stirred overnight at room temperature and then quenched with water. The 
organic and aqueous layer were separated, the dichloromethane layer was then washed 3x with 
NaCl, dried using MgSO4, and concentrated. The resulting clear syrup was purified with flash 
chromatography using a gradient of 10% EtOAc/Hexanes to give the title compound as a clear 
liquid (2.816 g, 74% yield). 
1
H NMR (500 MHz, DMSO-d6) δ 7.32 (dd, J = 8.4, 5.7 Hz, 2H), 
7.18 – 7.10 (m, 2H), 4.66 (s, 2H), 0.88 (s, 9H), 0.05 (s, 6H). 
 
5-(((tert-butyldimethylsilyl)oxy)methyl)-2-fluorobenzaldehyde (32, hvw 5 – 74): To a dry 250 mL 
round bottom flask flushed with argon at -78 ºC was added THF (18 mL) followed by 
tetramethylethylenediamine (1.38 mL., 9.20 mmol). The reaction was stirred five minutes then 
sec-butyl lithium (6.57 mL, 9.20 mmol) was added and the reaction was stirred another ten 
minutes under argon at -78 ºC. Intermediate 31 (1.12 g, 4.60 mmol) dissolved in THF (18 mL) 
was then slowly added to the reaction and the reaction was stirred another hour at -78 ºC. 
Dimethylformamide (6 mL) was then added and the reaction was warmed to room temperature. 
The reaction color went from yellow to clear. The reaction was quenched with saturated 
ammonium chloride and then diluted further with water and EtOAc. The organic and aqueous 
layers were separated, the organic layer was washed 2x with NaCl, dried with MgSO4, and 
concentrated. Purification with flash chromatography using 2% EtOAc/Hex gave the title 
compound as a clear oil (0.9497 g, 77% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 10.23 (s, 1H), 
7.78 (dd, J = 6.8, 2.3 Hz, 1H), 7.71 – 7.62 (m, 1H), 7.39 (dd, J = 10.6, 8.6 Hz, 1H), 4.75 (d, J = 




2-fluoro-5-(hydroxymethyl)benzaldehyde (33, hvw6-2): To a 250 mL round bottom flask was 
added intermediate 32 (4.22 g, 15.71 mmol), tert-butyl ammonium fluoride (7.58 g, 31.41 
mmol), and THF (20 mL). The reaction was stirred under nitrogen for six hours. The reaction 
was diluted with water and EtOAc. The organic and aqueous layers were separated. The organic 
layer was washed 2x with saturated NaCl, dried with MgSO4, and concentrated. Purification 
using 25% EtOAc/Hexanes gave the title compound as a yellow oil (1.97 g, 74% yield). 
1
H 
NMR (500 MHz, DMSO-d6) δ 10.23 (d, J = 1.1 Hz, 1H), 7.78 (dd, J = 6.6, 2.0 Hz, 1H), 7.70 – 
7.63 (m, 1H), 7.39 (ddd, J = 10.3, 8.6, 1.1 Hz, 1H), 4.75 (s, 2H), 0.90 (d, J = 1.2 Hz, 9H), 0.09 
(d, J = 1.1 Hz, 6H). 
 
(E)-3-(2-fluoro-5-(hydroxymethyl)phenyl)acrylic acid (34, HVW5-92): To a 250 mL was added 
intermediate 33 (1.15 g, 6.76 mmol), malonic acid (0.70 g, 6.76 mmol), piperidine (1.34 mL, 
13.52 mmol) and  pyridine (5 mL). The reaction was heated to 100 ºC for four hours then 
neutralized to pH 4 with 2N HCl and then diluted with water and EtOAC. The aqueous and 
organic layers were separated. The organic layer was washed with NaCl 2x, dried over MgSO4, 
and concentrated. Purification with flash chromatography using a gradient of 0% - 5% 
EtOAc/Hexanes gave the title compound as a white solid (1.06 g, 80% yield). 
1
H NMR (400 
MHz, DMSO-d6) δ 12.57 (s, 1H), 7.71 (dd, J = 7.4, 2.1 Hz, 1H), 7.63 (d, J = 16.1 Hz, 1H), 7.40 
(ddd, J = 7.7, 5.1, 2.1 Hz, 1H), 7.23 (dd, J = 10.8, 8.5 Hz, 1H), 6.54 (d, J = 16.1 Hz, 1H), 5.26 (s, 
1H), 4.47 (t, J = 2.2 Hz, 2H). 
 
3-(2-fluoro-5-formylphenyl)propanoic acid (35 HVW6-3): To a dry 100 mL round flask was 
added intermediate 34 (0.480 g, 2.44 mmol), 10% Pd/C (0.05 g), and EtOAc (30 mL). Argon 
166 
 
was bubbled through the reaction mixture and then the atmosphere was vacuumed and replaced 
with H2 via a balloon. The reaction was stirred at room temperature for 24 hours then filtered 
through celite, washing with EtOAc. The resulting filtrate was concentrated to give the title 
compound as a white solid (0.438 g, 91% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 12.19 (s, 
1H), 7.24 (dd, J = 7.7, 2.2 Hz, 1H), 7.18 (ddd, J = 7.7, 5.2, 2.2 Hz, 1H), 7.08 (dd, J = 10.2, 8.3 
Hz, 1H), 5.18 (t, J = 5.7 Hz, 1H), 4.43 (d, J = 5.5 Hz, 2H), 2.83 (t, J = 7.7 Hz, 2H), 2.55 – 2.47 
(m, 2H). 
 
2,2,2-Trifluoro-N-(1H-indazol-5-yl)acetamide (36): To a dry 100mL flask at 0˚C was added 5-
amino-1H-indazole 1 (2.0g, 15.02 mmol) followed by THF (40 mL) and triethylamine (3.36 mL, 
24.03 mmol). Then trifluoroacetic anhydride (2.54 mL, 18.02 mmol) was added dropwise. The 
reaction warmed to room temperature and stirred for two hours. Using water the reaction was 
quenched then diluted with ethyl acetate and brine. After separating the layers the aqueous layer 
was extracted 1x with EtOAc. The organic layers were combined and then washed with NaCl 2x, 
dried over MgSO4, and concentrated to give as a slightly red solid 36 with  >95% purity by 
HPLC (3.302 g, 96% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 13.16 (s, 1H), 11.26 (s, 1H), 8.12 
(d, J = 6.3 Hz, 2H), 7.62 – 7.47 (m, 2H). 
 
Tert-butyl 5-(2,2,2-trifluoroacetamido)-1H-indazole-1-carboxylate (37):  THF (40 mL) was 
added to a 250 mL flask with 36 (3.30 g, 14.40 mmol) at 0˚C. Then 4-dimethylaminopyridine 
(0.176g, 1.44 mmol) and N,N-diisopropylethylamine (4.28 mL, 24.48 mmol) were added, 
followed, lastly, by boc anhydride (4.71g, 21.60 mmol). The reaction was allowed to warm to 
room temperature and stir 1.5 hours. Water was added to quench the reaction. The reaction was 
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then extracted with ethyl acetate 2x, washed with NaCl 2x, dried over MgSO4, and concentrated 
to give 37 as a white powder. Took as is to next step without further purification.  
 
Tert-butyl 5-(2,2,2-trifluoro-N-methylacetamido)-1H-indazole-1-carboxylate (38): To a 250 mL 
flask at 0˚C was added sodium hydride (60% on mineral oil) (1.02g, 25.51 mmol) and DMF 
(15mL). Then 37 (5.60g, 17.01 mmol) in DMF (15 mL) was added. The reaction bubbled and 
turned green. Once bubbling ceased ~15 minutes, methyl iodide (1.38 mL, 22.11 mmol) was 
added dropwise at 0˚C and the reaction was stirred for two hours. Quenched reaction slowly with 
water (10 mL). Diluted further with water, extracted with EtOAc 2x, washed organic layers with 
NaCl 2x, dried over MgSO4, and concentrated to give as an amorphous solid 38. Took as is to 
next step with no further purification.  
 
N-Methyl-1H-indazol-5-amine (39): To a 250 mL flask was added 38 (17.01 mmol, 5.84g), 
potassium carbonate (85.05 mmol, 11.75g), methanol (30 mL), and water (15 mL). The reaction 
was heated to 85
o
C and stirred overnight with a condenser. Cooled down reaction and 
neutralized with 1N HCl. Extracted the aqueous layer with ethyl acetate 2x, washed with NaCl 
2x, dried over MgSO4, and concentrated. Purified the residue with normal phase using 30% 
EtOAc/Hexanes to give 39 as a white solid (1.189 g, 56% over three steps). 
1
H NMR (400 MHz, 
DMSO-d6) δ 12.60 (s, 1H), 7.76 (s, 1H), 7.27 (d, J = 8.8 Hz, 1H), 6.79 (dd, J = 8.9, 2.1 Hz, 1H), 
6.56 (s, 0H), 5.39 (q, J = 5.3 Hz, 1H), 2.68 (d, J = 5.2 Hz, 3H). 
 
N-(1H-Indazol-5-yl)-N-methyl-3-oxobutanamide (40): To a 50 mL pressure vessel was added 39 
(0.800g, 5.44 mmol), 2,2,6-trimethyl-4H-1,3-dioxin-4-one (0.78 mL, 5.98 mmol), and 
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acetonitrile (7 mL). The reaction was then heated to 100˚C and stirred overnight. The reaction 
was then concentrated and purified using 2% MeOH/DCM to afford 40 as an off-white solid 
(1.25g, 98% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 13.25 (s, 1H), 8.11 (t, J = 1.3 Hz, 1H), 
7.70 (d, J = 1.9 Hz, 1H), 7.60 (d, J = 8.8 Hz, 1H), 7.25 (dd, J = 8.7, 1.9 Hz, 1H), 3.26 (s, 2H), 
3.20 (s, 3H), 1.95 (s, 3H). 
 
5-(5-((1H-Indazol-5-yl)(methyl)carbamoyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-4-yl)-2-
fluorobenzoic acid (41): To a 100 mL pressure vessel equipped with a stir bar was added 2-
fluoro-5-formylbenzoic acid 17 (0.800 g, 4.757 mmol), intermediate 40 (1.00 g, 4.324 mmol), 
urea (0.429 g, 7.135 mmol), ytterbium trifluormethanesulfonate (0.295 g, 0.476 mmol) and 
acetonitrile (15.0 mL).  The reaction mixture was heated to 100 
o
C and stirred. The reaction 
mixture went from a white suspension to a clear solution. After four hours the reaction was not 
complete and was stirred overnight. The solvent was evaporated off and the resulting residue was 
then washed with water and purified using 20% MeOH (1%TFA)/DCM to give 41 as a white 
powder (140mg, 8% yield). 
1
H NMR (500 MHz, DMSO-d6) δ 13.17 (s, 2H), 8.44 (s, 1H), 8.03 
(s, 1H), 7.64 (d, J = 6.9 Hz, 1H), 7.51 (d, J = 8.9 Hz, 1H), 7.39 – 7.31 (m, 2H), 7.24 (t, J = 9.2 
Hz, 1H), 7.16 (s, 1H), 7.11 (d, J = 9.0 Hz, 1H), 4.73 (s, 1H), 3.14 (s, 3H), 1.75 (s, 3H). 
 
4-(3-((2,6-Dimethylbenzyl)carbamoyl)-4-fluorophenyl)-N-(1H-indazol-5-yl)-N,6-dimethyl-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide (42): Compound 41 (0.140 g, 0.331 mmol), HATU 
(0.251 g, 0.661 mmol), DIEA (115.0 μL, 0.661 mmol) and 2,6-dimethylbenzylamine (0.089 g, 
0.661 mmol)  were added to a 10 mL round bottom flask with 3.0 mL DMF and stirred at room 
temperature overnight. The reaction was quenched with water and diluted with ethyl acetate. The 
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organic layer was then washed 1x with brine, 1x with 10% citric acid, 1x with saturated 
NaHCO3, and then 2x with NaCl. The organic layer was then dried over MgSO4, concentrated, 
and purified using a gradient of 2-7% MeOH/DCM on flash chromatography to give, as a white 
solid, 42 (40.9 mg, 23% yield). 
1
H NMR (500 MHz, MeOD) δ ppm 8.07 (s, 1H), 7.60-7.56 (m, 
2H), 7.50 (dd, J1=10.0 Hz, J2=0 Hz, 1H), 7.37 (bs, 1H), 7.24-7.01 (m, 6H), 4.63 (d, J=5.0 Hz, 
2H), 3.24 (s, 3H), 2.41 (s, 6H), 1.93 (s, 3H). 
13
CNMR (500 MHz, MeOD) δ ppm 170.74, 166.64, 
161.99, 159.50, 140.71, 138.80, 137.71, 134.67, 131.98, 131.89, 129.90, 129.44, 129.38, 128.87, 
126.67, 125.04, 124.89, 124.35, 119.21, 117.70, 117.47, 112.18, 57.16, 39.76, 19.92, 17.03; 
HPLC: 89% purity; MS (ESI+) m/z: 541.2 (M+1). 
 
N-(Benzo[d][1,3]dioxol-5-yl)-3-oxobutanamide (46): To a 25 mL round bottom flask was added 
ethylacetoacete (0.775 mL, 6.08 mmol) and pyridine (0.881 mL, 10.94 mmol). The reaction was 
refluxed at 120˚C while stirring for three hours. 3,4-(methylenedioxy)aniline 43 (1.0 g, 7.29 
mmol) was then added in one portion and the reaction continued to reflux overnight at 120˚C. 
Cooled reaction down and concentrated in vacuo to give a black oil. The residue was purified 
using a gradient of 15%-40% EtOAc/Hexanes to give 46 as a light brown crystalline solid 
(0.536g, 40% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 10.00 (s, 1H), 7.28 (d, J = 2.0 Hz, 1H), 
6.93 (dd, J = 8.4, 2.0 Hz, 1H), 6.85 (d, J = 8.4 Hz, 1H), 5.98 (s, 2H), 3.50 (s, 2H), 2.20 (s, 3H). 
 
N-(3,4-dichlorophenyl)-3-oxobutanamide (47): Intermediate 47 was prepared as described for 
compound 46 replacing 3, 4 – (methylenedioxy)aniline 43 with 3,4 dichloroaniline 44. The 
residue was purified using an isocratic gradient of 2% MeOH/DCM to give the desired product 
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47 as a light yellow oil (23% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 10.36 (s, 1H), 7.97 (s, 
1H), 7.56 (d, J = 8.1 Hz, 1H), 7.44 (d, J = 8.8 Hz, 1H), 3.57 (d, J = 3.0 Hz, 2H), 2.20 (s, 3H). 
3-oxo-N-(pyridin-4-yl)butanamide (48):Intermediate 48 was prepared as described for compound 
46 replacing 3, 4 – (methylenedioxy)aniline 43 with 4 – amino – pyridine 45. The residue was 
purified using an isocratic gradient of 2% MeOH/DCM to give the desired product 48 as a light 
yellow solid (41% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 10.44 (s, 1H), 8.43 (d, J = 6.4 Hz, 
2H), 7.53 (d, J = 6.4 Hz, 2H), 3.61 (s, 2H), 2.21 (s, 3H). 
 
5-(5-(Benzo[d][1,3]dioxol-5-ylcarbamoyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-4-yl)-2-
fluorobenzoic acid (49): Prepared as described for compound 7, replacing compound 4 with 46 
to give the desired compound 49 as a white solid (90% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 
13.32 (s, 1H), 9.49 (s, 1H), 8.80 (s, 1H), 7.79 (d, J = 6.8 Hz, 1H), 7.64 (s, 1H), 7.47 (s, 1H), 7.28 
(t, J = 9.7 Hz, 1H), 7.19 (s, 1H), 6.97 – 6.74 (m, 2H), 5.95 (s, 2H), 5.39 (s, 1H), 2.02 (s, 3H). 
 
5-(5-((3,4-dichlorophenyl)carbamoyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-4-yl)-2-
fluorobenzoic acid (50): Intermediate 50 was prepared as described for compound 7 replacing 
compound 4 with intermediate 47 to give the desired compound 50 as a white solid (20% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 13.30 (s, 1H), 9.82 (s, 1H), 8.92 (s, 1H), 7.91 (d, J = 2.1 Hz, 
1H), 7.78 (dd, J = 6.4, 2.0 Hz, 1H), 7.72 (s, 1H), 7.54 – 7.41 (m, 3H), 7.33 – 7.22 (m, 1H), 5.42 
(s, 1H), 2.06 (s, 3H). 
 
2-fluoro-5-(6-methyl-2-oxo-5-(pyridin-4-ylcarbamoyl)-1,2,3,4-tetrahydropyrimidin-4-yl)benzoic 
acid (51): Intermediate 51 was prepared as described for compound 7 replacing compound 4 
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with intermediate 48 to give the desired compound 51 as an off white solid (22% yield). Took 
forward as is without further characterization. 
 
Final Analogues (52):  
N-(Benzo[d][1,3]dioxol-5-yl)-4-(4-fluoro-3-((pyridin-2-ylmethyl)carbamoyl)phenyl)-6-methyl-2-
oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (52 - 222682): To a 15 mL flask with DMF (5 
mL) was added 49 (0.125 g, 0.300 mmol), 2-(aminomethyl)pyridine (0.062 mL, 0.600 mmol), 
HATU (0.228g, 0.600 mmol), and DIEA (0.105 mL, 0.600 mmol). The reaction was stirred 
overnight at room temperature then diluted with EtOAc and brine and separated. Washed organic 
layer with sodium carbonate 1x, then NaCl 1x, and concentrated. The residue was purified using 
a gradient of 5% - 8% MeOH/DCM to give compound 52 as a white solid (112 mg, 74% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 9.51 (s, 1H), 8.89 (td, J = 5.8, 3.1 Hz, 1H), 8.79 (d, J = 1.9 
Hz, 1H), 8.55 – 8.47 (m, 1H), 7.76 (td, J = 7.7, 1.8 Hz, 1H), 7.68 – 7.61 (m, 2H), 7.40 (ddd, J = 
7.8, 4.9, 2.4 Hz, 1H), 7.36 – 7.23 (m, 4H), 7.21 (d, J = 2.0 Hz, 1H), 6.93 (dd, J = 8.4, 2.1 Hz, 
1H), 6.79 (d, J = 8.4 Hz, 1H), 5.94 (q, J = 1.0 Hz, 2H), 5.40 (d, J = 2.9 Hz, 1H), 4.56 (d, J = 5.9 
Hz, 2H), 2.04 (s, 3H).
13
C NMR (101 MHz, DMSO) δ 164.71, 163.44, 158.00, 157.08, 152.21, 
148.73, 146.74, 142.73, 140.50, 138.59, 136.62, 133.33, 130.31, 128.28, 123.23, 123.09, 122.00, 
120.54, 116.19, 115.95, 112.38, 107.72, 104.74, 101.76, 100.74, 54.19, 44.58, 40.01, 39.80, 




1,2,3,4-tetrahydropyrimidine-5-carboxamide (222681 – 2-47): The final compound 222681 was 
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synthesized as described for compound 222682 (52a) replacing pyridin-2-ylmethanamine with 
(3-fluorophenyl)methanamine to give the desired compound as a white solid (112 mg, 72% 
yield). 
1
H NMR (400 MHz, Methanol-d4) δ 7.73 (d, J = 6.0 Hz, 1H), 7.50 (s, 1H), 7.33 (q, J = 
7.5 Hz, 1H), 7.25 – 7.12 (m, 2H), 7.08 (d, J = 10.0 Hz, 1H), 7.04 – 6.93 (m, 2H), 6.79 – 6.65 (m, 
2H), 5.89 (s, 2H), 5.48 (s, 1H), 4.56 (s, 2H), 2.08 (s, 3H). 
13
C NMR (101 MHz, dmso) δ 165.26, 
164.09, 161.43, 157.48, 152.76, 147.30, 143.29, 142.74, 142.67, 141.05, 141.01, 139.21, 133.88, 
130.72, 130.63, 128.71, 123.47, 116.69, 116.46, 114.28, 114.06, 113.87, 112.94, 108.27, 105.26, 
102.33, 101.30, 54.71, 42.62, 40.57, 40.36, 40.15, 39.94, 39.73, 39.52, 39.31, 17.53. HPLC 
purity: 98%; MS (ESI+) m/z: 421.1 (M+1). 
 
N-(benzo[d][1,3]dioxol-5-yl)-4-(4-fluoro-3-((2-(pyridin-2-yl)ethyl)carbamoyl)phenyl)-6-methyl-
2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (222683 – 2-49): The final compound 
222683 was synthesized as described for compound 222682 (52a) replacing pyridin-2-
ylmethanamine with 2-(pyridin-2-yl)ethan-1-amine to give the desired compound as a white 
solid (84% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 9.50 (s, 1H), 8.79 (s, 1H), 8.50 (d, J = 4.6 
Hz, 1H), 7.70 (t, J = 7.6 Hz, 1H), 7.63 (s, 1H), 7.55 (d, J = 6.7 Hz, 1H), 7.25 (dd, J = 18.1, 8.3 
Hz, 4H), 6.93 (d, J = 8.6 Hz, 1H), 6.79 (d, J = 8.4 Hz, 1H), 5.94 (s, 2H), 5.39 (s, 1H), 3.60 (q, J = 
6.8 Hz, 2H), 2.96 (t, J = 7.2 Hz, 2H), 2.03 (s, 3H). HPLC purity: 99%; MS (ESI+) m/z: 518.1 
(M+1), 541.0 (M+Na). 
 
N-(benzo[d][1,3]dioxol-5-yl)-4-(4-fluoro-3-((2-(pyridin-4-yl)ethyl)carbamoyl)phenyl)-6-methyl-
2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (222684 – 2-50): The final compound 
222684 was synthesized as described for compound 222682 (52a) replacing pyridin-2-
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ylmethanamine with 4-(pyridin-2-yl)ethan-1-amine to give the desired compound as a white 
solid (103 mg, 66% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 9.53 (s, 1H), 8.79 (s, 1H), 8.50 (d, 
J = 5.9 Hz, 2H), 8.43 (s, 1H), 7.63 (s, 1H), 7.55 – 7.48 (m, 1H), 7.38 – 7.30 (m, 3H), 7.26 – 7.20 
(m, 2H), 6.97 – 6.91 (m, 1H), 6.79 (d, J = 8.4 Hz, 1H), 5.21 (s, 1H), 5.94 (s, 2H), 3.52 (d, J = 
11.1 Hz, 2H), 2.86 (t, J = 7.0 Hz, 2H), 2.04 (s, 3H). HPLC purity: 99%; MS (ESI+) m/z: 518.0 
(M+1), 540.0 (M+Na). 
 
N-(benzo[d][1,3]dioxol-5-yl)-4-(3-((2,6-difluorobenzyl)carbamoyl)-4-fluorophenyl)-6-methyl-2-
oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (222686 – 2 – 65): The final compound 
222686 was synthesized as described for compound 222682 (52a) replacing pyridin-2-
ylmethanamine with 2,6 – difluoro-benzylamine to give the desired compound as a white solid 
(141 mg, 86% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 9.48 (s, 1H), 8.80 – 8.69 (m, 2H), 7.61 
(t, J = 2.5 Hz, 1H), 7.51 (dd, J = 6.8, 2.4 Hz, 1H), 7.46 – 7.34 (m, 1H), 7.34 (dq, J = 4.8, 2.5 Hz, 
1H), 7.26 – 7.17 (m, 2H), 7.08 (t, J = 7.8 Hz, 2H), 6.92 (dd, J = 8.4, 2.1 Hz, 1H), 6.79 (d, J = 8.4 
Hz, 1H), 5.95 (s, 2H), 5.37 (d, J = 3.0 Hz, 1H), 4.49 (d, J = 5.3 Hz, 2H), 2.01 (d, J = 15.0 Hz, 
3H). HPLC purity: 91%; MS (ESI+) m/z: 539.0 (M+1), 561.0 (M+Na). 
 
N-(benzo[d][1,3]dioxol-5-yl)-4-(4-fluoro-3-((4-methoxybenzyl)carbamoyl)phenyl)-6-methyl-2-
oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (222880 – 2 -62): The final compound 222880 
was synthesized as described for compound 222682 (52a) replacing pyridin-2-ylmethanamine 
with 4-methoxy-benzylamine to give the desired compound as a white solid (123 mg, 77% 
yield). 
1
H NMR (400 MHz, DMSO-d6) δ 9.50 (s, 1H), 8.78 (s, 2H), 7.63 (s, 1H), 7.57 (dd, J = 
6.7, 2.2 Hz, 1H), 7.37 (ddd, J = 7.4, 4.8, 2.3 Hz, 1H), 7.29 – 7.20 (m, 4H), 6.95 – 6.85 (m, 3H), 
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6.79 (d, J = 8.4 Hz, 1H), 5.94 (s, 2H), 4.37 (d, J = 5.9 Hz, 2H), 3.73 (s, 3H), 2.03 (s, 3H). HPLC 
purity: 92%; MS (ESI+) m/z: 533.2 (M+1), 555.2 (M+Na). 
 
N-(benzo[d][1,3]dioxol-5-yl)-4-(4-fluoro-3-((2-methoxybenzyl)carbamoyl)phenyl)-6-methyl-2-
oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (222883 – 2 – 69): The final compound 
222883 was synthesized as described for compound 222682 (52a) replacing pyridin-2-
ylmethanamine with 2-methoxy-benzylamine to give the desired compound as a white solid (105 
mg, 65% yield). 
1
H NMR (400 MHz, Methanol-d4) δ 7.74 (dd, J = 6.9, 2.4 Hz, 1H), 7.48 (ddd, J 
= 8.6, 4.8, 2.5 Hz, 1H), 7.25 (t, J = 7.4 Hz, 2H), 7.17 (dd, J = 10.6, 8.5 Hz, 1H), 7.04 – 6.92 (m, 
2H), 6.89 (td, J = 7.5, 1.1 Hz, 1H), 6.75 (dd, J = 8.3, 2.1 Hz, 1H), 6.68 (d, J = 8.3 Hz, 1H), 5.89 
(q, J = 1.2 Hz, 2H), 5.47 (d, J = 1.3 Hz, 1H), 4.55 (d, J = 1.9 Hz, 2H), 3.86 (s, 3H), 2.08 (d, J = 
1.1 Hz, 3H). HPLC purity: 95%; MS (ESI+) m/z: 533.2 (M+1), 555.2 (M+Na). 
 
N-(benzo[d][1,3]dioxol-5-yl)-4-(4-fluoro-3-((pyridin-3-ylmethyl)carbamoyl)phenyl)-6-methyl-2-
oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (222884 – 2 – 72): The final compound 
222884 was synthesized as described for compound 222682 (52a) replacing pyridin-2-
ylmethanamine with pyridin-2-ylmethanamine to give the desired compound as a white solid 
(102 mg, 67% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 9.49 (s, 1H), 8.93 (s, 1H), 8.78 (s, 1H), 
8.46 (d, J = 3.3 Hz, 1H), 7.95 (s, 1H), 7.70 (d, J = 7.6 Hz, 1H), 7.62 (s, 1H), 7.59 (dd, J = 6.8, 
2.3 Hz, 1H), 7.37 (tt, J = 8.1, 3.7 Hz, 2H), 7.31 – 7.24 (m, 1H), 7.20 (d, J = 1.9 Hz, 1H), 6.92 
(dd, J = 8.5, 2.0 Hz, 1H), 6.79 (d, J = 8.4 Hz, 1H), 5.95 (s, 2H), 5.39 (s, 1H), 4.48 (d, J = 6.0 Hz, 
2H), 2.03 (s, 3H). 
13
C NMR (126 MHz, dmso) δ 165.28, 164.10, 159.72, 157.75, 152.76, 149.17, 
148.55, 147.31, 143.31, 141.03, 139.17, 135.41, 135.15, 133.88, 130.87, 130.80, 128.78, 123.90, 
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123.85, 116.67, 116.49, 112.99, 108.28, 105.29, 102.36, 101.31, 54.76, 40.90, 40.47, 40.39, 
40.30, 40.22, 40.13, 40.06, 39.97, 39.89, 39.80, 39.63, 39.47, 17.54. HPLC purity: 97%; MS 
(ESI+) m/z: 504.2 (M+1). 
 
N-(benzo[d][1,3]dioxol-5-yl)-4-(4-fluoro-3-((3-methoxybenzyl)carbamoyl)phenyl)-6-methyl-2-
oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (222885 – 2-73): The final compound 222885 
was synthesized as described for compound 222682 (52a) replacing pyridin-2-ylmethanamine 
with 3-methoxy-benzylamine to give the desired compound as a white solid (116 mg, 72% 
yield). 
1
H NMR (400 MHz, DMSO-d6) δ 9.48 (s, 1H), 8.83 (td, J = 6.2, 3.3 Hz, 1H), 8.76 (d, J = 
1.9 Hz, 1H), 7.64 – 7.52 (m, 2H), 7.36 (ddd, J = 7.7, 4.8, 2.4 Hz, 1H), 7.30 – 7.16 (m, 3H), 6.93 
– 6.84 (m, 3H), 6.81 – 6.74 (m, 2H), 5.92 (d, J = 1.1 Hz, 2H), 5.40 – 5.34 (m, 1H), 4.41 (d, J = 
6.1 Hz, 2H), 3.71 (s, 3H), 2.01 (s, 3H). 
13
C NMR (126 MHz, dmso) δ 165.28, 164.04, 159.74, 
157.70, 152.78, 147.31, 143.31, 141.25, 141.00, 139.20, 133.90, 130.61, 129.78, 128.66, 124.25, 
119.63, 116.62, 116.44, 113.06, 112.98, 112.66, 108.28, 105.31, 102.36, 101.30, 55.38, 54.74, 
43.00, 40.48, 40.40, 40.31, 40.23, 40.14, 40.07, 39.97, 39.90, 39.81, 39.64, 39.47, 17.54. HPLC 
purity: 92%; MS (ESI+) m/z: 533.2 (M+1), 555.2 (M+Na). 
 
N-(3,4-dichlorophenyl)-4-(4-fluoro-3-((pyridin-2-ylmethyl)carbamoyl)phenyl)-6-methyl-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide (53): The final compound 53 was synthesized as 
described for compound 52 replacing intermediate 49 with intermediate 50 to give the desired 
compound as a white solid (63% yield). 
1
H NMR (400 MHz, Methanol-d4) δ 8.48 (ddd, J = 5.0, 
1.8, 0.9 Hz, 1H), 7.80 (dd, J = 6.4, 2.1 Hz, 2H), 7.75 (d, J = 2.4 Hz, 1H), 7.51 (ddt, J = 7.4, 4.8, 
2.5 Hz, 1H), 7.45 – 7.35 (m, 2H), 7.36 – 7.27 (m, 2H), 7.21 (dd, J = 10.7, 8.5 Hz, 1H), 5.50 (d, J 
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tetrahydropyrimidine-5-carboxamide (54): The final compound 54 was synthesized as described 
for compound 52 replacing intermediate 49 with intermediate 51 to give the desired compound 
as a pale yellow solid (75% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 9.99 (s, 1H), 8.99 (s, 1H), 
8.89 (s, 1H), 8.51 (d, J = 4.9 Hz, 1H), 8.37 (d, J = 6.3 Hz, 2H), 7.80 – 7.71 (m, 2H), 7.64 (dd, J = 
7.1, 2.0 Hz, 1H), 7.59 – 7.52 (m, 2H), 7.40 (dq, J = 6.3, 2.3, 1.6 Hz, 1H), 7.29 (ddd, J = 12.6, 
7.8, 3.7 Hz, 3H), 5.46 (s, 1H), 4.55 (d, J = 5.8 Hz, 2H), 2.09 (s, 3H). 
13
CNMR (500 MHz, 
DMSO-d6) δ 165.83, 163.40, 157.98, 152.00, 150.03, 148.73, 145.64, 141.00, 140.44, 136.62, 
130.35, 128.27, 128.20, 122.01, 120.56, 116.25, 113.30, 109.43, 104.01, 53.95, 44.58, 17.17. 
HPLC purity: 95%; MS (ESI+) m/z: 461.1 (M+1).  
 
2,6-bis(trifluoromethyl)benzamide (56). To a 100 mL flask was added 2,6 – trifluoromethyl 
benzoyl chloride (0.70 g, 2.53 mmol), 28% aqueous ammonium hydroxide (7.56 mL, 189.8 
mmol), and THF (13 mL). The reaction was stirred vigorously overnight. The THF was 
evaporated off in vacuo and then the resulting aqueous layer was extracted 3x with EtOAC. The 
organic layers were combined and washed 2x with NaCl, dried over magnesium sulfate, and 
concentrated to give the desired product as a white solid (0.525 g, 2.05 mmol, 81% yield).  
1
H 
NMR (500 MHz, DMSO-d6) δ 8.14 (s, 1H), 8.10 (d, J = 8.0 Hz, 2H), 7.93 (s, 1H), 7.86 – 7.81 





2,6-bis(trifluoromethyl)benzonitrile (57). To a 100 mL flask flushed with argon was added 2,6-
bis(trifluoromethyl)benzamide 56 (1.31 g, 5.10 mmol) and DMF (15 mL). The flask was cooled 
to 0 ˚C and then thionyl chloride (0.741 mL, 10.2 mmol) was slowly added. The reaction was 
stirred overnight allowing to come to room temperature. The reaction was then poured over ice 
and filtered to give a white solid as the desired product (1.21 g, 5.06 mmol, 99% yield). 
1
H NMR 
(400 MHz, DMSO-d6) δ 8.38 (d, J = 8.1 Hz, 2H), 8.19 (t, J = 8.1 Hz 1H). HPLC (gradient A): 
retention time = 7.277 min; purity = 98%. 
 
(2,6-bis(trifluoromethyl)phenyl)methanamine (58). To a 100 mL pressure vessel was added 2,6-
bis(trifluoromethyl)benzonitrile 57 (1.30 g, 5.44 mmol) followed by 1M BH3 in THF (27.2 mL, 
27.2 mmol) at 0 ˚C. The vessel was then sealed and heated to 80 ˚C for two days. The reaction 
was cooled to 0 ˚C and then 1N HCl was added. THF was removed in vacuo and then the 
aqueous layer was extracted 2x with dichloromethane. The aqueous layer was then adjusted to 
pH of 14 using 2N NaOH and extracted 3x with dichloromethane. The last 3 dichloromethane 
extractions were combined and washed 1x with saturated NaCl, dried over sodium sulfate, and 
concentrated to give a white solid (1.22 g, 5.0 mmol, 92% yield).  
1
H NMR (400 MHz, DMSO-
d6) δ 8.63 – 8.56 (m, 2H), 8.20 (d, J = 8.0 Hz, 2H), 7.92 (t, J = 8.0 Hz, 1H), 4.24 (s, 2H). MS 
(ESI+) m/z: 244.0 (M+1).  
 
Phenyl(3S,4R)-3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(4-fluorophenyl)piperidine-1-
carboxylate (60): To a 250 mL round bottom flask was added ((3S,4R)-4-(4-fluorophenyl)-1-
methylpiperidin-3-yl)methanol (4.0 g, 17.91 mmol) and dichloromethane (40 mL). Tert-
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butyldimethylsilyl chloride (4.05 g, 26.9 mmol) and imidazole (1.22 g, 17.9 mmol) were added 
to the reaction vessel producing a cloudy white mixture. Lastly, N,N-diisopropylethylamine (4.68 
mL, 26.9 mmol) was added, giving a clear solution. The reaction was stirred overnight at room 
temperature.  Methylene chloride was used to dilute the reaction followed by washing with brine 
(2x). The organic layer was dried over MgSO4, concentrated in vacuo, and purified using flash 
chromatography with a 20%-40% EtOAc/Hexane gradient to give (3S,4R)-3-(((tert-
butyldimethylsilyl)oxy)methyl)-4-(4-fluorophenyl)-1-methylpiperidine (5.51 g, 16.3 mmol, 91% 
yield).  1H NMR (500 MHz, Chloroform-d) δ 7.13 (dd, J = 8.5, 5.5 Hz, 2H), 6.96 (t, J = 8.7 Hz, 
2H), 3.29 (dd, J = 10.3, 2.3 Hz, 1H), 3.15 (dd, J = 10.1, 6.0 Hz, 1H), 3.08 (dd, J = 7.6, 1.8 Hz, 
1H), 2.92 (ddt, J = 11.2, 4.0, 2.4 Hz, 1H), 2.33 (s, 3H), 2.32 – 2.28 (m, 1H), 2.00 – 1.88 (m, 3H), 
1.85 – 1.72 (m, 2H), 0.84 (s, 9H), -0.11 (d, J = 9.3 Hz, 6H). MS (ESI+) m/z: 338.2 (M+1).  
Phenyl (3S,4R)-3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(4-fluorophenyl)piperidine-1-
carboxylate (0.47 g, 1.40 mmol)  and toluene (8 mL) were added to a 50mL flask and refluxed at 
110ºC. Phenyl chloroformate (0.32 mL, 2.53 mmol) was then added dropwise and the reaction 
was stirred another four hours at reflux. The reaction was then cooled to 60ºC and 
trimethylamine (0.20 mL, 1.44 mmol) was added to quench the reaction which was stirred 
another 40 minutes and then cooled to room temperature. The reaction was diluted with toluene 
and brine. The layers were separated and the toluene layer was washed 2x with brine, dried over 
MgSO4, and concentrated. Purified the resulting clear viscous liquid with flash chromatography 
(0 – 10% EtOAc/Hexanes) to give a clear syrup, phenyl (3S,4R)-3-(((tert-
butyldimethylsilyl)oxy)methyl)-4-(4-fluorophenyl)piperidine-1-carboxylate 60 (0.467g, 75% 





carboxylate (61). Compound 60 (6.03 g, 13.6 mmol) was added to a 250 mL round bottom flask 
and dissolved in isopropanol (45 mL). Sodium hydroxide (8 N, 15mL) was then added and the 
reaction was refluxed at 80ºC overnight. The reaction was diluted with water and toluene. The 
layers were separated and the organic layer was washed 2x with brine, dried over MgSO4, and 
concentrated. Purified using flash chromatography (0-20% MeOH/DCM) to give as a clear oil 
(3S,4R)-3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(4-fluorophenyl)piperidine (2.41 g, 55% 
yield). 
1
H NMR (DMSO – d6, 400 MHz) δ: 7.24-7.19 (m, 2H), 7.10 (t, J=8 Hz, 2H), 3.21 (dd, J = 
10.2, 3.0 Hz, 1H), 3.12 (td, J = 11.2, 10.2, 7.7 Hz, 2H), 2.98 – 2.92 (m, 1H), 2.40 (td, J = 11.4, 
4.6 Hz, 1H), 2.34 (dd, J = 12.0, 10.7 Hz, 1H), 2.18 (s, 1H), 1.70 (tdt, J = 11.0, 7.2, 3.5 Hz, 1H), 
1.60 – 1.47 (m, 2H), 0.8 (s, 9H), -0.13 (d, J = 6.7 Hz, 6H). MS (ESI+) m/z: 444.3 (M+1).    (3S, 
4R)-3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(4-fluorophenyl)piperidine (1.05 g, 3.25 mmol), 
boc anhydride (0.99 g, 4.54 mmol), N,N-diisopropylethylamine (0.85 mL, 4.88 mmol) and THF 
(30 mL) were added to a 250 mL round bottom flask and stirred under nitrogen overnight. 
Reaction was quenched with water and diluted with EtOAc. The organic layer was washed 2x 
with brine, dried with MgSO4, and concentrated to give a clear oil. The oil was further purified 
using flash chromatography (10% EtOAc/Hexanes) to give, as a clear syrup, tert-butyl (3S,4R)-
3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(4-fluorophenyl)piperidine-1-carboxylate (61, 1.35 g, 
98% yield). 
1
H NMR (DMSO – d6, 400 MHz) δ: 7.26-7.19 (m, 2H), 7.09 (t, J=8 Hz, 2H), 4.26 
(d, J=8.0 Hz, 1H), 4.01 (br s, 1H), 3.46-3.02 (m, 4H), 2.69 (s, 1H), 1.81-1.43 (m, 3H), 1.39 (s, 








fluorobenzoic acid (62). N1,N1,N2,N2-tetramethylethylene-1,2-diamine (0.549 g, 4.72 mmol) 
was added to THF (10 mL) in a 50 mL round bottom flask cooled to -78 ⁰ C under argon. Sec-
buytllithium (3.63 mL, 4.72 mmol) was added and the reaction mixture was stirred for thirty 
minutes then (3S,4R)-tert-butyl 3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(4-
fluorophenyl)piperidine-1-carboxylate 61 (1.0 g, 2.36 mmol) in THF (10 mL) was added and the 
solution was stirred at -78 ⁰ C for 1 hour. Freshly broken CO2 was added and the mixture 
allowed to warm to room temperature. The reaction was extracted with ether 2x, washed with 
NaCl 2x, dried with MgSO4 and concentrated in vacuo. The resulting intermediate was used 
without further purification. 
 
(3S,4R)-tert-Butyl-3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(4-fluoro-3-
(hydroxymethyl)phenyl)piperidine-1-carboxylate (63).  N1,N1,N2,N2-tetramethylethylene-1,2-
diamine (0.548 g, 4.72 mmol) was added to THF (10 mL) in a 50 mL round bottom flask cooled 
to -78 ⁰ C under nitrogen. Sec-buytllithium (3.63 mL, 4.72 mmol) was added and the reaction 
mixture was stirred for ten minutes then (3S,4R)-tert-butyl 3-(((tert-
butyldimethylsilyl)oxy)methyl)-4-(4-fluorophenyl)piperidine-1-carboxylate 61 (0.998 g, 2.36 
mmol) in THF (10 mL) was added and the solution was stirred at -78 ⁰ C for 1 hour. A solution 
of anhydrous DMF (2 ml) in THF (5 mL) was added and the reaction was allowed to warm to 
room temperature (4 hours). The reaction was quenched with NH4Cl (10 mL), extracted with 
ether 2x, washed with NaCl 3x, dried over MgSO4, concentrated in vacuo, and purified using 




(1.075g crude, took all crude to next step, Rf:0.46 (10% EtOAc/Hexanes)). 
1
H NMR (DMSO – 
d6, 400 MHz) δ: 10.20 (s, 1H), 7.71-7.26 (m, 2H), 7.35 (t, J=8.0 Hz, 1H), 4.27 (d, J=12.0 Hz, 
1H), 4.05 (br s, 1H), 3.55-3.10 (m, 4H), 2.63-2.55 (m, 1H), 1.83-1.52 (m, 3H), 1.57 (s, 9H), 0.82 
(s, 9H), -0.12 (s, 6H); HPLC purity: 95%;  MS (ESI+) m/z: 452.4 (M+1). (3S,4R)-tert-butyl 3-
(((tert-butyldimethylsilyl)oxy)methyl)-4-(4-fluoro-3-formylphenyl)-piperidine-1-carboxylate 
(crude, 1.075 g, 2.38 mmol) was added to THF (15 mL) in a 50 mL round bottom flask cooled to 
0 ⁰ C. Sodium borohydride (0.0262 g, 1.19 mmol) was added and the reaction mixture was 
allowed to come to room temperature and stirred 3 hours. Methanol (10 mL) and citric acid (5%, 
10 mL) were added to the reaction mixture and allowed to stir 30 minutes. The reaction was 
extracted with ether/ethyl acetate 2x, washed with NaCl 2x, dried over MgSO4, concentrated in 
vacuo, and purified using flash chromatography (80 mL silica gel) of 20% EtOAc/Hexane to 
give (3S,4R)-tert-butyl 3-(((tert-butyldi- methylsilyl)oxy)methyl)-4-(4-fluoro-3-
(hydroxymethyl)phenyl)piperidine-1-carboxylate 63 (0.627 g, Rf:0.22 (20% EtOAc/Hexanes), 
59% yield from 7). 
1
H NMR (DMSO – d6, 400 MHz) δ: 7.30 (d, J=8.0 Hz, 1H) 7.15-7.08 (m, 
1H) 7.05 (t, J=8.0 Hz, 1H), 5.24 (s, 1H), 4.52 (s, 2H), 4.30 (d, J=12.0 Hz, 1H), 4.05 (br s, 1H), 
3.35 (s, 1H), 3.24 (s, 1H), 3.14 (t, J=8.0 Hz, 1H), 2.72 (s, 2H), 1.82-1.46 (m, 3H), 1.42 (s, 9H), 





(methoxycarbonyl)phenyl) piperidine-1-carboxylate (64). To a solution of 5-((3S,4R)-1-(tert-
butoxycarbonyl)-3-(((tert-butyldimethylsilyl)oxy)methyl)piperidin-4-yl)-2-fluorobenzoic acid 62 
(1.08 g, 2.31 mmol) in 20% (V/V) Methanol/toluene (30 mL) was added drop wise TMS-
diazomethane (1.27 mL, 2.54 mmol). Gas evolved and reaction is slightly yellow. The reaction 
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was stirred for 30 minutes and was then quenched with acetic acid until gas no longer evolved 
and the yellow color was gone. Then the reaction was concentrated in vacuo. Dissolved in ethyl 
acetate and ether and washed 2x with brine, dried with MgSO4 and concentrated. The crude 
product was purified using flash chromatography with a 20%-30% EtOAc/Hexane gradient to 
give (3S,4R)-tert-butyl 3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(4-fluoro-3-
(methoxycarbonyl)phenyl) piperidine-1-carboxylate 60 (0.96 g crude, 1.99 mmol, 86% yield 
over two steps). 
1
H NMR (400 MHz, DMSO-d6) δ 7.69 (dd, J = 7.2, 2.3 Hz, 1H), 7.56 (dq, J = 
7.2, 2.3 Hz, 1H), 7.29 (dd, J = 10.8, 8.5 Hz, 1H), 4.25 (d, J = 13.0 Hz, 1H), 4.03 (d, J = 8.2 Hz, 
1H), 3.84 (s, 3H), 3.22 (s, 1H), 3.14 (dd, J = 10.5, 7.4 Hz, 1H), 2.72 (s, 1H), 2.58 (s, 2H), 1.76 (s, 
1H), 1.67 (d, J = 12.5 Hz, 1H), 1.63 – 1.48 (m, 1H), 1.41 (s, 9H), 0.82 (s, 9H), -0.11 (d, J = 4.4 
Hz, 6H). MS (ESI+) m/z: 482.3 (M+1).   
 
(3S,4R)-tert-Butyl-3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(3-(cyanomethyl)-4-
fluorophenyl)piperidine-1-carboxylate (65). (3S,4R)-tert-butyl 3-(((tert-
butyldimethylsilyl)oxy)methyl)-4-(4-fluoro-3-(hydroxymethyl)phenyl)piperidine-1-carboxylate 
63 (0.344 g, 0.759 mmol) was added to anhydrous dichloromethane (8 mL) in a 50 mL round 
bottom flask cooled to 0 ⁰ C under nitrogen. Diisopropylethylamine (0.265 mL, 1.517 mmol) 
was added to the reaction mixture followed by methanesulfonic anhydride and the reaction 
mixture was stirred for 0.5 hours. The reaction mixture was washed 1x with distilled water, dried 
over MgSO4, and concentrated in vacuo. Anhydrous dimethyl sulfoxide (8 mL) was added to the 
50 mL flask followed by sodium cyanide (0.112 g, 2.276 mmol) and stirred overnight at room 
temperature under nitrogen. The reaction was diluted with ether and washed with NaCl (6x). The 
aqueous layers were then washed 2x with ether. The organic layers were combined, dried over 
183 
 
MgSO4, concentrated in vacuo, and purified using flash chromatography (30 mL silica gel) of 
10-20% gradient of EtOAc/Hexane to give (3S,4R)-tert-butyl-3-(((tert-
butyldimethylsilyl)oxy)methyl)-4-(3-(cyanomethyl)-4-fluorophenyl)piperidine-1-carboxylate 65 
(0.210g, Rf:0.51 (20% EtOAc/Hexanes), 60% yield). 
1
H NMR (CDCl3, 400 MHz) δ: 7.25-7.18 
(m, 1H) 7.13 (s, 1H) 7.03 (t, J=9.0 Hz, 1H), 4.37-4.16 (m, 2H), 3.74 (s, 2H), 3.37-3.23 (m, 1H), 
3.19-3.08 (m, 1H), 2.68 (br s, 2H), 1.82-1.56 (m, 4H), 1.48 (s, 9H), 1.24 (s, 9H), -0.07 (s, 6H); 





carboxylate (66). To a solution of (3S,4R)-tert-butyl 3-(((tert-butyldimethylsilyl)oxy)methyl)-4-
(4-fluoro-3-(methoxycarbonyl)phenyl) piperidine-1-carboxylate 64 (1.68 g, 3.49 mmol) in THF 
(50 mL) was added acetic acid (0.60 mL, 10.46 mmol) followed by tetrabutylammonium fluoride 
(1.0 M, 10.46 mL, 10.46 mmol). The resulting mixture was stirred overnight at 60 
o
C. Diluted 
with ethyl acetate/ether and treated with saturated aq. NH4Cl. The layers were separated and the 
organic layer was washed with NaCl (2x), dried with MgSO4, and concentrated in vacuo. 
Purified using flash chromatography with a 10%-30% EtOAc/Hexane gradient to give (3S,4R)-
tert-butyl 4-(4-fluoro-3-(methoxycarbonyl)phenyl)-3-(hydroxymethyl)piperidine-1-carboxylate 
62 as a clear oil (1.29 g, 3.51 mmol, 100% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 7.75 
(dd, J = 6.9, 2.4 Hz, 1H), 7.34 (ddd, J = 8.4, 4.5, 2.4 Hz, 1H), 7.08 (dd, J = 10.5, 8.5 Hz, 1H), 
4.36 (d, J = 13.0 Hz, 1H), 4.21 (s, 1H), 3.92 (s, 3H), 3.43 (dt, J = 11.1, 3.8 Hz, 1H), 3.25 (dt, J = 
11.3, 6.0 Hz, 1H), 2.85 – 2.68 (m, 2H), 2.61 (s, 1H), 1.83 (dq, J = 7.1, 3.9, 3.5 Hz, 1H), 1.77 (d, 
J = 13.1 Hz, 1H), 1.67 (qd, J = 12.3, 4.2 Hz, 1H), 1.48 (s, 9H), 1.20 (s, 1H). MS (ESI+) m/z: 





carboxylate (67). (3S,4R)-tert-butyl 3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(3-
(cyanomethyl)-4-fluoropheny l)piperidine-1-carboxylate 65 (0.501 g, 1.081 mmol) and tetra-n-
butyl ammonium fluoride (1.30mL, 1.30 mmol) were added to THF (10 mL) in a 50 mL round 
bottom flask at room temperature and allowed to stir overnight. The next day another equivalent 
of tetra-n-butylammonium fluoride (1.30 mL, 1.30 mmol) was added to the reaction mixture and 
stirred for 3.0 hours. The reaction mixture was quenched with NH4Cl, extracted with ether/ethyl 
acetate 1x and washed with NaCl (2x). The organic layers were combined, dried over MgSO4, 
concentrated in vacuo, and purified using flash chromatography (25mL silica gel) of 30-50% 
gradient of EtOAc/Hexane to give (3S,4R)-tert-butyl-4-(3-(cyanomethyl)-4-fluorophenyl)-3-
(hydroxymethyl) piperidine -1-carboxylate 67 (0.240g, Rf:0.33 (30% EtOAc/Hexanes), 64% 
yield). 
1
H NMR (CDCl3, 400 MHz) δ: 7.24 (dd, J1=2.4 Hz, J2=7.2 Hz, 1H) 7.18-7.12 (m, 1H) 
7.03 (t, J=9.0 Hz, 1H), 4.41-4.32 (m, 2H), 4.19 (br s, 1H), 3.74 (s, 1H), 3.42 (dd, J1=3.0 Hz, 
J2=11.0 Hz, 1H), 3.24 (q, J=6.4 Hz, 1H), 2.87-2.52 (m, 3H), 1.87-1.57 (m, 4H), 1.48 (s, 9H) ; 





(methoxycarbonyl)phenyl) piperidine-1-carboxylate (68). To a 0 
o
C solution of (3S,4R)-tert-butyl 
4-(4-fluoro-3-(methoxycarbonyl) phenyl)-3-(hydroxymethyl)piperidine-1-carboxylate 66 (0.687 
g, 1.87 mmol) in 25 mL DCM was added diisopropylethylamine (0.980 mL, 5.61 mmol) 
followed by methanesulfonylchloride (0.651 g, 3.74 mmol). The reaction was allowed to warm 
to room temperature and stirred overnight. The resulting product was washed with water (1x), 
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then brine (1x), dried over MgSO4, and concentrated in vacuo to give a clear oil (0.833 g crude). 
The product was used in subsequent reactions without further purification. To a 0 
o
C solution of 
benzo[d][1,3]dioxol-5-ol (0.543 g, 3.93 mmol) in 5 mL DMF was added 60% sodium hydride in 
mineral oil (0.164g, 4.11 mmol). The solution turned light pink and was stirred for five minutes. 
To the reaction was added (3S,4R)-tert-butyl 4-(4-fluoro-3-(methoxycarbonyl)phenyl)-3-
(((methylsulfonyl)oxy)methyl)piperidine-1-carboxylate (0.833 g, 1.87 mmol) in 5 mL DMF. The 
reaction was heated to 70 
o
C for 1 hour then cooled to room temperature and treated with sat. 
NH4Cl solution. Extracted with ethyl acetate/ether (2x), washed with brine, dried with MgSO4, 
and concentrated in vacuo. The crude product was purified by flash chromatography using a 
gradient of 5% MeOH/DCM to give as a clear oil (3S,4R)-tert-butyl 3-((benzo[d][1,3]dioxol-5-
yloxy)methyl)-4-(4-fluoro-3-(methoxycarbonyl)phenyl)piperidine-1-carboxylate 68 (0.452 g, 
0.927 mmol, 50% yield over two steps). 
1
H NMR (400 MHz, Methanol-d4) δ 7.76 (dd, J = 6.9, 
2.4 Hz, 1H), 7.49 (ddd, J = 8.5, 4.6, 2.5 Hz, 1H), 7.14 (dd, J = 10.7, 8.5 Hz, 1H), 6.61 (d, J = 8.5 
Hz, 1H), 6.35 (d, J = 2.5 Hz, 1H), 6.16 (dd, J = 8.5, 2.5 Hz, 1H), 5.85 (q, J = 1.2 Hz, 2H), 4.40 
(d, J = 13.3 Hz, 1H), 4.22 (d, J = 3.3 Hz, 1H), 3.87 (s, 3H), 3.61 (dd, J = 9.8, 2.8 Hz, 1H), 3.50 
(dd, J = 9.9, 6.6 Hz, 1H), 2.82 (td, J = 11.7, 3.8 Hz, 3H), 2.11 – 1.97 (m, 1H), 1.86 – 1.77 (m, 




fluorophenyl)-3-(hydroxymethyl)piperidine-1-carboxylate 67 was added to a dry 25 mL round 
bottom flask, with 5 mL anhydrous dichloromethane cooled to 0 
o
C followed by DIEA (0.346 
mL, 1.979 mmol) and lastly, methanesulfonic anhydride (0.230 g, 1.319 mmol) and stirred for 2 
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hours. The reaction mixture was washed 1x with NaCl, dried of MgSO4, and concentrated in 
vacuo. To a separate 25 mL round bottom flask sodium hydride (0.058 g, 1.451 mmol) was 
added with DMF under nitrogen at 0
o
C followed by sesamol (0.1913 g, 1.385 mmol) in 2 mL 
DMF and stirred for 20 minutes. The dried, mesylated (3S,4R)-tert-butyl-4-(3-(cyanomethyl)-4-
fluorophenyl)-3-(hydroxymethyl)piperidine-1-carboxylate was then added with 2 mL DMF to 
the reaction vessel with the activated sesamol, heated to 70
o
C, and stirred for 10 minutes. The 
reaction was quenched with NH4Cl, extracted with EtOAc/ether 2x, washed with brine 3x, dried 
over MgSO4 and purified using flash chromatography with a 0% to 80% gradient of 
EtOAc/Hexanes to give (3S,4R)-tert-butyl 3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(3-
(cyanomethyl)-4-fluorophenyl) piperidine-1-carboxylate 69 (0.138 g, Rf: 0.40 (40% 
EtOAc/Hexanes), 46% yield). 
1
H NMR (CDCl3, 400 MHz) δ: 7.25-7.21 (m, 1H), 7.16-7.12 (m, 
1H), 7.02 (t, J=8.8 Hz, 1H), 6.63 (d, J=8.8, 1H), 6.35 (d, J=2.4, 1H), 6.14 (dd, J1=2.4 Hz, J2=8.4 
Hz, 1H), 5.88 (s, 2H), 4.43 (broad s, 1H), 4.25 (broad s, 1H), 3.72 (s, 2H), 3.62-3.59 (m, 1H), 
3.46-3.42 (m, 1H), 2.90-2.67 (m, 3H),  2.10-1.60 (m, 3H), 1.50 (s, 9H) ; HPLC purity: 98%;  MS 
(ESI+) m/z: 469.1 (M+1), 491.1 (M+Na
+
).     
 
5-((3S,4R)-3-((Benzo[d][1,3]dioxol-5-yloxy)methyl)-1-(tert-butoxycarbonyl)piperidin-4-yl)-2-
fluorobenzoic acid (70). To a round bottom flask equipped with a stir bar was added (3S,4R)-
tert-butyl 3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluoro-3-
(methoxycarbonyl)phenyl)piperidine-1-carboxylate 68 (0.297g, 0.608 mmol), 1M NaOH (1.83 
mL, 1.825 mmol), H2O (5 mL), and Methanol (12 mL). The reaction was stirred overnight at 
room temperature. Ether was added to the reaction and the resulting layers were separated. To 
the aqueous layer, 10% citric acid was added to give a pH of 4. The aqueous layer was then 
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extracted 2x with ethyl acetate. The ethyl acetate layers were then combined and washed 1x with 
NaCl, dried with MgSO4, and concentrated to give, with no further purification, as an amorphous 
solid 5-((3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-1-(tert-butoxycarbonyl)piperidin-4-
yl)-2-fluorobenzoic acid 70 (0.226 g, 0.477 mmol, 79% yield).
1
H NMR (400 MHz, Methanol-d4) 
δ 7.77 (dd, J = 7.0, 2.4 Hz, 1H), 7.47 (ddd, J = 8.6, 4.5, 2.5 Hz, 1H), 7.13 (dd, J = 10.7, 8.5 Hz, 
1H), 6.61 (d, J = 8.5 Hz, 1H), 6.36 (d, J = 2.4 Hz, 1H), 6.16 (dd, J = 8.5, 2.5 Hz, 1H), 5.84 (s, 
2H), 4.41 (d, J = 13.4 Hz, 1H), 4.20 (d, J = 13.3 Hz, 1H), 3.61 (dd, J = 9.8, 3.0 Hz, 1H), 3.52 
(dd, J = 9.9, 6.7 Hz, 1H), 2.87 (s, 1H), 2.81 (td, J = 11.7, 3.9 Hz, 2H), 2.05 (ddd, J = 15.0, 7.1, 
4.0 Hz, 1H), 1.81 (dd, J = 13.5, 3.7 Hz, 1H), 1.70 (qd, J = 12.7, 4.6 Hz, 1H), 1.49 (s, 9H). MS 
(ESI+) m/z: 474.2 (M+1). 
 
2-(5-((3S,4R)-3-((Benzo[d][1,3]dioxol-5-yloxy)methyl)-1-(tert-butoxycarbonyl) piperidin-4-yl)-
2-fluorophenyl)acetic acid (71). (3S,4R)-tert-butyl 3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-
(3-(cyanomethyl)-4-fluorophenyl) piperidine-1-carboxylate 69 (0.459 g) in EtOH (3.0 mL) was 
added to a 25 mL pressure vessel followed by 50% NaOH (0.26 mL) and heated to 98 ⁰ C 
overnight. The following day further excess 50% NaOH (0.10 mL) was added and the reaction 
was again stirred overnight. The reaction mixture was cooled to room temperature and diluted 
with H2O then 2N HCl was added to reach pH 2.0. The resulting suspension was extracted with 
dichloromethane 3x, washed with NaCl 2x, dried with MgSO4, and concentrated in vacuo to give 
2-(5-((3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-1-(tert-butoxycarbonyl)piperidin-4-yl)-
2-fluorophenyl)acetic acid 71 without further purification (0.372 g, 78% yield).
1
H NMR (CDCl3, 
400 MHz) δ: 7.11-7.04 (m, 2H), 7.00 (t, J=9.0 Hz, 1H), 6.20 (d, J=8.8, 1H), 6.34 (2, 1H), 6.14 (d, 
J=8.4 Hz, 1H), 5.88 (s, 2H), 4.42 (broad s, 1H), 4.23 (broad s, 1H), 3.66 (s, 2H), 3.64-3.58 (m, 
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1H), 3.48-3.42 (m, 1H), 2.88-2.72 (m, 2H), 2.71-2.60 (m, 1H), 2.04-1.92 (m, 1H), 1.85-1.63 (m, 
3H), 1.49 (s, 9H) ; HPLC purity: 87%;  MS (ESI+) m/z: 488.2 (M+1), 410.2 (M+Na
+
); (ESI-) 
m/z: 486.2 (M-1).   
 
Intermediate compounds 72 
tert-Butyl (3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluoro-3-
(methylcarbamoyl)phenyl)piperidine-1-carboxylate. (72a). 5-((3S,4R)-3-((benzo[d][1,3] dioxol-
5-yloxy)methyl)-1-(tert-butoxycarbonyl)piperidin-4-yl)-2-fluorobenzoic acid 70 (0.08 g, 0.169 
mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (0.073 g, 0.338 mmol), N,N-
diisopropylethylamine (0.131 mL, 0.676 mmol), hydroxybenzotriazole (0.051g, 0.338 mmol), 
and 2M methylamine in THF (0.169 mL, 0.338 mmol) were added to THF (5 mL) in a 15 mL 
round bottom flask and stirred overnight at room temperature. The resulting solution was diluted 
with ethyl acetate and saturated sodium bicarbonate, and then the layers were separated. The 
organic layer was then washed with brine (2x), dried with MgSO4, and concentrated in vacuo. 
The crude product was purified using flash chromatography using 30% - 90% EtOAc/Hexanes to 
give as an amorphous solid tert-butyl (3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-
fluoro-3-(methylcarbamoyl)phenyl)piperidine-1-carboxylate 72a (0.070 g, 0.144 mmol, 85% 
yield).  
1
H NMR (400 MHz, Chloroform-d) δ 7.94 (dd, J = 7.6, 2.4 Hz, 1H), 7.30 – 7.22 (m, 1H), 
7.04 (dd, J = 11.8, 8.4 Hz, 1H), 6.78 – 6.65 (m, 1H), 6.62 (d, J = 8.4 Hz, 1H), 6.33 (t, J = 1.8 Hz, 
1H), 6.12 (dt, J = 8.6, 1.8 Hz, 1H), 5.88 (d, J = 1.3 Hz, 2H), 4.44 (s, 1H), 4.24 (s, 2H), 3.58 (dd, 
J = 9.4, 2.8 Hz, 1H), 3.44 (dd, J = 9.4, 6.7 Hz, 1H), 3.03 (d, J  = 4.0 Hz, 3H), 2.76 (q, J = 12.5, 
11.8 Hz, 3H), 2.15 – 2.05 (m, 1H), 1.74 (dq, J = 17.3, 13.5, 13.0 Hz, 2H), 1.50 (d, J = 1.3 Hz, 





fluorophenyl)piperidine-1-carboxylate (72b). Compound 72b was synthesized as described for 
intermediate 72a from intermediate 70 replacing methylamine with benzylamine (59% yield). 
1
H 
NMR (500 MHz, Chloroform-d) δ 7.97 (dd, J = 7.5, 2.5 Hz, 1H), 7.38 – 7.34 (m, 3H), 7.29 (ddt, 
J = 8.7, 6.4, 3.4 Hz, 2H), 7.03 (ddd, J = 14.9, 10.0, 4.2 Hz, 2H), 6.62 (d, J = 8.4 Hz, 1H), 6.34 (d, 
J = 2.5 Hz, 1H), 6.13 (dd, J = 8.5, 2.5 Hz, 1H), 5.87 (s, 2H), 4.68 (d, J = 5.6 Hz, 2H), 4.45 (s, 
1H), 4.25 (s, 1H), 3.59 (dd, J = 9.4, 2.8 Hz, 1H), 3.45 (dd, J = 9.5, 6.5 Hz, 1H), 2.77 (dt, J = 
23.6, 11.9 Hz, 3H), 2.10 (ddq, J = 11.5, 7.7, 4.0 Hz, 1H), 1.80 (d, J = 13.2 Hz, 1H), 1.76 – 1.68 
(m, 1H), 1.50 (s, 9H). MS (ESI+) m/z: 562.7 (M+1). 
 
tert-Butyl (3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluoro-3-
(phenethylcarbamoyl)phenyl)piperidine-1-carboxylate (72c). Compound 72c was synthesized as 
described for intermediate 72a from intermediate 70 replacing methylamine with 2-
phenylethylamine (77% yield).  
1
H NMR (500 MHz, Chloroform-d) δ 7.93 (dd, J = 7.5, 2.4 Hz, 
1H), 7.37 – 7.30 (m, 2H), 7.29 – 7.23 (m, 4H), 7.01 (dd, J = 11.6, 8.4 Hz, 1H), 6.80 – 6.71 (m, 
1H), 6.63 (d, J = 8.4 Hz, 1H), 6.35 (d, J = 2.5 Hz, 1H), 6.14 (dd, J = 8.5, 2.5 Hz, 1H), 5.88 (s, 
2H), 4.46 (s, 1H), 4.25 (s, 1H), 3.74 (q, J = 5.9 Hz, 2H), 3.59 (dd, J = 9.5, 2.9 Hz, 1H), 3.45 (dd, 
J = 9.5, 6.6 Hz, 1H), 2.94 (t, J = 7.0 Hz, 2H), 2.87 – 2.69 (m, 3H), 2.10 (tdt, J = 10.4, 7.0, 3.0 
Hz, 1H), 1.83 – 1.67 (m, 2H), 1.51 (s, 9H). MS (ESI+) m/z: 576.8 (M+1). 
 
(3S,4R)-tert-Butyl -3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(3-((2,6-
difluorobenzyl)carbamoyl)-4-fluorophenyl)piperidine-1-carboxylate. (72d) Compound 72d was 
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synthesized as described for intermediate 72a from intermediate 70 replacing methylamine with 
2,6-difluorobenzylamine (24% yield).
1
H NMR (CDCl3, 400 MHz) δ 7.95 (dd, J = 7.5, 2.4 Hz, 
1H), 7.35 – 7.20 (m, 2H), 7.16-7.13 (m, 1H), 7.01 (dd, J = 11.8, 8.4 Hz, 1H), 6.94 – 6.75 (m, 
2H), 6.60 (d, J = 8.5 Hz, 1H), 6.32 (d, J = 2.4 Hz, 1H), 6.11 (dd, J = 8.5, 2.5 Hz, 1H), 5.87 (s, 
2H), 4.46 (br s, 1H), 4.19 (br s,  1H), 3.56 (dd, J = 9.5, 2.8 Hz, 1H), 3.42 (dd, J = 9.4, 6.6 Hz, 




difluorophenethyl)carbamoyl)-4-fluorophenyl)piperidine-1-carboxylate (72e). Compound 72e 
was synthesized as described for intermediate 72a from intermediate 70 replacing methylamine 
with 2-(2,6-difluorophenyl)ethan-1-amine (87% yield). 
1
H NMR (CDCl3, 400 MHz) δ 7.90 (dd, J 
= 7.5, 2.4 Hz, 1H), 7.24 – 7.07 (m, 2H), 7.00 (dd, J = 11.6, 8.4 Hz, 1H), 6.95 – 6.65 (m, 4H), 
6.60 (d, J = 8.5 Hz, 1H), 6.32 (d, J = 2.4 Hz, 1H), 6.11 (dd, J = 8.5, 2.5 Hz, 1H), 5.86 (s, 2H), 
4.41 (br s, 1H), 4.22 (br s, 1H), 3.70 (q, J = 6.9 Hz, 1H), 3.56 (m, 1H), 3.49 – 3.28 (m, 1H), 3.02 
(t, J = 6.8 Hz, 2H), 2.79 – 2.68 (m, 2H), 2.10-2.04 (m, 1H), 1.87 – 1.65 (m, 2H), 1.48 (s, 9H). 
MS (ESI+) m/z: 612.0 (M+1). 
 
tert-Butyl (3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluoro-3-((2-
(trifluoromethyl)benzyl)carbamoyl)phenyl)piperidine-1-carboxylate (72f). Compound 72f was 
synthesized as described for intermediate 72a from intermediate 70 replacing methylamine with 
(2-(trifluoromethyl)phenyl)methanamine (28% yield). Yellow oil. 
1
H NMR (400 MHz, 
Chloroform-d) δ 7.91 (m, 1H), 7.65 (t, J = 6.2 Hz, 2H), 7.52 (t, J = 7.6 Hz, 1H), 7.38 (t, J = 7.7 
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Hz, 1H), 7.25-7.23 (m, 3H), 7.12 – 6.92 (m, 2H), 6.20 (br s, 1H), 5.87 (m, 2H), 5.09-4.96 (m, 
2H), 4.83 (d, J = 5.9 Hz, 2H), 4.26 (br s, 1H), 3.64 (m, 2H), 2.71-2.61 (m, 2H), 1.75 (m, 1H), 
1.49 (s, 9H). MS (ESI+) m/z 629.7 (M+1) 
 
(3S,4R)-tert-Butyl -3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(3-((2,6-
dimethylbenzyl)carbamoyl)-4-fluorophenyl)piperidine-1-carboxylate (72g). Compound 72g was 
synthesized as described for intermediate 72a from intermediate 70 replacing methylamine with 
2,6-dimethylbenzylamine (75% yield).  
1
H NMR (400 MHz, Methanol-d4) δ 7.48 (dd, J = 6.8, 
2.3 Hz, 1H), 7.35 (ddd, J = 8.5, 4.9, 2.4 Hz, 1H), 7.13 – 6.98 (m, 4H), 6.59 (d, J = 8.5 Hz, 1H), 
6.34 (d, J = 2.5 Hz, 1H), 6.14 (dd, J = 8.5, 2.5 Hz, 1H), 5.83 (q, J = 1.2 Hz, 2H), 4.60 (s, 2H), 
4.40 (d, J = 13.3 Hz, 1H), 4.18 (dt, J = 13.5, 2.4 Hz, 1H), 3.58 (dd, J = 9.8, 2.9 Hz, 1H), 3.49 
(dd, J = 9.8, 6.9 Hz, 1H), 2.89 (s, 1H), 2.77 (td, J = 11.7, 3.9 Hz, 2H), 2.38 (s, 6H), 2.04 (dtq, J = 
11.0, 7.0, 3.5 Hz, 1H), 1.82 – 1.61 (m, 2H), 1.48 (s, 8H). MS (ESI+) m/z: 590.8 (M+1). 
 
(3S,4R)-tert-Butyl 3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(3-((2,6-
dichlorobenzyl)carbamoyl)-4-fluorophenyl)piperidine-1-carboxylate (72h). Compound 72h was 
synthesized as described for intermediate 72a from intermediate 70 replacing methylamine with 
2,6-dichlorobenzylamine (41% yield).  
1
H NMR (CD3OD, 400 MHz) δ 7.52 (dd, J = 6.9, 2.4 Hz, 
1H), 7.45-7.33 (m, 3H), 7.29 (dd, J = 8.7, 7.4 Hz, 1H), 7.10 (dd, J = 10.5, 8.5 Hz, 1H), 6.59 (d, J 
= 8.4 Hz, 1H), 6.34 (d, J = 2.4 Hz, 1H), 6.14 (dd, J = 8.5, 2.5 Hz, 1H), 5.84 (q, J = 1.2 Hz, 2H), 
4.86 (s, 2H), 4.40 (d, J = 13.2 Hz, 1H), 4.23-4.14 (m, 1H), 3.59 (dd, J = 9.8, 3.0 Hz, 1H), 3.49 
(dd, J = 9.9, 6.9 Hz, 1H), 2.98-2.72 (m, 3H), 2.10-1.99 (m, 1H), 1.82-1.74 (m, 1H), 1.68 (qd, J = 





dimethoxybenzyl)carbamoyl)-4-fluorophenyl)piperidine-1-carboxylate (72i). Compound 72i was 
synthesized as described for intermediate 72a from intermediate 70 replacing methylamine with 
2,6-dimethoxybenzylamine (71% yield).   
1
H NMR (400 MHz, DMSO-d6) δ 12.86 (s, 1H), 7.99 
(q, J = 4.8 Hz, 1H), 7.86 (s, 1H), 7.51 (dd, J = 7.0, 2.3 Hz, 1H), 7.44 – 7.36 (m, 2H), 7.25 (t, J = 
8.3 Hz, 1H), 7.16 (dd, J = 10.6, 8.5 Hz, 1H), 6.92 – 6.86 (m, 2H), 6.66 (d, J = 8.4 Hz, 2H), 4.48 
(d, J = 5.0 Hz, 2H), 4.36 (s, 1H), 4.09 – 4.04 (m, 1H), 3.78 (s, 6H), 3.64 – 3.56 (m, 2H), 2.82 (s, 
0H), 2.71 (qd, J = 11.9, 2.8 Hz, 1H), 2.11 (dt, J = 8.9, 4.4 Hz, 1H), 1.71 (d, J = 11.3 Hz, 1H), 
1.61 (dd, J = 13.8, 9.5 Hz, 1H), 1.42 (s, 9H). MS (ESI+) m/z: 622.8 (M+1). 
 
(3S,4R)-tert-Butyl-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluoro-3-((2-
methoxybenzyl)carbamoyl)phenyl)piperidine-1-carboxylate (72j). Compound 72j was 
synthesized as described for intermediate 72a from intermediate 70 replacing methylamine with 
2-methoxy benzylamine (71% yield).  
1
H NMR (CDCl3, 400 MHz) δ 8.71 (s, 1H), 8.05 – 7.82 
(m, 1H), 7.43 (dd, J = 13.1, 6.0 Hz, 1H), 7.33 (dd, J = 7.4, 1.7 Hz, 1H), 7.29 – 7.13 (m, 2H), 7.00 
(t, J = 10.0 Hz, 1H), 6.96 – 6.78 (m, 2H), 6.19 (s, 1H), 5.98 – 5.75 (m, 2H), 5.58 (dd, J = 5.9, 2.0 
Hz, 1H), 4.97 (s, 2H), 4.65 (d, J = 5.7 Hz, 2H), 3.93 – 3.78 (m, 3H), 3.74 – 3.53 (m, 2H), 2.70 (d, 
J = 45.6 Hz, 3H), 1.67 – 1.53 (m, 1H), 1.36 – 0.97 (m, 9H). MS (ESI+) m/z: 592.9 (M+1). 
 
 (3S,4R)-tert-Butyl 3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluoro-3-((pyridin-2-
ylmethyl)carbamoyl)phenyl)piperidine-1-carboxylate (72k). Compound 72k was synthesized as 
described for intermediate 72a from intermediate 70 replacing methylamine with pyridin-2-
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ylmethanamine (74% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 8.56 (ddd, J = 5.0, 1.8, 1.0 
Hz, 1H), 8.04 – 7.91 (m, 2H), 7.67 (td, J = 7.7, 1.7 Hz, 1H), 7.32 (d, J = 7.9 Hz, 1H), 7.30 – 7.26 
(m, 1H), 7.20 (ddd, J = 7.6, 4.9, 1.1 Hz, 1H), 7.05 (dd, J = 11.5, 8.4 Hz, 1H), 6.60 (d, J = 8.5 Hz, 
1H), 6.33 (d, J = 2.4 Hz, 1H), 6.11 (dd, J = 8.5, 2.4 Hz, 1H), 5.85 (s, 2H), 4.78 (d, J = 4.8 Hz, 
2H), 4.44 (s, 1H), 4.23 (s, 1H), 3.58 (dd, J = 9.6, 2.8 Hz, 1H), 3.44 (dd, J = 9.5, 6.6 Hz, 1H), 2.90 




ylmethyl)carbamoyl)phenyl)piperidine-1-carboxylate (72l). Compound 72l was synthesized as 
described for intermediate 72a from intermediate 70 replacing methylamine with 3-picoylamine 
(94% yield). 
1
H NMR (500 MHz, Chloroform-d) δ 8.62 (d, J = 2.3 Hz, 1H), 8.55 (dd, J = 4.7, 1.6 
Hz, 1H), 7.96 (dd, J = 7.5, 2.4 Hz, 1H), 7.71 (d, J = 7.7 Hz, 1H), 7.29 (td, J = 7.9, 4.9 Hz, 2H), 
7.12 – 7.01 (m, 2H), 6.62 (d, J = 8.4 Hz, 1H), 6.34 (d, J = 2.4 Hz, 1H), 6.13 (dd, J = 8.4, 2.5 Hz, 
1H), 5.87 (s, 2H), 4.69 (d, J = 5.9 Hz, 2H), 4.44 (s, 1H), 4.24 (s, 1H), 3.59 (dd, J = 9.4, 2.8 Hz, 
1H), 3.45 (dd, J = 9.5, 6.5 Hz, 1H), 2.78 (dt, J = 22.3, 13.0 Hz, 3H), 2.14 – 2.06 (m, 1H), 1.84 – 
1.69 (m, 2H), 1.50 (s, 9H). MS (ESI+) m/z: 563.8 (M+1). 
 
tert-Butyl (3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluoro-3-((pyridin-4-
ylmethyl)carbamoyl)phenyl)piperidine-1-carboxylate (72m). Compound 72m was synthesized as 
described for intermediate 72a from intermediate 70 replacing methylamine with 4-
(aminomethyl)pyridine (94% yield).  
1
H NMR (500 MHz, Chloroform-d) δ 8.60 – 8.53 (m, 2H), 
7.96 (dd, J = 7.5, 2.4 Hz, 1H), 7.32 (ddd, J = 7.9, 4.8, 2.4 Hz, 1H), 7.28 – 7.23 (m, 2H), 7.21 (dt, 
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J = 12.7, 6.0 Hz, 1H), 7.07 (dd, J = 11.7, 8.5 Hz, 1H), 6.62 (d, J = 8.4 Hz, 1H), 6.34 (d, J = 2.4 
Hz, 1H), 6.13 (dd, J = 8.5, 2.5 Hz, 1H), 5.87 (s, 2H), 4.68 (d, J = 6.0 Hz, 2H), 4.44 (s, 1H), 4.25 
(s, 1H), 3.59 (dd, J = 9.5, 2.8 Hz, 1H), 3.45 (dd, J = 9.5, 6.4 Hz, 1H), 2.87 – 2.70 (m, 3H), 2.09 
(dtt, J = 10.4, 6.9, 3.4 Hz, 1H), 1.85 – 1.67 (m, 2H), 1.50 (s, 9H). MS (ESI+) m/z: 563.8 (M+1). 
 
tert-Butyl (3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluoro-3-((2-(pyridin-2-
yl)ethyl)carbamoyl)phenyl)piperidine-1-carboxylate (72n). Compound 72n was synthesized as 
described for intermediate 72a from intermediate 70 replacing methylamine with 2-(2-
aminoethyl)pyridine (66% yield). 
1
H NMR (500 MHz, Chloroform-d) δ 8.56 (dt, J = 5.1, 1.2 Hz, 
1H), 7.91 (dd, J = 7.4, 2.4 Hz, 1H), 7.70 – 7.63 (m, 1H), 7.62 (td, J = 7.6, 1.8 Hz, 1H), 7.25 – 
7.22 (m, 1H), 7.19 (d, J = 7.8 Hz, 1H), 7.16 (ddd, J = 7.7, 4.9, 1.1 Hz, 1H), 7.00 (dd, J = 11.5, 
8.4 Hz, 1H), 6.61 (d, J = 8.5 Hz, 1H), 6.33 (d, J = 2.4 Hz, 1H), 6.12 (dd, J = 8.5, 2.5 Hz, 1H), 
5.87 (s, 2H), 4.44 (s, 1H), 4.24 (s, 1H), 3.90 (q, J = 5.9 Hz, 2H), 3.58 (dd, J = 9.5, 2.9 Hz, 1H), 
3.44 (dd, J = 9.4, 6.7 Hz, 1H), 3.10 (t, J = 6.4 Hz, 2H), 2.82 – 2.68 (m, 3H), 2.09 (dtd, J = 11.0, 
7.5, 3.4 Hz, 1H), 1.80 – 1.66 (m, 2H), 1.50 (s, 9H). MS (ESI+) m/z: 577.8 (M+1). 
 
tert-Butyl (3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluoro-3-((2-(pyridin-3-
yl)ethyl)carbamoyl)phenyl)piperidine-1-carboxylate (72o). Compound 72o was synthesized as 
described for intermediate 72a from intermediate 70 replacing methylamine with 3-(2-
aminoethyl)pyridine (82% yield). 
1
H NMR (500 MHz, Chloroform-d) δ 8.52 – 8.48 (m, 2H), 
7.92 (dd, J = 7.5, 2.4 Hz, 1H), 7.58 (dt, J = 7.8, 2.0 Hz, 1H), 7.30 – 7.27 (m, 1H), 7.02 (dd, J = 
11.7, 8.4 Hz, 1H), 6.76 (dt, J = 12.4, 5.8 Hz, 1H), 6.62 (d, J = 8.5 Hz, 1H), 6.34 (d, J = 2.4 Hz, 
1H), 6.13 (dd, J = 8.5, 2.5 Hz, 1H), 5.87 (s, 2H), 4.44 (s, 1H), 4.24 (s, 1H), 3.73 (q, J = 6.8 Hz, 
195 
 
2H), 3.58 (dd, J = 9.5, 2.9 Hz, 1H), 3.44 (dd, J = 9.5, 6.5 Hz, 1H), 2.95 (t, J = 7.1 Hz, 2H), 2.88 
– 2.69 (m, 3H), 2.09 (dtt, J = 10.8, 7.3, 3.5 Hz, 1H), 1.83 – 1.67 (m, 2H), 1.50 (s, 9H). MS 
(ESI+) m/z: 577.8 (M+1). 
 
tert-Butyl (3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluoro-3-((2-(pyridin-4-
yl)ethyl)carbamoyl)phenyl)piperidine-1-carboxylate (72p). Compound 72p was synthesized as 
described for intermediate 72a from intermediate 70 replacing methylamine with 4-(2-
aminoethyl)pyridine (79% yield). 
1
H NMR (500 MHz, Chloroform-d) δ 8.56 – 8.52 (m, 2H), 
7.92 (dd, J = 7.5, 2.4 Hz, 1H), 7.31 – 7.25 (m, 4H), 7.18 – 7.15 (m, 2H), 7.02 (dd, J = 11.7, 8.5 
Hz, 1H), 6.76 (dt, J = 12.4, 5.8 Hz, 1H), 6.62 (d, J = 8.5 Hz, 1H), 6.34 (d, J = 2.5 Hz, 1H), 6.13 
(dd, J = 8.5, 2.5 Hz, 1H), 5.87 (s, 2H), 4.44 (s, 1H), 4.24 (s, 1H), 3.75 (q, J = 6.8 Hz, 2H), 3.58 
(dd, J = 9.5, 2.9 Hz, 1H), 3.49 (d, J = 4.9 Hz, 1H), 3.44 (dd, J = 9.5, 6.5 Hz, 1H), 2.95 (t, J = 7.0 
Hz, 2H), 2.86 – 2.69 (m, 3H), 2.08 (dtd, J = 13.1, 6.8, 5.9, 3.2 Hz, 1H), 1.79 (d, J = 13.7 Hz, 
1H), 1.76 – 1.66 (m, 1H), 1.50 (s, 9H). MS (ESI+) m/z: 577.8 (M+1). 
 
tert-Butyl (3S,4R)-4-(3-(((1H-imidazol-2-yl)methyl)carbamoyl)-4-fluorophenyl)-3-
((benzo[d][1,3]dioxol-5-yloxy)methyl)piperidine-1-carboxylate (72q). Compound 72q was 
synthesized as described for intermediate 72a from intermediate 70 replacing methylamine with 
1H-imidazole-2-methanamine dihydrochloride (66% yield). 
1
H NMR (400 MHz, Chloroform-d) 
δ 7.93 (dd, J = 7.4, 2.4 Hz, 1H), 7.64 (dd, J = 12.7, 6.1 Hz, 1H), 7.30 (ddd, J = 7.9, 4.8, 2.4 Hz, 
1H), 7.05 (dd, J = 11.7, 8.5 Hz, 1H), 6.98 (s, 2H), 6.61 (d, J = 8.4 Hz, 1H), 6.34 (d, J = 2.5 Hz, 
1H), 6.12 (dd, J = 8.5, 2.5 Hz, 1H), 5.88 (d, J = 1.2 Hz, 2H), 4.66 (d, J = 5.8 Hz, 2H), 4.45 (s, 
1H), 4.25 (s, 1H), 3.59 (dd, J = 9.6, 2.8 Hz, 1H), 3.43 (dd, J = 9.5, 6.3 Hz, 1H), 2.88 – 2.71 (m, 
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3H), 2.15 – 2.00 (m, 1H), 1.87 – 1.60 (m, 2H), 1.50 (s, 9H). MS (ESI+) m/z: 552.8 (M+1). 
 
tert-Butyl (3S,4R)-4-(3-((2-(1H-imidazol-4-yl)ethyl)carbamoyl)-4-fluorophenyl)-3-
((benzo[d][1,3]dioxol-5-yloxy)methyl)piperidine-1-carboxylate (72r). Compound 72r was 
synthesized as described for intermediate 72a from intermediate 70 replacing methylamine with 
histamine (86% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 7.87 (dd, J = 7.4, 2.4 Hz, 1H), 7.59 
(s, 1H), 7.35 – 7.28 (m, 1H), 7.24 (dq, J = 7.2, 2.4 Hz, 1H), 7.01 (dd, J = 11.4, 8.5 Hz, 1H), 6.85 
(s, 1H), 6.61 (d, J = 8.4 Hz, 1H), 6.33 (d, J = 2.4 Hz, 1H), 6.12 (dd, J = 8.5, 2.5 Hz, 1H), 5.87 (s, 
2H), 4.44 (s, 1H), 4.24 (s, 1H), 3.76 (q, J = 6.3 Hz, 2H), 3.57 (dd, J = 9.5, 2.8 Hz, 1H), 3.43 (dd, 
J = 9.5, 6.6 Hz, 1H), 2.92 (t, J = 6.5 Hz, 2H), 2.88 – 2.66 (m, 3H), 2.14 – 2.03 (m, 1H), 1.82 – 
1.64 (m, 2H), 1.50 (s, 9H). MS (ESI+) m/z: 566.7 (M+1). 
 
tert-Butyl (3S,4R)-4-(3-(((1H-pyrazol-5-yl)methyl)carbamoyl)-4-fluorophenyl)-3-
((benzo[d][1,3]dioxol-5-yloxy)methyl)piperidine-1-carboxylate (72s). Compound 72s was 
synthesized as described for intermediate 72a from intermediate 70 replacing methylamine with 
2H-pyrazol-3-ylmethylamine hydrochloride (69% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 
10.71 (bs, IH) 7.95 (dd, J = 7.5, 2.4 Hz, 1H), 7.52 (d, J = 2.1 Hz, 1H), 7.37 (dt, J = 11.8, 5.5 Hz, 
1H), 7.28 (d, J = 5.7 Hz, 1H), 7.03 (dd, J = 11.6, 8.4 Hz, 1H), 6.61 (d, J = 8.5 Hz, 1H), 6.34 (d, J 
= 2.5 Hz, 1H), 6.28 (d, J = 2.1 Hz, 1H), 6.12 (dd, J = 8.5, 2.5 Hz, 1H), 5.87 (q, J = 1.4 Hz, 2H), 
4.73 – 4.65 (m, 2H), 4.45 (s, 1H), 4.25 (s, 1H), 3.58 (dd, J = 9.5, 2.8 Hz, 1H), 3.43 (dd, J = 9.5, 
6.5 Hz, 1H), 2.85 – 2.68 (m, 3H), 2.09 (td, J = 7.7, 7.0, 3.8 Hz, 1H), 1.73 (dq, J = 18.5, 14.0 Hz, 





((benzo[d][1,3]dioxol-5-yloxy)methyl)piperidine-1-carboxylate (72t) Compound 72t was 
synthesized as described for intermediate 72a from intermediate 70 replacing methylamine with 
2-(1H-pyrazol-3-yl)ethan-1-amine (64% yield). 
1
H NMR (500 MHz, Chloroform-d) δ 10.78 (s, 
1H), 7.90 (dd, J = 7.5, 2.4 Hz, 1H), 7.52 (d, J = 2.2 Hz, 1H), 7.25 (ddd, J = 8.4, 4.8, 2.5 Hz, 1H), 
7.17 (dt, J = 11.7, 5.7 Hz, 1H), 7.00 (dd, J = 11.5, 8.4 Hz, 1H), 6.61 (d, J = 8.5 Hz, 1H), 6.33 (d, 
J = 2.5 Hz, 1H), 6.17 (d, J = 2.2 Hz, 1H), 6.12 (dd, J = 8.5, 2.5 Hz, 1H), 5.89 – 5.85 (m, 4H), 
4.44 (s, 1H), 4.24 (s, 1H), 3.79 (q, J = 6.3, 5.9 Hz, 2H), 3.58 (dd, J = 9.5, 2.9 Hz, 1H), 3.43 (dd, J 
= 9.5, 6.6 Hz, 1H), 3.01 (t, J = 6.6 Hz, 2H), 2.85 – 2.68 (m, 3H), 2.14 – 2.02 (m, 1H), 1.74 (dtd, 
J = 24.7, 13.0, 3.9 Hz, 2H), 1.50 (s, 9H), 8.04 – 7.99 (m, 1H). MS (ESI+) m/z: 566.7 (M+1). 
 
tert-Butyl (3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluoro-3-(((5-methyl-1H-
pyrazol-3-yl)methyl)carbamoyl)phenyl)piperidine-1-carboxylate (72u). Compound 72u was 
synthesized as described for intermediate 72a from intermediate 70 replacing methylamine with 
(5-methyl-1H-pyrazol-3-yl)methanamine (91% yield).  
1
H NMR (400 MHz, Chloroform-d) δ 
9.71 (d, J = 105.6 Hz, 1H), 7.96 (dd, J = 7.4, 2.4 Hz, 1H), 7.33 – 7.27 (m, 2H), 7.03 (dd, J = 
11.7, 8.5 Hz, 1H), 6.62 (d, J = 8.4 Hz, 1H), 6.34 (d, J = 2.5 Hz, 1H), 6.12 (dd, J = 8.5, 2.5 Hz, 
1H), 6.03 (s, 1H), 5.88 (s, 2H), 4.62 (d, J = 5.3 Hz, 2H), 4.45 (s, 1H), 4.25 (s, 1H), 3.58 (dd, J = 
9.5, 2.8 Hz, 1H), 3.44 (dd, J = 9.5, 6.6 Hz, 1H), 2.76 (dt, J = 19.9, 10.7 Hz, 3H), 2.29 (s, 3H), 
2.09 (dp, J = 7.5, 4.2 Hz, 1H), 1.84 – 1.62 (m, 2H), 1.50 (s, 8H). MS (ESI+) m/z: 566.7 (M+1). 
 
 tert-Butyl (3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluoro-3-(((1-methyl-1H-
pyrazol-3-yl)methyl)carbamoyl)phenyl)piperidine-1-carboxylate (72v). Compound 72v was 
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synthesized as described for intermediate 72a from intermediate 70 replacing methylamine with 
(1-methyl-1H-pyrazol-3-yl)methanamine (78% yield).  
1
H NMR (500 MHz, Chloroform-d) δ 
7.96 (dd, J = 7.5, 2.5 Hz, 1H), 7.30 (d, J = 2.2 Hz, 1H), 7.30 – 7.18 (m, 2H), 7.02 (dd, J = 11.6, 
8.4 Hz, 1H), 6.61 (d, J = 8.4 Hz, 1H), 6.34 (d, J = 2.5 Hz, 1H), 6.22 (d, J = 2.2 Hz, 1H), 6.12 (dd, 
J = 8.5, 2.5 Hz, 1H), 5.87 (s, 2H), 4.66 (dd, J = 5.3, 1.2 Hz, 2H), 4.45 (s, 1H), 4.24 (s, 1H), 3.87 
(s, 3H), 3.58 (dd, J = 9.5, 2.9 Hz, 1H), 3.44 (dd, J = 9.5, 6.6 Hz, 1H), 2.85 – 2.68 (m, 3H), 2.09 
(dtd, J = 11.4, 7.0, 2.9 Hz, 1H), 1.87 – 1.66 (m, 1H), 1.50 (s, 9H). MS (ESI+) m/z: 566.7 (M+1). 
 
tert-Butyl (3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluoro-3-(((1-methyl-1H-
pyrazol-5-yl)methyl)carbamoyl)phenyl)piperidine-1-carboxylate (72w) Compound 72w was 
synthesized as described for intermediate 72a from intermediate 70 replacing methylamine with 
(1-methyl-1H-pyrazol-5-yl)methanamine (67% yield).   
1
H NMR (500 MHz, Chloroform-d) δ 
7.94 (dd, J = 7.5, 2.4 Hz, 1H), 7.42 (d, J = 1.8 Hz, 1H), 7.30 (ddd, J = 7.8, 4.8, 2.4 Hz, 1H), 7.05 
(dd, J = 11.6, 8.4 Hz, 1H), 6.91 (dt, J = 12.2, 5.5 Hz, 1H), 6.62 (d, J = 8.7 Hz, 1H), 6.33 (dd, J = 
2.5, 0.8 Hz, 1H), 6.23 (d, J = 1.8 Hz, 1H), 6.13 (dd, J = 8.5, 1.7 Hz, 1H), 5.87 (s, 2H), 4.71 (d, J 
= 5.4 Hz, 2H), 4.44 (s, 1H), 4.23 (d, J = 19.4 Hz, 1H), 3.89 (d, J = 0.8 Hz, 3H), 3.59 (dd, J = 9.5, 
2.8 Hz, 1H), 3.44 (dd, J = 9.5, 6.4 Hz, 1H), 2.85 – 2.71 (m, 3H), 2.09 (dtq, J = 10.6, 6.5, 3.4 Hz, 




((benzo[d][1,3]dioxol-5-yloxy)methyl)piperidine-1-carboxylate (72x) Compound 72x was 
synthesized as described for intermediate 72a from intermediate 70 replacing methylamine with 
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(1H-pyrazol-4-yl)methanamine (41% yield).   
1
H NMR (500 MHz, Chloroform-d) δ 7.94 (dd, J = 
7.5, 2.4 Hz, 1H), 7.63 – 7.61 (m, 2H), 7.28 – 7.25 (m, 1H), 7.02 (dd, J = 11.6, 8.4 Hz, 1H), 6.94 
(dt, J = 12.0, 5.5 Hz, 1H), 6.61 (d, J = 8.4 Hz, 1H), 6.33 (d, J = 2.5 Hz, 1H), 6.12 (dd, J = 8.5, 
2.5 Hz, 1H), 5.87 (s, 2H), 4.57 (d, J = 4.7 Hz, 1H), 4.44 (s, 1H), 4.24 (s, 1H), 3.58 (dd, J = 9.5, 
2.8 Hz, 1H), 3.44 (dd, J = 9.5, 6.5 Hz, 1H), 2.85 – 2.70 (m, 3H), 2.13 – 2.04 (m, 1H), 1.83 – 1.65 
(m, 2H), 1.50 (s, 9H). MS (ESI+) m/z: 552.8 (M+1). 
 
(3S,4R)-tert-Butyl 4-(3-((2-(1H-pyrazol-4-yl)ethyl)carbamoyl)-4-fluorophenyl)-3-
((benzo[d][1,3]dioxol-5-yloxy)methyl)piperidine-1-carboxylate (72y). Compound 72y was 
synthesized as described for intermediate 72a from intermediate 70 replacing pyridin-2-
ylmethanamine with 2-(1H-pyrazol-4-yl)ethan-1-amine (36% yield).  
1
H NMR (500 MHz, 
Methanol-d4) δ 7.55 (dd, J = 6.9, 2.4 Hz, 1H), 7.50 (s, 2H), 7.39 (ddd, J = 8.5, 4.8, 2.4 Hz, 1H), 
7.13 (dd, J = 10.6, 8.5 Hz, 1H), 6.61 (d, J = 8.5 Hz, 1H), 6.36 (d, J = 2.5 Hz, 1H), 6.16 (dd, J = 
8.5, 2.5 Hz, 1H), 5.84 (s, 2H), 4.42 (d, J = 13.2 Hz, 1H), 4.25 – 4.16 (m, 1H), 3.60 (dd, J = 9.8, 
3.0 Hz, 1H), 3.57 – 3.51 (m, 3H), 2.86 (bs, 2H), 2.83 – 2.78 (m, 3H), 2.06 (dtq, J = 11.0, 7.1, 3.8 




((benzo[d][1,3]dioxol-5-yloxy)methyl)piperidine-1-carboxylate (72y). Compound 72y was 
synthesized as described for intermediate 72a from intermediate 70 replacing pyridin-2-
ylmethanamine with 2-(1H-pyrazol-4-yl)ethan-1-amine (36% yield).  
1
H NMR (500 MHz, 
Methanol-d4) δ 7.55 (dd, J = 6.9, 2.4 Hz, 1H), 7.50 (s, 2H), 7.39 (ddd, J = 8.5, 4.8, 2.4 Hz, 1H), 
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7.13 (dd, J = 10.6, 8.5 Hz, 1H), 6.61 (d, J = 8.5 Hz, 1H), 6.36 (d, J = 2.5 Hz, 1H), 6.16 (dd, J = 
8.5, 2.5 Hz, 1H), 5.84 (s, 2H), 4.42 (d, J = 13.2 Hz, 1H), 4.25 – 4.16 (m, 1H), 3.60 (dd, J = 9.8, 
3.0 Hz, 1H), 3.57 – 3.51 (m, 3H), 2.86 (bs, 2H), 2.83 – 2.78 (m, 3H), 2.06 (dtq, J = 11.0, 7.1, 3.8 




bis(trifluoromethyl)benzyl)carbamoyl)-4-fluorophenyl)piperidine-1-carboxylate (72z – 5-10). 
Compound 72z was synthesized as described for intermediate 72a from intermediate 70 
replacing pyridine-2-ylmethanamine with 2,6 – ditrifluoromethylamine (79% yield). 
1
H NMR 
(400 MHz, Methanol-d4) δ 8.06 (d, J = 8.0 Hz, 2H), 7.75 (t, J = 8.0 Hz, 1H), 7.46 (dd, J = 6.8, 
2.3 Hz, 1H), 7.36 (ddd, J = 8.5, 4.8, 2.4 Hz, 1H), 7.08 (dd, J = 10.3, 8.5 Hz, 1H), 6.59 (d, J = 8.5 
Hz, 1H), 6.34 (d, J = 2.4 Hz, 1H), 6.14 (dd, J = 8.5, 2.5 Hz, 1H), 5.84 (d, J = 0.8 Hz, 2H), 4.85 
(s, 2H), 4.44 – 4.35 (m, 1H), 4.18 (dp, J = 13.4, 2.0 Hz, 1H), 3.58 (dd, J = 9.8, 2.9 Hz, 1H), 3.49 
(dd, J = 9.8, 7.0 Hz, 1H), 2.88 (s, 1H), 2.77 (td, J = 11.7, 3.9 Hz, 2H), 2.03 (ddq, J = 10.5, 7.0, 
3.2 Hz, 1H), 1.77 (dd, J = 13.2, 3.4 Hz, 1H), 1.69 (td, J = 12.6, 4.3 Hz, 1H), 1.48 (s, 9H). HPLC 
purity: 98%. MS (ESI+) m/z: 713.4 (M+1). 
 
tert-butyl (3S,4R)-4-(3-(((1H-indazol-3-yl)methyl)carbamoyl)-4-fluorophenyl)-3-
((benzo[d][1,3]dioxol-5-yloxy)methyl)piperidine-1-carboxylate (72aa – 9-47). Compound 72aa 
was synthesized as described for intermediate 72a from intermediate 70 replacing pyridine-2-
ylmethanamine with 3H – (aminomethyl) – 1H – indazole using a purification step of 40% 
EtOAc/Hexanes (104 mg, 82% yield). 
1
H NMR (400 MHz, Methanol-d4) δ 7.97 (s, 1H), 7.85 (d, 
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J = 8.2 Hz, 1H), 7.60 (d, J = 6.9 Hz, 1H), 7.48 (d, J = 8.4 Hz, 1H), 7.37 (t, J = 7.8 Hz, 2H), 7.11 
(t, J = 7.7 Hz, 2H), 6.57 (d, J = 8.5 Hz, 1H), 6.33 (d, J = 2.2 Hz, 1H), 6.13 (dd, J = 8.9, 2.4 Hz, 
1H), 5.82 (s, 2H), 4.94 (s, 2H), 4.40 (d, J = 13.0 Hz, 1H), 4.18 (d, J = 13.6 Hz, 1H), 3.57 (d, J = 
9.4 Hz, 1H), 3.49 (t, J = 8.6 Hz, 1H), 2.88 (s, 1H), 2.82 – 2.71 (m, 2H), 2.05 (s, 1H), 1.76 (s, 
1H), 1.75 – 1.61 (m, 1H), 1.48 (s, 9H). HPLC purity: 98%.   
 
Intermediate compounds 73 
(3S,4R)-tert-Butyl-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluoro-3-(2-((2-
methoxybenzyl)amino)-2-oxoethyl)phenyl)piperidine-1-carboxylate  (73a). 2-(5-((3S,4R)-3-
((benzo[d][1,3]dioxol-5-yloxy)methyl)-1-(tert-butoxycarbonyl)piperidin-4-yl)-2-
fluorophenyl)acetic acid 71 (0.060 g, 0.123 mmol), 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (0.027 g, 0.172 mmol), N,N-diisopropylethylamine 
(0.021mL, 0.123 mmol), 1-hydroxybenzotriazole (0.008 g, 0.062 mmol) and 2-
methoxybenzylamine (0.038 mL, 0.369 mmol) were added to THF (5 mL) in a 15 mL round 
bottom flask and stirred overnight at room temperature. Diluted with ethyl acetate and saturated 
sodium bicarbonate and then separated the layers. The organic layer was then washed with 10% 
citric acid (1x), brine (2x), dried with MgSO4, and concentrated in vacuo. Purified using flash 
chromatography in a gradient of 20% - 50% EtOAc/Hexanes to give as an amorphous solid 
(3S,4R)-tert-butyl 3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluoro-3-(2-((2-
methoxybenzyl)amino)-2-oxoethyl)phenyl)piperidine-1-carboxylate (0.030 g, 41% yield). 
1
H 
NMR (CDCl3, 400 MHz) δ:  7.24 (dd, J = 8.0, 4.0 Hz, 1H), 7.20 (dd, J = 8.0, 4.0 Hz, 1H), 7.11-
7.04 (m. 2H), 7.0 – 6.95 (m, 1H), 6.88 (t, J = 6.0 Hz, 1H), 6.83 (d, J = 8.0 Hz, 1H), 6.61 (d, J = 
8.0 Hz, 1H), 6.33 (d, J = 2.0 Hz, 1H), 6.12 (dd, J = 8.0, 4.0 Hz, 1H), 6.04 (bs, 1H), 5.87 (s, 2H), 
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4.42-4.39 (m, 2H), 4.23 (bs, 1H), 3.75 (s, 3H), 3.65-3.44 (m, 3H), 3.41 (dd, J = 10.0, 8.0 Hz, 
1H), 2.78 (bs, 2H), 2.63 (t, J = 12.0 Hz, 1H), 1.98 (bs, 1H), 1.88-1.63 (m, 3H), 1.50 (s, 9H). MS 
(ESI+) m/z: 606.4 (M+1) 
 
(3S,4R)-tert-Butyl 3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluoro-3-(2-oxo-2-((pyridin-2-
ylmethyl)amino)ethyl)phenyl)piperidine-1-carboxylate (73b). Compound 73b was prepared as 
described for compound 73a replacing 2-methoxy benzyl amine with pyridin-2-ylmethanamine 
(36% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 8.44 (d, J = 4.9 Hz, 1H), 7.65 (t, J = 7.7 Hz, 
1H), 7.24 (d, J = 8.1 Hz, 1H), 7.20 – 7.11 (m, 2H), 7.07 (s, 1H), 6.99 (t, J = 8.9 Hz, 1H), 6.89 (d, 
J = 5.2 Hz, 1H), 6.59 (d, J = 8.1 Hz, 1H), 6.33 (d, J = 2.6 Hz, 1H), 6.17 – 6.08 (m, 1H), 5.87 (s, 
2H), 4.52 (d, J = 4.9 Hz, 2H), 4.43 (s, 1H), 4.24 (s, 1H), 3.65 – 3.57 (m, 2H), 3.45 (m, 1H), 2.80 
(m, 2H), 2.65 (dd, J = 14.0, 10.2 Hz, 1H), 2.13 (bs, 1H), 2.0 (m, 1H), 1.78 (m, 1H), 1.69 (dd, J = 
12.6, 4.2 Hz, 1H), 1.49 (s, 9H). MS (ESI+) m/z: 577.4 (M+1) 
 
(3S,4R)-tert-Butyl 3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluoro-3-(2-oxo-2-((2-(pyridin-
2-yl)ethyl)amino)ethyl)phenyl)piperidine-1-carboxylate (73c). Compound 73c was prepared as 
described for compound 73a replacing 2-methoxy benzyl amine with 2-(pyridin-2-yl)ethan-1-
amine (17% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 8.40 (s, 1H), 7.79 – 7.68 (m, 1H), 7.08 
– 6.99 (m, 2H), 6.91 (t, J = 9.0 Hz, 1H), 6.58 (d, J = 8.3 Hz, 1H), 6.30 (s, 1H), 6.09 (d, J = 8.5 
Hz, 1H), 5.84 (s, 2H), 4.40 (s, 1H), 4.21 (s, 1H), 3.65 – 3.33 (m, 4H), 3.05 – 2.55 (m, 7H), 1.99 







Compound 73d was 
prepared as described for compound 73a replacing 2-methoxy benzyl amine with 2-(1H-pyrazol-
4-yl)ethan-1-amine (65% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 7.32 (s, 2H), 7.05 (s, 2H), 
6.98 (t, J = 8.6 Hz, 1H), 6.62 (d, J = 8.3 Hz, 1H), 6.33 (s, 1H), 6.13 (d, J = 8.1 Hz, 1H), 5.87 (s, 
2H), 5.55 (s, 1H), 4.42 (s, 1H), 4.24 (s, 1H), 3.57 (d, J = 8.6 Hz, 2H), 3.50 (d, J = 6.9 Hz, 3H), 
3.41 (s, 3H), 2.79 (s, 2H), 2.65 (s, 2H), 1.93 (s, 1H), 1.77 (d, J = 12.5 Hz, 1H), 1.51 (s, 9H). MS 
(ESI+) m/z: 581.4 (M+1) 
tert-butyl (3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(3-(2-((2,6-difluorobenzyl)amino)-
2-oxoethyl)-4-fluorophenyl)piperidine-1-carboxylate (73e – 1-81).
 
Compound 73e was prepared 
as described for compound 73a replacing 2-methoxy benzyl amine with (2,6-
difluorophenyl)methanamine (36% yield). 
1
H NMR (500 MHz, Chloroform-d) δ 7.22 (tt, J = 8.4, 
6.4 Hz, 1H), 7.12 – 7.02 (m, 2H), 6.97 (dd, J = 9.5, 8.4 Hz, 1H), 6.90 – 6.81 (m, 2H), 6.62 (d, J = 
8.5 Hz, 1H), 6.32 (d, J = 2.5 Hz, 1H), 6.13 (dd, J = 8.5, 2.5 Hz, 1H), 5.87 (q, J = 1.5 Hz, 2H), 
5.84 (s, 1H), 4.60 – 4.46 (m, 2H), 4.42 (s, 1H), 4.23 (s, 1H), 3.61 – 3.54 (m, 1H), 3.55 – 3.46 (m, 
2H), 3.42 (dd, J = 9.6, 6.6 Hz, 1H), 2.81 – 2.74 (m, 2H), 2.63 (td, J = 11.8, 3.8 Hz, 1H), 2.01 – 
1.93 (m, 1H), 1.76 (dd, J = 13.1, 3.3 Hz, 1H), 1.67 (td, J = 12.7, 4.4 Hz, 1H), 1.50 (s, 9H). HPLC 
purity: 93% MS (ESI+) m/z: 613.1 (M+1), 635.1 (M+Na).  
 
tert-butyl (3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(3-(2-((2,6-
difluorophenethyl)amino)-2-oxoethyl)-4-fluorophenyl)piperidine-1-carboxylate (73f – 1-82).
 
Compound 73f was prepared as described for compound 73a replacing 2-methoxy benzyl amine 
with (2,6-difluorophenyl)ethanamine (74% yield). 
1
H NMR (500 MHz, Chloroform-d) δ 7.19 – 
7.05 (m, 3H), 6.97 (t, J = 8.7 Hz, 1H), 6.81 (t, J = 7.6 Hz, 2H), 6.61 (d, J = 8.4 Hz, 1H), 6.33 (d, 
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J = 2.3 Hz, 1H), 6.12 (dd, J = 8.8, 2.2 Hz, 1H), 5.86 (s, 2H), 5.58 (broad s, 1H),  4.43 (broad s, 
1H), 4.24 (broad s, 1H), 3.61 – 3.54 (m, 1H), 3.55 – 3.42 (m, 4H), 2.85 – 2.61 (m, 3H), 2.66 (td, 
J = 11.8, 3.8 Hz, 1H), 2.01 – 1.95 (m, 1H), 1.77 – 1.76 (m, 1H), 1.70 (td, J = 12.7, 4.4 Hz, 1H), 
1.50 (s, 9H). HPLC purity: 92% MS (ESI+) m/z: 627.2 (M+1), 649.1 (M+Na).  
 
tert-butyl (3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(3-(2-((3-chlorobenzyl)amino)-2-
oxoethyl)-4-fluorophenyl)piperidine-1-carboxylate (73g – 2-04). Compound 73g was prepared as 
described for compound 73a replacing 2-methoxy benzyl amine with (3-
chlorophenyl)methanamine (39% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 7.26 – 7.16 (m, 
2H), 7.18 – 7.03 (m, 4H), 7.00 (t, J = 8.9 Hz, 1H), 6.61 (d, J = 8.5 Hz, 1H), 6.32 (d, J = 2.5 Hz, 
1H), 6.11 (dd, J = 8.4, 2.5 Hz, 1H), 5.90 (t, J = 5.9 Hz, 1H), 5.87 (s, 2H), 4.55 – 4.28 (m, 3H), 
4.23 (s, 1H), 3.65 – 3.51 (m, 3H), 3.42 (dd, J = 9.5, 6.4 Hz, 1H), 2.79 (s, 2H), 2.66 (td, J = 11.8, 
3.8 Hz, 1H), 1.98 (ddt, J = 10.5, 7.0, 3.6 Hz, 1H), 1.83 – 1.60 (m, 2H), 1.50 (s, 9H). HPLC 
purity: 98% MS (ESI+) m/z: 611.2 (M+1), 633.1 (M+Na).  
 
tert-butyl (3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluoro-3-(2-oxo-2-((2-(pyridin-
2-yl)ethyl)amino)ethyl)phenyl)piperidine-1-carboxylate (73h – 2-08). Compound 73h was 
prepared as described for compound 73a replacing 2-methoxy benzylamine with 2-(pyridin-2-
yl)ethan-1-amine (17% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 8.40 (s, 1H), 7.75 (s, 1H), 
7.06 (d, J = 9.2 Hz, 2H), 6.91 (s, 1H), 6.58 (d, J = 8.3 Hz, 1H), 6.31 (d, J = 2.1 Hz, 1H), 6.09 (d, 
J = 8.3 Hz, 1H), 5.84 (s, 2H), 4.41 (s, 1H), 4.21 (s, 1H), 3.64 – 3.37 (m, 4H), 2.99 (s, 1H), 2.82 – 
2.56 (m, 6H), 1.98 (s, 1H), 1.83 – 1.58 (m, 2H), 1.48 (s, 9H). 





Final compounds 74 
5-((3S,4R)-3-((Benzo[d][1,3]dioxol-5-yloxy)methyl)piperidin-4-yl)-2-fluoro-N-methylbenzamide 
(74a – 258753 – 9-78). tert-Butyl (3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluoro-
3-(methylcarbamoyl)phenyl)piperidine-1-carboxylate (72a) (0.07 g, 0.144 mmol) was dissolved 
in 1,4-dioxanes (2 mL) followed by 4M HCl/1,4-dioxanes (2 mL) and stirred at room 
temperature for two hours. The reaction was concentrated in vacuo, then purified using 0-20% 
MeOH (3 M ammonia)/dichloromethane to give 5-((3S,4R)-3-((benzo[d][1,3]dioxol-5-
yloxy)methyl)piperidin-4-yl)-2-fluoro-N-methylbenzamide as a white solid (0.025 g, 0.064 
mmol, 44% yield). 
1
H NMR (400 MHz, Methanol-d4) δ 7.61 (dd, J = 7.0, 2.3 Hz, 1H), 7.40 (d, J 
= 9.1 Hz, 1H), 7.13 (dd, J = 10.7, 8.5 Hz, 1H), 6.60 (d, J = 8.5 Hz, 1H), 6.33 (d, J = 2.5 Hz, 1H), 
6.14 (dd, J = 8.5, 2.5 Hz, 1H), 5.84 (s, 2H), 3.70 – 3.64 (m, 1H), 3.56 (dt, J = 9.0, 3.9 Hz, 2H), 
3.49 (dd, J = 9.7, 6.5 Hz, 1H), 3.39 – 3.32 (m, 1H), 2.91 (s, 3H), 2.76 (dd, J = 11.9, 5.0 Hz, 2H), 
2.13 (bs, 1H), 1.85 – 1.73 (m, 2H). MS (ESI+) m/z: 387.2 (M+1).  HPLC purity: 95%. 
 
5-((3S,4R)-3-((Benzo[d][1,3]dioxol-5-yloxy)methyl)piperidin-4-yl)-N-benzyl-2-fluorobenzamide 
(74b – 258202 – 8-81). Prepared from Intermediate 72b as described for compound 74a (76% 
yield). 
1
H NMR (400 MHz, Methanol-d4) δ 7.61 (dd, J = 6.9, 2.4 Hz, 1H), 7.41 (ddd, J = 8.5, 
4.8, 2.4 Hz, 1H), 7.37 – 7.28 (m, 4H), 7.27 – 7.22 (m, 1H), 7.15 (dd, J = 10.6, 8.5 Hz, 1H), 6.59 
(d, J = 8.5 Hz, 1H), 6.35 (d, J = 2.5 Hz, 1H), 6.14 (dd, J = 8.5, 2.5 Hz, 1H), 5.83 (d, J = 1.3 Hz, 
2H), 4.57 (s, 2H), 3.59 (dd, J = 9.7, 3.0 Hz, 1H), 3.50 (dd, J = 9.7, 6.5 Hz, 1H), 3.42 (dd, J = 
12.5, 3.8 Hz, 1H), 3.23 (d, J = 12.5 Hz, 1H), 2.90 – 2.76 (m, 3H), 2.19 (dtd, J = 16.0, 8.1, 4.0 Hz, 
206 
 
1H), 1.89 – 1.82 (m, 2H). MS (ESI+) m/z: 463.2 (M+1). HPLC purity: 95%. 
 
5-((3S,4R)-3-((Benzo[d][1,3]dioxol-5-yloxy)methyl)piperidin-4-yl)-2-fluoro-N-
phenethylbenzamide (74c – 258201 – 8-80). Prepared from Intermediate 72c as described for 
compound 74a (76% yield). 
1
H NMR (400 MHz, Methanol-d4) δ 7.54 (dd, J = 7.0, 2.4 Hz, 1H), 
7.39 (ddd, J = 8.5, 4.8, 2.4 Hz, 1H), 7.30 – 7.23 (m, 4H), 7.22 – 7.16 (m, 1H), 7.11 (dd, J = 10.6, 
8.5 Hz, 1H), 6.60 (d, J = 8.5 Hz, 1H), 6.34 (d, J = 2.4 Hz, 1H), 6.14 (dd, J = 8.5, 2.5 Hz, 1H), 
5.82 (s, 2H), 3.62 – 3.54 (m, 3H), 3.47 (dd, J = 9.6, 6.6 Hz, 1H), 3.39 – 3.32 (m, 1H), 3.17 – 3.10 
(m, 1H), 2.89 (dd, J = 8.1, 6.7 Hz, 2H), 2.80 – 2.64 (m, 3H), 2.11 (dtd, J = 11.0, 7.3, 3.3 Hz, 1H), 
1.83 – 1.71 (m, 2H). MS (ESI+) m/z: 477.2 (M+1). HPLC purity: 95%. 
 
5-((3S,4R)-3-((Benzo[d][1,3]dioxol-5-yloxy)methyl)piperidin-4-yl)-N-(2,6-difluorobenzyl)-2-
fluorobenzamide hydrochloride (74d - 208947). Prepared from Intermediate 72d as described for 
compound 74a (78 % yield).
1
H NMR (CDCl3, 400MHz) δ 7.98 (dd, J = 7.6, 2.4 Hz, 1H), 7.26 (s, 
5H), 7.14 (s, 1H), 7.02 (dd, J = 11.8, 8.4 Hz, 1H), 6.91 (t, J = 7.8 Hz, 2H), 6.60 (d, J = 8.4 Hz, 
1H), 6.10 (dd, J = 8.5, 2.5 Hz, 1H), 5.86 (s, 2H), 4.77 (d, J = 5.7 Hz, 2H), 3.53- 3.40 (m, 3H), 
3.19- 3.16 (m, 1H), 2.70 – 2.63 (m, 2H), 2.12 (s, 1H), 1.77- 1.67 (m, 3H). MS (ESI+) m/z: 499.3 
(M+1). HPLC purity: 97%. 
 
5-((3S,4R)-3-((Benzo[d][1,3]dioxol-5-yloxy)methyl)piperidin-4-yl)-N-(2,6-difluorophenethyl)-2-
fluorobenzamide (74e -211990). Prepared from Intermediate 72e as described for compound 74a 
(50% yield). 
1
H NMR (CDCl3, 400MHz) δ 7.98 (dd, J = 7.6, 2.4 Hz, 1H), 7.26 (s, 5H), 7.14 (s, 
1H), 7.02 (dd, J = 11.8, 8.4 Hz, 1H), 6.91 (t, J = 7.8 Hz, 2H), 6.60 (d, J = 8.4 Hz, 1H), 6.10 (dd, 
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J = 8.5, 2.5 Hz, 1H), 5.86 (s, 2H), 4.77 (d, J = 5.7 Hz, 2H), 3.53- 3.40 (m, 3H), 3.19- 3.16 (m, 




(trifluoromethyl)benzyl)benzamide (74f - 211991). Prepared from Intermediate 72f as described 
for compound 72a (83% yield). 
1
H NMR (400 MHz, Methanol-d4) δ 8.75 (s, 2H), 7.81 – 7.01 
(m, 9H), 6.94 (d, J = 11.2 Hz, 2H), 6.37 (s, 2H), 5.91 (d, J = 35.8 Hz, 2H), 4.77 (s, 3H), 4.06 – 
3.33 (m, 5H), 2.88 (s, 3H), 2.05 (s, 2H), 1.78 (s, 2H), 1.41 – 0.82 (m, 9H), 5.01 – 4.91 (m, 1H). 
MS (ESI+) m/z 530.1 (M+1) HPLC purity: 96%.  
 
5-((3S,4R)-3-((Benzo[d][1,3]dioxol-5-yloxy)methyl)piperidin-4-yl)-N-(2,6-dimethylbenzyl)-2-
fluorobenzamide hydrochloride (74g – 232403 – 5-11). Prepared from intermediate 72g as 
described for compound 74a (92% yield) 
1
H NMR (500 MHz, Methanol-d4) δ 7.54 (dd, J = 6.7, 
2.2 Hz, 1H), 7.41 (ddd, J = 8.5, 4.7, 2.3 Hz, 1H), 7.13 (dd, J = 10.2, 8.5 Hz, 1H), 7.08 (dd, J = 
8.6, 6.2 Hz, 1H), 7.02 (d, J = 8.2 Hz, 2H), 6.60 (d, J = 8.4 Hz, 1H), 6.38 (d, J = 2.4 Hz, 1H), 6.17 
(dd, J = 8.5, 2.5 Hz, 1H), 5.85 – 5.83 (m, 2H), 4.60 (s, 2H), 3.69 – 3.65 (m, 2H), 3.54 (ddd, J = 
12.6, 9.8, 4.2 Hz, 2H), 3.16 (td, J = 12.2, 5.2 Hz, 2H), 3.03 (td, J = 11.2, 5.4 Hz, 1H), 2.45 (dddd, 
J = 14.6, 11.2, 6.2, 3.2 Hz, 1H), 2.38 (s, 6H), 2.10 – 2.02 (m, 2H). MS (ESI+) m/z: 491.2 (M+1). 
HPLC purity: 98%. 
 
5-((3S,4R)-3-((Benzo[d][1,3]dioxol-5-yloxy)methyl)piperidin-4-yl)-N-(2,6-dichlorobenzyl)-2-





H NMR (CD3OD, 400 MHz) δ 7.57 (dd, J = 6.9, 2.4 Hz, 1H), 7.45-7.37 (m, 3H), 
7.30 (dd, J = 8.6, 7.6 Hz, 1H), 7.15 (dd, J = 10.4, 8.5 Hz, 1H), 6.61 (d, J = 8.5 Hz, 1H), 6.39 (d, J 
= 2.4 Hz, 1H), 6.17 (dd, J = 8.5, 2.5 Hz, 1H), 5.86 (d, J = 1.2 Hz, 2H), 4.87 (s, 2H), 3.70 – 3.63 
(m, 2H), 3.61 – 3.44 (m, 2H), 3.16 (td, J = 12.5, 3.9 Hz, 2H), 3.03 (td, J = 11.5, 4.6 Hz, 1H), 




fluorobenzamide hydrochloride (74i – 232402 – 5-48). Prepared from Intermediate 72i as 
described for compound 74a. (91% yield) 
1
H NMR (500 MHz, Methanol-d4) δ 7.67 (dd, J = 7.0, 
2.4 Hz, 1H), 7.41 (ddd, J = 8.4, 4.8, 2.4 Hz, 1H), 7.25 (t, J = 8.4 Hz, 1H), 7.15 (dd, J = 11.0, 8.5 
Hz, 1H), 6.65 (d, J = 8.3 Hz, 2H), 6.60 (d, J = 8.5 Hz, 1H), 6.37 (d, J = 2.4 Hz, 1H), 6.17 (dd, J = 
8.5, 2.5 Hz, 1H), 5.84 (t, J = 1.6 Hz, 2H), 4.66 (d, J = 2.5 Hz, 2H), 3.84 (s, 6H), 3.67 (dd, J = 9.6, 
3.3 Hz, 2H), 3.62 – 3.49 (m, 2H), 3.16 (td, J = 12.3, 3.3 Hz, 2H), 3.02 (td, J = 11.2, 5.5 Hz, 1H), 




methoxybenzyl)benzamide hydrochloride (74j - 211993). Prepared from Intermediate 72j as 
described for compound 74a. (68%yield) 
1
H NMR (CDCl3, 400MHz) δ 7.97 (m, 1H), 7.44 (m, 
1H), 7.38 – 7.22 (m, 4H), 7.04 (m, 2H), 6.98 – 6.79 (m, 2H), 6.20 (s, 1H), 5.87 (s, 2H), 4.67 (d, J 
= 5.9 Hz, 2H), 3.89 (s, 3H), 3.57 (m, 1H), 3.48- 3.39 (m, 3H), 3.19 (m, 1H), 2.72 – 2.57 (m, 1H), 






ylmethyl)benzamide hydrochloride (74k - 211998). Prepared from Intermediate 72k as described 
for compound 74a. (34% yield). 
1
H NMR (400 MHz, Methanol-d4) δ 8.80 (s, 1H), 8.58 (t, J = 
7.8 Hz, 1H), 8.06 (m, 1H), 7.98 (m,  1H), 7.91 – 7.67 (m, 1H), 7.51 (m,  1H), 7.26 (dd, J = 10.9, 
8.5 Hz, 1H), 6.61 (d, J = 8.4 Hz, 1H), 6.39 (m, 1H), 6.18 (m, 1H), 5.85 (s, 2H), 4.92 (s, 2H), 3.68 
– 3.66 (m, 2H), 3.58- 3.51 (m, 2H), 3.21-3.14 (m, 2H), 2.48 (m, 1H), 2.07-1.28  (m, 3H).  MS 
(ESI+) m/z: 464.2 (M+1). HPLC purity: 95%. 
 
5-((3S,4R)-3-((Benzo[d][1,3]dioxol-5-yloxy)methyl)piperidin-4-yl)-2-fluoro-N-(pyridin-3-
ylmethyl)benzamide (74l – 258203 – 8 - 82). Prepared from Intermediate 72l as described for 
compound 74a (87% yield) 
1
H NMR (400 MHz, Methanol-d4) δ 8.57 (d, J = 2.2 Hz, 1H), 8.44 
(dd, J = 4.9, 1.6 Hz, 1H), 7.85 (dt, J = 8.0, 1.9 Hz, 1H), 7.65 (dd, J = 6.9, 2.4 Hz, 1H), 7.44 (ddd, 
J = 12.8, 7.9, 4.8 Hz, 2H), 7.20 (dd, J = 10.5, 8.5 Hz, 1H), 6.61 (d, J = 8.5 Hz, 1H), 6.38 (d, J = 
2.5 Hz, 1H), 6.17 (dd, J = 8.5, 2.5 Hz, 1H), 5.85 (s, 2H), 4.61 (s, 2H), 3.64 (td, J = 11.6, 10.6, 3.1 
Hz, 2H), 3.55 (dd, J = 9.9, 6.0 Hz, 1H), 3.47 (d, J = 12.8 Hz, 1H), 3.19 – 3.04 (m, 2H), 3.07 – 




ylmethyl)benzamide (74m – 258204 – 8 - 83). Prepared from Intermediate 72m as described for 
compound 74a (57% yield) 
1
H NMR (400 MHz, Methanol-d4) δ 8.49 – 8.44 (m, 2H), 7.65 (dd, J 
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= 6.9, 2.4 Hz, 1H), 7.44 (ddd, J = 8.5, 4.8, 2.4 Hz, 1H), 7.41 – 7.37 (m, 2H), 7.18 (dd, J = 10.6, 
8.5 Hz, 1H), 6.59 (d, J = 8.5 Hz, 1H), 6.34 (d, J = 2.5 Hz, 1H), 6.14 (dd, J = 8.5, 2.5 Hz, 1H), 
5.83 (d, J = 1.4 Hz, 2H), 4.62 (s, 2H), 3.58 (dd, J = 9.7, 3.0 Hz, 1H), 3.49 (dd, J = 9.7, 6.4 Hz, 
1H), 3.37 (dd, J = 12.7, 3.8 Hz, 1H), 3.22 – 3.14 (m, 1H), 2.85 – 2.69 (m, 3H), 2.21 – 2.11 (m, 
1H), 1.86 – 1.75 (m, 2H). MS (ESI+) m/z: 464.2 (M+1). HPLC purity: 95%. 
 
5-((3S,4R)-3-((Benzo[d][1,3]dioxol-5-yloxy)methyl)piperidin-4-yl)-2-fluoro-N-(2-(pyridin-2-
yl)ethyl)benzamide (74n – 258205 – 8-84). Prepared from Intermediate 72n as described for 
compound 74a (24% yield).  
1
H NMR (400 MHz, Methanol-d4) δ 8.46 (ddd, J = 5.0, 1.8, 1.0 Hz, 
1H), 7.76 (td, J = 7.7, 1.8 Hz, 1H), 7.59 (dd, J = 6.9, 2.4 Hz, 1H), 7.42 (ddd, J = 8.5, 4.7, 2.4 Hz, 
1H), 7.36 (dt, J = 7.8, 1.1 Hz, 1H), 7.27 (ddd, J = 7.5, 5.0, 1.2 Hz, 1H), 7.17 (dd, J = 10.5, 8.6 
Hz, 1H), 6.63 (d, J = 8.5 Hz, 1H), 6.40 (d, J = 2.5 Hz, 1H), 6.19 (dd, J = 8.5, 2.5 Hz, 1H), 5.85 
(s, 2H), 3.74 (t, J = 7.1 Hz, 2H), 3.71 – 3.63 (m, 2H), 3.60 – 3.49 (m, 2H), 3.21 – 3.11 (m, 2H), 
3.08 (t, J = 7.1 Hz, 2H), 3.02 (dd, J = 11.1, 5.8 Hz, 1H), 2.48 – 2.37 (m, 1H), 2.09 – 2.00 (m, 
2H). MS (ESI+) m/z: 478.2 (M+1). HPLC purity: 97%. 
 
5-((3S,4R)-3-((Benzo[d][1,3]dioxol-5-yloxy)methyl)piperidin-4-yl)-2-fluoro-N-(2-(pyridin-3-
yl)ethyl)benzamide (74o – 258207 – 8-99). Prepared from Intermediate 72o as described for 
compound 74a (82% yield) 
1
H NMR (400 MHz, Methanol-d4) δ 8.45 (d, J = 1.7 Hz, 1H), 8.39 
(dd, J = 5.0, 1.6 Hz, 1H), 7.78 (dt, J = 7.9, 1.9 Hz, 1H), 7.52 (dd, J = 6.9, 2.4 Hz, 1H), 7.38 
(dddd, J = 10.7, 7.8, 4.9, 1.7 Hz, 2H), 7.13 (dd, J = 10.5, 8.5 Hz, 1H), 6.61 (d, J = 8.5 Hz, 1H), 
6.36 (d, J = 2.5 Hz, 1H), 6.16 (dd, J = 8.5, 2.5 Hz, 1H), 5.84 (d, J = 1.2 Hz, 2H), 3.64 (t, J = 7.0 
Hz, 2H), 3.59 (dd, J = 9.7, 3.0 Hz, 1H), 3.53 – 3.42 (m, 2H), 3.27 (d, J = 12.7 Hz, 1H), 2.95 (t, J 
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= 7.0 Hz, 2H), 2.86 (qd, J = 12.4, 11.8, 3.8 Hz, 3H), 2.21 (tq, J = 7.8, 4.4, 3.8 Hz, 1H), 1.91 – 
1.79 (m, 2H). MS (ESI+) m/z: 478.2 (M+1). HPLC purity: 96%. 
 
5-((3S,4R)-3-((Benzo[d][1,3]dioxol-5-yloxy)methyl)piperidin-4-yl)-2-fluoro-N-(2-(pyridin-4-
yl)ethyl)benzamide (74p – 258206 – 8-88). Prepared from Intermediate 72p as described for 
compound 74a (90% yield). 
1
H NMR (500 MHz, Methanol-d4) δ 8.44 (d, J = 5.1 Hz, 2H), 7.55 
(dd, J = 6.8, 2.4 Hz, 1H), 7.43 (ddd, J = 8.5, 4.8, 2.4 Hz, 1H), 7.39 – 7.35 (m, 2H), 7.17 (dd, J = 
10.5, 8.5 Hz, 1H), 6.63 (d, J = 8.5 Hz, 1H), 6.41 (d, J = 2.5 Hz, 1H), 6.19 (dd, J = 8.5, 2.5 Hz, 
1H), 5.85 (s, 2H), 3.72 – 3.64 (m, 4H), 3.59 – 3.50 (m, 2H), 3.22 – 3.14 (m, 2H), 3.04 (ddd, J = 
11.4, 9.3, 6.9 Hz, 1H), 2.98 (t, J = 7.1 Hz, 2H), 2.45 (dddt, J = 11.5, 8.4, 5.9, 3.2 Hz, 1H), 2.09 – 
2.02 (m, 2H). MS (ESI+) m/z: 478.2 (M+1). HPLC purity: 96%. 
 
N-((1H-Imidazol-2-yl)methyl)-5-((3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)piperidin-4-
yl)-2-fluorobenzamide (74q – 258209 – 9 - 11). Prepared from Intermediate 72q as described for 
compound 74a (78% yield). 
1
H NMR (400 MHz, Methanol-d4) δ 7.72 (dd, J = 6.9, 2.4 Hz, 1H), 
7.43 (ddd, J = 8.6, 4.8, 2.4 Hz, 1H), 7.17 (dd, J = 10.7, 8.5 Hz, 1H), 6.98 (s, 2H), 6.60 (d, J = 8.5 
Hz, 1H), 6.37 (d, J = 2.5 Hz, 1H), 6.16 (dd, J = 8.5, 2.5 Hz, 1H), 5.84 (d, J = 1.4 Hz, 2H), 4.62 
(s, 2H), 3.62 (td, J = 11.0, 10.4, 3.2 Hz, 2H), 3.54 (dd, J = 9.8, 6.3 Hz, 1H), 3.40 (d, J = 12.6 Hz, 
1H), 3.08 – 2.90 (m, 3H), 2.40 – 2.29 (m, 1H), 2.01 – 1.90 (m, 2H). MS (ESI+) m/z: 453.2 
(M+1). HPLC purity: 95%. 
 
N-(2-(1H-Imidazol-4-yl)ethyl)-5-((3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)piperidin-4-
yl)-2-fluorobenzamide (74r – 258210 – 9-17) Prepared from Intermediate 72r as described for 
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compound 74a (72% yield).
 1
H NMR (400 MHz, Methanol-d4) δ 7.57 (dd, J = 6.9, 2.2 Hz, 1H), 
7.40 (ddd, J = 8.4, 4.8, 2.4 Hz, 1H), 7.14 (dd, J = 10.6, 8.5 Hz, 1H), 7.62 – 7.59 (m, 1H), 6.89 (s, 
1H), 6.62 (d, J = 8.5 Hz, 1H), 6.37 (d, J = 2.5 Hz, 1H), 6.17 (dd, J = 8.5, 2.5 Hz, 1H), 5.84 (s, 
2H), 3.66 – 3.59 (m, 3H), 3.57 – 3.47 (m, 2H), 3.33 (d, J = 12.3 Hz, 2H), 3.01 – 2.84 (m, 5H), 
2.31 – 2.22 (m, 1H), 1.96 – 1.89 (m, 2H). MS (ESI+) m/z: 467.2 (M+1). HPLC purity: 95%. 
 
N-((1H-Pyrazol-5-yl)methyl)-5-((3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)piperidin-4-yl)- 
2-fluorobenzamide (74s – 258208 – 9 - 10). Prepared from Intermediate 72s as described for 
compound 74a (81% yield). 
1
H NMR (400 MHz, Methanol-d4) δ 7.64 (dd, J = 6.9, 2.4 Hz, 1H), 
7.57 (s, 1H), 7.42 (ddd, J = 8.5, 4.8, 2.4 Hz, 1H), 7.15 (dd, J = 10.6, 8.5 Hz, 1H), 6.60 (d, J = 8.5 
Hz, 1H), 6.36 (d, J = 2.5 Hz, 1H), 6.29 (d, J = 2.2 Hz, 1H), 6.15 (dd, J = 8.5, 2.5 Hz, 1H), 5.84 
(q, J = 1.1 Hz, 2H), 4.60 (s, 2H), 3.60 (dd, J = 9.7, 3.0 Hz, 1H), 3.51 (dd, J = 9.8, 6.4 Hz, 1H), 
3.45 (dd, J = 12.7, 3.8 Hz, 1H), 3.26 (d, J = 12.9 Hz, 1H), 2.92 – 2.80 (m, 3H), 2.27 – 2.16 (m, 
1H), 1.92 – 1.79 (m, 2H). MS (ESI+) m/z: 453.2 (M+1). HPLC purity: 95%. 
 
N-(2-(1H-Pyrazol-3-yl)ethyl)-5-((3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)piperidin-4-yl)-
2-fluorobenzamide (74t -258750 – 9-75). Prepared from Intermediate 72t as described for 
compound 74a  (90% yield). 
1
H NMR (400 MHz, Methanol-d4) δ 7.60 (dd, J = 6.9, 2.4 Hz, 1H), 
7.52 (d, J = 2.1 Hz, 1H), 7.41 (ddd, J = 8.4, 4.8, 2.4 Hz, 1H), 7.17 (dd, J = 10.6, 8.5 Hz, 1H), 
6.62 (d, J = 8.5 Hz, 1H), 6.39 (d, J = 2.5 Hz, 1H), 6.21 (d, J = 2.1 Hz, 1H), 6.18 (dd, J = 8.5, 2.5 
Hz, 1H), 5.85 (s, 2H), 3.71 – 3.61 (m, 4H), 3.58 – 3.48 (m, 2H), 3.16 (td, J = 12.5, 3.8 Hz, 2H), 
3.08 – 2.99 (m, 1H), 2.96 (t, J = 7.2 Hz, 2H), 2.41 (bs, 1H), 2.10 – 1.98 (m, 2H). MS (ESI+) m/z: 





pyrazol-3-yl)methyl)benzamide (74u – 258754 – 9-79). Prepared from Intermediate 72u as 
described for compound 74a (85% yield). 
1
H NMR (400 MHz, Methanol-d4) δ 7.66 (dd, J = 6.9, 
2.3 Hz, 1H), 7.42 (ddd, J = 7.5, 4.7, 2.4 Hz, 1H), 7.18 (dd, J = 10.5, 8.5 Hz, 1H), 6.61 (d, J = 8.5 
Hz, 1H), 6.39 (d, J = 2.5 Hz, 1H), 6.18 (dd, J = 8.5, 2.5 Hz, 1H), 6.04 (s, 1H), 5.85 (s, 2H), 4.52 
(s, 2H), 3.72 – 3.62 (m, 2H), 3.61 – 3.48 (m, 2H), 3.16 (t, J = 12.4 Hz, 2H), 3.03 (td, J = 11.5, 
4.5 Hz, 1H), 2.41 (bs, 1H), 2.25 (s, 3H), 2.04 (d, J = 13.0 Hz, 3H). MS (ESI+) m/z: 467.2 (M+1). 
HPLC purity: 97%. 
 
5-((3S,4R)-3-((Benzo[d][1,3]dioxol-5-yloxy)methyl)piperidin-4-yl)-2-fluoro-N-((1-methyl-1H-
pyrazol-3-yl)methyl)benzamide (74v – 259752 – 9-77). Prepared from Intermediate 72v as 
described for compound 74a (69% yield). 
1
H NMR (400 MHz, Methanol-d4) δ 7.65 (dd, J = 6.9, 
2.4 Hz, 1H), 7.51 (d, J = 2.3 Hz, 1H), 7.44 – 7.39 (m, 1H), 7.18 (dd, J = 10.6, 8.5 Hz, 1H), 6.61 
(d, J = 8.5 Hz, 1H), 6.39 (d, J = 2.5 Hz, 1H), 6.23 (d, J = 2.3 Hz, 1H), 6.17 (dd, J = 8.5, 2.5 Hz, 
1H), 5.85 (d, J = 0.8 Hz, 2H), 4.54 (s, 2H), 3.85 (s, 3H), 3.65 (td, J = 9.5, 9.0, 3.8 Hz, 2H), 3.56 
(dd, J = 9.9, 6.1 Hz, 1H), 3.49 (d, J = 12.5 Hz, 1H), 3.18 – 3.08 (m, 2H), 3.01 (td, J = 11.7, 4.3 
Hz, 1H), 2.37 (bs, 1H), 2.09 – 1.92 (m, 2H). MS (ESI+) m/z: 467.2 (M+1). HPLC purity: 95%. 
 
5-((3S,4R)-3-((Benzo[d][1,3]dioxol-5-yloxy)methyl)piperidin-4-yl)-2-fluoro-N-((1-methyl-1H-
pyrazol-5-yl)methyl)benzamide (74w – 258751 – 9-76). Prepared from Intermediate 72w as 
described for compound 74a (70% yield). 
1
H NMR (400 MHz, Methanol-d4) δ 7.65 (dd, J = 6.8, 
2.4 Hz, 1H), 7.51 (d, J = 2.4 Hz, 1H), 7.42 (ddd, J = 7.6, 4.7, 2.4 Hz, 1H), 7.18 (dd, J = 10.6, 8.5 
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Hz, 1H), 6.61 (d, J = 8.5 Hz, 1H), 6.39 (d, J = 2.6 Hz, 1H), 6.23 (d, J = 2.3 Hz, 1H), 6.17 (dd, J = 
8.5, 2.6 Hz, 1H), 5.85 (d, J = 1.5 Hz, 2H), 4.54 (s, 2H), 3.85 (s, 3H), 3.65 (td, J = 9.6, 3.7 Hz, 
2H), 3.56 (dd, J = 9.9, 6.1 Hz, 1H), 3.49 (d, J = 12.4 Hz, 1H), 3.12 (td, J = 12.5, 3.3 Hz, 2H), 




2-fluorobenzamide (74x – 258749 – 9-74). Prepared from Intermediate 72x as described for 
compound 72a (85% yield). 
1
H NMR (400 MHz, Methanol-d4) δ 7.65 – 7.58 (m, 3H), 7.41 (ddd, 
J = 8.5, 4.9, 2.4 Hz, 1H), 7.17 (dd, J = 10.5, 8.5 Hz, 1H), 6.61 (d, J = 8.5 Hz, 1H), 6.39 (d, J = 
2.5 Hz, 1H), 6.18 (dd, J = 8.5, 2.5 Hz, 1H), 5.85 (s, 2H), 4.47 (s, 2H), 3.67 (dd, J = 13.3, 3.4 Hz, 
2H), 3.58 – 3.48 (m, 2H), 3.16 (t, J = 12.4 Hz, 2H), 3.03 (td, J = 11.6, 4.2 Hz, 1H), 2.46 – 2.32 
(m, 1H), 2.11 – 1.94 (m, 2H). MS (ESI+) m/z: 453.2 (M+1). HPLC purity: 95%. 
 
N-(2-(1H-Pyrazol-4-yl)ethyl)-5-((3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)piperidin-4-yl)-
2-fluorobenzamide hydrochloride (74y – 222060 – 3-54, 6-62). Prepared from Intermediate 72y 
as described for compound 74a  (46% yield).
 1
H NMR (500 MHz, Methanol-d4) δ 7.54 (dd, J = 
6.9, 2.4 Hz, 1H), 7.50 (s, 2H), 7.39 (ddd, J = 8.5, 4.9, 2.4 Hz, 1H), 7.12 (dd, J = 10.6, 8.5 Hz, 
1H), 6.60 (d, J = 8.5 Hz, 1H), 6.34 (d, J = 2.5 Hz, 1H), 6.14 (dd, J = 8.5, 2.5 Hz, 1H), 5.83 (s, 
2H), 3.60 – 3.52 (m, 3H), 3.49 (dd, J = 9.7, 6.6 Hz, 1H), 3.36 (dd, J = 12.6, 3.9 Hz, 1H), 3.17 (dt, 
J = 12.6, 3.0 Hz, 1H), 2.83 – 2.69 (m, 5H), 2.13 (dddt, J = 14.6, 10.9, 6.8, 3.5 Hz, 1H), 1.87 – 





bis(trifluoromethyl)benzyl)-2-fluorobenzamide hydrochloride (74z – 232404). Prepared from 
Intermediate 72z as described for compound 74a  (94% yield). 
1
H NMR (500 MHz, Methanol-
d4) δ 8.07 (d, J = 8.0 Hz, 2H), 7.76 (t, J = 8.0 Hz, 1H), 7.53 (dd, J = 6.4, 2.0 Hz, 1H), 7.44 – 
7.39 (m, 1H), 7.14 (dd, J = 10.1, 8.4 Hz, 1H), 6.60 (d, J = 8.3 Hz, 1H), 6.38 (d, J = 2.2 Hz, 1H), 
6.11 (dd, J = 8.5, 2.3 Hz, 1H), 5.85 (s, 2H), 4.86 (s, 2H), 3.71 – 3.63 (m, 2H), 3.58 – 3.50 (m,  
2H), 3.17 (dd, J = 15.1, 9.9 Hz, 2H), 3.10 - 2.99 (m, 1H), 2.46 (s, 1H), 2.11 – 2.01 (m, 2H). 
13
C 
NMR (125 MHz, Methanol-d4) δ 166.04, 161.14, 159.15, 155.20, 149.66, 143.44, 139.58, 
139.55, 134.62, 133.36, 133.12, 131.69, 131.64, 131.60, 131.55, 130.69, 129.92, 128.45, 126.27, 
124.74, 124.62, 124.09, 117.79, 108.77, 106.69, 102.47, 98.88, 68.92, 68.10, 47.73, 45.44, 42.60, 
40.61, 38.66, 31.47.   MS (ESI+) m/z: 635.2 (M+1). HPLC purity: 98%.  
 
N-((1H-indazol-3-yl)methyl)-5-((3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)piperidin-4-yl)-
2-fluorobenzamide (74aa – 258747 – 9-50/10-34). Prepared from intermediate 72aa as described 
for compound 72a with a purification step using 10% MeOH/DCM to give an amorphous solid 
(44 mg, 51% yield). 
1
H NMR (400 MHz, Methanol-d4) δ 7.85 (dd, J = 8.2, 1.1 Hz, 1H), 7.61 (dd, 
J = 6.9, 2.3 Hz, 1H), 7.48 (dd, J = 8.5, 1.0 Hz, 1H), 7.36 (tq, J = 6.8, 1.8, 1.0 Hz, 2H), 7.14 – 
7.04 (m, 2H), 6.54 (d, J = 8.5 Hz, 1H), 6.30 (d, J = 2.5 Hz, 1H), 6.09 (dd, J = 8.5, 2.5 Hz, 1H), 
5.86 – 5.77 (m, 2H), 4.93 (s, 2H), 3.52 (dd, J = 9.7, 3.0 Hz, 1H), 3.44 (dd, J = 9.7, 6.7 Hz, 1H), 
3.34 – 3.26 (m, 1H), 3.14 – 3.05 (m, 1H), 2.76 – 2.58 (m, 3H), 2.08 (dtd, J = 10.8, 7.3, 6.7, 3.1 
Hz, 1H), 1.78 – 1.63 (m, 2H). MS (ESI+) m/z: 503.2 (M+1). HPLC purity: 98%. 
 




methoxybenzyl)acetamide hydrochloride (75a -215140 – 2-05). (3S,4R)-tert-butyl 3-
((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluoro-3-(2-((2-methoxybenzyl)amino)-2-
oxoethyl)phenyl)piperidine-1-carboxylate 73a  (0.029 g, 0.048 mmol) was dissolved in 1,4-
dioxanes (0.5 mL) followed by 4M HCl/1,4-dioxanes (0.186 mL) and stirred at room 
temperature for one hour. The reaction was concentrated in vacuo, then diethyl ether was added 
to precipitate a white solid which was then concentrated to give 2-(5-((3S,4R)-3-
((benzo[d][1,3]dioxol-5-yloxy)methyl)piperidin-4-yl)-2-fluorophenyl)-N-(2-
methoxybenzyl)acetamide hydrochloride as a white solid (0.018 g, 0.037 mmol, 77% yield) 
(95% purity).
1
H NMR (400 MHz, Chloroform-d) δ 9.82 (s, 1H), 7.18 – 7.02 (m, 3H), 6.95 (d, J 
= 8.4 Hz, 1H), 6.86 – 6.72 (m, 2H), 6.54 (d, J = 7.7 Hz, 1H), 6.26 (s, 1H), 6.09 – 5.95 (m, 2H), 
5.81 (s, 2H), 4.32 (bs, 2H), 3.71 (s, 3H), 3.66 – 3.30 (m, 4H), 3.16 – 2.75 (m, 3H), 2.57 (s, 1H), 
2.30 (s, 1H), 1.96 (s, 1H). MS (ESI+) m/z: 506.9 (M+1), 528.9 (M+Na). HPLC purity: 95% 
 
2-(5-((3S,4R)-3-((Benzo[d][1,3]dioxol-5-yloxy)methyl)piperidin-4-yl)-2-fluorophenyl)-N- 
(pyridin-2-ylmethyl)acetamide hydrochloride (75b – 215143 – 1-99). Prepared from Intermediate 
73b as described for compound 72a  (95% yield) 
1
H NMR (400 MHz, Methanol-d4) δ 8.75 (d, J 
= 5.7 Hz, 1H), 8.54 (t, J = 7.9 Hz, 1H), 7.94 (t, J = 9.7 Hz, 2H), 7.30 (d, J = 7.0 Hz, 1H), 7.20 (d, 
J = 6.2 Hz, 1H), 7.06 (t, J = 9.1 Hz, 1H), 6.61 (d, J = 8.3 Hz, 1H), 6.39 (s, 1H), 6.18 (d, J = 8.4 
Hz, 1H), 5.85 (s, 2H), 4.72 (s, 2H), 3.71 – 3.61 (m, 3H), 3.60 – 3.47 (m, 3H), 3.15 (t, J = 12.4 
Hz, 2H), 2.95 (s, 1H), 2.45 (s, 1H), 2.13 – 1.99 (m, 2H). MS (ESI+) m/z: 477.9 (M+1), 499.9 





(pyridin-2-yl)ethyl)acetamide hydrochloride (75c – 215142 – 2-11). Prepared from Intermediate 
73c as described for compound 72a (93% yield). 
1
H NMR (400 MHz, Methanol-d4) δ 8.70 (s, 
1H), 8.47 – 8.38 (m, 1H), 7.88 (d, J = 7.5 Hz, 2H), 7.23 – 7.16 (m, 2H), 7.04 (t, J = 8.7 Hz, 1H), 
6.63 (d, J = 8.3 Hz, 1H), 6.40 (s, 1H), 6.20 (d, J = 8.4 Hz, 1H), 5.85 (s, 2H), 3.71 – 3.45 (m, 8H), 
3.23 – 3.14 (m, 4H), 2.43 (s, 1H), 2.14 (s, 1H), 2.04 (s, 1H), 1.29 (s, 1H). MS (ESI+) m/z: 491.9 
(M+1), 513.9 (M+Na). HPLC purity: 98%. 
 
N-(2-(1H-Pyrazol-4-yl)ethyl)-2-(5-((3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)piperidin-4-
yl)-2-fluorophenyl)acetamide (75d – 222886 – 6-55). Prepared from Intermediate 73d as 
described for compound 72a (75% yield). 
1
H NMR (500 MHz, Methanol-d4) δ 7.41 (s, 2H), 7.20 
– 7.13 (m, 2H), 7.02 (t, J = 9.3 Hz, 1H), 6.60 (d, J = 8.5 Hz, 1H), 6.34 (d, J = 2.5 Hz, 1H), 6.15 
(dd, J = 8.5, 2.5 Hz, 1H), 5.82 (s, 2H), 3.59 (dd, J = 9.7, 2.9 Hz, 1H), 3.53 – 3.47 (m, 3H), 3.43 
(dd, J = 12.6, 3.9 Hz, 1H), 3.38 – 3.30 (m, 4H), 3.27 – 3.19 (m, 1H), 2.87 – 2.77 (m, 2H), 2.73 
(ddd, J = 16.5, 10.7, 5.2 Hz, 2H), 2.67 (t, J = 7.2 Hz, 2H), 2.17 (dtt, J = 11.2, 7.5, 3.3 Hz, 1H), 
1.89 – 1.76 (m, 2H). MS (ESI+) m/z: 481.9 (M+1). HPLC purity: 95%. 
 
2-(5-((3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)piperidin-4-yl)-2-fluorophenyl)-N-(2,6-
difluorobenzyl)acetamide hydrochloride (75e – 208945 – 1-84). Prepared from Intermediate 73e 
as described for compound 72a  (82% yield) 
1
H NMR (500 MHz, DMSO-d6) δ 8.52 (t, J = 5.3 
Hz, 1H), 7.39 (tt, J = 8.4, 6.6 Hz, 1H), 7.16 – 7.04 (m, 5H), 6.73 (d, J = 8.5 Hz, 1H), 6.48 (d, J = 
2.5 Hz, 1H), 6.18 (dd, J = 8.5, 2.5 Hz, 1H), 5.92 (s, 2H), 4.32 (d, J = 5.3 Hz, 2H), 3.57 (dd, J = 
9.9, 3.0 Hz, 1H), 3.52 – 3.39 (m, 4H), 3.28 (d, J = 13.1 Hz, 1H), 2.92 – 2.78 (m, 2H), 2.72 (td, J 
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= 11.8, 3.9 Hz, 1H), 2.34 (t, J = 7.8 Hz, 1H), 2.01 – 1.85 (m, 1H), 1.82 – 1.74 (m, 1H). MS 
(ESI+) m/z: 512.9 (M+1), 534.9 (M+Na). HPLC purity: 87% 
 
2-(5-((3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)piperidin-4-yl)-2-fluorophenyl)-N-(2,6-
difluorophenethyl)acetamide hydrochloride (75f - 1-87 – 215086). Prepared from Intermediate 
73f as described for compound 72a  (86% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 9.89 (s, 
2H), 7.19 – 7.10 (m, 3H), 7.00 (t, J = 8.7 Hz, 1H), 6.81 (t, J = 7.6 Hz, 2H), 6.60 (d, J = 8.4 Hz, 
1H), 6.32 (d, J = 2.3 Hz, 1H), 6.11 (dd, J = 8.8, 2.2 Hz, 1H), 5.86 (s, 2H), 5.56 (s, 1H), 3.73 (d, J 
= 18.9 Hz, 1H), 3.60 (d, J = 9.4 Hz, 1H), 3.53 – 3.41 (m, 4H), 3.16 (s, 1H), 3.04 (s, 1H), 2.90 (s, 
1H), 2.82 (t, J = 6.7 Hz, 2H), 2.65 (s, 1H), 2.38 (d, J = 13.6 Hz, 1H), 2.03 (d, J = 9.2 Hz, 1H). 
MS (ESI+) m/z: 526.9 (M+1), 548.9 (M+Na). HPLC purity: 90%. 
 
2-(5-((3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)piperidin-4-yl)-2-fluorophenyl)-N-(3-
chlorobenzyl)acetamide hydrochloride (75g – 2-09 – 215141). Prepared from Intermediate 73g 
as described for compound 72a (98% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 9.86 (s, 2H), 
7.24 – 7.14 (m, 5H), 7.09 (s, 1H), 7.02 (s, 1H), 6.60 (d, J = 7.4 Hz, 1H), 6.32 (s, 1H), 6.10 (d, J = 
8.1 Hz, 1H), 6.02 (s, 1H), 5.87 (s, 2H), 4.36 (s, 2H), 3.80 - 3.47 (m, 5H), 3.17 (broad s, 1H), 3.05 
(broad s, 1H), 2.92 (broad s, 1H), 2.68 (s, 1H), 2.40 (s, 1H), 1.91 – 1.79 (m, 2H).  MS (ESI+) 
m/z: 510.9 (M+1), 532.8 (M+Na). HPLC purity: 90%. 
 
2-(5-((3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)piperidin-4-yl)-2-fluorophenyl)-N-(2-
(pyridin-2-yl)ethyl)acetamide (75h – 215142 – 2-11). Prepared from Intermediate 73h as 
described for compound 72a (93% yield). 
1
H NMR (400 MHz, Methanol-d4) δ 8.70 (s, 1H), 8.43 
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(s, 1H), 7.87 (s, 2H), 7.20 (s, 2H), 7.04 (t, J = 8.8 Hz, 1H), 6.63 (d, J = 8.3 Hz, 1H), 6.40 (d, J = 
2.1 Hz, 1H), 6.19 (d, J = 8.0 Hz, 1H), 5.85 (s, 2H), 5.49 (s, 1H), 3.70 – 3.43 (m, 8H), 3.22 (s, 
2H), 3.16 (s, 2H), 2.96 (broad s, 1H), 2.44 (broad s, 1H), 2.04 (s, 2H). MS (ESI+) m/z: 491.9 
(M+1), 513.9 (M+Na). HPLC purity: 99%. 
 
tert-butyl 5-(((3S,4R)-1-(tert-butoxycarbonyl)-4-(4-fluoro-3-(methoxycarbonyl)phenyl)piperidin-
3-yl)methoxy)-1H-indazole-1-carboxylate (76). To a 0 
o
C solution of (3S,4R)-tert-butyl 4-(4-
fluoro-3-(methoxycarbonyl) phenyl)-3-(hydroxymethyl)piperidine-1-carboxylate 66 (0.687 g, 
1.87 mmol) in 25 mL DCM was added diisopropylethylamine (0.980 mL, 5.61 mmol) followed 
by methanesulfonylchloride (0.651 g, 3.74 mmol). The reaction was allowed to warm to room 
temperature and stirred overnight. The resulting product was washed with water (1x), then brine 
(1x), dried over MgSO4, and concentrated in vacuo to give a clear oil (0.833 g crude). The 
product was used in subsequent reactions without further purification. To a 0 
o
C solution of 
intermediate 87 (0.345g, 1.474 mmol) in 4 mL DMF was added 60% sodium hydride in mineral 
oil (0.062g, 1.54 mmol). The solution stirred for five minutes. To the reaction was added 
(3S,4R)-tert-butyl 4-(4-fluoro-3-(methoxycarbonyl)phenyl)-3-
(((methylsulfonyl)oxy)methyl)piperidine-1-carboxylate (0.313 g, 0.702 mmol) in 4 mL DMF. 
The reaction was heated to 70 
o
C for 10 minutes then cooled to room temperature and treated 
with sat. NH4Cl solution. Extracted with ethyl acetate/ether (2x), washed with brine, dried with 
MgSO4, and concentrated in vacuo. Purified by flash chromatography using a gradient of 10% 
MeOH/DCM to give as a clear oil tert-butyl 5-(((3S,4R)-1-(tert-butoxycarbonyl)-4-(4-fluoro-3-
(methoxycarbonyl)phenyl)piperidin-3-yl)methoxy)-1H-indazole-1-carboxylate (76) (0.135 g, 
0.279 mmol, 40% yield over two steps).  
1
H NMR (400 MHz, DMSO-d6) δ 8.22 (d, J = 0.9 Hz, 
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1H), 7.92 (d, J = 9.6 Hz, 1H), 7.75 – 7.71 (m, 1H), 7.62 (d, J = 3.6 Hz, 1H), 7.28 (dd, J = 10.8, 
8.5 Hz, 1H), 7.14 – 7.09 (m, 2H), 4.36 (s, 1H), 4.11 – 4.02 (m, 2H), 3.80 (s, 3H), 3.71 – 3.61 (m, 
2H), 2.93 – 2.68 (m, 3H), 2.15 (s, 1H), 1.74 (d, J = 12.8 Hz, 1H), 1.62 (s, 9H), 1.43 (s, 9H). 
 
tert-butyl 5-(((3S,4R)-1-(tert-butoxycarbonyl)-4-(4-fluoro-3-(methoxycarbonyl)phenyl)piperidin-
3-yl)methoxy)-6-fluoro-1H-indazole-1-carboxylate (77). Intermediate (77) was prepared as 
described for intermediate 76 replacing intermediate 91 with intermediate 92. Purification from 
residual intermediate 92 was difficult and the mixture of 92 and 77 was carried forward as is. 
 
5-((3S,4R)-3-(((1H-indazol-5-yl)oxy)methyl)-1-(tert-butoxycarbonyl)piperidin-4-yl)-2-
fluorobenzoic acid (78). To a round bottom flask equipped with a stir bar was added tert-butyl 6-
(((3S,4R)-1-(tert-butoxycarbonyl)-4-(4-fluoro-3-(methoxycarbonyl)phenyl) piperidin-3-
yl)methoxy)-1H-indazole-1-carboxylate (76) (0.270g, 0.463 mmol), 1M NaOH (1.39 mL, 1.388 
mmol), H2O (10 mL), tetrahydrofuran (4 mL) and methanol (6 mL). The reaction was stirred 
overnight at room temperature. Ether was added to the reaction and the resulting layers were 
separated. To the aqueous layer 10% citric acid was added to give a pH of 4. The aqueous layer 
was then extracted 2x with ethyl acetate. The ethyl acetate layers were then combined and 
washed 1x with NaCl, dried with MgSO4, and concentrated to give as an amorphous white solid 
5-((3S,4R)-3-(((1H-indazol-5-yl)oxy)methyl)-1-(tert-butoxycarbonyl)piperidin-4-yl)-2-
fluorobenzoic acid (78) (0.201g, 0.428 mmol, 92% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 
13.03 (s, 2H), 7.86 (d, J = 1.0 Hz, 1H), 7.74 (dd, J = 7.1, 2.4 Hz, 1H), 7.59 – 7.53 (m, 1H), 7.39 
(d, J = 8.9 Hz, 1H), 7.23 (dd, J = 10.7, 8.5 Hz, 1H), 6.94 – 6.86 (m, 2H), 4.37 (s, 1H), 4.08 (s, 
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1H), 3.61 (t, J = 5.2 Hz, 2H), 2.94 – 2.62 (m, 3H), 2.20 – 2.04 (m, 1H), 1.74 (d, J = 11.2 Hz, 
1H), 1.69 – 1.53 (m, 1H), 1.42 (s, 9H). 
 
5-((3S,4R)-1-(tert-butoxycarbonyl)-3-(((6-fluoro-1H-indazol-5-yl)oxy)methyl)piperidin-4-yl)-2-
fluorobenzoic acid (79). Intermediate 79 was prepared as described for intermediate 78 replacing 
intermediate 76 with intermediate 77. The crude mixture was then purified using flash 
chromatography 5% MeOH (2% AcOH)/ dichloromethane to give the desired product as a white 
amorphous solid (yield over three steps 35%). 
1
H NMR (400 MHz, Chloroform-d) δ 9.19 (s, 
1H), 7.83 (d, J = 1.0 Hz, 1H), 7.77 (dd, J = 7.4, 2.2 Hz, 1H), 7.40 (ddd, J = 7.6, 4.3, 2.4 Hz, 1H), 
7.23 (d, J = 10.2 Hz, 1H), 7.12 (dd, J = 10.5, 8.4 Hz, 1H), 6.91 (d, J = 7.8 Hz, 1H), 4.48 (d, J = 
13.0 Hz, 1H), 4.30 (s, 1H), 3.87 (d, J = 10.2 Hz, 1H), 3.67 (dd, J = 10.4, 5.6 Hz, 1H), 2.99 (t, J = 
12.4 Hz, 1H), 2.89 (d, J = 17.8 Hz, 2H), 2.05 (s, 1H), 1.91 – 1.71 (m, 2H), 1.50 (s, 9H). 
 
tert-butyl (3S,4R)-3-(((1H-indazol-5-yl)oxy)methyl)-4-(3-((2,6-dimethoxybenzyl)carbamoyl)-4-
fluorophenyl)piperidine-1-carboxylate (80aa). To a round bottom flask equipped with a stir bar 
was added 5-((3S,4R)-3-(((1H-indazol-6-yl)oxy)methyl)-1-(tert-butoxycarbonyl)piperidin-4-yl)-
2-fluorobenzoic acid 78 (0.090 g, 0.190 mmol), HATU (0.146 g, 0.383 mmol), 
diisopropylbenzylamine (0.067 mL, 0.383 mmol), 2,6-dimethoxybenzylamine (0.064g, 0.383 
mmol), and 2 mL THF. The reaction was stirred overnight at room temperature. The reaction 
was diluted with ethyl acetate and water and the layers were separated. The organic layer was 
washed 1x with saturated sodium bicarbonate, washed 2x with brine, dried with MgSO4, and 
concentrated to give a yellow oil. The oil was then purified using flash chromatography (50-60% 





(DMSO, 400 MHz) δ: 12.87 (s, 1H), 7.99 (q, J = 4.7 Hz, 1H), 7.86 (s, 1H), 7.52 (dd, J = 7.0, 2.3 
Hz, 1H), 7.43-7.38 (m, 2H), 7.25 (t, J = 8.3 Hz, 1H), 7.17 (dd, J = 10.6, 8.5 Hz, 1H), 6.94-6.86 
(m, 2H), 6.67 (d, J = 8.4 Hz, 2H), 4.48 (d, J = 5.0 Hz, 2H), 4.37 (bs, 1H), 4.07 (s, 1H), 3.78 (s, 
6H), 3.61-3.57 (m, 2H), 2.86-2.66 (m, 3H), 2.17-2.09 (m, 1H), 1.72 (d, J = 10.8 Hz, 1H), 1.59 
(qd, J = 13.5, 12.9, 4.0 Hz, 1H), 1.42 (s, 9H). 
 
5-((3S,4R)-3-(((1H-indazol-6-yl)oxy)methyl)piperidin-4-yl)-N-(2,6-dimethoxybenzyl)-2-
fluorobenzamide hydrochloride (CCG232406 – 5-49, 80ab). Intermediate 80aa (0.063g, 0.102 
mmol) was dissolved in dioxanes (1 mL) and then 4M HCl/dioxanes (1 mL) was added 
dropwise. The reaction was stirred for three hours. Upon completion via monitoring by TLC the 
reaction was concentrated in vacuo. The crude residue was then purified using flash 
chromatography 5% - 15% MeOH/DCM to give as a white solid 5-((3S,4R)-3-(((1H-indazol-6-
yl)oxy)methyl)piperidin-4-yl)-N-(2,6-dimethoxybenzyl)-2-fluorobenzamide hydrochloride 
(0.052g, 92% yield). 
1
H NMR (500 MHz, Methanol-d4) δ 7.97 (s, 1H), 7.73 (dd, J = 7.0, 2.4 Hz, 
1H), 7.47 – 7.40 (m, 2H), 7.25 (t, J = 8.4 Hz, 1H), 7.15 (dd, J = 10.9, 8.5 Hz, 1H), 7.07 (dd, J = 
9.0, 2.3 Hz, 1H), 6.98 (d, J = 2.3 Hz, 1H), 6.65 (d, J = 8.4 Hz, 2H), 4.69 – 4.62 (m, 2H), 3.84 (s, 
6H), 3.80 (dd, J = 9.9, 3.0 Hz, 1H), 3.76 – 3.66 (m, 2H), 3.58 – 3.51 (m, 1H), 3.26 – 3.16 (m, 
2H), 3.09 (td, J = 11.7, 4.1 Hz, 1H), 2.54 – 2.45 (m, 1H), 2.13 – 1.98 (m, 2H). MS (ESI+) m/z: 




Intermediate 80ba was prepared as described previously for intermediate 80aa replacing 2,6-
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dimethoxybenzylamine with 2-picoylamine (yield: 41%). 
1
H NMR (400 MHz, Methanol-d4) δ 
8.47 (ddd, J = 5.0, 1.8, 0.9 Hz, 1H), 7.84 (s, 1H), 7.76 (td, J = 7.7, 1.8 Hz, 1H), 7.71 (dd, J = 7.0, 
2.3 Hz, 1H), 7.46 (ddd, J = 8.4, 4.8, 2.3 Hz, 1H), 7.43 – 7.35 (m, 2H), 7.29 (ddd, J = 7.6, 5.0, 1.1 
Hz, 1H), 7.17 (dd, J = 10.8, 8.5 Hz, 1H), 6.99 (dd, J = 9.2, 2.2 Hz, 1H), 6.92 (d, J = 2.3 Hz, 1H), 
4.66 (s, 2H), 4.48 (d, J = 13.0 Hz, 1H), 4.22 (d, J = 13.5 Hz, 1H), 3.73 (dd, J = 9.8, 3.0 Hz, 1H), 
3.63 (dd, J = 9.8, 6.9 Hz, 1H), 2.97 – 2.83 (m, 3H), 2.16 (dq, J = 7.4, 3.8 Hz, 1H), 1.83 (d, J = 
13.2 Hz, 1H), 1.74 (dd, J = 12.6, 4.3 Hz, 1H), 1.49 (s, 9H). 
 
5-((3S,4R)-3-(((1H-indazol-6-yl)oxy)methyl)piperidin-4-yl)-2-fluoro-N-(pyridin-2-
ylmethyl)benzamide dihydrochloride (CCG257284 – 6-80, 80bb). Compound 80bb (0.041g, 
0.073 mmol) was dissolved in dichloromethane (3 mL) and then trifluoroacetic acid (0.30 mL) 
was added dropwise. The reaction was stirred for three hours. Upon completion via monitoring 
by TLC the reaction was concentrated in vacuo to give as a white solid 5-((3S,4R)-3-(((1H-
indazol-6-yl)oxy)methyl)piperidin-4-yl)-2-fluoro-N-(pyridin-2-ylmethyl)benzamide 
hydrochloride (0.032g, 97% yield). 
1
H NMR (400 MHz, Methanol-d4) δ 8.74 (d, J = 5.3 Hz, 
1H), 8.49 (td, J = 7.9, 1.6 Hz, 1H), 7.98 (d, J = 8.1 Hz, 1H), 7.92 (ddd, J = 7.4, 5.8, 1.2 Hz, 1H), 
7.87 (s, 1H), 7.80 (dd, J = 6.9, 2.4 Hz, 1H), 7.54 (ddd, J = 8.5, 4.8, 2.4 Hz, 1H), 7.41 (d, J = 9.0 
Hz, 1H), 7.25 (dd, J = 10.9, 8.5 Hz, 1H), 7.03 (dd, J = 9.0, 2.3 Hz, 1H), 6.95 (d, J = 2.2 Hz, 1H), 
4.88 (s, 2H), 3.83 – 3.65 (m, 3H), 3.55 (d, J = 12.7 Hz, 1H), 3.25 – 3.08 (m, 3H), 2.60 – 2.48 (m, 
1H), 2.08 (dt, J = 9.4, 4.7 Hz, 2H). MS (ESI+) m/z: 532.2  (M+1). HPLC purity: 99%. 
 
tert-butyl (3S,4R)-3-(((1H-indazol-5-yl)oxy)methyl)-4-(3-(((1H-pyrazol-3-yl)methyl)carbamoyl)-
4-fluorophenyl)piperidine-1-carboxylate (80ca). Intermediate 80ca was prepared as described 
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previously for intermediate 80aa replacing 2,6-dimethoxybenzylamine with 2H–pyrazol–5-yl 
methylamine hydrochloride (yield: 20%). 
1
H NMR (400 MHz, Methanol-d4) δ 8.58 (s, 1H), 7.83 
(d, J = 1.0 Hz, 1H), 7.63 (dd, J = 7.0, 2.3 Hz, 1H), 7.51 (d, J = 2.1 Hz, 1H), 7.41 (ddd, J = 8.0, 
4.8, 2.4 Hz, 1H), 7.38 – 7.34 (m, 1H), 7.12 (dd, J = 10.6, 8.5 Hz, 1H), 6.97 (dd, J = 9.2, 2.2 Hz, 
1H), 6.90 (d, J = 2.2 Hz, 1H), 6.23 (d, J = 2.2 Hz, 1H), 4.58 – 4.53 (m, 2H), 4.46 (d, J = 13.1 Hz, 
1H), 4.20 (d, J = 13.8 Hz, 1H), 3.71 (dd, J = 9.9, 2.9 Hz, 1H), 3.61 (dd, J = 9.8, 7.0 Hz, 1H), 2.90 
– 2.77 (m, 3H), 2.13 (dt, J = 6.9, 3.1 Hz, 1H), 1.85 – 1.65 (m, 2H), 1.47 (s, 9H).  
 
5-((3S,4R)-3-(((1H-indazol-5-yl)oxy)methyl)piperidin-4-yl)-N-((1H-pyrazol-3-yl)methyl)-2-
fluorobenzamide (80cb, CCG258748 – 9-63). Prepared from intermediate 80ca as described for 
80bb (yield: 98%). 
1
H NMR (400 MHz, Methanol-d4) δ 7.87 (s, 1H), 7.70 (dd, J = 7.0, 2.3 Hz, 
1H), 7.64 (d, J = 2.3 Hz, 1H), 7.45 (ddd, J = 7.5, 4.5, 2.2 Hz, 1H), 7.41 (d, J = 9.0 Hz, 1H), 7.17 
(dd, J = 10.6, 8.5 Hz, 1H), 7.02 (dd, J = 9.0, 2.3 Hz, 1H), 6.94 (d, J = 2.2 Hz, 1H), 6.31 (d, J = 
2.2 Hz, 1H), 4.60 (s, 2H), 3.73 (dtd, J = 32.9, 9.9, 4.4 Hz, 3H), 3.54 (d, J = 12.8 Hz, 1H), 3.27 – 




indazol-5-yl)oxy)methyl)piperidine-1-carboxylate (81aa). Intermediate 81aa was prepared as 
described for intermediate 80aa replacing intermediate 78 with intermediate 79 (yield: 57%).
 1
H 
NMR (500 MHz, Chloroform-d) δ 8.01 (dd, J = 7.5, 2.4 Hz, 1H), 7.87 (s, 1H), 7.47 (dt, J = 12.1, 
5.3 Hz, 1H), 7.21 (d, J = 8.3 Hz, 1H), 7.15 (d, J = 10.3 Hz, 1H), 6.98 (dd, J = 11.6, 8.4 Hz, 1H), 
6.89 (d, J = 7.8 Hz, 1H), 6.57 (d, J = 8.4 Hz, 2H), 4.80 – 4.76 (m, 2H), 4.55 – 4.48 (m, 1H), 4.25 
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(s, 1H), 4.03 (hept, J = 6.0 Hz, 1H), 3.85 (s, 6H), 3.70 (dd, J = 9.5, 2.8 Hz, 1H), 3.55 (dd, J = 9.6, 
6.6 Hz, 1H), 2.86 (dd, J = 13.4, 11.2 Hz, 2H), 2.16 (s, 1H), 1.82 – 1.67 (m, 2H), 1.50 (s, 9H).  
 
N-(2,6-dimethoxybenzyl)-2-fluoro-5-((3S,4R)-3-(((6-fluoro-1H-indazol-5-
yl)oxy)methyl)piperidin-4-yl)benzamide dihydrochloride (81ab, 258003, HVW 8-45). Prepared 
from intermediate 81aa as described for 80ab without need of a purification step (yield: 95%). 
1
H NMR (400 MHz, Methanol-d4) δ 8.31 (s, 1H), 7.73 – 7.69 (m, 1H), 7.46 (s, 1H), 7.41 (d, J = 
10.3 Hz, 1H), 7.24 (t, J = 8.3 Hz, 2H), 7.16 (dd, J = 10.8, 8.4 Hz, 1H), 6.64 (d, J = 8.4 Hz, 2H), 
4.69 – 4.57 (m, 2H), 3.93 – 3.87 (m, 1H), 3.83 (s, 6H), 3.80 – 3.72 (m, 3H), 3.69 – 3.63 (m, 1H), 
3.58 – 3.51 (m, 1H), 3.30 – 3.14 (m, 3H), 3.14 – 3.05 (m, 1H), 2.85 (s, 1H), 2.62 (s, 1H). MS 
(ESI+) m/z:607.0 (M+1). HPLC purity 96%. 
 
2-fluoro-5-methyl-4-nitrophenol (83): Added 2-fluoro-5-methylphenol 82 (0.200 g, 1.59 mmol) 
to a 5 mL flask followed by AcOH (0.40 mL) and H2SO4 (0.058 mL) at 0 ⁰ C (ice-salt bath). 
Then sodium nitrite (0.29 mL of 5.5 M in water) was slowly added to the reaction to give a burnt 
orange color. The reaction was stirred for thirty minutes on the ice bath. Poured reaction over ice 
and then filtered off a light orange solid. Warmed 20% nitric Acid in water (5 mL) to 45 ⁰ C then 
added the orange solid in portions while stirring. The reaction was stirred for twenty minutes 
then diluted with water and cooled. The light orange solid was filtered off to give 2-fluoro-5-
methyl-4-nitrophenol (83) as a light orange solid (0.124g, 46% yield). 
1
H NMR (500 MHz, 
DMSO-d6) δ 13.86 (s, 1H), 7.42 (d, J = 11.6 Hz, 1H), 6.47 (dq, J = 8.2, 1.3 Hz, 1H), 2.23 (d, J = 




4-amino-2-fluoro-5-methylphenol (84): To a dry round bottom flask was added intermediate 83 
(2.64 g, 15.42 mmol), 10% Pd/C (0.528 g), EtOH (20 mL), and THF (20 mL). Argon was 
bubbled through the reaction mixture and then the atmosphere was replaced with H2. The 
reaction was stirred overnight at room temperature. Filtered the reaction through a pad of celite 
with EtOH/THF to give 4-amino-2-fluoro-5-methylphenol (84) as an off white solid (2.0 g, 
92%). 
1
H NMR (500 MHz, DMSO-d6) δ 8.48 (s, 1H), 6.53 (d, J = 9.8 Hz, 1H), 6.38 (d, J = 13.2 
Hz, 1H), 4.42 (s, 2H), 1.94 (s, 3H). 
 
6-fluoro-1H-indazol-5-ol (86): In a pressure vessel intermediate 84 (0.659g, 4.67 mmol) and 
potassium acetate (11.39 mmol, 1.12 g) were dissolved in chloroform (30 mL) at 0⁰ C. Then 
acetic anhydride (21.01 mmol, 1.98 mL) was added drop wise to the reaction. The reaction was 
then warmed to room temperature and stirred for thirty minutes. After thirty minutes the reaction 
was heated to 80 ⁰ C and isopentyl nitrite (5.14 mmol, 0.69 mL) was added drop wise. The 
reaction was further stirred at 80 ⁰ C overnight turning a dark brown color. The reaction was 
neutralized with NaHCO3 to pH 7. Dichloromethane was then added to dilute the reaction and 
the layers were separated. The organic layer was then washed 2x with NaCl, dried over MgSO4, 
and concentrated. Dissolved resulting residue in MeOH (15 mL) and 6N HCl (15 mL) and 
refluxed overnight at 40 
o
C. Neutralized the reaction with NaOH and then concentrated off the 
MeOH. Extracted the aqueous layer with ethyl acetate 2x, then washed the ethyl acetate 2x with 
NaCl, dried over MgSO4, and concentrated to give a brown residue. Purified the resulting residue 
using a gradient of 40% - 100% EtOAc/Hexanes to give 6-fluoro-1H-indazol-5-ol (85) (1.571 g, 
60%).
1
H NMR (400 MHz, DMSO-d6) δ 12.83 (s, 1H), 9.55 (s, 1H), 7.88 (s, 1H), 7.30 (dd, J = 




5-((tert-butyldimethylsilyl)oxy)-1H-indazole (87). 1H-indazol-5-ol 85 (1.00 g, 7.45 mmol) 
dissolved in 20 mL of anhydrous methylene chloride was added to a 100 mL round bottom flask. 
Tert-butyldimethylsilyl chloride (1.69 g, 11.18 mmol) and imidazole (0.51 g, 7.45 mmol) were 
added to the reaction vessel producing a cloudy white mixture. Lastly, N,N-
diisopropylethylamine (1.95 mL, 11.18 mmol) was added, giving a clear solution. The reaction 
was stirred overnight at room temperature.  Methylene chloride was used to dilute the reaction 
followed by washing with NaCl (2x). The organic layer was dried over MgSO4, concentrated in 
vacuo, and purified using flash chromatography with a 20% EtOAc/Hexane gradient to give 5-
((tert-butyldimethylsilyl)oxy)-1H-indazole (87) (1.72g, 93%). 
1
H NMR (DMSO – d6, 400 MHz) 
δ: 12.91 (s, 1H), 7.92 (s, 1H), 7.41 (d, J=9.0 Hz, 1H),  7.12 (d, J=1.5 Hz, 1H), 6.91 (dd, J = 8.8, 
2.3 Hz, 1H), 0.96 (s, 9H), 0.18 (s, 6H). 
 
5-((tert-butyldimethylsilyl)oxy)-6-fluoro-1H-indazole (88): Intermediate 88 was prepared as 
described for intermediate 87 replacing 1H-indazol-5-ol 85 with intermediate 86 (yield: 93%). 
1
H NMR (400 MHz, DMSO-d6) δ 12.98 (s, 1H), 7.95 (s, 1H), 7.37 (d, J = 10.6 Hz, 1H), 7.31 (d, 
J = 8.2 Hz, 1H), 0.99 (s, 9H), 0.18 (d, J = 0.8 Hz, 6H). 
 
tert-butyl 5-((tert-butyldimethylsilyl)oxy)-1H-indazole-1-carboxylate / tert-butyl 5-((tert-
butyldimethylsilyl)oxy)-2H-indazole-2-carboxylate (89): 5-((tert-butyldimethylsilyl)oxy)-1H-
indazole (87) (1.00 g, 4.85 mmol) was dissolved in 20 mL of anhydrous tetrahydrofuran and 
added to a 100 mL round bottom flask. Di-tert-butyl dicarbonate (1.67 mL, 7.27 mmol), 
dimethylaminopyridine (0.06 g, 0.48 mmol), and diisopropylethylamine (1.44 mL, 8.24 mmol) 
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were added to the reaction vessel and stirred overnight. Ethyl acetate and water were used to 
dilute the reaction followed by washing with NaCl (2x). The organic layer was dried over 
MgSO4, concentrated in vacuo, and purified to give the regioisomers of tert-butyl 5-((tert-
butyldimethylsilyl)oxy)-1H-indazole-1-carboxylate and tert-butyl 5-((tert-
butyldimethylsilyl)oxy)-2H-indazole-2-carboxylate (89) (yield: 1.07g, 63%). 
1
H NMR (DMSO – 
d6, 400 MHz) δ: 8.67 (d, J = 1.1 Hz, 1H), 8.28 (d, J = 0.9 Hz, 1H), 7.95 (d, J = 8.0 Hz, 1H), 7.61 
(dt, J = 8.9 Hz, 1.2 Hz, 1H),7.28 (dd, J = 2.4 Hz, 0.7 Hz, 1H), 7.15 (dd, J = 8.9 Hz, 2.4 Hz, 1H), 
7.03-6.94 (m, 2H), 1.63 (d, J = 3.5 Hz, 18H), 0.96 (d, J = 2.0 Hz, 18H), 0.21 (d, J = 3.5 Hz, 
12H). 
 
tert-butyl 5-((tert-butyldimethylsilyl)oxy)-6-fluoro-1H-indazole-1-carboxylate (90): Intermediate 
90 was prepared as described for intermediate 89 replacing intermediate 87 with intermediate 88 
(yield: 67%). 
1
H NMR (400 MHz, DMSO-d6) δ 8.30 (s, 1H), 7.81 (d, J = 10.8 Hz, 1H), 7.50 (d, 
J = 8.2 Hz, 1H), 1.63 (s, 9H), 0.98 (s, 9H), 0.20 (s, 6H). 
 
tert-butyl 5-hydroxy-1H-indazole-1-carboxylate/ tert-butyl 5-hydroxy-2H-indazole-2-carboxylate 
(91): Tert-butyl 5-((tert-butyldimethylsilyl)oxy)-1H-indazole-1-carboxylate / tert-butyl 5-((tert-
butyldimethylsilyl)oxy)-2H-indazole-2-carboxylate (89) (1.69 g, 4.85 mmol) and tetra n-
butylammonium fluoride (2.34 g, 9.70 mmol)  was added to 20 mL of anhydrous tetrahydrofuran 
in a 100 mL round bottom flask at 0 °C and stirred for 2.5 hours. Ethyl acetate and water were 
used to dilute the reaction followed by washing with NaCl (2x). The organic layer was dried over 
MgSO4, concentrated in vacuo, and purified using flash chromatography (0-10% 
EtOAc/Hexanes) to give the regioisomers tert-butyl 5-((tert-butyldimethylsilyl)oxy)-1H-
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indazole-1-carboxylate/ tert-butyl 5-((tert-butyldimethylsilyl)oxy)-2H-indazole-2-carboxylate 
(91) (0.4769g, 42%). 
1
H NMR (DMSO – d6, 400 MHz) δ: 9.60 (s, 1H), 8.55 (d, J = 1.1 Hz, 1H), 
8.21 (d, J = 0.8 Hz, 1H), 7.87 (dt, J = 8.8 Hz, 0.9 Hz, 1H), 7.53 (dt, J = 9.4 Hz, 1.0 Hz, 1H),7.12-
7.03 (m, 2H), 6.97 (dd, J = 9.4 Hz, 2.3 Hz, 1H), 6.77 (dd, J = 2.3 Hz, 0.9 Hz, 1H) , 1.61 (d, J = 
2.8 Hz, 18H). 
 
tert-butyl 6-fluoro-5-hydroxy-1H-indazole-1-carboxylate (92). Intermediate 92 was prepared as 
described for intermediate 91 replacing intermediate 89 with intermediate 90 (yield: 94%). 
1
H 
NMR (400 MHz, Chloroform-d) δ 8.06 (d, J = 0.9 Hz, 1H), 7.95 (d, J = 10.7 Hz, 1H), 7.28 (d, J 
= 8.2 Hz, 2H), 5.48 (s, 1H), 1.71 (s, 9H). 
 
((3S,4R)-1-ethyl-4-(4-fluorophenyl)piperidin-3-yl)methanol (94). Preparation of compound 94 
was accomplished by dissolving ((3S,4R)-4-(4-fluorophenyl)piperidin-3-yl)methanol 93 (1.49 
mmol, 0.311 g) in DMF (6.0 mL). Potassium carbonate (3.73 mmol, 0.515g) and ethyl iodide 
(1.63 mmol, 0.13 mL) were then added and the reaction was stirred overnight at room 
temperature. The reaction was then concentrated in vacuo and the crude residue was purified 
using flash chromatography 4 – 10 % MeOH (3M ammonia)/DCM to give ((3S,4R)-1-ethyl-4-
(4-fluorophenyl)piperidin-3-yl)methanol 94 (0.167g, 47% yield). 
1
H NMR (400 MHz, DMSO-
d6) δ 7.27 – 7.21 (m, 2H), 7.10 (t, J = 8.8 Hz, 2H), 4.31 (s, 1H), 3.17 (d, J = 8.9 Hz, 1H), 3.08 (d, 
J = 10.8 Hz, 1H), 2.93 (dt, J = 10.2, 6.6 Hz, 2H), 2.34 (d, J = 8.3 Hz, 2H), 2.25 (s, 1H), 1.81 (s, 




((3S,4R)-4-(4-fluorophenyl)-1-isopropylpiperidin-3-yl)methanol (95). Preparation of compound 
95 was accomplished by dissolving ((3S,4R)-4-(4-fluorophenyl)piperidin-3-yl)methanol 93 
(0.765 mmol, 0.160 g) and sodium cyanoborohydride (2.30 mmol, 0.144 g)  in THF (2.0 mL) 
and acetone (2.0 mL) at 0
o 
C. Acetic acid (3.06 mmol, 0.175 mL) was then added dropwise and 
the reaction was stirred overnight warming to room temperature. The reaction was neutralized 
with 2N NaOH and then extracted with ethyl acetate. The organic layer was washed 2x with 
NaCl, dried over MgSO4 and concentrated to give the desired product 95 (0.15 g, 78% yield). 
1
H 
NMR (400 MHz, Chloroform-d) δ 7.20 – 7.13 (m, 2H), 7.01 – 6.94 (m, 2H), 3.42 (dd, J = 10.9, 
3.3 Hz, 1H), 3.25 (dd, J = 10.9, 6.9 Hz, 1H), 3.18 (ddd, J = 11.1, 3.7, 1.9 Hz, 1H), 2.96 (dd, J = 
11.1, 2.4 Hz, 1H), 2.80 (p, J = 6.5 Hz, 1H), 2.35 – 2.17 (m, 2H), 2.11 (t, J = 10.9 Hz, 1H), 1.96 
(ddp, J = 10.8, 7.2, 3.4 Hz, 1H), 1.80 (td, J = 7.4, 6.9, 3.1 Hz, 2H), 1.09 (d, J = 6.6 Hz, 6H). 
 
tert-butyl 5-(((3S,4R)-1-(tert-butoxycarbonyl)-4-(4-fluorophenyl)piperidin-3-yl)methoxy)-1H-
indazole-1-carboxylate (98). Intermediate 98 was synthesized as described for intermediate 76 
replacing (3S,4R)-tert-butyl 4-(4-fluoro-3-(methoxycarbonyl) phenyl)-3-
(hydroxymethyl)piperidine-1-carboxylate 66 with (3S,4R) -tert-butyl 4-(4-fluorophenyl)-3-
(hydroxymethyl)piperidine-1-carboxylate 96. Purification proceeded using preparative 




H NMR (400 MHz, Chloroform-d) δ 8.03 (d, J = 9.6 Hz, 1H), 8.00 (d, J = 0.8 Hz, 1H), 
7.18 – 7.12 (m, 2H), 7.08 (dd, J = 9.1, 2.4 Hz, 1H), 6.97 (t, J = 8.7 Hz, 2H), 6.85 (d, J = 2.3 Hz, 
1H), 4.49 (s, 1H), 4.25 (s, 1H), 3.73 (dd, J = 9.4, 2.9 Hz, 1H), 3.57 (dd, J = 9.4, 6.6 Hz, 1H), 2.87 
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(d, J = 21.0 Hz, 3H), 2.72 (td, J = 11.7, 3.9 Hz, 1H), 2.07 (d, J = 17.0 Hz, 1H), 1.88 – 1.74 (m, 
1H), 1.71 (s, 9H), 1.50 (s, 9H). 
 
tert-butyl 5-(((3S,4R)-1-(tert-butoxycarbonyl)-4-(4-fluorophenyl)piperidin-3-yl)methoxy)-6-
fluoro-1H-indazole-1-carboxylate (99). Intermediate 99 was synthesized as described for 
intermediate 98 replacing 91 with intermediate 92.
 1
H NMR (400 MHz, Chloroform-d) δ 7.98 (s, 
1H), 7.90 (d, J = 11.0 Hz, 1H), 7.19 – 7.14 (m, 2H), 6.97 (t, J = 8.5 Hz, 2H), 6.90 (d, J = 7.8 Hz, 
1H), 4.49 (d, J = 13.3 Hz, 1H), 4.22 (s, 1H), 3.79 (dd, J = 9.4, 2.7 Hz, 1H), 3.61 (dd, J = 9.3, 6.1 




carboxylate (100). Intermediate 100 was synthesized as described for intermediate 64 replacing 
(3S,4R)-tert-butyl 4-(4-fluoro-3-(methoxycarbonyl) phenyl)-3-(hydroxymethyl)piperidine-1-
carboxylate 62 with ((3S,4R)-4-(4-fluorophenyl)-1-methylpiperidin-3-yl)methanol 97 (26% 
yield).
 1
H NMR (400 MHz, Chloroform-d) δ 8.02 (d, J = 9.2 Hz, 1H), 8.00 (d, J = 0.8 Hz, 1H), 
7.17 (dt, J = 8.5, 6.0 Hz, 3H), 7.07 (dd, J = 9.1, 2.4 Hz, 1H), 7.04 – 6.94 (m, 3H), 6.85 (d, J = 2.3 
Hz, 1H), 3.93 (dd, J = 9.9, 3.1 Hz, 1H), 3.81 (dd, J = 9.9, 6.9 Hz, 1H), 3.70 (dd, J = 9.3, 3.0 Hz, 
1H), 3.57 (dd, J = 9.3, 7.0 Hz, 1H), 3.38 – 3.30 (m, 1H), 3.25 (ddd, J = 11.2, 3.8, 1.6 Hz, 1H), 
3.12 (ddd, J = 11.3, 3.7, 1.8 Hz, 1H), 2.97 (dd, J = 16.7, 12.2 Hz, 2H), 2.87 (s, 1H), 2.49 (td, J = 
11.4, 4.7 Hz, 1H), 2.38 (s, 3H), 2.36 (s, 1H), 2.33 – 2.20 (m, 2H), 2.08 (dt, J = 11.8, 4.2 Hz, 2H), 





carboxylate (101). Compound 101 was synthesized as described for intermediate 64 replacing 
(3S,4R)-tert-butyl 4-(4-fluoro-3-(methoxycarbonyl) phenyl)-3-(hydroxymethyl)piperidine-1-
carboxylate 62 with intermediate 94. The product was inseparable from starting material 94. The 
mixture was taken forward as is.  
 
tert-butyl 5-(((3S,4R)-4-(4-fluorophenyl)-1-isopropylpiperidin-3-yl)methoxy)-1H-indazole-1-
carboxylate (102). Compound 102 was synthesized as described for intermediate 64 replacing 
(3S,4R)-tert-butyl 4-(4-fluoro-3-(methoxycarbonyl) phenyl)-3-(hydroxymethyl)piperidine-1-
carboxylate 62 with intermediate 95. The product was inseparable from starting material 95. The 
mixture was taken forward as is.  
 
5-(((3S,4R)-4-(4-fluorophenyl)piperidin-3-yl)methoxy)-1H-indazole (1103, CCG224061). 
Prepared from intermediate 98 as described for 80bb (yield: 86%).
 1
H NMR (500 MHz, DMSO-
d6) δ 12.89 (s, 1H), 7.86 (s, 1H), 7.38 (d, J = 9.3 Hz, 1H), 7.29 (dd, J = 8.4, 5.5 Hz, 2H), 7.11 (t, 
J = 8.8 Hz, 2H), 6.92 – 6.85 (m, 2H), 3.55 (qd, J = 9.7, 5.3 Hz, 2H), 3.31 – 3.26 (m, 2H), 3.01 
(dd, J = 12.5, 3.4 Hz, 1H), 2.59 (qd, J = 13.0, 12.2, 4.5 Hz, 2H), 2.05 (dtt, J = 11.0, 7.3, 4.2 Hz, 
1H), 1.63 (q, J = 4.3 Hz, 2H). MS (ESI+) m/z:371.2 (M+2Na). HPLC purity 97%. 
 
6-fluoro-5-(((3S,4R)-4-(4-fluorophenyl)piperidin-3-yl)methoxy)-1H-indazole (104, 258002). 
Prepared from Intermediate 99 as described for 80ab with a further purification step of flash 
chromatography 5% - 10% MeOH (7M Ammonia) in dichloromethane to give the desired 
product (yield 25%). 
1
H NMR (500 MHz, Methanol-d4) δ 7.86 (d, J = 1.0 Hz, 1H), 7.31 – 7.19 
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(m, 3H), 7.01 (td, J = 8.8, 8.4, 5.9 Hz, 3H), 3.75 (dd, J = 9.6, 2.9 Hz, 1H), 3.67 – 3.60 (m, 1H), 
3.42 (dd, J = 13.1, 4.1 Hz, 1H), 3.15 (d, J = 12.5 Hz, 1H), 2.77 (ddq, J = 15.9, 7.8, 3.7 Hz, 3H), 




CCG258001). Compound 105 was prepared from intermediate 100 as described for 80ab. 
Further purification using flash chromatography 5% MeOH (7M ammonia) in dichloromethane 
gave the desired product (60% yield). 
1
H NMR (500 MHz, Methanol-d4) δ 7.84 (d, J = 1.0 Hz, 
1H), 7.38 (dt, J = 9.0, 0.8 Hz, 1H), 7.29 – 7.24 (m, 2H), 7.05 – 6.95 (m, 3H), 6.89 (d, J = 2.3 Hz, 
1H), 3.69 (dd, J = 9.6, 3.0 Hz, 1H), 3.60 (dd, J = 9.7, 6.9 Hz, 1H), 3.29 – 3.24 (m, 1H), 3.01 (ddt, 
J = 11.5, 4.1, 2.3 Hz, 1H), 2.60 (td, J = 11.6, 4.6 Hz, 1H), 2.39 (s, 3H), 2.28 (tdt, J = 10.7, 6.7, 
3.3 Hz, 1H), 2.20 – 2.15 (m, 2H), 1.95 – 1.81 (m, 2H).  MS (ESI+) m/z:340.2 (M+1). HPLC 
purity 95%. 
 
5-(((3S,4R)-1-ethyl-4-(4-fluorophenyl)piperidin-3-yl)methoxy)-1H-indazole (106 -258211 – 9-
13). Compound 106 was prepared as described for 80ab replacing intermediate 80aa with 
intermediate 101. Further purification with 0 – 6% MeOH (3M ammonia)/DCM gave the desired 
product (42% yield over two steps). 
1
H NMR (500 MHz, Methanol-d4) δ 7.85 (d, J = 1.0 Hz, 
1H), 7.39 (dt, J = 9.0, 0.8 Hz, 1H), 7.29 – 7.25 (m, 2H), 7.05 – 6.99 (m, 2H), 6.98 (dd, J = 9.0, 
2.3 Hz, 1H), 6.90 (d, J = 2.2 Hz, 1H), 3.71 (dd, J = 9.7, 2.9 Hz, 1H), 3.61 (dd, J = 9.7, 6.7 Hz, 
1H), 3.40 (ddd, J = 11.3, 3.4, 1.8 Hz, 1H), 3.18 – 3.13 (m, 1H), 2.63 (dtt, J = 17.3, 7.2, 3.9 Hz, 
234 
 
3H), 2.35 – 2.26 (m, 1H), 2.26 – 2.18 (m, 2H), 1.20 (t, J = 7.2 Hz, 3H), 1.15 (d, J = 6.2 Hz, 2H). 
HPLC purity: 95%. 
 
5-(((3S,4R)-4-(4-fluorophenyl)-1-isopropylpiperidin-3-yl)methoxy)-1H-indazole (107, 258746 -
9-34). Compound 107 was prepared as described for 80ab replacing intermediate 80aa with 
intermediate 102. Further purification with 5– 10% MeOH (3M ammonia)/DCM gave the 
desired product as a white crystalline solid (43% yield over two steps). 
1
H NMR (400 MHz, 
Methanol-d4) δ 7.84 (d, J = 1.1 Hz, 1H), 7.38 (d, J = 9.0 Hz, 1H), 7.25 (dd, J = 8.5, 5.5 Hz, 2H), 
7.04 – 6.94 (m, 3H), 6.88 (d, J = 2.3 Hz, 1H), 3.68 (dd, J = 9.6, 2.7 Hz, 1H), 3.59 (dd, J = 9.6, 
6.8 Hz, 1H), 3.28 (d, J = 2.5 Hz, 1H), 3.07 – 2.99 (m, 1H), 2.86 (p, J = 6.6 Hz, 1H), 2.57 (td, J = 
10.7, 6.2 Hz, 1H), 2.40 – 2.21 (m, 3H), 1.85 (dq, J = 6.6, 3.3, 2.8 Hz, 2H), 1.14 (d, J = 6.6 Hz, 
6H). HPLC purity: 96%. 
 
2,4-dichloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine (9 – 81, 109): To a 100 mL round bottom 
flask was added 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine 108 (1.0 g, 5.32 mmol), 4 – 
methylbenzene – 1 – sulfonyl chloride (1.12 g, 5.85 mmol), tetra – butyl ammonium chloride 
(0.07 g, 0.27 mmol), and dichloromethane (20 mL). Then 6N sodium hydroxide (2.66 mL, 15.96 
mmol) was added dropwise. The slurry was stirred at room temperature vigorously for 1.5 hours 
going from cloudy to clear. The reaction was then diluted with water and the layers were 
separated. The organic layer was washed with NaCl (1x), and then dried with MgSO4. The 
MgSO4 was filtered off and the filtrate was then concentrated. The resulting off white solid was 
purified using 100% dichloromethane to give the title compound as a white solid (1.64 g, 4.79 
mmol, 89% yield). 
1
H NMR (500 MHz, DMSO-d6) δ 8.13 (d, J = 4.0 Hz, 1H), 8.07 – 8.01 (m, 
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2H), 7.51 (d, J = 8.2 Hz, 2H), 6.99 (d, J = 4.1 Hz, 1H), 2.39 (s, 4H). HPLC (gradient A): 
retention time = 8.207 min; purity = 98%. 
 
 2-((2-chloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)benzamide (10 – 10, 111): To a 
100 mL round bottom flask was added 2,4-dichloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine 109 
(0.93 g, 2.72 mmol) and 2 – aminobenzamide 110 (1.48 g, 10.88 mmol). Isopropanol (16 mL) 
and di-isopropylethylamine (2.38 mL, 13.6 mmol) were then added and the reaction was heated 
to reflux at 85 ˚C. All solids went into solution upon heating. After refluxing overnight the 
reaction was cooled down and the resulting white precipitate was filtered off and washed with 
additional isopropanol to give the title compound (1.10 g, 2.49 mmol, 92% yield). 
1
H NMR (400 
MHz, DMSO-d6) δ 12.34 (s, 1H), 8.50 – 8.43 (m, 1H), 8.32 (s, 1H), 8.00 (d, J = 8.2 Hz, 2H), 
7.85 (d, J = 7.9 Hz, 1H), 7.81 (s, 1H), 7.77 (d, J = 3.9 Hz, 1H), 7.59 (t, J = 7.9 Hz, 1H), 7.49 (d, 
J = 8.1 Hz, 2H), 7.19 (t, J = 7.6 Hz, 1H), 6.70 (d, J = 4.0 Hz, 1H), 2.38 (s, 3H). HPLC (gradient 
A): retention time = 7.890 min; purity = 99%.  
 
(9H-fluoren-9-yl)methyl (4-methoxy-3-((7-oxo-3-tosyl-3,7-
dihydropyrrolo[2',3':4,5]pyrimido[6,1-b]quinazolin-5-yl)amino)phenyl)carbamate (10 – 5, 113): 
To a 100 mL pressure vessel was added 2-((2-chloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-
yl)amino)benzamide 111 (0.60 g, 1.36 mmol), (9H-fluoren-9-yl)methyl (3-amino-4-
methoxyphenyl)carbamate 112 (0.515 g, 1.43 mmol), 4M HCl in dioxanes (1.36 mL, 5.44 
mmol), potassium iodide (0.04 g, 0.24 mmol), and trifluoroethanol (40 mL). The sealed reaction 
was then heated overnight at 90 ˚C. The following day the reaction was cooled to room 
temperature and then diluted with water and an excessive amount of dichloromethane (~100 mL, 
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otherwise an emulsion will form). The layers were separated and the organic was washed with 
NaCl (1x) and dried with sodium sulfate. The sodium sulfate was then filtered off and the filtrate 
was concentrated to give a light yellow/orange solid which was taken as is to the next step. 
 
(9H-fluoren-9-yl)methyl (4-methoxy-3-((7-oxo-3-tosyl-3,7-
dihydropyrrolo[2',3':4,5]pyrimido[6,1-b]quinazolin-5-yl)amino)phenyl)carbamate (10-8, 114): 
To a 100 mL pressure vessel was added (9H-fluoren-9-yl)methyl (4-methoxy-3-((7-oxo-3-tosyl-
3,7-dihydropyrrolo[2',3':4,5]pyrimido[6,1-b]quinazolin-5-yl)amino)phenyl)carbamate 113 (1.02 
g, 1.36 mmol), 28% ammonium hydroxide in water (20 mL), and THF (20mL). The reaction was 
heated to 60 ˚C overnight. After cooling the reaction was diluted with ethyl acetate and water. 
The layers were separated and the organic layer was washed with NaCl (2x) and then dried of 
sodium sulfate. The sodium sulfate was filtered off and the filtrate was concentrated. The 
resulting orange solid was triturated in dichloromethane to give the title compound as an off 
white solid (0.378 g, 0.70 mmol, 51% yield over two steps). 
1
H NMR (400 MHz, DMSO-d6) δ 
12.13 (s, 1H), 8.76 (dd, J = 8.5, 1.1 Hz, 1H), 8.31 (s, 1H), 8.03 – 7.97 (m, 2H), 7.93 (s, 1H), 7.83 
(dd, J = 8.0, 1.5 Hz, 1H), 7.76 (s, 1H), 7.49 (ddd, J = 8.6, 5.7, 1.5 Hz, 2H), 7.41 (d, J = 4.0 Hz, 
1H), 7.38 (d, J = 8.2 Hz, 2H), 7.09 – 7.02 (m, 1H), 6.81 (d, J = 8.6 Hz, 1H), 6.53 (d, J = 4.0 Hz, 
1H), 6.37 (dd, J = 8.5, 2.7 Hz, 1H), 4.55 (s, 2H), 3.72 (s, 3H), 2.34 (s, 3H). HPLC (gradient A): 
retention time = 5.850 min; purity = 88%.  
 
2-((2-((5-amino-2-methoxyphenyl)amino)-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-4-




5-yl)amino)phenyl)carbamate 114 (0.158 g, 0.291 mmol), methanol (2 mL), 3N potassium 
hydroxide (2 mL) and THF (4.5 mL). The reaction was heated to 65 ˚C and stirred overnight for 
two days. The reaction was then cooled and the organic layers were concentrated off. The 
resulting suspension in the aqueous layer was then filtered off to give adequately pure compound 
(0.082 mg, 72% yield). 
1
H NMR (500 MHz, DMSO-d6) δ 11.99 (s, 1H), 11.33 (s, 1H), 8.97 (d, J 
= 8.1 Hz, 1H), 8.28 (s, 1H), 7.83 (dd, J = 8.0, 1.5 Hz, 1H), 7.72 (s, 1H), 7.59 – 7.49 (m, 2H), 
7.39 (s, 1H), 7.06 – 6.97 (m, 2H), 6.73 (d, J = 8.6 Hz, 1H), 6.29 (dd, J = 3.5, 1.9 Hz, 1H), 6.21 
(dd, J = 8.5, 2.7 Hz, 1H), 4.47 (s, 2H), 3.74 (s, 3H). HPLC (gradient A): retention time = 4.166 
min; purity = 91%. 
 
2-((2-((5-acrylamido-2-methoxyphenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-
yl)amino)benzamide (10 – 57, CCG258904, 116a): In a 25 mL flask 2-((2-((5-amino-2-
methoxyphenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)benzamide 115 (0.088 g, 0.226 
mmol) was dissolved in THF (6.0 mL). Diisopropylethylamine (0.12 mL, 0.678 mmol) and 1-
Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.087 g, 0.452 mmol) were then 
added and the reaction was stirred ten minutes and cooled to 0 ˚C. Acrylic acid (0.017 mL, 0.249 
mmol) was then added and the reaction was allowed to warm to room temperature and stir 
overnight. Water was added to quench the reaction and then ethyl acetate was added to extract 
the organics. The layers were separated and the organic layer was washed with NaCO3 (1x), 
dried over magnesium sulfate, and concentrated. The resulting residue was subjected to flash 
chromatography (5 – 10% MeOH/DCM) and then repurified using reverse phase 
chromatography (30 – 60% Acetonitrile/Water) to give the desired compound as a light yellow 
solid (0.012 g, 0.026 mmol, 12% yield). 
1
H NMR (500 MHz, DMSO-d6) δ 12.05 (s, 1H), 11.44 
238 
 
(s, 1H), 10.05 (s, 1H), 8.94 (d, J = 8.4 Hz, 1H), 8.28 (d, J = 2.8 Hz, 2H), 7.82 (dd, J = 7.9, 1.6 
Hz, 1H), 7.73 (s, 1H), 7.59 (s, 1H), 7.44 – 7.36 (m, 2H), 6.98 (q, J = 7.1, 5.9 Hz, 3H), 6.45 (dd, J 
= 17.0, 10.2 Hz, 1H), 6.29 (d, J = 3.5 Hz, 1H), 6.22 (dd, J = 17.0, 2.1 Hz, 1H), 5.71 (dd, J = 10.0, 
2.1 Hz, 1H), 3.84 (s, 3H). HPLC (gradient A): retention time = 4.921 min; purity = 93%. 
 
(E)-2-((2-((4-(4-(dimethylamino)but-2-enamido)-2-methoxyphenyl)amino)-7H-pyrrolo[2,3-
d]pyrimidin-4-yl)amino)benzamide (11 – 22, CCG263115, 116b): In a 25 mL flask 2-((2-((5-
amino-2-methoxyphenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)benzamide 115 (0.073 
g, 0.187 mmol) was dissolved in THF (4.0 mL). Diisopropylethylamine (0.10 mL, 0.561 mmol) 
and 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.047 g, 0.243 mmol) were 
then added and the reaction was stirred ten minutes and cooled to 0 ˚C. Trans – 4 – 
dimethylamino crotic acid hydrochloride (0.034 g, 0.206 mmol) was then added and the reaction 
was allowed to warm to room temperature and stir three hours. Water was added to quench the 
reaction and then ethyl acetate was added to extract the organics. The layers were separated and 
the organic layer was washed with NaCl (1x), dried over magnesium sulfate, and concentrated. 
The resulting residue was purified using flash chromatography (5 – 10% MeOH/DCM) to give a 
light brown solid as the desired compound (0.012 g, 0.024 mmol, 13% yield). 
1
H NMR (500 
MHz, DMSO-d6) δ 12.07 (s, 1H), 11.34 (s, 1H), 9.88 (s, 1H), 8.94 (dd, J = 8.6, 1.2 Hz, 1H), 8.30 
(s, 1H), 8.24 (d, J = 2.5 Hz, 1H), 7.82 (dd, J = 7.9, 1.6 Hz, 1H), 7.74 (s, 1H), 7.60 (s, 1H), 7.43 – 
7.34 (m, 2H), 7.05 – 6.94 (m, 3H), 6.75 – 6.65 (m, 1H), 6.30 – 6.22 (m, 2H), 3.83 (s, 3H), 3.04 






7(3H)-one (119): To a 100 mL pressure vessel was added 2-((2-chloro-7-tosyl-7H-pyrrolo[2,3-
d]pyrimidin-4-yl)amino)benzamide 111 (0.221 g, 0.500 mmol), (9H-fluoren-9-yl)methyl (4-
amino-3-methoxyphenyl)carbamate 117 (0.189 g, 0.525 mmol), 4M HCl in dioxanes (0.50 mL, 
2.0 mmol), potassium iodide (0.01 g, 0.06 mmol), and trifluoroethanol (10 mL). The sealed 
reaction was then heated overnight at 90 ˚C. The following day the reaction was cooled to room 
temperature and then a light yellow/orange solid was filtered off and taken as is to the next step. 
 
2-((2-((4-amino-2-methoxyphenyl)amino)-7-tosyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-4-
yl)amino)benzamide (10-13 – 119): To a 50 mL pressure vessel was added 5-((4-amino-2-
methoxyphenyl)amino)-3-tosylpyrrolo[2',3':4,5]pyrimido[6,1-b]quinazolin-7(3H)-one 118 (0.264 
g, 0.50 mmol), 28% ammonium hydroxide in water (10 mL), and THF (10mL). The reaction was 
heated to 60 ˚C overnight. After cooling the reaction was diluted with dichloromethane and 
water. The layers were separated and the organic layer was washed with NaCl (2x) and then 
dried of sodium sulfate. The sodium sulfate was filtered off and the filtrate was concentrated. 
The resulting orange solid was purified using 0-10% MeOH/DCM to give the title compound as 
a white solid (0.120 g, 0.065 mmol, 44% yield over two steps).
 1
H NMR (400 MHz, DMSO-d6) δ 
12.12 (s, 1H), 8.80 (s, 1H), 8.31 (s, 1H), 7.93 (d, J = 7.8 Hz, 2H), 7.84 – 7.80 (m, 1H), 7.75 (s, 
1H), 7.36 (d, J = 8.1 Hz, 3H), 7.33 (d, J = 4.0 Hz, 1H), 7.02 (t, J = 7.6 Hz, 1H), 6.46 (d, J = 4.0 
Hz, 1H), 6.38 (d, J = 2.2 Hz, 1H), 6.32 – 6.24 (m, 1H), 5.02 (s, 2H), 3.70 (s, 3H), 2.36 (s, 3H). 





yl)amino)benzamide (10-66, 120): To a 50 mL round bottom flask was added 2-((2-((4-amino-2-
methoxyphenyl)amino)-7-tosyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)benzamide 
119 (0.315 g, 0.579 mmol) followed by THF (10 mL), MeOH (2 mL), and 3N potassium 
hydroxide (6.0 mL). The reaction was stirred, refluxing, at 65 ˚C overnight. After cooling the 
organic solvents were concentrated off and then the reaction was diluted with ethyl acetate. The 
layers were then separated and the organic layer was washed with NaCl (1x) and dried over 
sodium sulfate. The sodium sulfate was then filtered off and the resulting filtrate was 
concentrated and purified using 0% - 8% MeOH/DCM to give the title compound as a slightly 
grey solid (0.132 g, 0.339 mmol, 59% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 11.95 (s, 1H), 
11.19 (s, 1H), 8.97 (d, J = 8.5 Hz, 1H), 8.28 (s, 1H), 7.88 – 7.77 (m, 1H), 7.77 – 7.65 (m, 1H), 
7.52 (d, J = 8.3 Hz, 1H), 7.41 (t, J = 7.9 Hz, 1H), 7.29 (s, 1H), 6.98 (t, J = 7.5 Hz, 1H), 6.91 (dd, 
J = 3.4, 2.2 Hz, 1H), 6.33 (d, J = 2.3 Hz, 1H), 6.22 (dd, J = 3.5, 1.9 Hz, 1H), 6.18 (dd, J = 8.4, 




yl)amino)benzamide (10-56, 121a, CCG258903)): In a 25 mL flask 2-((2-((4-amino-2-
methoxyphenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)benzamide 120 (0.10 g, 0.257 
mmol) was dissolved in THF (6.0 mL). Diisopropylethylamine (0.134 mL, 0.770 mmol) and 1-
Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.098 g, 0.512 mmol) were then 
added and the reaction was stirred ten minutes and cooled to 0 ˚C. Acrylic acid (0.02 mL, 0.282 
mmol) was then added and the reaction was allowed to warm to room temperature and stir 
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overnight. Water was added to quench the reaction and then ethyl acetate was added to extract 
the organics. The layers were separated and the organic layer was washed with NaCO3 (1x), 
dried over magnesium sulfate, and concentrated. The resulting residue was purified using flash 
chromatography (0 – 10% MeOH/DCM) to give a light yellow solid as the desired compound 
(0.0107 g, 0.024 mmol, 10% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 11.99 (s, 1H), 11.36 (s, 
1H), 10.10 (s, 1H), 8.93 (d, J = 8.5 Hz, 1H), 8.30 (s, 1H), 8.20 (d, J = 8.7 Hz, 1H), 7.83 (d, J = 
7.7 Hz, 1H), 7.74 (s, 1H), 7.56 – 7.43 (m, 3H), 7.24 – 7.16 (m, 1H), 7.07 – 6.97 (m, 2H), 6.44 
(dd, J = 17.0, 10.1 Hz, 1H), 6.32 – 6.20 (m, 2H), 5.78 – 5.70 (m, 1H), 3.85 (s, 3H). HPLC 
(gradient A): retention time = 4.987 min; purity = 95%. 
 
(E)-2-((2-((4-(4-(dimethylamino)but-2-enamido)-2-methoxyphenyl)amino)-7H-pyrrolo[2,3-
d]pyrimidin-4-yl)amino)benzamide (10 – 78, CCG263045, 121): In a 25 mL flask 2-((2-((4-
amino-2-methoxyphenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)benzamide 120 (0.137 
g, 0.352 mmol) was dissolved in THF (6.0 mL). Diisopropylethylamine (0.246 mL, 0.1.41 
mmol) and 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.108 g, 0.563 
mmol) were then added and the reaction was stirred ten minutes and cooled to 0 ˚C. Trans – 4 – 
dimethylamino crotic acid hydrochloride (0.070 g, 0.422 mmol) was then added and the reaction 
was allowed to warm to room temperature and stir overnight. Water was added to quench the 
reaction and then ethyl acetate was added to extract the organics. The layers were separated and 
the organic layer was washed with NaCl (1x), dried over magnesium sulfate, and concentrated. 
The resulting residue was purified using flash chromatography (5 – 10% MeOH/DCM) to give a 
light brown solid as the desired compound (0.017 g, 0.034 mmol, 10% yield). 
1
H NMR (400 
MHz, DMSO-d6) δ 11.99 (s, 1H), 11.36 (s, 1H), 10.02 (s, 1H), 8.94 (dd, J = 8.4, 1.2 Hz, 1H), 
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8.30 (s, 1H), 8.17 (d, J = 8.7 Hz, 1H), 7.83 (dd, J = 8.1, 1.6 Hz, 1H), 7.75 (s, 1H), 7.56 – 7.42 
(m, 3H), 7.17 (dd, J = 8.7, 2.1 Hz, 1H), 7.07 – 6.96 (m, 2H), 6.72 (dt, J = 15.4, 5.9 Hz, 1H), 6.31 
– 6.24 (m, 2H), 3.84 (s, 3H), 3.10 – 3.03 (m, 2H), 2.19 (s, 6H). HPLC (gradient A): retention 
time = 4.305 min; purity = 97%. 
 
(9H-fluoren-9-yl)methyl (4-methoxy-3-nitrophenyl)carbamate (123 – 10 -49): In a 100 mL round 
bottom flask 4-methoxy-3-nitroaniline 122 (0.78 g, 4.64 mmol) and sodium carbonate (0.516 g, 
4.87 mmol) were dissolved in water (15 mL). Fluorenylmethyloxycarbonyl chloride (1.26 g, 4.87 
mmol) dissolved in dioxanes (31 mL) was then added dropwise to the reaction vessel and the 
reaction was stirred overnight. The resulting white precipitate was then filtered off to afford the 
desired product (1.20 g, 3.07 mmol, 66% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 9.92 (s, 1H), 
8.05 (s, 1H), 7.91 (d, J = 7.5 Hz, 2H), 7.74 (d, J = 7.5 Hz, 2H), 7.66 (s, 1H), 7.43 (t, J = 7.3 Hz, 
2H), 7.35 (td, J = 7.5, 1.2 Hz, 2H), 7.31 (s, 1H), 4.52 (d, J = 6.5 Hz, 2H), 4.31 (d, J = 6.6 Hz, 
1H), 3.87 (s, 3H). HPLC (gradient A): retention time = 8.154 min; purity = 97%. 
 
(9H-fluoren-9-yl)methyl (3-amino-4-methoxyphenyl)carbamate (112 – 10-51): To a 250 mL 
round bottom flask was added (9H-fluoren-9-yl)methyl (4-methoxy-3-nitrophenyl)carbamate 
123 (1.0 g, 2.56 mmol), Fe (II) powder (0.715 g, 12.81 mmol), water (10 mL), and EtOH (40 
mL). Concentrated HCl was then added (12M, 0.1 mL) and the reaction was heated to 75 ˚C and 
stirred for two hours. The reaction was filtered through celite and washed with ethanol then the 
filtrate was concentrated. The resulting crude material was then purified using flash 
chromatography with a gradient of 5% - 10% MeOH/DCM to afford the desired product as a 
solid (0.699 g, 1.94 mmol, 76% yield). 
1
H NMR (500 MHz, DMSO-d6) δ 9.29 (s, 1H), 7.91 (d, J 
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= 7.6 Hz, 2H), 7.75 (d, J = 7.5 Hz, 2H), 7.43 (t, J = 7.4 Hz, 2H), 7.35 (td, J = 7.5, 1.1 Hz, 2H), 
6.84 (s, 1H), 6.67 (d, J = 8.6 Hz, 1H), 6.61 (d, J = 25.3 Hz, 1H), 4.71 (s, 2H), 4.39 (d, J = 7.0 Hz, 
2H), 4.28 (t, J = 6.9 Hz, 1H), 3.70 (s, 3H). HPLC (gradient A): retention time = 6.143 min; 
purity = 86%. 
 
tert-butyl (2-methoxy-4-nitrophenyl)carbamate (9-82, 125): To a 100 mL flask was added 2-
methoxy-4-nitroaniline 124 (1.0 g, 5.95 mmol), di-tertbutyl carbonate (1.95 g, 8.92 mmol), 
diisopropyl ethylamine (1.66 mL, 9.52 mmol), 4-dimethylaminopyridine (0.15 g, 1.19 mmol), 
and THF (30 mL). The reaction was stirred at room temperature overnight then diluted with 
water and ethyl acetate. The layers were separated and the organic layer was washed with water 
(2x), then with NaCl (2x) and then dried with magnesium sulfate. The magnesium sulfate was 
then filtered off and the filtrate was concentrated. The resulting crude material was purified by 
flash chromatography to give the desired compound (0.527 g, 1.96 mmol, 33% yield). 
1
H NMR 
(400 MHz, DMSO-d6) δ 8.56 (s, 1H), 8.09 (d, J = 9.0 Hz, 1H), 7.89 (dd, J = 9.0, 2.5 Hz, 1H), 
7.77 (d, J = 2.5 Hz, 1H), 3.94 (s, 3H), 1.49 (s, 9H). 
 
tert-butyl (4-amino-2-methoxyphenyl)carbamate (9-92, 126): To a 100 mL round bottom flask 
was added tert-butyl (2-methoxy-4-nitrophenyl)carbamate 125 (0.839 g, 3.13 mmol), 10% 
palladium on carbon (0.08 g), Ethanol (10 mL), and THF (10 mL). Argon was then bubbled 
through the reaction mixture. The vessel was then vacuumed and the atmosphere replaced with 
H2. The reaction was stirred overnight at room temperature and then filtered through celite with 
ethanol. The filtrate was then concentrated to give an amorphous deep red solid that was taken as 
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is to the next step (0.746 g, 3.13 mmol, quantitative crude yield). HPLC (gradient A): retention 
time = 4.598 min; purity = 93%. 
(9H-fluoren-9-yl)methyl tert-butyl (2-methoxy-1,4-phenylene)dicarbamate (10-4, 127): In a 100 
mL round bottom flask tert-butyl (4-amino-2-methoxyphenyl)carbamate 126 (0.746 g, 3.13 
mmol) was dissolved in dichloromethane (30 mL) followed by fluorenylmethyloxycarbonyl 
chloride (0.891 g, 3.44 mmol) and diisopropylethylamine (2.73 mL, 15.65 mmol). The` reaction 
was stirred at room temperature overnight. Approximately 15 mL of dichloromethane were then 
concentrated off and white crystals began to form. The reaction was left to sit for four hours at 
room temperature and then the resulting white crystals were filtered off to afford the desired 
product (0.983 g, 2.13 mmol, 68% yield over two steps). 
1
H NMR (400 MHz, Chloroform-d) δ 
7.97 (s, 1H), 7.78 (d, J = 7.6 Hz, 2H), 7.61 (d, J = 7.5 Hz, 2H), 7.41 (t, J = 7.5 Hz, 2H), 7.33 (t, J 
= 7.4 Hz, 2H), 6.95 (s, 1H), 6.66 (dd, J = 8.8, 2.3 Hz, 1H), 6.58 (s, 1H), 4.51 (d, J = 6.7 Hz, 2H), 
4.27 (t, J = 6.8 Hz, 1H), 3.86 (s, 3H), 1.52 (s, 9H). HPLC (gradient A): retention time = 9.053 
min; purity = 81%. 
 
(9H-fluoren-9-yl)methyl (4-amino-3-methoxyphenyl)carbamate (10 -38, 117): In a 25 mL flask 
(9H-fluoren-9-yl)methyl tert-butyl (2-methoxy-1,4-phenylene)dicarbamate 126 (0.242 g, 0.525 
mmol) was dissolved in dichloromethane (3.0 mL) and then 4M HCl in dioxanes (3.0 mL) was 
slowly added. The reaction was stirred for two hours at room temperature and then concentrated 
to give (9H-fluoren-9-yl)methyl (4-amino-3-methoxyphenyl)carbamate as the HCl salt (0.189 g, 





yl)amino)benzamide (10-12, 128): To a 25 mL round bottom flask was added (9H-fluoren-9-
yl)methyl (4-methoxy-3-((7-oxo-3-tosyl-3,7-dihydropyrrolo[2',3':4,5]pyrimido[6,1-b]quinazolin-
5-yl)amino)phenyl)carbamate  114 (0.100 g, 0.184 mmol), 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (0.071 g, 0.368 mmol), diisopropylethylamine 
(0.096 mL, 0.552 mmol), and THF (4.0 mL). The reaction was cooled to 0 ˚C and then stirred for 
ten minutes before adding propionic acid (0.017 mL, 0.221 mmol).  The reaction was further 
stirred overnight. Water was added to quench the reaction and then the reaction was further 
diluted with ethyl acetate. The two layers were separated. The organic layer was washed with 
10% citric acid (1x), NaCl (2x), and then dried with sodium sulfate. The sodium sulfate was then 
filtered off and the filtrate was concentrated. The resulting residue was purified using 0 – 5% 
isopropanol/dichloromethane to give the title compound as a white solid (0.065 g, 0.108 mmol, 
59% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 12.20 (s, 1H), 9.71 (s, 1H), 8.71 (d, J = 8.4 Hz, 
1H), 8.32 (s, 1H), 8.26 (s, 1H), 7.97 (d, J = 8.2 Hz, 2H), 7.93 (d, J = 2.5 Hz, 1H), 7.82 (dd, J = 
8.0, 1.5 Hz, 1H), 7.77 (s, 1H), 7.39 (d, J = 4.0 Hz, 1H), 7.38 – 7.28 (m, 4H), 7.07 – 6.99 (m, 2H), 
6.50 (d, J = 4.0 Hz, 1H), 3.79 (s, 3H), 2.34 (s, 3H), 2.29 (q, J = 7.6 Hz, 2H), 1.07 (t, J = 7.6 Hz, 
3H). HPLC (gradient A): retention time = 7.195 min; purity = 93%.  
 
2-((2-((2-methoxy-5-propionamidophenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-
yl)amino)benzamide (10-15, 129, CCG262606): In a 25 mL flask 2-((2-((2-methoxy-5-
propionamidophenyl)amino)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)benzamide 128 
(0.062 g, 0.104 mmol)  was suspended in 1,4 – dioxanes (5.0 mL) and 2N NaOH (5.0 mL) and 
the reaction was stirred vigorously. After 2 hours the reaction was still cloudy and THF (3 mL) 
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and MeOH (1 mL) were then added and the reaction was stirred overnight. The organics were 
then concentrated off and the pH was lowered with concentrated HCl at which point a new side 
product formed. Assuming it was the cyclized lactam the compound was then stirred in a sealed 
reaction vessel with 28% NH4OH (4 mL) and THF (4 mL) at 40 ˚C for four hours, concentrated, 
and extracted with ethyl acetate (disappearance of the side product was observed confirming 
likelihood of it being the cyclized lactam). The organic was then washed with NaCl (1x), dried 
over MgSO4, and concentrated. The resulting residue was then purified on flash chromatography 
using a gradient of 0 – 5% MeOH/DCM to afford the desired product as a pale yellow solid 
(0.036 mg, 0.081 mmol, 78% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 12.07 (s, 1H), 11.33 (s, 
1H), 9.65 (s, 1H), 8.97 – 8.90 (m, 1H), 8.30 (s, 1H), 8.15 (d, J = 2.5 Hz, 1H), 7.83 (d, J = 7.9 Hz, 
1H), 7.75 (s, 1H), 7.58 (s, 1H), 7.39 (t, J = 7.8 Hz, 1H), 7.30 (dd, J = 8.8, 2.5 Hz, 1H), 7.04 – 
6.92 (m, 3H), 6.29 (dd, J = 3.5, 1.9 Hz, 1H), 3.82 (s, 3H), 2.27 (q, J = 7.6 Hz, 2H), 1.07 (t, J = 
7.6 Hz, 3H). HPLC (gradient A): retention time = 4.927 min; purity = 95% 
.  
2-((2-((2-methoxy-4-propionamidophenyl)amino)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-
yl)amino)benzamide (10-17, 130): To a 25 mL round bottom flask was added 2-((2-((4-amino-2-
methoxyphenyl)amino)-7-tosyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)benzamide  
119 (0.070 g, 0.128 mmol), 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(0.049 g, 0.258 mmol), diisopropylethylamine (0.068 mL, 0.387 mmol), and THF (4.0 mL). The 
reaction was cooled to 0 ˚C and then stirred for ten minutes before adding propionic acid (0.012 
mL, 0.155 mmol).  The reaction was further stirred overnight. Water was added to quench the 
reaction and then the reaction was further diluted with ethyl acetate. The two layers were 
separated. The organic layer was washed with 10% citric acid (1x), NaCl (2x), and then dried 
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with sodium sulfate. The sodium sulfate was then filtered off and the filtrate was concentrated. 
The resulting residue was purified using 0 – 5% methanol/dichloromethane to give the title 
compound as a light pink solid (0.022 g, 0.041 mmol, 32% yield). 
1
H NMR (400 MHz, DMSO-
d6) δ 12.12 (s, 1H), 9.88 (s, 1H), 8.75 (d, J = 8.4 Hz, 1H), 8.31 (s, 1H), 8.04 (s, 1H), 7.94 (d, J = 
8.1 Hz, 3H), 7.82 (dd, J = 8.0, 1.6 Hz, 1H), 7.76 (s, 1H), 7.50 (d, J = 2.1 Hz, 1H), 7.48 – 7.34 (m, 
4H), 7.20 (dd, J = 8.6, 2.1 Hz, 1H), 7.10 – 7.02 (m, 1H), 6.52 (d, J = 4.0 Hz, 1H), 3.81 (s, 3H), 
2.41 – 2.30 (m, 5H), 1.12 (t, J = 7.6 Hz, 3H). HPLC (gradient A): retention time = 7.312 min; 
purity = 94%. 
 
2-((2-((2-methoxy-4-propionamidophenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-
yl)amino)benzamide (10-18¸ 131, CCG262604): In a 25 mL round bottom flask a suspension of 
2-((2-((2-methoxy-4-propionamidophenyl)amino)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-
yl)amino)benzamide (0.022 g, 0.037 mmol), MeOH (1.0 mL), THF (4.0 mL), and 2N NaOH (4.0 
mL) was stirred overnight becoming clearer. The reaction was diluted with ethyl acetate and 
water. The layers were separated and the organic was washed with NaCl (1x), dried over MgSO4, 
and concentrated. The resulting crude residue was purified using 5% - 10% MeOH/DCM and 
then further purified by recrystallizing from 15% MeOH/DCM overnight (~ 1.5 mL) to give the 
title compound as an off white solid (0.013 g, 0.029 mmol, 78% yield). 
1
H NMR (400 MHz, 
DMSO-d6) δ 11.99 (s, 1H), 11.34 (s, 1H), 9.79 (s, 1H), 8.93 (d, J = 8.5 Hz, 1H), 8.30 (s, 1H), 
8.13 (d, J = 8.6 Hz, 1H), 7.83 (d, J = 8.0 Hz, 1H), 7.75 (s, 1H), 7.53 – 7.40 (m, 3H), 7.10 (d, J = 
8.7 Hz, 1H), 7.05 – 6.95 (m, 2H), 6.28 (s, 1H), 3.82 (s, 3H), 2.31 (q, J = 8.5, 7.5 Hz, 2H), 1.09 (t, 




2-((2-chloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)benzoic acid (140, HVW11-18): To 
a 100 mL flask was added 2,4-dichloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine 108 (0.50 g, 1.46 
mmol) followed by anthranilic acid (0.24 g, 1.75 mmol), and iPrOH (12 mL). 
Diisopropylethylamine (1.27 mL, 7.30 mmol) was then added and the suspension was refluxed at 
80 ˚C. After seven hours the reaction had become translucent and was then cooled and the iPOH 
was concentrated off in vacuo. The resulting yellow oil was taken up in ethyl acetate, washed 
with 1N HCl (10 mL), then saturated NaHCO3  (10 mL), and then brine (20 mL). The ethyl 
acetate layer was then dried over magnesium sulfate and concentrated to give a light yellow solid 
as the desired product 140 (0.61g, 1.38 mmol, 95% yield). 
1
H NMR (500 MHz, DMSO-d6) δ 
8.61 (dd, J = 8.3, 1.2 Hz, 1H), 8.04 (dt, J = 8.5, 2.0 Hz, 1H), 8.02 – 7.97 (m, 2H), 7.73 (d, J = 3.9 
Hz, 1H), 7.50 – 7.47 (m, 2H), 7.39 (ddd, J = 8.4, 7.2, 1.7 Hz, 1H), 7.00 (dd, J = 7.4, 1.2 Hz, 1H), 
6.72 (d, J = 3.9 Hz, 1H), 2.38 (s, 3H). HPLC (gradient A): retention time = 8.361 min; purity = 
90%. 
 
5-chloro-3-tosylpyrrolo[2',3':4,5]pyrimido[6,1-b]quinazolin-7(3H)-one (137, HVW11-19): To a 
100mL round bottom flask was added intermediate 140 (0.61 g, 1.38 mmol) and THF (18 mL) 
followed by a drop of DMF. Oxalyl chloride (0.24 mL, 2.75 mmol) was then added to the 
reaction dropwise. After stirring the reaction for three hours a milky white mixture developed. 
The reaction was then cooled to 4 ˚C for three hours. The white precipitate was then filtered off 
and washed with cold THF to afford the desired product 137 was a white solid (0.57 g, 97% 
yield). 
1
H NMR (400 MHz, DMSO-d6) δ 9.29 (dd, J = 9.0, 1.0 Hz, 1H), 8.17 (dd, J = 7.8, 1.8 Hz, 
1H), 8.03 – 7.98 (m, 2H), 7.86 (ddd, J = 9.0, 7.3, 1.8 Hz, 1H), 7.63 – 7.57 (m, 1H), 7.52 – 7.47 
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(m, 2H), 7.36 (d, J = 4.2 Hz, 1H), 7.09 (d, J = 4.2 Hz, 1H), 2.39 (s, 3H). HPLC (gradient A): 
retention time = 8.241 min; purity = 96%. 
 
(9H-fluoren-9-yl)methyl (3-amino-4-methoxybenzyl)carbamate (142, HVW11-13): In a 100 mL 
flask intermediate 5-(aminomethyl)-2-methoxyaniline 148 (0.55 g, 3.63 mmol) and Fmoc 
succinimide (1.23 g, 3.63 mmol) were dissolved in DCM (30 mL) at 0 ˚C. N-methylmorpholine 
(0.40 mL, 3.63 mmol) was then added and the reaction was stirred at 0 ˚C for one hour. The 
reaction was then diluted further with dichloromethane, washed with saturated NaHCO3 (1x), 
brine (2x), dried over MgSO4, and then concentrated. The resulting residue was purified using 
flash chromatography with a gradient of 0 – 5% MeOH/DCM to give the desired product 138 as 
a white solid (1.12 g, 2.98 mmol, 82% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 7.89 (d, J = 7.5 
Hz, 2H), 7.71 (d, J = 7.6 Hz, 2H), 7.42 (t, J = 7.5 Hz, 2H), 7.33 (td, J = 7.4, 1.2 Hz, 2H), 6.70 (d, 
J = 8.1 Hz, 1H), 6.54 (d, J = 2.1 Hz, 1H), 6.40 (dd, J = 8.1, 2.1 Hz, 1H), 4.68 (s, 2H), 4.29 (d, J = 
7.0 Hz, 2H), 4.21 (t, J = 7.0 Hz, 1H), 4.01 (d, J = 6.1 Hz, 2H), 3.73 (s, 3H). HPLC (gradient A): 
retention time = 5.919 min; purity = 87%. 
 
(9H-fluoren-9-yl)methyl (4-methoxy-3-((7-oxo-3-tosyl-3,7-dihydropyrrolo[2',3':4,5]pyrimido 
[6,1-b]quinazolin-5-yl)amino)benzyl)carbamate: (143, HVW11-20): To a pressure vessel was 
added intermediate 141 (0.295 g, 0.69g),  (9H-fluoren-9-yl)methyl (3-amino-4-
methoxybenzyl)carbamate 142 (0.26 g, 0.69 mmol) and trifluoroethanol (10 mL). The reaction 
was heated at 80 ˚C for two hours, cooled, and then concentrated to give a yellow solid. The 





yl)amino)benzamide (144, HVW 11-21): To a pressure vessel was added the crude 143 (0.39 g, 
0.69 mmol), 27% aqueous ammonium hydroxide (15 mL) and THF (15 mL). The reaction was 
then heated to 80 ˚C for one hour, cooled, and diluted with ethyl acetate and water resulting in an 
emulsion. Brine was added to alleviate the emulsion and the layers were separated. The organic 
layer was dried over magnesium sulfate and then concentrated in vacuo. The resulting residue 
was then absorbed onto silica gel and purified using a 24g column with a gradient of 0 – 10% 
MeOH/DCM to give the desired product as a white solid (0.157 g, 56% yield over two steps). 
1
H 
NMR (500 MHz, Chloroform-d) δ 11.36 (s, 1H), 9.03 (s, 1H), 8.93 (d, J = 8.5 Hz, 1H), 8.04 (d, J 
= 8.1 Hz, 2H), 7.67 (s, 1H), 7.55 (t, J = 8.8 Hz, 2H), 7.29 (d, J = 4.0 Hz, 1H), 7.20 (d, J = 8.0 Hz, 
2H), 7.04 (t, J = 7.6 Hz, 1H), 6.94 – 6.84 (m, 2H), 6.60 (d, J = 4.1 Hz, 1H), 3.95 (s, 3H), 3.90 (s, 
2H), 2.32 (s, 3H), 1.59 (s, 2H). HPLC (gradient A): retention time = 5.995 min; purity = 95%. 
 
5-(aminomethyl)-2-methoxyaniline (148, HVW11-2): In a 100 mL flask 3-amino-4-methoxy 
benzamide (1.0 g, 6.02 mmol) was dissolved in THF (50 mL) and cooled to 0 ˚C. Lithium 
aluminum hydride (2M in THF, 6.02 mL, 12.04 mmol) was then added to the reaction slowly. 
The reaction was then heat to 65 ˚C and refluxed for six hours. The reaction was then cooled to 0 
˚C. The Feiser method was then used for work-up of the reaction: 0.457 mL of water were added 
dropwise, then 0.457 mL of 15% NaOH, and then another 1.371 mL of water. Magnesium 
sulfate was then added and the reaction was stirred 15 minutes further. The solids were filtered 
off and the filtrate was concentrated to give the desired product 148 as an off-white solid (0.70 g, 
4.60 mmol, 76% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 6.69 (d, J = 8.1 Hz, 1H), 6.59 (d, J = 
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2.1 Hz, 1H), 6.46 (dd, J = 8.1, 2.1 Hz, 1H), 4.59 (s, 2H), 3.72 (s, 3H), 3.52 (s, 2H), 1.63 (s, 2H). 


















































1. Benjamin, E. J.; Blaha, M. J.; Chiuve, S. E.; Cushman, M.; Das, S. R.; Deo, R.; de 
Ferranti, S. D.; Floyd, J.; Fornage, M.; Gillespie, C.; Isasi, C. R.; Jiménez, M. C.; Jordan, L. C.; 
Judd, S. E.; Lackland, D.; Lichtman, J. H.; Lisabeth, L.; Liu, S.; Longenecker, C. T.; Mackey, R. 
H.; Matsushita, K.; Mozaffarian, D.; Mussolino, M. E.; Nasir, K.; Neumar, R. W.; Palaniappan, 
L.; Pandey, D. K.; Thiagarajan, R. R.; Reeves, M. J.; Ritchey, M.; Rodriguez, C. J.; Roth, G. A.; 
Rosamond, W. D.; Sasson, C.; Towfighi, A.; Tsao, C. W.; Turner, M. B.; Virani, S. S.; Voeks, J. 
H.; Willey, J. Z.; Wilkins, J. T.; Wu, J. H.; Alger, H. M.; Wong, S. S.; Muntner, P., Heart 
Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association. 
Circulation 2017. 
 
2. Kemp, C. D.; Conte, J. V., The pathophysiology of heart failure. Cardiovascular 
Pathology 2012, 21, 365-371. 
 
3. Ambrosy, A. P.; Fonarow, G. C.; Butler, J.; Chioncel, O.; Greene, S. J.; Vaduganathan, 
M.; Nodari, S.; Lam, C. S. P.; Sato, N.; Shah, A. N.; Gheorghiade, M., The Global Health and 
Economic Burden of Hospitalizations for Heart Failure. Lessons Learned From Hospitalized 
Heart Failure Registries 2014, 63, 1123-1133. 
 
4. Kazi, D. S.; Mark, D. B., The Economics of Heart Failure. Heart Failure Clinics 9, 93-
106. 
 
5. Johnson, F. L., Pathophysiology and Etiology of Heart Failure. Cardiology Clinics 2014, 
32, 9-19. 
 
6. Jackson, G.; Gibbs, C.; Davies, M.; Lip, G., ABC of heart failure: Pathophysiology. Bmj 
2000, 320, 167-170. 
 
7. Triposkiadis, F.; Karayannis, G.; Giamouzis, G.; Skoularigis, J.; Louridas, G.; Butler, J., 
The Sympathetic Nervous System in Heart Failure: Physiology, Pathophysiology, and Clinical 
Implications. Journal of the American College of Cardiology 2009, 54, 1747-1762. 
 
8. Lymperopoulos, A.; Rengo, G.; Funakoshi, H.; Eckhart, A. D.; Koch, W. J., Adrenal 
GRK2 upregulation mediates sympathetic overdrive in heart failure. Nature Medicine 2007, 13, 
315-323. 
 
9. Cohn, J. N.; Levine, T. B.; Olivari, M. T.; Garberg, V.; Lura, D.; Francis, G. S.; Simon, 
A. B.; Rector, T., Plasma norepinephrine as a guide to prognosis in patients with chronic 




10. Port J.D. and Bristow, M. R., Altered Beta-adrenergic receptor gene regulation and 
signaling in chronic heart failure. Journal of Molecular and Cellular Cardiology 2001, 33, 887-
905. 
 
11. Lefkowitz, R. J.; Stadel, J. M.; Caron, M. G., Adenylate cyclase-coupled beta-adrenergic 
receptors - structure and mechanisms of activation and desensitization. Annu. Rev. Biochem. 
1983, 52, 159-186. 
 
12. Sutherland, E. W.; Robison, G. A.; Butcher, R. W., Some Aspects of the Biological Role 
of Adenosine 3',5'-monophosphate (Cyclic AMP). Circulation 1968, 37, 279-306. 
 
13. Rosenbaum, D. M.; Rasmussen, S. G. F.; Kobilka, B. K., The structure and function of 
G-protein-coupled receptors. Nature 2009, 459, 356-363. 
 
14. Stevens, R. C.; Cherezov, V.; Katritch, V.; Abagyan, R.; Kuhn, P.; Rosen, H.; Wuthrich, 
K., The GPCR Network: a large-scale collaboration to determine human GPCR structure and 
function. Nat Rev Drug Discov 2013, 12, 25-34. 
 
15. Kobilka, B. K., G protein coupled receptor structure and activation. Biochimica et 
Biophysica Acta (BBA) - Biomembranes 2007, 1768, 794-807. 
 
16. Madamanchi, A., β-Adrenergic receptor signaling in cardiac function and heart failure. 
McGill Journal of Medicine : MJM 2007, 10, 99-104. 
 
17. Lohse, M. J.; Engelhardt, S.; Eschenhagen, T., What Is the Role of β-Adrenergic 
Signaling in Heart Failure? Circ.Res. 2003, 93, 896-906. 
 
18. Cannavo, A.; Liccardo, D.; Koch, W., Targeting cardiac β-adrenergic signaling via 
GRK2 inhibition for heart failure therapy. Frontiers in Physiology 2013, 4. 
 
19. Xiao, R.-P., β-Adrenergic Signaling in the Heart: Dual Coupling of the β<sub>2</sub>-
Adrenergic Receptor to G<sub>s</sub> and G<sub>i</sub> Proteins. Science's STKE 2001, 
2001, re15-re15. 
 
20. Kaumann, A. J.; Preitner, F.; Sarsero, D.; Molenaar, P.; Revelli, J.-P.; Giacobino, J. P., 
(−)-CGP 12177 Causes Cardiostimulation and Binds to Cardiac Putative β<sub>4</sub>-
Adrenoceptors in Both Wild-Type and β<sub>3</sub>-Adrenoceptor Knockout Mice. 
Molecular Pharmacology 1998, 53, 670-675. 
 
21. Oldham, W. M.; Hamm, H. E., Heterotrimeric G protein activation by G-protein-coupled 
receptors. Nat Rev Mol Cell Biol 2008, 9, 60-71. 
 
22. Ho, D.; Yan, L.; Iwatsubo, K.; Vatner, D. E.; Vatner, S. F., Modulation of β-Adrenergic 
Receptor Signaling in Heart Failure and Longevity: Targeting Adenylyl Cyclase Type 5. Heart 




23. Gerhardstein, B. L.; Puri, T. S.; Chien, A. J.; Hosey, M. M., Identification of the Sites 
Phosphorylated by Cyclic AMP-Dependent Protein Kinase on the β2 Subunit of L-Type 
Voltage-Dependent Calcium Channels†. Biochemistry 1999, 38, 10361-10370. 
 
24. Sulakhe, P. V.; Vo, X. T., Regulation of phospholamban and troponin-I phosphorylation 
in the intact rat cardiomyocytes by adrenergic and cholinergic stimuli: roles of cyclic 
nucleotides, calcium, protein kinases and phosphatases and depolarization. Molecular and 
cellular biochemistry 1995, 149-150, 103-26. 
 
25. Zhao, X. L.; Gutierrez, L. M.; Chang, C. F.; Hosey, M. M., The α1-Subunit of Skeletal 
Muscle L-Type Ca Channels Is the Key Target for Regulation by A-Kinase and Protein 
Phosphatase-1C. Biochemical and Biophysical Research Communications 1994, 198, 166-173. 
 
26. Eschenhagen, T., Beta-adrenergic signaling in heart failure - adapt or die. Nature 
Medicine 2008, 14, 485-487. 
 
27. Gurevich, E. V.; Tesmer, J. J. G.; Mushegian, A.; Gurevich, V. V., G protein-coupled 
receptor kinases: More than just kinases and not only for GPCRs. Pharmacology & Therapeutics 
2012, 133, 40-69. 
 
28. Kohout, T. A.; Lefkowitz, R. J., Regulation of G Protein-Coupled Receptor Kinases and 
Arrestins During Receptor Desensitization. Molecular Pharmacology 2003, 63, 9-18. 
 
29. Pitcher, J. A.; Freedman, N. J.; Lefkowitz, R. J., G PROTEIN–COUPLED RECEPTOR 
KINASES. Annu. Rev. Biochem. 1998, 67, 653-692. 
 
30. Ungerer, M.; Böhm, M.; Elce, J. S.; Erdmann, E.; Lohse, M. J., Altered expression of 
beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. 
Circulation 1993, 87, 454-463. 
 
31. Huang, Z. M.; Gold, J. I.; Koch, W. J., G protein-coupled receptor kinases in normal and 
failing myocardium. Frontiers in Bioscience-Landmark 2011, 16, 3047-3060. 
 
32. Hullmann, J.; Traynham, C. J.; Coleman, R. C.; Koch, W. J., The expanding GRK 
interactome: Implications in cardiovascular disease and potential for therapeutic development. 
Pharmacological Research 2016, 110, 52-64. 
 
33. Bristow Md, P. M. R., Mechanism of Action of Beta-Blocking Agents in Heart Failure. 
The American Journal of Cardiology 1997, 80, 26L-40L. 
 
34. Satwani, S.; Dec, G. W.; Narula, J., β-Adrenergic Blockers in Heart Failure: Review of 
Mechanisms of Action and Clinical Outcomes. Journal of Cardiovascular Pharmacology and 
Therapeutics 2004, 9, 243-255. 
 
35. Packer, M., Current role of beta-adrenergic blockers in the management of chronic heart 




36. Anastasios, L.; Giuseppe, R.; Walter, J. K., GRK2 Inhibition in Heart Failure: Something 
Old, Something New. Current Pharmaceutical Design 2012, 18, 186-191. 
 
37. Homan, K. T.; Tesmer, J. J. G., Molecular basis for small molecule inhibition of G 
protein-coupled receptor kinases. ACS Chem. Biol. 2015, 10, 246-256. 
 
38. Ren, X. R.; Reiter, E.; Ahn, S.; Kim, J.; Chen, W.; Lefkowitz, R. J., Different G protein-
coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 
vasopressin receptor. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 1448-1453. 
 
39. Wada, Y.; Sugiyama, J.; Okano, T.; Fukada, Y., GRK1 and GRK7: Unique cellular 
distribution and widely different activities of opsin phosphorylation in the zebrafish rods and 
cones. Journal of Neurochemistry 2006, 98, 824-837. 
 
40. Claing, A.; Laporte, S. A.; Caron, M. G.; Lefkowitz, R. J., Endocytosis of G protein-
coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. 
Progress in Neurobiology 2002, 66, 61-79. 
 
41. Ribas, C.; Penela, P.; Murga, C.; Salcedo, A.; García-Hoz, C.; Jurado-Pueyo, M.; 
Aymerich, I.; Mayor Jr, F., The G protein-coupled receptor kinase (GRK) interactome: Role of 
GRKs in GPCR regulation and signaling. Biochimica et Biophysica Acta (BBA) - Biomembranes 
2007, 1768, 913-922. 
 
42. Homan, K. T.; Tesmer, J. J. G., Structural Insights into G Protein-Coupled Receptor 
Kinase Function. Current opinion in cell biology 2014, 0, 25-31. 
 
43. Rockman, H. A.; Koch, W. J.; Lefkowitz, R. J., Seven-transmembrane-spanning 
receptors and heart function. Nature 2002, 415, 206-212. 
 
44. Raake, P. W. J.; Schlegel, P.; Ksienzyk, J.; Reinkober, J.; Barthelmes, J.; Schinkel, S.; 
Pleger, S.; Mier, W.; Haberkorn, U.; Koch, W. J.; Katus, H. A.; Most, P.; Muller, O. J., 
AAV6.beta ARKct cardiac gene therapy ameliorates cardiac function and normalizes the 
catecholaminergic axis in a clinically relevant large animal heart failure model. Eur. Heart J. 
2013, 34, 1437-1447. 
 
45. Raake, P. W.; Vinge, L. E.; Gao, E. H.; Boucher, M.; Rengo, G.; Chen, X. W.; 
DeGeorge, B. R.; Matkovich, S.; Houser, S. R.; Most, P.; Eckhart, A. D.; Dorn, G. W.; Koch, W. 
J., G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial 
infarction prevents heart failure. Circ.Res. 2008, 103, 413-422. 
 
46. Ciccarelli, M.; Chuprun, J. K.; Rengo, G.; Gao, E.; Wei, Z. Y.; Peroutka, R. J.; Gold, J. 
I.; Gumpert, A.; Chen, M.; Otis, N. J.; Dorn, G. W.; Trimarco, B.; Iaccarino, G.; Koch, W. J., G 
Protein-Coupled Receptor Kinase 2 Activity Impairs Cardiac Glucose Uptake and Promotes 




47. Martini, J. S.; Raake, P.; Vinge, L. E.; DeGeorge, B. R.; Chuprun, J. K.; Harris, D. M.; 
Gao, E.; Eckhart, A. D.; Pitcher, J. A.; Koch, W. J., Uncovering G protein-coupled receptor 
kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proceedings of the 
National Academy of Sciences 2008, 105, 12457-12462. 
 
48. Johnson, L. R.; Scott, M. G. H.; Pitcher, J. A., G protein-coupled receptor kinase 5 
contains a DNA-binding nuclear localization sequence. Mol. Cell. Biol. 2004, 24, 10169-10179. 
 
49. Yi, Y. P.; Gerdes, A. M.; Li, F. Q., Myocyte redistribution of GRK2 and GRK5 in 
hypertensive, heart-failure-prone rats. Hypertension 2002, 39, 1058-1063. 
 
50. McKinsey, T. A.; Olson, E. N., Toward transcriptional therapies for the failing heart: 
chemical screens to modulate genes. Journal of Clinical Investigation 2005, 115, 538-546. 
 
51. Chang, S. R.; McKinsey, T. A.; Zhang, C. L.; Richardson, J. A.; Hill, J. A.; Olson, E. N., 
Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and 
play redundant roles in heart development. Molecular and Cellular Biology 2004, 24, 8467-
8476. 
 
52. Gold, J. I.; Gao, E.; Shang, X.; Premont, R. T.; Koch, W. J., Determining the Absolute 
Requirement of G Protein–Coupled Receptor Kinase 5 for Pathological Cardiac Hypertrophy: 
Short Communication. Circulation Research 2012, 111, 1048-1053. 
 
53. Rockman, H. A.; Choi, D. J.; Rahman, N. U.; Akhter, S. A.; Lefkowitz, R. J.; Koch, W. 
J., Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in 
transgenic mice. Proceedings of the National Academy of Sciences 1996, 93, 9954-9959. 
 
54. Kassack, M. U.; Högger, P.; Gschwend, D. A.; Kameyama, K.; Haga, T.; Graul, R. C.; 
Sadée, W., Molecular modeling of G-protein coupled receptor kinase 2: Docking and 
biochemical evaluation of inhibitors. AAPS PharmSci 2000, 2, 9-21. 
 
55. Kannan, N.; Haste, N.; Taylor, S. S.; Neuwald, A. F., The hallmark of AGC kinase 
functional divergence is its C-terminal tail, a cis-acting regulatory module. Proceedings of the  
National Academy of Sciences 2007, 104, 1272-1277. 
 
56. Homan, K. T.; Waldschmidt, H. V.; Glukhova, A.; Cannavo, A.; Song, J.; Cheung, J. Y.; 
Koch, W. J.; Larsen, S. D.; Tesmer, J. J. G., Crystal Structure of G Protein-Coupled Receptor 
Kinase 5 in Complex with a Rationally Designed Inhibitor. Journal of Biological Chemistry 
2015. 
 
57. Benovic, J. L.; Stone, W. C.; Caron, M. G.; Lefkowitz, R. J., Inhibition of the beta-
adrenergic receptor kinase by polyanions. Journal of Biological Chemistry 1989, 264, 6707-
6710. 
 
58. Benovic, J. L.; Onorato, J.; Lohse, M. J.; Dohlman, H. G.; Staniszewski, C.; Caron, M. 
G.; Lefkowitz, R. J., Synthetic peptides of the hamster β(2)-adrenoceptor as substrates and 
257 
 




59. Winstel, R.; Ihlenfeldt, H.-G.; Jung, G.; Krasel, C.; Lohse, M. J., Peptide inhibitors of G 
protein-coupled receptor kinases. Biochemical Pharmacology 2005, 70, 1001-1008. 
 
60. Onorato, J. J.; Palczewski, K.; Regan, J. W.; Caron, M. G.; Lefkowitz, R. J.; Benovic, J. 
L., Role of acidic amino acids in peptide substrates of the .beta.-adrenergic receptor kinase and 
rhodopsin kinase. Biochemistry 1991, 30, 5118-5125. 
 
61. Baameur, F.; Hammitt, R. A.; Friedman, J.; McMurray, J. S.; Clark, R. B., Biochemical 
and Cellular Specificity of Peptide Inhibitors of G Protein-Coupled Receptor Kinases. 
International Journal of Peptide Research and Therapeutics 2014, 20, 1-12. 
 
62. Mayer, G.; Wulffen, B.; Huber, C.; Brockmann, J.; Flicke, B.; Neumann, L.; Hafenbradl, 
D.; Klebl, B. M.; Lohse, M. J.; Krasel, C.; Blind, M., An RNA molecule that specifically inhibits 
G-protein-coupled receptor kinase 2 in vitro. RNA 2008, 14, 524-534. 
 
63. Tesmer, Valerie M.; Lennarz, S.; Mayer, G.; Tesmer, John J. G., Molecular Mechanism 
for Inhibition of G Protein-Coupled Receptor Kinase 2 by a Selective RNA Aptamer. Structure 
2012, 20, 1300-1309. 
 
64. Iino, M.; Furugori, T.; Mori, T.; Moriyama, S.; Fukuzawa, A.; Shibano, T., Rational 
Design and Evaluation of New Lead Compound Structures for Selective βARK1 Inhibitors. J. 
Med. Chem. 2002, 45, 2150-2159. 
 
65. Palczewski, K.; Kahn, N.; Hargrave, P. A., Nucleoside inhibitors of rhodopsin kinase. 
Biochemistry 1990, 29, 6276-6282. 
 
66. Cho, S. Y.; Lee, B. H.; Jung, H.; Yun, C. S.; Ha, J. D.; Kim, H. R.; Chae, C. H.; Lee, J. 
H.; Seo, H. W.; Oh, K.-S., Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-
(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled 
receptor kinase-2 and -5 inhibitors. Bioorganic & Medicinal Chemistry Letters 2013, 23, 6711-
6716. 
 
67. Lee, J.; Han, S.-Y.; Jung, H.; Yang, J.; Choi, J.-W.; Chae, C. H.; Park, C. H.; Choi, S. U.; 
Lee, K.; Ha, J. D.; Lee, C. O.; Ryu, J. W.; Kim, H. R.; Koh, J. S.; Cho, S. Y., Synthesis and 
structure–activity relationship of aminopyridines with substituted benzoxazoles as c-Met kinase 
inhibitors. Bioorganic & Medicinal Chemistry Letters 2012, 22, 4044-4048. 
 
68. Tesmer, J. J. G.; Tesmer, V. M.; Lodowski, D. T.; Steinhagen, H.; Huber, J., Structure of 
Human G Protein-Coupled Receptor Kinase 2 in Complex with the Kinase Inhibitor Balanol. J. 




69. Setyawan, J.; Koide, K.; Diller, T. C.; Bunnage, M. E.; Taylor, S. S.; Nicolaou, K. C.; 
Brunton, L. L., Inhibition of protein kinases by balanol: Specificity within the serine/threonine 
protein kinase subfamily. Molecular Pharmacology 1999, 56, 370-376. 
 
70. Thal, D. M.; Yeow, R. Y.; Schoenau, C.; Huber, J.; Tesmer, J. J. G., Molecular 
Mechanism of Selectivity among G Protein-Coupled Receptor Kinase 2 Inhibitors. Molecular 
Pharmacology 2011, 80, 294-303. 
 
71. Waldschmidt, H. V.; Homan, K. T.; Cruz-Rodríguez, O.; Cato, M. C.; Waninger-Saroni, 
J.; Larimore, K. M.; Cannavo, A.; Song, J.; Cheung, J. Y.; Kirchhoff, P. D.; Koch, W. J.; 
Tesmer, J. J. G.; Larsen, S. D., Structure-Based Design, Synthesis, and Biological Evaluation of 
Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors. J. Med. Chem. 
2016, 59, 3793-3807. 
 
72. Thal, D. M.; Homan, K. T.; Chen, J.; Wu, E. K.; Hinkle, P. M.; Huang, Z. M.; Chuprun, 
J. K.; Song, J.; Gao, E.; Cheung, J. Y.; Sklar, L. A.; Koch, W. J.; Tesmer, J. J. G., Paroxetine Is a 
Direct Inhibitor of G Protein-Coupled Receptor Kinase 2 and Increases Myocardial Contractility. 
ACS Chemical Biology 2012, 7, 1830-1839. 
 
73. Schumacher, S. M.; Gao, E.; Zhu, W.; Chen, X.; Chuprun, J. K.; Feldman, A. M.; G. 
Tesmer, J. J.; Koch, W. J., Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction 
and remodeling after myocardial infarction. Science Translational Medicine 2015, 7, 277ra31. 
 
74. Homan, K. T.; Wu, E.; Wilson, M. W.; Singh, P.; Larsen, S. D.; Tesmer, J. J. G., 
Structural and Functional Analysis of G Protein–Coupled Receptor Kinase Inhibition by 
Paroxetine and a Rationally Designed Analog. Molecular Pharmacology 2014, 85, 237-248. 
 
75. Homan, K. T.; Larimore, K. M.; Elkins, J. M.; Szklarz, M.; Knapp, S.; Tesmer, J. J. G., 
Identification and Structure–Function Analysis of Subfamily Selective G Protein-Coupled 
Receptor Kinase Inhibitors. ACS Chemical Biology 2014, 10, 310-319. 
 
76. Sehon, C. A.; Wang, G. Z.; Viet, A. Q.; Goodman, K. B.; Dowdell, S. E.; Elkins, P. A.; 
Semus, S. F.; Evans, C.; Jolivette, L. J.; Kirkpatrick, R. B.; Dul, E.; Khandekar, S. S.; Yi, T.; 
Wright, L. L.; Srnith, G. K.; Behm, D. J.; Bentley, R.; Doe, C. P.; Hu, E.; Lee, D., Potent, 
Selective and Orally Bioavailable Dihydropyrimidine Inhibitors of Rho Kinase (ROCK1) as 
Potential Therapeutic Agents for Cardiovascular Diseases. J. Med. Chem. 2008, 51, 6631-6634. 
 
77. Ikeda S, K. M., and Fujiwara S, et. al. Cardiotonic agent comprising GRK inhibitor. 
WO2007034846, March 29 2007, 2007. 
 
78. Baumli, S.; Endicott, J. A.; Johnson, L. N., Halogen Bonds Form the Basis for Selective 
P-TEFb Inhibition by DRB. Chemistry & Biology 2010, 17, 931-936. 
 
79. Huber, K.; Brault, L.; Fedorov, O.; Gasser, C.; Filippakopoulos, P.; Bullock, A. N.; 
Fabbro, D.; Trappe, J.; Schwaller, J.; Knapp, S.; Bracher, F., 7,8-Dichloro-1-oxo-β-carbolines as 
259 
 
a Versatile Scaffold for the Development of Potent and Selective Kinase Inhibitors with Unusual 
Binding Modes. J. Med. Chem. 2012, 55, 403-413. 
 
80. Komolov, K. E.; Bhardwaj, A.; Benovic, J. L., Atomic Structure of GRK5 Reveals 
Distinct Structural Features Novel for G Protein-coupled Receptor Kinases. Journal of 
Biological Chemistry 2015, 290, 20629-20647. 
 
81. Li, R.; Martin, M. P.; Liu, Y.; Wang, B.; Patel, R. A.; Zhu, J.-Y.; Sun, N.; Pireddu, R.; 
Lawrence, N. J.; Li, J.; Haura, E. B.; Sung, S.-S.; Guida, W. C.; Schonbrunn, E.; Sebti, S. M., 
Fragment-Based and Structure-Guided Discovery and Optimization of Rho Kinase Inhibitors. J. 
Med. Chem. 2012, 55, 2474-2478. 
 
82. Sridharan, V.; Ruiz, M.; Menéndez, J. C., Mild and High-Yielding Synthesis of β-Keto 
Esters and β-Ketoamides. Synthesis 2010, 2010, 1053-1057. 
 
83. Drewry, D. H. E., Brian; Goodman, Krista B.; Green, Darren, Victor, Steven; Jung, 
David, Kendall; Lee, Denis; Stavenger, Robert, A.; Wad, Sjoerd, Nocolaas Chemical 
Compounds. 29 December 2004, 2004. 
 
84. Houlihan, W. J.; Cooke, G.; Denzer, M.; Nicoletti, J., 1-Alkyl-4-aryl-3,4-dihydro-2(1H)-
quinazolinones and thiones. Synthesis and 1H-NMR spectra. Journal of Heterocyclic Chemistry 
1982, 19, 1453-1456. 
 
85. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J., Experimental and 
computational approaches to estimate solubility and permeability in drug discovery and 
development settings. Advanced Drug Delivery Reviews 1997, 23, 3-25. 
 
86. Waldschmidt, H. V.; Homan, K. T.; Cato, M. C.; Cruz-Rodríguez, O.; Cannavo, A.; 
Wilson, M. W.; Song, J.; Cheung, J. Y.; Koch, W. J.; Tesmer, J. J. G.; Larsen, S. D., Structure-
Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors 
Based on Paroxetine. Journal of Medicinal Chemistry 2017, 60, 3052-3069. 
 
87. Muller, S.; Chaikuad, A.; Gray, N. S.; Knapp, S., The ins and outs of selective kinase 
inhibitor development. Nat Chem Biol 2015, 11, 818-821. 
 
88. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. 
T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; 
Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; 
Wodicka, L. M.; Zarrinkar, P. P., A quantitative analysis of kinase inhibitor selectivity. Nat 
Biotech 2008, 26, 127-132. 
 
89. Zhang, J.; Yang, P. L.; Gray, N. S., Targeting cancer with small molecule kinase 
inhibitors. Nat Rev Cancer 2009, 9, 28-39. 
 
90. Goodman, K. B.; Cui, H.; Dowdell, S. E.; Gaitanopoulos, D. E.; Ivy, R. L.; Sehon, C. A.; 
Stavenger, R. A.; Wang, G. Z.; Viet, A. Q.; Xu, W.; Ye, G.; Semus, S. F.; Evans, C.; Fries, H. 
260 
 
E.; Jolivette, L. J.; Kirkpatrick, R. B.; Dul, E.; Khandekar, S. S.; Yi, T.; Jung, D. K.; Wright, L. 
L.; Smith, G. K.; Behm, D. J.; Bentley, R.; Doe, C. P.; Hu, E.; Lee, D., Development of 
Dihydropyridone Indazole Amides as Selective Rho-Kinase Inhibitors. Journal of Medicinal 
Chemistry 2007, 50, 6-9. 
 
91. Gangula, S.; Kolla, N. K.; Elati, C.; Dongamanti, A.; Bandichhor, R., Improved Process 
for Paroxetine Hydrochloride Substantially Free from Potential Impurities. Synthetic 
Communications 2012, 42, 3344-3360. 
 
92. J. Bridges, A.; Lee, A.; Maduakor, E. C.; Schwartz, C. E., Fluorine as an ortho-directing 
group in aromatic metalation: Generality of the reaction and the high position of fluorine in the 
Dir-Met potency scale. Tetrahedron Letters 1992, 33, 7495-7498. 
 
93. Flaugh, M. E.; Crowell, T. A.; Clemens, J. A.; Sawyer, B. D., Synthesis and evaluation of 
the antiovulatory activity of a variety of melatonin analogs. J. Med. Chem. 1979, 22, 63-69. 
 
94. Iwakubo, M.; Takami, A.; Okada, Y.; Kawata, T.; Tagami, Y.; Ohashi, H.; Sato, M.; 
Sugiyama, T.; Fukushima, K.; Iijima, H., Design and synthesis of Rho kinase inhibitors (II). 
Bioorganic & Medicinal Chemistry 2007, 15, 350-364. 
 
95. Premont, R. T.; Koch, W. J.; Inglese, J.; Lefkowitz, R. J., IDENTIFICATION, 
PURIFICATION, AND CHARACTERIZATION OF GRK5, A MEMBER OF THE FAMILY 
OF G-PROTEIN-COUPLED RECEPTOR KINASES. J. Biol. Chem. 1994, 269, 6832-6841. 
 
96. Bauer, R. A., Covalent inhibitors in drug discovery: from accidental discoveries to 
avoided liabilities and designed therapies. Drug Discovery Today 2015, 20, 1061-1073. 
 
97. Singh, J.; Petter, R. C.; Baillie, T. A.; Whitty, A., The resurgence of covalent drugs. Nat 
Rev Drug Discov 2011, 10, 307-317. 
 
98. Potashman, M. H.; Duggan, M. E., Covalent Modifiers: An Orthogonal Approach to 
Drug Design. Journal of Medicinal Chemistry 2009, 52, 1231-1246. 
 
99. Robertson, J. G., Mechanistic Basis of Enzyme-Targeted Drugs. Biochemistry 2005, 44, 
5561-5571. 
 
100. Mah, R.; Thomas, J. R.; Shafer, C. M., Drug discovery considerations in the development 
of covalent inhibitors. Bioorganic & Medicinal Chemistry Letters 2014, 24, 33-39. 
 
101. Johnson, D. S.; Weerapana, E.; Cravatt, B. F., Strategies for discovering and derisking 
covalent, irreversible enzyme inhibitors. Future medicinal chemistry 2010, 2, 949-964. 
 
102. Hallenbeck, K. K.; Turner, D. M.; Renslo, A. R.; Arkin, M. R., Targeting Non-Catalytic 
Cysteine Residues Through Structure-Guided Drug Discovery. Current topics in medicinal 




103. Krishnan, S.; Miller, R. M.; Tian, B.; Mullins, R. D.; Jacobson, M. P.; Taunton, J., 
Design of Reversible, Cysteine-Targeted Michael Acceptors Guided by Kinetic and 
Computational Analysis. Journal of the American Chemical Society 2014, 136, 12624-12630. 
 
104. Lee, C.-U.; Grossmann, T. N., Reversible Covalent Inhibition of a Protein Target. 
Angewandte Chemie International Edition 2012, 51, 8699-8700. 
 
105. Leproult, E.; Barluenga, S.; Moras, D.; Wurtz, J. M.; Winssinger, N., Cysteine Mapping 
in Conformationally Distinct Kinase Nucleotide Binding Sites: Application to the Design of 
Selective Covalent Inhibitors. Journal of Medicinal Chemistry 2011, 54, 1347-1355. 
 
106. Liu, Q.; Sabnis, Y.; Zhao, Z.; Zhang, T.; Buhrlage, Sara J.; Jones, Lyn H.; Gray, 
Nathanael S., Developing Irreversible Inhibitors of the Protein Kinase Cysteinome. Chemistry & 
Biology 2013, 20, 146-159. 
 
107. Schwartz, P. A.; Kuzmic, P.; Solowiej, J.; Bergqvist, S.; Bolanos, B.; Almaden, C.; 
Nagata, A.; Ryan, K.; Feng, J.; Dalvie, D.; Kath, J. C.; Xu, M.; Wani, R.; Murray, B. W., 
Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and 
mechanisms of drug resistance. Proceedings of the National Academy of Sciences 2014, 111, 
173-178. 
 
108. Chong, C. R.; Janne, P. A., The quest to overcome resistance to EGFR-targeted therapies 
in cancer. Nat Med 2013, 19, 1389-1400. 
 
109. Kwak, E. L.; Sordella, R.; Bell, D. W.; Godin-Heymann, N.; Okimoto, R. A.; Brannigan, 
B. W.; Harris, P. L.; Driscoll, D. R.; Fidias, P.; Lynch, T. J.; Rabindran, S. K.; McGinnis, J. P.; 
Wissner, A.; Sharma, S. V.; Isselbacher, K. J.; Settleman, J.; Haber, D. A., Irreversible inhibitors 
of the EGF receptor may circumvent acquired resistance to gefitinib. Proceedings of the National 
Academy of Sciences of the United States of America 2005, 102, 7665-7670. 
 
110. Fry, D. W.; Bridges, A. J.; Denny, W. A.; Doherty, A.; Greis, K. D.; Hicks, J. L.; Hook, 
K. E.; Keller, P. R.; Leopold, W. R.; Loo, J. A.; McNamara, D. J.; Nelson, J. M.; Sherwood, V.; 
Smaill, J. B.; Trumpp-Kallmeyer, S.; Dobrusin, E. M., Specific, irreversible inactivation of the 
epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. 
Proceedings of the National Academy of Sciences 1998, 95, 12022-12027. 
 
111. Discafani, C. M.; Carroll, M. L.; Floyd Jr, M. B.; Hollander, I. J.; Husain, Z.; Johnson, B. 
D.; Kitchen, D.; May, M. K.; Malo, M. S.; Minnick Jr, A. A.; Nilakantan, R.; Shen, R.; Wang, 
Y.-F.; Wissner, A.; Greenberger, L. M., Irreversible inhibition of epidermal growth factor 
receptor tyrosine kinase with In Vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-
2-butynamide (CL-387,785). Biochemical Pharmacology 1999, 57, 917-925. 
 
112. Keating, G. M., Afatinib: A Review of Its Use in the Treatment of Advanced Non-Small 




113. Zhang, T.; Inesta-Vaquera, F.; Niepel, M.; Zhang, J.; Ficarro, Scott B.; Machleidt, T.; 
Xie, T.; Marto, Jarrod A.; Kim, N.; Sim, T.; Laughlin, John D.; Park, H.; LoGrasso, Philip V.; 
Patricelli, M.; Nomanbhoy, Tyzoon K.; Sorger, Peter K.; Alessi, Dario R.; Gray, Nathanael S., 
Discovery of Potent and Selective Covalent Inhibitors of JNK. Chemistry & Biology 2012, 19, 
140-154. 
 
114. Chamberlain, S. D.; Redman, A. M.; Wilson, J. W.; Deanda, F.; Shotwell, J. B.; Gerding, 
R.; Lei, H.; Yang, B.; Stevens, K. L.; Hassell, A. M.; Shewchuk, L. M.; Leesnitzer, M. A.; 
Smith, J. L.; Sabbatini, P.; Atkins, C.; Groy, A.; Rowand, J. L.; Kumar, R.; Mook Jr, R. A.; 
Moorthy, G.; Patnaik, S., Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R 
tyrosine kinase inhibitors towards JNK selectivity. Bioorganic & Medicinal Chemistry Letters 
2009, 19, 360-364. 
 
115. Boguth, C. A.; Singh, P.; Huang, C. c.; Tesmer, J. J. G., Molecular basis for activation of 
G protein‐ coupled receptor kinases. The EMBO Journal 2010, 29, 3249-3259. 
 
116. Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, 
R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; 
Greulich, H.; Wong; K, K., BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in 
preclinical lung cancer models. Oncogene 2008, 27, 4702-4711. 
 
117. Yoshimura, N.; Kudoh, S.; Kimura, T.; Mitsuoka, S.; Matsuura, K.; Hirata, K.; Matsui, 
K.; Negoro, S.; Nakagawa, K.; Fukuoka, M., EKB-569, a new irreversible epidermal growth 
factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung 
cancer with acquired resistance to gefitinib. Lung Cancer 2006, 51, 363-368. 
 
118. Chan, A.; Delaloge, S.; Holmes, F. A.; Moy, B.; Iwata, H.; Harvey, V. J.; Robert, N. J.; 
Silovski, T.; Gokmen, E.; von Minckwitz, G.; Ejlertsen, B.; Chia, S. K. L.; Mansi, J.; Barrios, C. 
H.; Gnant, M.; Buyse, M.; Gore, I.; Smith, J., II; Harker, G.; Masuda, N.; Petrakova, K.; Zotano, 
A. G.; Iannotti, N.; Rodriguez, G.; Tassone, P.; Wong, A.; Bryce, R.; Ye, Y.; Yao, B.; Martin, 
M., Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast 
cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. 
The Lancet Oncology 17, 367-377. 
 
119. Chamberlain, S. D.; Gerding, R. M.; Lei, H.; Moorthy, G.; Patnaik, S.; Redman, A. M.; 
Stevens, K. L.; Wilson, J. W.; Yang, B.; Shotwell, J. B., Reversible Carboxamide-Mediated 
Internal Activation at C(6) of 2-Chloro-4-anilino-1H-pyrrolo[2,3-d]pyrimidines. The Journal of 
Organic Chemistry 2008, 73, 9511-9514. 
 
120. Wissner, A.; Mansour, T. S., The Development of HKI-272 and Related Compounds for 
the Treatment of Cancer. Archiv der Pharmazie 2008, 341, 465-477. 
 
121. Tan, L.; Akahane, K.; McNally, R.; Reyskens, K. M. S. E.; Ficarro, S. B.; Liu, S.; Herter-
Sprie, G. S.; Koyama, S.; Pattison, M. J.; Labella, K.; Johannessen, L.; Akbay, E. A.; Wong, K.-
K.; Frank, D. A.; Marto, J. A.; Look, T. A.; Arthur, J. S. C.; Eck, M. J.; Gray, N. S., 
263 
 
Development of Selective Covalent Janus Kinase 3 Inhibitors. J. Med. Chem. 2015, 58, 6589-
6606. 
 
122. Kwarcinski, F. E.; Fox, C. C.; Steffey, M. E.; Soellner, M. B., Irreversible Inhibitors of c-
Src Kinase That Target a Nonconserved Cysteine. ACS Chemical Biology 2012, 7, 1910-1917. 
 
123. Singh, J.; Dobrusin, E. M.; Fry, D. W.; Haske, T.; Whitty, A.; McNamara, D. J., 
Structure-Based Design of a Potent, Selective, and Irreversible Inhibitor of the Catalytic Domain 
of the erbB Receptor Subfamily of Protein Tyrosine Kinases. J. Med. Chem. 1997, 40, 1130-
1135. 
 
124. Wu, C.-H.; Coumar, M. S.; Chu, C.-Y.; Lin, W.-H.; Chen, Y.-R.; Chen, C.-T.; Shiao, H.-
Y.; Rafi, S.; Wang, S.-Y.; Hsu, H.; Chen, C.-H.; Chang, C.-Y.; Chang, T.-Y.; Lien, T.-W.; Fang, 
M.-Y.; Yeh, K.-C.; Chen, C.-P.; Yeh, T.-K.; Hsieh, S.-H.; Hsu, J. T. A.; Liao, C.-C.; Chao, Y.-
S.; Hsieh, H.-P., Design and Synthesis of Tetrahydropyridothieno[2,3-d]pyrimidine Scaffold 
Based Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors: The Role of Side Chain 
Chirality and Michael Acceptor Group for Maximal Potency. J. Med. Chem. 2010, 53, 7316-
7326. 
 
125. Homan, K.; Wu, E.; Cannavo, A.; Koch, W.; Tesmer, J., Identification and 
Characterization of Amlexanox as a G Protein-Coupled Receptor Kinase 5 Inhibitor. Molecules 
2014, 19, 16937. 
 
126. Srimani, D.; Feller, M.; Ben-David, Y.; Milstein, D., Catalytic coupling of nitriles with 
amines to selectively form imines under mild hydrogen pressure. Chemical Communications 
2012, 48, 11853-11855. 
 
127. Caddick, S.; Judd, D. B.; Lewis, A. K. d. K.; Reich, M. T.; Williams, M. R. V., A generic 
approach for the catalytic reduction of nitriles. Tetrahedron 2003, 59, 5417-5423. 
 
128. Murray, C. W.; Berdini, V.; Buck, I. M.; Carr, M. E.; Cleasby, A.; Coyle, J. E.; Curry, J. 
E.; Day, J. E. H.; Day, P. J.; Hearn, K.; Iqbal, A.; Lee, L. Y. W.; Martins, V.; Mortenson, P. N.; 
Munck, J. M.; Page, L. W.; Patel, S.; Roomans, S.; Smith, K.; Tamanini, E.; Saxty, G., 
Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors. ACS Medicinal 
Chemistry Letters 2015, 6, 798-803. 
 
129. Zhao, G.; Bolton, S. A.; Kwon, C.; Hartl, K. S.; Seiler, S. M.; Slusarchyk, W. A.; Sutton, 
J. C.; Bisacchi, G. S., Synthesis of potent and selective 2-azepanone inhibitors of human 
tryptase. Bioorganic & Medicinal Chemistry Letters 2004, 14, 309-312. 
 
130. Bolinger, M. T.; Ramshekar, A.; Waldschmidt, H. V.; Larsen, S. D.; Bewley, M. C.; 
Flanagan, J. M.; Antonetti, D. A., Occludin S471 Phosphorylation Contributes to Epithelial 




131. Zhang, Y.; Matkovich, S. J.; Duan, X.; Gold, J. I.; Koch, W. J.; Dorn, G. W., Nuclear 
Effects of G-Protein Receptor Kinase 5 on Histone Deacetylase 5–Regulated Gene Transcription 
in Heart Failure. Circulation: Heart Failure 2011, 4, 659-668. 
 
132. Suo, W. Z.; Li, L., Dysfunction of G Protein-Coupled Receptor Kinases in Alzheimer’'s 
Disease. TheScientificWorldJOURNAL 2010, 10. 
 
133. Guccione, M.; Ettari, R.; Taliani, S.; Da Settimo, F.; Zappalà, M.; Grasso, S., G-Protein-
Coupled Receptor Kinase 2 (GRK2) Inhibitors: Current Trends and Future Perspectives. Journal 
of Medicinal Chemistry 2016, 59, 9277-9294. 
 
134. Suo, W. Z.; Li, L., Dysfunction of G Protein-Coupled Receptor Kinases in Alzheimer’'s 
Disease. TheScientificWorldJOURNAL 2010, 10. 
 
135. Obrenovich, M. E.; Palacios, H. H.; Gasimov, E.; Leszek, J.; Aliev, G., The GRK2 
Overexpression Is a Primary Hallmark of Mitochondrial Lesions during Early Alzheimer 
Disease. Cardiovascular Psychiatry and Neurology 2009, 2009, 327360. 
 
136. Er, B.; Vv, G.; Jn, J.; Jl, B.; Ev, G., Arrestins and two receptor kinases are upregulated in 
Parkinson's disease with dementia. Neurobiology of aging 2008, 29, 379-396. 
 
137. Wu, C.-C.; Tsai, F.-M.; Shyu, R.-Y.; Tsai, Y.-M.; Wang, C.-H.; Jiang, S.-Y., G protein-
coupled receptor kinase 5 mediates Tazarotene-induced gene 1-induced growth suppression of 
human colon cancer cells. BMC Cancer 2011, 11, 175-175. 
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